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Human  immunodeficiency  virus  type  1  (HIV-­‐‑1)  infection  of  the  central  nervous  
system  (CNS)  can  occur  shortly  after  transmission  and  compartmentalized  HIV-­‐‑1  variants,  
genetically  distinct  from  virus  in  the  blood,  can  be  detected  in  the  cerebrospinal  fluid  (CSF)  
in  some  individuals  throughout  the  course  of  infection.    HIV-­‐‑1  replication  can  induce  
neuropathogenesis  and  may  also  represent  a  distinct  reservoir  from  that  found  in  CD4+  T  
cells  in  the  blood  and  lymphoid  tissue.    We  do  not  know  the  time  course  of  the  virologic  
events  that  lead  to  neurological  dysfunction  and  the  potential  establishment  of  a  CNS  
reservoir,  or  the  extent  to  which  these  long-­‐‑term  outcomes  are  predicted  by  the  initial  
aspects  of  virus-­‐‑host  interaction.    In  this  dissertation,  I  examined  the  viral  genetic  and  
phenotypic  determinants  associated  with  CNS  compartmentalization  early  following  both  
vertical  and  horizontal  transmission.    Additionally,  I  examined  CNS  compartmentalization  
over  the  full  course  of  disease  in  simian  immunodeficiency  virus  (SIV)-­‐‑infected  rhesus  
macaques.      
Using  single  genome  amplification  (SGA),  sequencing  and  phylogenetic  analysis,  I  
detected  significant  compartmentalization  in  both  the  pediatric  and  adult  cohorts,  
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predominantly  associated  with  a  longer  time  since  HIV-­‐‑1  infection.    Compartmentalization  
was  also  shown  to  persist  and  evolve  over  a  period  of  up  to  two  years  in  the  adult  cohort.    
Through  the  use  of  Bayesian  Evolutionary  Analysis  by  Sampling  Trees  (BEAST),  I  identified  
and  examined  multiple  variant  transmission  events  and  defined  two  distinct  pathways  to  
compartmentalization:  the  early  sequestration  of  a  transmitted  virus  in  the  CNS;  and  the  
later  establishment  of  an  independently  replicating  population  within  the  CNS  that  
originated  from  the  periphery.    I  also  concluded  via  entry  tropism  analyses  that  in  most  
children  and  adults,  replication  in  the  CNS  is  sustained  by  growth  in  CD4+  T  cells,  while  in  
some  young  children  the  virus  in  the  CNS  evolves  to  replicate  in  cells  with  low  CD4  surface  
expression,  potentially  macrophages  and/or  microglia.    The  observation  of  significant  
compartmentalization  early  following  both  vertical  and  horizontal  transmission,  evidence  of  
adaptation  of  virus  to  the  CNS,  and  the  potential  for  early  CNS  involvement  to  result  in  
long-­‐‑term  neurocognitive  damage  and  reservoir  establishment  adds  further  justification  to  
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Genome organization and virion structure 
Human  immunodeficiency  virus  type  1  (HIV-­‐‑1)  is  a  member  of  the  Lentivirus  genus  
within  the  Retroviridae  family.    HIV-­‐‑1  is  classified  into  four  groups  (M,  N,  O  and  P),  each  
representing  independent  cross-­‐‑species  transmission  events.    The  M  group,  the  first  to  be  
discovered  and  encompassing  95%  of  the  circulation  viral  strains  worldwide,  is  further  
divided  into  nine  subtypes  (A,  D,  C,  D,  F,  G,  H,  J,  and  K).    Subtype  C,  the  most  dominant  
subtype  worldwide,  in  predominant  in  Africa,  while  subtype  B  isolates  are  the  most  
prevalent  in  Europe  and  North  America  (101).  
The  HIV-­‐‑1  genome,  two  copies  of  which  are  encapsulated  per  viral  particle,  is  a  
single-­‐‑stranded,  positive-­‐‑sense  RNA  genome  approximately  9.7  kilobases  in  length  that  
contains  nine  genes  flanked  by  HIV-­‐‑1  long  terminal  repeats  (LTR):  gag,  pol,  env,  vif,  vpr,  tat,  
rev,  vpu,  and  nef.    These  genes  encode  the  precursors  to  the  structure  proteins  in  Env  and  
Gag  (further  processed  into  the  matrix  (MA),  capsid  (CA),  and  nucleocapsid  proteins  (NC)),  
the  precursors  to  the  non-­‐‑structural  enzymes  in  Pol  (further  processed  into  the  reverse  
transcriptase  (RT)  and  integrase  (IN)  enzymes)  and  Pro,  the  accessory  proteins  Vif,  Vpr,  Vpu  
and  Nef,  and  the  regulatory  proteins  Tat  and  Rev.  
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The  full-­‐‑length  dimeric  RNA  genome  associates  with  the  NC  protein  through  a  short  
packaging  signal  located  within  the  5’  end  of  the  unspliced  RNA.    The  NC-­‐‑RNA  complex  is  
surrounded  by  the  CA  protein,  which  is  arranged  into  a  conical  core  that  also  contains  
several  copies  of  viral  protease  (PR),  IN,  and  RT  enzymes  required  for  productive  infection.    
The  conical  core  of  CA  is  surrounded  by  a  spherical  shell  composed  of  the  matrix  (MA)  
protein,  which  is  embedded  in  the  viral  envelope,  a  lipid  bilayer  gained  during  budding  
from  the  infected  cell,  that  contains  the  Env  protein  associated  in  trimers,  as  well  as  various  
cellular  proteins  (101,  115).  
 
HIV-1 envelope binding and fusion 
HIV-­‐‑1  relies  on  the  Env  spike  to  engage  cellular  receptors  and  fuse  the  viral  and  
target  membranes  in  order  to  enter  host  cells  (9,  259,  342).    Synthesized  and  folded  in  the  
endoplasmic  reticulum,  the  precursor  gp160  is  heavily  modified  by  N-­‐‑linked  glycosylation  
in  the  Golgi  complex  and  folded  into  trimers  with  the  help  of  host  chaperones  (84,  94,  101,  
185).    The  heavy  glycosylation  generates  a  glycan  shield,  providing  protection  against  
neutralizing  antibodies.    The  gp160  trimer  is  proteolytically  cleaved  by  cellular  proteases  
into  the  surface  glycoprotein  gp120  and  the  transmembrane  glycoprotein  gp41,  and  
transported  to  the  cell  surface  for  incorporation  into  virions  (209,  337).    The  surface  gp120  
subunit  contains  conserved  domains  C1-­‐‑C5  and  variable  domains  V1-­‐‑V5.    The  exposed  
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variable  domains  evolve  rapidly  in  response  to  antibody  selection  and  shield  the  conserved  
domains  (321).      
Env  first  binds  the  cellular  surface  receptor  CD4  (67),  a  member  of  the  
immunoglobulin  family  that  is  highly  expressed  on  CD4+  T  cells  and  expressed  at  low  levels  
on  macrophages  (64,  169),  followed  by  binding  with  the  chemokine  coreceptors  CCR5  (56,  
75)  or  CXCR4  (93).    The  binding  of  HIV-­‐‑1  Env  protein  determines  the  cellular  tropism  of  
HIV-­‐‑1  variants.    Attachment  factors  such  as  heparin  sulfate  proteoglycans,  α4β7  integrin,  or  
dendritic  cell-­‐‑specific  intercellular  adhesion  molecule  3-­‐‑grabbing  non-­‐‑integrin  (DC-­‐‑SIGN)  
help  bring  Env  into  close  proximity  to  CD4,  although  these  factors  are  not  essential  for  entry  
(336).    Within  the  gp120  monomer,  the  CD4  binding  site  is  located  within  a  deep  binding  
pocket  that  is  likely  protected  from  antibodies  by  glycosylated  variable  loops  (143,  165).    The  
sequential  receptor/coreceptor  binding  induces  a  conformation  change  that  exposes  the  
hydrophobic  gp41  N-­‐‑terminal  fusion  peptide,  promoting  its  insertion  into  the  target  
membrane  and  forming  the  stable  gp41  six-­‐‑helix  bundle  that  mediates  viral-­‐‑cell  membrane  
fusion  (52,  103,  203,  333).  
 
HIV-1 replication strategy 
After  successful  cellular  attachment  and  fusion,  the  viral  core  is  delivered  into  the  
cytoplasm  of  the  host  cell.    Following  uncoating,  which  releases  the  genomic  RNA  and  
packaged  viral  enzymes,  reverse  transcription  begins,  a  highly  ordered  and  complex  
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reaction  preformed  by  the  viral  RT.    HIV-­‐‑1  RT  contains  two  crucial  domains;  a  DNA  
polymerase  responsible  for  incorporation  of  deoxynucleotides  onto  a  nucleotide  template,  
and  an  RNase  H  activity  responsible  for  degradation  of  the  RNA  strand  of  the  RNA:DNA  
replication  intermediate.    HIV-­‐‑1  is  genetically  very  heterogeneous  due  to  the  error  prone  
viral  DNA  polymerase  and  the  high  recombination  frequency  observed  during  reverse  
transcription  when  a  single  cell  is  infected  by  multiple  virions.    The  linear  DNA  is  then  
integrated  into  the  cellular  DNA  via  the  actions  of  the  viral  IN,  most  often  into  areas  of  the  
cellular  genome  experiencing  active  gene  expression  (288).    Integration  into  host  cells  
enables  the  virus  to  persist  in  the  infected  cell  and  form  latent  reservoirs  when  infected  cells  
become  dormant.      
Integration  of  the  provirus  signals  the  transition  from  the  early  to  the  late  stages  of  
HIV-­‐‑1  replication.    The  synthesis  of  viral  RNA  from  the  integrated  viral  DNA,  performed  by  
the  cellular  RNA  polymerase  II,  generates  RNA  transcripts.    The  viral  Tat  protein  binds  the  
transactivation  response  region  (TAR),  a  bulged  hairpin  structure  on  the  5’  end  of  the  
nascent  viral  RNA,  and  recruits  host  proteins  that  enhance  the  ability  of  RNA  polymerase  II  
to  elongate  down  the  genome  with  high  processivity  (115,  173,  186).    RNA  transcripts  are  
exported  from  the  nucleus  into  the  cytoplasm  for  translation  or  packaging  into  the  virion  
particle.    RNA  export  is  mediated  by  HIV-­‐‑1  Rev,  which  binds  the  Rev-­‐‑responsive  elements  
(RRE)  and  recruits  Crm1,  a  cellular  nuclear  export  factor,  to  the  viral  RNA  (65,  115).    The  
gag,  pro,  pol  and  env  genes  are  then  expressed  to  form  precursor  polyproteins,  which  are  
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further  processed/cleaved  during  and  after  viral  assembly  and  budding  by  the  HIV-­‐‑1  PR  
(156).    
The  HIV-­‐‑1  accessory  proteins  serve  various  functions  in  HIV-­‐‑1  replication.    Nef  
downregulates  the  surface  expression  of  CD4  receptor  (105)  and  the  major  
histocompatibility  complex  (MHC)  class  I  (62)  ,  facilitating  virus  release  and  inhibiting  the  
cytotoxic  T  lymphocyte  (CTL)-­‐‑mediated  lysis  of  HIV-­‐‑1  infected  cell,  respectively.    The  Vpr  
protein,  packaged  within  virion  particles,  facilitates  the  import  of  the  preintegration  
complex  into  the  nucleus  in  nondividing  cells  (245)  and  can  induce  cell  cycle  arrest  (155).    
HIV-­‐‑1  Vpu  enhances  virus  production,  mediates  the  degradation  of  CD4  by  the  ubiquitin-­‐‑
conjugating  pathway,  and  antagonizes  tetherin  (215,  289,  314,  338).      Lastly,  Vif  neutralizes  
the  potent  antiviral  activity  of  APOBEC3G,  found  within  nonpermissive  cells  including  
human  T  lymphocytes,  enhancing  the  infectivity  of  HIV-­‐‑1  (187,  295,  344).  
 
HIV-1 DISEASE PROGRESSION: ACUTE INFECTION THROUGH END-STAGE 
AIDS 
  
Viral  sequences  during  the  earliest  stages  of  horizontal  infection  are  typically  highly  
homogenous,  representing  productive  clinical  infection  by  one  variant  (3,  158,  273).    
Additionally,  vertically  transmitted  viruses  are  often  highly  homogeneous,  characterized  by  
low  diversity  (5,  210,  264,  279).    Due  to  this  transmission  bottleneck,  the  infecting  variant  is  
genetically  less  complex  than  the  diverse  number  of  quasispecies  in  the  exposure  inoculum.    
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Following  transmission,  there  is  an  initial  eclipse  phase,  up  to  ten  days  long,  during  which  
time  infection  is  localized  to  the  exposure  site  (172)  and  systemic  circulation  has  not  yet  
occurred.      
Acute  HIV-­‐‑1  infection  (AHI)  is  associated  with  an  exponential  increase  and  then  
subsequent  decline  in  HIV-­‐‑1  RNA  in  the  plasma  (61,  201).    Peak  plasma  HIV-­‐‑1  viremia  is  
reached  between  fourteen  to  twenty-­‐‑one  days  post  infection  (175)  and  levels  above  one  
million  RNA  copies/mL  can  be  measured.    During  this  time,  individuals  have  a  robust  
inflammatory  response,  characterized  by  a  “cytokine  storm”  (310),  and  can  develop  
symptoms  of  HIV-­‐‑1  acute  retroviral  syndrome,  such  as  fever,  rash,  severe  fatigue,  headache,  
and  diarrhea.    HIV-­‐‑1  replicates  rapidly  and  spreads  throughout  the  body,  resulting  in  a  
drastic  decline  in  CD4+  T  cells,  particularly  in  the  gut-­‐‑associated  lymphoid  tissue  (GALT)  
(34,  194).      
Several  weeks  post  infection  the  HIV-­‐‑1  viral  load  begins  to  decrease  in  response  to  
virus-­‐‑specific  CD8+  CTLs  (32,  229)  and  a  partial  rebound  of  CD4+  T  cell  counts  occurs.    
Patients  progress  from  AHI  to  early  chronic  infection  as  the  plasma  viral  load  begins  to  
plateau  and  a  viral  set  point  is  obtained  (142,  281).    The  acute  and  early  phases  of  infection  
are  referred  to  as  primary  HIV-­‐‑1  infection  (PHI)  (66,  174,  343).  
The  chronic  phase  of  infection  is  a  long  asymptomatic  period  that  can  last  for  years,  
characterized  by  persistent  viral  replication  and  evolution  and  a  steady  loss  of  peripheral  
CD4+  T  cells,  leading  to  immunodeficiency.    According  to  the  U.S.  Centers  for  Disease  
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Control  and  Prevention  (CDC),  HIV-­‐‑1  infected  individuals  are  clinically  diagnosed  with  
AIDS  when  CD4+  T  cells  counts  drop  below  200  cells/µμl,  compared  to  approximately  1,000  
cells/µμl  in  healthy  individuals,  or  when  one  or  more  AIDS-­‐‑defining  illness  (opportunistic  
infection)  is  recorded.    Early  symptomatic  conditions  of  immunodeficiency  include  
candidiasis  and  shingles,  while  more  severe  AIDS-­‐‑defining  conditions  include  HIV-­‐‑1-­‐‑
associated  dementia  (HAD),  cryptococcosis,  pneumonia  caused  by  Pneumocystis  jiroveci  
(PCP),  tuberculosis,  Toxoplasma  gondii  infection  of  the  brain,  Kaposi’s  sarcoma,  and  wasting  
syndrome.    Eventually,  HIV-­‐‑1  infected  individuals  succumb  to  the  opportunistic  infections  
caused  by  severe  immunodeficiency.  
 
HIV-1 PATHOGENESIS: OTHER AGENTS AND OPPORTUNISTIC INFECTIONS 
 
The earliest signs of immunodeficiency 
Mucosal  infections  including  Candida  albicans  and  Pneumocystis  jiroveci  pneumonia  
(PCP)  are  often  early  signs  of  immunodeficiency.    Candida  species  are  normal  inhabitants  of  
the  human  gastrointestinal  tract  and  can  be  recovered  from  the  mouth  in  up  to  one-­‐‑third  of  
normal  individuals  and  two-­‐‑third  of  HIV-­‐‑1  infected  individuals.    Mucocutaneous  
candidiasis  can  occur  in  three  forms  in  HIV-­‐‑1  infected  individuals,  oropharyngeal,  
esophageal,  and  vulvovaginal  disease  (162,  252).    While  immunosuppression  is  a  crucial  
driving  factor  of  Candidia  infection,  other  host  factors  such  as  salivary  flow  rates,  condition  
of  the  epithelial  barrier,  antimicrobial  constituents  of  saliva,  and  the  presence  of  normal  
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bacterial  flora  also  play  a  role  (196,  197).    Candida  albicans  may  also  disseminate  to  other  
organs,  including  the  CNS  where  it  can  result  in  other  complications  such  as  meningitis.  
Pneumocystis  jiroveci  pneumonia  (PCP)  of  the  lungs  is  a  presenting  feature  of  
previously  undiagnosed  HIV-­‐‑1  infection  in  up  to  85%  of  infected  individuals.    A  ubiquitous  
fungus,  PCP  rarely  causes  disease  in  the  absence  of  underlying  conditions,  such  as  
immunosuppression.    While  the  incidence  of  PCP  has  decreased  in  the  HAART  era  (227),  
PCP  remains  a  major  concern  for  HIV-­‐‑1  infected  individuals  who  do  not  know  their  
infection  status  or  are  not  on/cannot  tolerate  therapy  (157).    PCP  infection  has  been  
hypothesized  to  result  from  reactivation  of  latent  infection  or  via  direct  exposure  from  the  
environment  or  an  infected  individual  (206).    While  not  widely  studied,  polymorphisms  in  
the  gene  encoding  the  Fc  segment  of  IgG  have  been  predicted  to  influence  the  risk  of  PCP  
(98).    Previous  PCP,  oral  candidiasis,  and  persistent  fevers  are  also  risk  factors  for  PCP.  
Herpes  simplex  virus  2  (HSV-­‐‑2)  infection  is  also  a  significant  opportunistic  infection  
in  individuals  with  HIV-­‐‑1,  resulting  in  HIV-­‐‑1/HSV-­‐‑2  coinfections  in  up  to  90%  of  HIV-­‐‑1  
infected  individuals  (246).    Primarily  transmitted  via  sexual  contact  and  frequently  
reactivated  following  exposure,  HSV-­‐‑2  infection  causes  severe,  long-­‐‑lasting  sores,  or  fever  
blisters,  on  the  mouth,  genitals,  or  anal  area.    The  prevalence  of  HSV-­‐‑2  shedding  is  4-­‐‑5  times  
greater  in  HIV-­‐‑1  infected  individuals,  resulting  in  increased  transmission,  and  genital  HSV  
reactivation  may  increase  the  efficiency  of  HIV-­‐‑1  transmission  (14,  246).    As  exposure  to  
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HIV-­‐‑1  often  occurs  at  mucosal  surfaces,  prior  or  co-­‐‑infection  with  HSV-­‐‑2  is  a  major  health  
concern  for  HIV-­‐‑1  infected  individuals.    
  
HIV-1 and cancer 
Cancers  will  occur  in  approximately  40%  of  individuals  with  HIV-­‐‑1  infection,  often  
associated  with  infection  with  other  pathogenic  viruses.    The  connection  between  HIV-­‐‑1  and  
malignancies  is  likely  the  result  of  immune  suppression,  which  leads  to  reduced  immune  
surveillance  and  an  inability  to  control  viral  replication  or  the  growth  of  transformed  calls,  
as  well  as  due  to  a  disrupted  balance  of  cytokine  levels  (170).    Additionally,  immune  
suppression  seems  to  be  a  driving  factor  in  HIV-­‐‑1  associated  malignancies,  as  cancers  
developing  in  the  presence  of  HIV-­‐‑1  are  much  more  aggressive  than  those  found  in  
uninfected  patients  (181).      
Kaposi’s  Sarcoma  (KS)  is  a  well-­‐‑demarcated  angioproliferative  multifocal  
malignancy  of  the  skin.    While  the  disease  may  follow  a  less  severe  course  with  restricted  
skin  or  lymph  node  involvement,  in  HIV-­‐‑1  infected  individuals  KS  often  presents  in  its  
aggressive  form  with  widespread  cutaneous  and  visceral  involvement  (92).    KS  lesions  on  
the  skin,  mucus  membranes  and  viscera  are  formed  via  excessive  proliferation  of  spindle,  
endothelial,  fibroblasts  and  inflammatory  cells  as  well  as  the  formation  of  new  blood  
vessels,  or  neoangiogenesis  (263,  270).    KSHV,  also  known  as  human  herpesvirus  type  8  
(HHV8),  has  been  isolated  from  biopsy  samples  of  KS  lesions  (54).    KSHV  is  also  associated  
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with  the  rare  occurrence  of  body  cavity  lymphomas  in  AIDS  patients  (50).    Studies  have  
suggested  that  various  cytokines  and  growth  factors,  including  IL-­‐‑1β,  IL-­‐‑6,  TNF-­‐‑α,  and  GM-­‐‑
CSF,  as  well  as  the  HIV-­‐‑1  Tat  gene,  are  involved  in  the  development  of  KS  (92).      
HIV-­‐‑1  infection  is  associated  with  an  increased  susceptibility  to  B-­‐‑cell  lymphomas  
and  anogenital  carcinomas.    HIV-­‐‑1  infection  increases  the  risk  of  developing  B-­‐‑cell  
lymphomas  over  60-­‐‑fold  compared  to  the  general  population  (24).    Infected  individuals  
heterozygous  for  the  CCR5  Δ32  deletion  have  been  shown  to  have  a  reduced  risk  of  
developing  B-­‐‑cell  lymphomas  (71,  249)  while  subjects  with  SDF-­‐‑1  polymorphisms  may  have  
increased  susceptibility  (170).    EBV  is  the  causative  agent  in  approximately  40-­‐‑60%  of  these  
lymphomas  outside  of  the  brain  and  in  virtually  all  CNS  lymphomas  (182,  296,  301).    EBV  
can  induce  B-­‐‑cell  proliferation  and  enhance  production  of  B-­‐‑cell  cytokines  (i.e.  IL-­‐‑6  and  IL-­‐‑
10),  starting  the  process  of  cellular  transformation  to  lymphomas.    Anal  and  cervical  
carcinomas  are  also  AIDS-­‐‑defining  conditions.    In  approximately  90%  of  such  cancers,  HPV  
promotes  carcinoma  development  (347)  through  suppression  of  cellular  proteins  that  
control  cell  division  (p53  tumor  suppression  protein  and  retinoblastoma  gene  product)  by  
viral  proteins  E6  and  E7  (170).      
  
Opportunistic infections of the CNS  
In  a  small  subset  of  individuals,  the  first  presentation  of  HIV-­‐‑1  is  with  neurological  
opportunistic  infections.    Additionally,  many  chronically  infected  individuals,  even  those  on  
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ART,  are  vulnerable  to  neurological  opportunistic  infections  as  a  result  of  persistent  
immune  suppression  and  maintained  HIV-­‐‑1  CNS  replication.    Viruses,  bacteria,  fungi,  and  
parasites  can  cause  CNS  opportunistic  infections.  
CMV,  a  DNA  virus  of  the  herpesvirus  family,  can  cause  AIDS-­‐‑associated  CMV  
encephalitis  associated  with  confusion,  disorientation,  apathy,  and  withdrawal,  and  is  
difficult  to  distinguish  from  HAD.    Between  40-­‐‑100%  of  the  general  population  is  infected  
with  CMV  and  reactivation  of  endogenous  CMV  accounts  for  much  of  the  CMV-­‐‑associated  
diseases  in  immunocompromised  individuals  (124,  200).    Acquired  by  close  contact  at  
mucosal  surfaces,  CMV  is  spread  via  infected  circulating  leukocytes  and  has  a  wide  tropism  
for  neural  cells  (200).    While  less  common,  HSV  infection  can  also  cause  encephalitis,  often  
concurrent  with  a  CMV  infection  (25).    PML  is  a  demyelinating  disease  that  results  from  
lytic  infection  of  oligodendrocytes  with  the  John  Cunningham  (JC)  virus,  a  DNA  
polyomavirus.    The  incidence  of  the  normally  rare  PML  increased  50-­‐‑fold  with  the  HIV-­‐‑1  
epidemic  and  lesions  can  be  found  throughout  the  brain  (21,  255).    Patients  with  PML  
experience  weakness,  gait  abnormalities,  speech  disorders,  visual  effects,  and  cognitive  
abnormalities  (36).    The  natural  disease  course  is  progressive  and  leads  to  death  within  
months  if  a  patient  remains  immunocompromised  (21).    
Cryptococcus  neoformans  is  the  most  common  cause  of  opportunistic  meningitis  in  
AIDS  patients  (25).    Inhaled  from  environmental  sources,  C.  neoformans  replicates  within  
macrophages  and  generates  a  polysaccharide  capsule  that  allows  the  fungus  to  execute  
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functions  such  as  resist  phagocytosis,  inhibit  neutrophil  migration,  deplete  complement,  
dysregulate  cytokine  production,  and  interfere  with  antigen  presentation  (20).    Patients  with  
cryptococcal  meningitis  typically  experience  headache,  fever,  nausea,  occasionally  vision  
and  behavior  changes  as  well  as  an  elevation  of  intercranial  pressure  (ICP).    The  parasite  
Toxoplasma  gondii,  acquired  through  ingestion  of  undercooked  meats  or  items  contaminated  
by  cat  excrement  (253),  is  also  a  common  cause  of  various  neurological  diseases,  including  
encephalitis,  in  AIDS  patients  (37).    Gamma  interferon  (IFN-­‐‑γ)-­‐‑dependent  cell-­‐‑mediated  
immunity  is  important  in  combating  T.  gondii  infection  as  it  activates  CNS  cells  that  
suppress  the  parasite  through  production  of  oxygen  free  radicals  and  reactive  nitrogen  
intermediates  (145).      
 
HIV/HCV co-infection 
Worldwide,  an  estimated  170  million  people  are  infected  with  Hepatitis  C  virus  
(HCV),  with  up  to  10  million  of  those  representing  HIV/HCV  co-­‐‑infections  (168).    HCV  
infection  is  common  among  HIV-­‐‑1  infected  individuals  as  the  two  RNA  viruses  share  
multiple  biological  properties,  including  similar  routes  of  transmission.    HIV/HCV  co-­‐‑
infections  occur  in  approximately  one-­‐‑third  of  HIV-­‐‑1  infected  individuals,  but  this  number  
increases  to  approximately  75%  among  intravenous  drug  users  (IDU)  or  other  individuals  
exposed  to  HIV-­‐‑1  parenterally  (250,  340).    In  up  to  85%  of  HCV  infected  individuals,  HCV  
infection  persists  indefinitely,  resulting  in  chronic  hepatitis  C  (CHC),  cirrhosis,  and  
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hepatocellular  carcinoma.    Similar  to  HIV-­‐‑1,  HCV  is  characterized  by  high  genetic  
heterogeneity,  contributing  to  the  development  of  variants  capable  of  evading  immune  and  
therapeutic  defenses.    
HCV  and  HIV-­‐‑1  appear  to  do  more  than  coexist  within  dually  infected  individuals.    
For  example,  mother-­‐‑to  child-­‐‑transmission  (MTCT)  of  HCV  is  more  common  in  mothers  
infected  with  both  HIV-­‐‑1  and  HCV,  as  opposed  to  only  HCV  (120,  188)  and  HIV-­‐‑1  infection  
accelerates  the  development  of  severe  liver  disease  (106,  256).    As  a  result  of  the  additive  
effects  of  HIV/HCV  dual  infection,  end-­‐‑stage  liver  disease  now  accounts  for  nearly  half  of  
the  deaths  among  HIV-­‐‑positive  patients  (307).    HCV  infection  has  also  been  shown  to  affect  
the  CNS,  with  HCV  RNA  detected  in  the  cerebrospinal  fluid  (CSF)  of  both  HIV-­‐‑positive  and  
HIV-­‐‑negative  patients  (183,  207).    Additionally,  HCV  infection  has  been  shown  to  contribute  
to  HIV-­‐‑1-­‐‑associated  minor  cognitive/motor  disorders  and  HIV-­‐‑1-­‐‑associated  dementia  
complex  (265).      
  
HIV-1 EFFECTS ON VARIOUS ORGAN SYSTEMS 
 
HIV-1 and the immune system 
Severe  immunodeficiency  is  a  hallmark  of  HIV-­‐‑1  infection,  characterized  not  only  by  
the  significant  reduction  of  CD4+  T  cells,  but  also  by  a  disruption  of  CD8+  lymphocyte,  B  
lymphocyte,  antigen  presenting  cell,  natural  killer  (NK)  cell  and  neutrophil  function.    
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Macrophage  abnormalities  primarily  include  reduced  chemotaxis  and  antigen-­‐‑presenting  
function,  which  results  in  reduced  lymphocyte  proliferation  (170).    Some  studies  suggest  
that  HIV-­‐‑1  infection  reduces  phagocytosis  in  macrophages,  but  the  small  number  of  these  
cells  infected  prevents  detailed  analysis.    HIV-­‐‑1  can  also  induce  damage  to  precursor  cells  or  
stromal  cells  in  the  thymus,  reducing  the  production  of  new  lymphocytes  (108).    There  is  
also  a  reduction  in  number  and  cytotoxic  activity  of  NK  cells  and  decreased  chemokine  
response  and  phagocytic  activity  of  neutrophils  (170).    
HIV-­‐‑1  viral  proteins  have  been  shown  to  have  detrimental  effects  on  the  immune  
response.    The  cytotoxic  Env  protein  gp120  can  increase  apoptosis  of  T  cells  and  alter  
cytokine  levels,  including  inhibiting  IL-­‐‑2  and  thereby  T  cell  proliferation  and  regulation  
(216,  226).    HIV-­‐‑1  gp120  also  induces  IL-­‐‑10  production  by  monocytes,  resulting  in  anergy  in  
human  peripheral  blood  lymphocytes  (286).    The  viral  protein  Gag  also  inhibits  T  cell  
function  through  binding  cyclophilins  (180).    Nef  downregulates  the  major  
histocompatibility  complex  (MHC)  class  I  levels  from  the  surface  of  T  cells  and  APCs,  
thereby  inhibiting  the  CTL-­‐‑mediated  lysis  of  HIV-­‐‑1  infected  cell  (62,  290).    Tat  induces  
apoptosis  of  T  cells,  B  cell  depletion,  as  well  as  reduces  mannose  receptor  expression  on  
APCs  crucial  for  phagocytosis  and  antigens  delivery  to  the  MHC  class  II  pathway  (47).  
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HIV-1 and the gut-associated lymphoid tissue 
The  GALT  is  the  largest  lymphoid  tissue  in  the  human  body,  containing  over  50%  of  
all  lymphoid  cells  (34).    Approximately  20%  of  CD4+  T  cells  in  the  GALT  are  infected  during  
acute  HIV-­‐‑1  and  SIV  infection  (194,  328),  attributed  to  their  high  coreceptor  expression  
levels  and  predominantly  active  state  (12).    Additionally,  up  to  60%  of  uninfected  CD4+  T  
cells  die  by  apoptosis  (107),  resulting  in  an  overall  depletion  of  approximately  80%  of  CD4+  
T  cells  in  the  GALT.    This  decrease  coincides  with  an  increase  in  CD8+  T  cells,  a  
dysregulation  in  T  cell  homeostasis  that  results  in  increased  inflammatory  cytokine  levels,  
inflammation  and  chronic  immune  activation  (198,  276).    Additional  CD4+  T  cells  are  then  
recruited  from  the  periphery  into  the  GALT,  providing  new  targets  for  HIV-­‐‑1  replication,  
and  contributing  to  the  maintenance  of  a  viral  reservoir.    While  CD4+  T  cell  counts  in  the  
blood  rebound  following  peak  viremia  (201),  there  is  a  significant  delay  in  the  restoration  of  
CD4+  T  cell  levels  in  the  GALT  (34,  125).    
The  massive  depletion  of  CD4+  T  cells  and  robust  HIV-­‐‑1  replication  in  the  GALT  
contribute  to  damage  to  the  intestinal  lining,  resulting  in  enhanced  bacterial  translocation  
and  generalized  immune  activation  (198,  276,  325).    A  reduction  in  the  expression  of  genes  
associated  with  drug  metabolism  is  also  observed,  potentially  contributing  to  the  reduced  
effectiveness  of  ART  observed  in  the  GALT  (276).    These  alterations  lead  to  gastrointestinal  
complications  such  as  nutrient  malabsorption,  malnutrition,  diarrhea  and  wasting  common  
throughout  HIV-­‐‑1  infection  (69).    Overall,  the  incomplete  viral  suppression  in  the  GALT  
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despite  therapy,  the  sustained  local  inflammation  and  damage,  and  the  extensive  CD4+  T  
cell  killing  pose  major  challenges  for  complete  mucosal  immune  restoration  and  eradication  
of  viral  reservoirs.  
  
HIV-1-associated nephropathy 
HIV-­‐‑1  associated  nephropathy  (HIVAN)  is  one  of  the  major  causes  of  end-­‐‑stage  renal  
disease  (ESRD)  in  HIV-­‐‑1  infected  individuals  (202).    HIV-­‐‑1  infects  resident  renal  epithelial  
cells  (REC),  which  may  constitute  a  distinct  viral  compartment,  as  viral  RNA  can  be  
detected  in  REC  despite  suppression  in  the  plasma  (39),  and  phylogenetic  analysis  
comparing  HIV-­‐‑1  sequences  from  REC  and  peripheral  blood  mononuclear  cells  (PBMC)  in  
patients  with  HIVAN  found  evidence  for  independent  viral  evolution  within  the  kidney  
(191).    However,  RECs  do  not  express  the  HIV-­‐‑1  surface  receptor  CD4  or  co-­‐‑receptors  CCR5  
or  CXCR4;  therefore,  the  mechanism  of  entry  of  HIV-­‐‑1  into  REC  remains  perplexing.    One  
study  proposed  that  HIV-­‐‑1  RNA  is  transferred  to  RECs  in  a  CD4  and  Env  independent  
manor  via  virological  synapses,  requiring  the  attachment  receptor  heparin  sulfate  
proteoglycans  (55).      
Genetic,  viral  and  host  response  factors  may  influence  HIVAN.    Approximately  90%  
of  all  cases  of  HIVAN  are  in  patients  of  African  descent,  an  increased  risk  associated  with  
Apolipoprotein  L1  gene  variants  G1  and  G2  (111).    The  viral  proteins  Nef  and  Vpr  have  also  
been  proposed  to  play  a  role  in  disease  progression.    Nef  has  been  shown  to  alter  
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proliferation  and  differentiation  of  podocytes  within  the  kidney  (146,  147)  through  
activation  of  the  Stat3  and  Ras-­‐‑c-­‐‑Raf-­‐‑MAPK  1,  2  pathways  (133)  and  a  disruption  of  the  
RhoA/Rac1  balance  (179).    Several  studies  have  also  suggested  roles  of  NFκB  and  oxidant  
stress  in  HIV-­‐‑1-­‐‑induced  podocyte  injury  (202).    Vpr  has  been  shown  to  induce  dysregulation  
of  cytokinesis  and  apoptosis  (261),  a  characteristic  of  HIVAN,  via  increased  expression  of  




The blood-brain barrier 
Brain  microvascular  endothelial  cells  (BMVEC)  within  the  CNS  form  the  blood-­‐‑brain  
barrier  (BBB),  a  selectively  permeable  barrier  that  regulates  brain  homeostasis  and  restricts  
the  movement  of  molecules,  ions,  and  pathogens  between  the  blood  and  the  brain.    The  BBB,  
formed  during  embryogenesis,  is  composed  of  and  regulated  by  interactions  between  
BMVEC,  pericytes,  and  astrocytes  along  the  capillaries  in  the  brain  (204).    Pericytes,  vascular  
support  cells  associated  with  BMVEC  as  nascent  vessels  are  generated,  are  critical  during  
BBB  development  (13,  70).    Astrocyte  foot  processes,  which  surround  BMVEC,  have  been  
shown  to  regulate  BBB  permeability  through  the  secretion  of  compounds  that  alter  tight  and  
adherin  junction  proteins  (1,  91).      Molecules  such  as  MCP-­‐‑1  (311),  TNF-­‐‑α  (100),  
apolipoprotein  E  (109),  and  interleukins  (1,  160)  have  been  shown  to  alter  BBB  permeability  
(204).      
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Substances  cross  the  BBB  through  several  mechanisms,  many  of  which  can  be  
exploited  by  HIV-­‐‑1  for  entry  into  the  CNS.    Serum  proteins,  such  as  albumin,  can  enter  the  
brain  at  a  low  rate  through  specific  points  within  the  BBB  termed  extracellular  pathways  (16,  
35).    Substances  can  also  enter  the  brain  when  the  BBB  is  disrupted,  for  example  by  trauma,  
hypertension,  infection,  and  cytokine  damage  (178,  195).  Transportation  via  endocytosis  
through  clathrin-­‐‑coated  vesicles  (absorptive  endocytosis)  as  well  as  simple  membrane  
diffusion  are  also  possible  mechanisms  for  crossing  the  BBB  (17).    Additionally,  immune  
cells  cross  the  BBB  through  diapedesis.  (315).  
 
HIV-1 CNS infection: timing and mechanisms of entry 
HIV-­‐‑1  appears  in  the  CNS  shortly  after  transmission,  with  the  detection  of  HIV-­‐‑1  in  
both  the  CSF  and  brain  tissue  during  the  weeks  after  initial  exposure  (70,  89,  238,  284,  308,  
318),  although  it  is  not  clear  if  the  virus  detected  is  actually  replicating  in  the  CNS.    Several  
different  mechanisms  have  been  proposed  for  HIV-­‐‑1  CNS  entry.    Two  theories  hypothesize  
infection  of  BMVEC  (90),  the  first  by  direct  infection  and  the  second  via  the  trancytosis  of  
HIV-­‐‑1  by  BMVEC,  with  the  subsequent  infection  of  additional  parenchyma  cells  or  release  
of  free  virus  into  the  CNS  (18,  231,  292).    However,  these  two  theories  are  controversial  as  
HIV-­‐‑1  infection  of  BMVEC  in  vitro  is  highly  restrictive  and  non-­‐‑productive  (208,  242,  291).      
A  third  and  more  widely  supported  model  is  the  transport  of  HIV-­‐‑1  across  the  BBB  
into  the  CNS  by  infected  CD4+  lymphocytes  (233).    During  inflammation,  expression  of  
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adhesion  molecules,  such  as  ICAM-­‐‑1  and  VCAM-­‐‑1,  is  upregulated  on  the  surface  of  BMVEC  
(87,  123,  277).    As  leukocytes  roll  along  the  endothelial  surface,  they  are  tethered  via  the  
interactions  between  BMVEC  adhesion  molecules  and  corresponding  ligands  on  their  
surface,  such  as  LFA-­‐‑1  (219).    This  tethering  is  then  followed  by  diapediesis  (90).  Leukocyte  
recruitment  and  transmigration  into  the  CNS  and  BBB  permeability  is  enhanced  via  the  
expression  of  chemoattractant  cytokines  and  chemokines,  including  MCP-­‐‑1  (102,  332),  MIP-­‐‑
1α,  MIP-­‐‑1β  (33,  282),  TNF-­‐‑α  and  IL-­‐‑1β    (220).    It  has  also  been  suggested  that  HIV-­‐‑1  infected  
cells  can  enter  the  CNS  via  migration  across  the  choroid  plexus,  and  on  rare  occasions,  via  
migration  from  the  peripheral  blood  to  the  subarachnoid  space  (45).      
  
CNS infection of other neurovirulent viruses 
The  CNS  is  particularly  vulnerable  to  viral  infection  due  to  the  longevity  of  CNS  
cells  and  the  immune-­‐‑privileged  nature  of  the  CNS.    There  are  five  important  cell  types  
critical  for  proper  CNS  function,  all  of  which  can  be  infected  by  neurotropic  viruses.    
Astrocytes,  the  most  abundant  cell  in  the  CNS,  execute  numerous  essential  functions  
including  managing  healthy  synaptic  transmission,  maintaining  BBB  function,  protecting  
neurons  from  injury  and  removing  toxic  materials  (305).    Microglia,  the  brain-­‐‑resident  
macrophages,  play  an  important  role  in  local  immune  response,  while  perivascular  
macrophages  reside  in  close  proximity  to  blood  vessels.    Neurons  use  electrical  impulses  to  
carry  out  the  information  processing  function  of  the  CNS,  controlling  both  cognitive  and  
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motor  functions.    Oligodendrocytes  generate  and  maintain  the  myelin  sheath  surrounding  
the  axons  of  neurons,  helping  to  support  efficient  transmission  of  electrical  signals  between  
neurons  (123).    
Neurotropic  viruses  can  differ  in  their  tropism,  route  of  entry,  and  mechanism  of  
spread.    Human  herpesvirus  6  and  JC  virus  primarily  target  oligodenrocytes,  while  
retroviruses  such  as  HIV-­‐‑1  and  Human  T  lymphotropic  virus  1  primarily  infect  
microglia/macrophages  and  astrocytes,  respectively.    Viruses  such  as  rabies  virus  (RV),  West  
Nile  virus  (WNV),  poliovirus,  adenovirus  and  cytomegalovirus  (CMV),  which  infect  
neurons,  are  more  likely  to  cause  fatal  diseases  as  these  cells  are  long-­‐‑lived  and  terminally  
differentiated.    Some  neurotropic  viruses,  such  as  RV  spread  from  neuron  to  neuron  via  
axonal  transport  (95).    Other  neurotropic  viruses,  such  as  poliovirus,  invade  the  CNS  by  
directly  infecting  BMVECs  within  the  BBB  (63),  while  measles  virus  and  lentiviruses  enter  
the  CNS  via  diapedesis  of  infected  leukocytes  (99,  128).  
The  clinical  manifestations  and  disease  severity  resulting  from  CNS  infection  can  
also  vary  between  neurotropic  viruses.    For  example,  RV  infection  of  neurons  and  the  
resulting  neuronal  impairment  is  100%  lethal  in  the  absence  of  early  treatment  (95)  and  PML  
caused  by  JC  virus  is  progressive  and  can  lead  to  death  within  months  if  a  patient  remains  
immunocompromised  (21).    Alternatively,  mumps  has  a  high  neuroinvasiveness  but  
neurological  disease  is  mild.  
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CNS COMPLICATIONS ASSOCIATED WITH HIV-1 INFECTION 
 
HIV-1-associated dementia 
The  consequences  of  HIV-­‐‑1  infection  of  the  CNS  have  been  well  documented  since  
the  beginning  of  the  epidemic  (213,  214,  302).    The  spectrum  of  HIV-­‐‑1-­‐‑associated  
neurocognitive  disorders  (HAND)  spans  from  minor  HIV-­‐‑1-­‐‑associated  minor  cognitive-­‐‑
motor  disorders  (MCMD)  to  the  more  severe  HAD  (31,  116,  117).    Clinically,  HAD  is  
characterized  by  motor  deficits  (leg  weakness,  unsteady  gait,  tremor,  and  loss  of  fine-­‐‑motor  
coordination),  cognitive  impairment  (mental  slowness,  forgetfulness  and  poor  
concentration),  and  behavior  abnormalities  (apathy,  lethargy,  withdrawal,  diminished  
emotional  responses,  and  sometime  psychosis  (214)),  significantly  impairing  an  individual’s  
ability  to  execute  daily  functions.    Histological  observation  of  brain  tissue  from  patients  with  
HAD  revealed  that  less  than  10%  of  the  brains  were  normal,  most  revealing  abnormalities  
including  perivascular  infiltrates  of  lymphocytes  and  macrophages  as  well  as  
multinucleated  giant  cells  (40,  117).      
Prior  to  HAART,  20-­‐‑30%  of  HIV-­‐‑1  infected  individuals  developed  dementia:  with  the  
introduction  of  HAART,  this  number  has  been  reduced  to  approximately  10%  of  infected  
adults  (116,  268).    The  insufficient  CNS  penetration  of  some  antiretroviral  drugs,  potentially  
enabling  HIV-­‐‑1  to  persist  within  the  CNS  throughout  infection  despite  therapy,  may  
contribute  to  the  continued  observation  of  severe  neurological  complications  (116,  243,  287).    
Additionally,  the  use  of  HAART  has  led  to  an  older  demographic  with  an  increased  
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susceptibility  to  HAD  (26,  149).    While  HAD  is  most  common  in  severely  immune-­‐‑
compromised  individuals,  individuals  can  be  diagnosed  with  dementia  prior  to  the  onset  of  




In  some  HIV-­‐‑1  infected  individuals  suffering  from  more  sever  neurological  
complications,  such  as  HAD,  significant  tissue  damage  can  occur,  leading  to  HIV-­‐‑1  
encephalitis  (HIVE).    This  neurodegenerative  condition  is  associated  with  productive  
infection  of  macrophages  and  microglia,  reactive  astrocytes,  as  well  as  damage  to  gray  and  
white  matter.    HIVE  brain  lesions  can  be  widespread  but  are  primarily  found  within  the  
corpus  callosum,  anterior  commissure,  basal  ganglia,  and  brainstem  within  the  white  matter  
(41).    While  HIVE  is  frequently  associated  with  HAD,  HIVE  refers  to  the  pathological  
features  identified  in  the  brain  and  not  the  clinical  syndrome;  therefore,  HIVE  can  occur  in  
the  absence  of  HAD.  
A  hallmark  of  HIVE  is  the  formation  of  microglial  nodules  containing  
multinucleated  giant  cells  (i.e.  syncytia)  during  chronic  inflammation,  resulting  from  the  
fusion  of  uninfected  and  infected  brain  resident  microglia/macrophages  (213,  294).    BBB  
abnormalities,  includin1  significant  tight  junction  disruption  and  accumulation  of  HIV-­‐‑1-­‐‑
infected  microglia/macrophages  in  the  brain  have  been  observed  in  brain  tissue  from  
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patients  with  HIVE  (68).    Microgliosis  and  astrogliosis  can  also  occur  in  HIVE  and  neuron  
damage  has  been  observed,  although  neurons  themselves  are  rarely  infected  (42,  43).    The  
neurodegeneration  associated  with  HIVE  has  also  been  linked  to  synaptic  loss  and  
dysfunction  that  culminates  in  neuronal  loss,  and  there  is  also  growing  interest  in  the  role  of  
cell-­‐‑cycle  proteins  such  as  p53,  pRb  and  E2F1  in  HIVE  (153).  
 
Mild-to-moderate HIV-1-associated neurocognitive disorders 
While  HAART  has  markedly  reduced  the  incidence  of  HAD,  the  prevalence  of  
milder  HAND,  including  asymptomatic  HIV-­‐‑1-­‐‑associated  neuropsychological  (NP)  
impairment  (ANI)  and  MCMD,  appears  to  have  increased  despite  treatment  (10,  96)  and  
affect  the  quality  of  life  for  infected  individuals  (269).    Several  factors  have  been  suggested  
to  account  for  the  consistently  high  rates  of  HAND  despite  HAART  including  irreversible  
brain  injury  prior  to  initiation  of  HAART,  neuronal  injury  or  dysfunction  due  to  a  
prolonged  CNS  inflammatory  response  to  persistent  CNS  viral  replication,  and  long-­‐‑term  
exposure  to  neurotoxic  viral  proteins  (134)  
Standardized  NP  testing  is  used  to  support  clinical  diagnosis  of  MCMD,  normalized  
for  age,  education  and  other  demographic  variables  (10).    Impairments  in  daily  activities  
such  as  employment,  medication  management,  and  driving  are  also  documented  (135).    The  
contributions  of  preexisting  comorbidities  including  drug  use,  depression,  learning  
disabilities,  previous  brain  trauma,  and  HCV  infection  must  also  be  considered  during  
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diagnosis  of  MCMD.    Neuroimaging  is  a  valuable  tool  for  characterizing  MCMD.    Proton-­‐‑
magnetic  resonance  spectroscopy  (MRS)  is  often  utilized,  a  noninvasive  imaging  method  
that  monitors  neuronal  injury  via  analysis  of  metabolite  abnormalities.    Additionally,  as  
MRS  has  generally  been  limited  to  clinical  studies,  there  has  been  an  increase  in  the  use  of  
blood  oxygen  level-­‐‑dependent  (BOLD)  functional  magnetic  resonance  imaging  to  evaluate  
HIV-­‐‑1  related  brain  dysfunction  (10).  
  
HIV-1 neurological complications in children 
Mother-­‐‑to-­‐‑child-­‐‑transmission  (MTCT)  can  occur  in  utero,  intrapartum,  or  postnatally  
through  breastfeeding.    In  the  absence  of  intervention,  a  25%  rate  of  MTCT  is  predicted  
based  on  numerous  studies  conducted  worldwide  (22),  affected  by  factors  such  as  maternal  
disease  status,  maternal  viral  loads,  vitamin  A  deficiencies,  and  placental-­‐‑membrane  
inflammation.    Neurodevelopmental  abnormalities  associated  with  HIV-­‐‑1  infection  have  
been  well  documented  in  children,  and  prior  to  the  advent  of  HAART,  upwards  of  50%  of  
infected  children  developed  neurological  impairment  and  encephalitis  (205,  327).    Pediatric  
neurological  complications  can  manifest  as  static  or  progressive  HIV-­‐‑1  encephalopathy  (22,  
59,  327,  329).    Clinical  signs  of  HIV-­‐‑1  encephalopathy  include  the  well-­‐‑described  classic  triad  
of  HIV-­‐‑1-­‐‑related  encephalopathy,  including  developmental  delays  (motor  and  expressive  
language),  acquired  microcephaly,  and  pyramidal  tract  motor  deficits  (23,  59).  
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Since  the  introduction  of  HAART,  the  incidence  of  encephalopathy  has  been  
significantly  reduced,  but  is  still  present  in  a  subset  of  children,  especially  during  the  first  
two  to  three  years  of  life  (327)  during  which  time  young  children  are  more  susceptible  to  
CNS  disease  compared  to  older  children  and  adolescents  (28,  88,  177).    HIV-­‐‑1  infection  in  
utero  increases  a  child’s  risk  for  neurodevelopmental  delay  and  encephalopathy  within  the  
first  30  months  of  life  (300).    After  the  first  two  years  of  infection,  the  incidence  of  
encephalopathy  in  children  compared  to  adults  is  similar,  indicating  that  in  contrast  to  
young  children  and  infants,  the  pathophysiology  of  CNS  disease  in  older  children  and  
adolescence  is  more  similar  to  what  has  been  observed  in  adults  (320).    HIV-­‐‑1  infection  in  
young  children  affects  an  immature  brain  and  as  a  result,  HIV-­‐‑1  CNS  disease  is  often  an  
AIDS-­‐‑defining  illness  (104,  329).  
    
CNS inflammatory response and CNS injury 
CNS  injury  and  neurodenegeration  can  be  due  to  several  factors  including  abnormal  
concentrations  of  CSF  biomarkers,  toxic  viral  proteins,  as  well  as  the  inflammation  resulting  
from  the  activation  of  CNS  immune  and  brain  resident  cells.    Neurofilament  light  chain  
(NFL),  a  structural  component  of  myelinated  axons,  and  amyloid-­‐‑beta  42,  a  component  of  
amyloid  plaques,  are  both  markers  for  neuronal  injury  and  are  associated  with  neurological  
disorders  such  as  Alzheimer  disease  (29,  112)  and  multiple  sclerosis  (218).    Both  are  elevated  
during  both  HAD  and  neuroasymptomatic  end-­‐‑stage  AIDS  (2,  113,  114).    Additionally,  both  
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can  be  elevated  during  primary  HIV-­‐‑1  infection,  corresponding  with  established  markers  of  
neuronal  injury,  suggesting  that  in  some  individuals,  neurodegeneraton  can  start  early  
(232).      
Pro-­‐‑inflammatory  cytokines  such  as  TNF-­‐‑α,  IFN-­‐‑γ,  IL-­‐‑1,  and  IL-­‐‑6  have  all  been  
shown  to  cause  neurotoxicity  (221),  and  TGF-­‐‑β  has  been  shown  to  cause  astrocytosis  (236)  
and  alter  BMVEC  permeability  (189,  204).    Additionally,  multiple  pro-­‐‑inflammatory  
cytokines  and  chemokines  such  as  MCP-­‐‑1,  IP-­‐‑10  and  M-­‐‑CSF  are  amplified  in  the  CSF  of  
HAD  patients  compared  to  neurologically  asymptomatic  patients  (235).    Additionally,  the  
increased  production  of  protanoids  by  infiltrating  immune  cells,  and  nitric  oxide  (NO),  a  
nitrogen  free  radical  produced  by  nitrogen  oxide  synthase  that  is  upregulated  on  activated  
microglia  and  astrocytes,  have  also  been  shown  to  contribute  to  neurodegeneration  in  HAD  
subjects  (176,  221).  
Numerous  studies  have  suggested  a  role  of  HIV-­‐‑1  proteins  as  neurotoxic  agents,  
including  Tat,  Vpr,  Nef  and  gp120.    These  viral  proteins  may  become  available  in  the  
extracellular  compartment  through  numerous  mechanisms  (212),  including  release  during  
cytopathic  infection  (i.e.  within  HIV-­‐‑1  infected  lymphocytes),  formation  of  defective  viral  
particles,  active  release  of  viral  proteins  (i.e.  HIV-­‐‑1  Tat  which  is  actively  secreted  (53)),  the  
shedding  of  the  viral  coat  (199),  and  interactions  with  viral  proteins  via  cell-­‐‑to-­‐‑cell  contacts.    
Tat,  Vpr,  and  gp120  have  all  been  measured  in  the  serum  of  HIV-­‐‑1  infected  individuals  (224,  
240,  334).    Once  released,  these  viral  proteins  can  interact  with  uninfected  cells  within  the  
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CNS,  causing  cellular  dysfunction  and  toxicity,  and  if  released  in  the  periphery,  can  often  
cross  the  BBB,  causing  neurotoxicity.    Both  Tat  (144)  and  gp120  (152)  can  be  found  by  




HIV-1 CNS compartmentalization is observed throughout the course of 
infection 
A  limitation  to  studying  viral  evolution  in  the  CNS  is  that  direct  sampling  of  HIV-­‐‑1  
in  brain  tissue  is  usually  possible  only  once,  at  biopsy  or  autopsy.    Therefore,  to  examine  
HIV-­‐‑1  viral  populations  in  the  CNS,  studies  often  rely  upon  repeated  sampling  of  virus  in  
the  CSF.    In  the  CSF  of  HIV-­‐‑1  infected  subjects,  it  is  possible  to  detect  CSF  virus  populations  
that  are  undergoing  independent,  or  compartmentalized  replication  (82,  132,  225,  238,  285).    
These  CSF  viral  populations  are  genetically  distinct  from  virus  in  the  periphery.    
Compartmentalized  CNS  populations  have  also  been  detected  using  autopsy  tissues  from  
HIV-­‐‑1  infected  patients  (164,  341).  
Compartmentalized  CNS  populations  can  be  detected  in  the  CSF  of  HIV-­‐‑1  infected  
individuals  throughout  the  course  of  infection.    Studies  using  both  heteroduplex  track  
assays  (HTA)  and  single  genome  amplification  (SGA)  have  shown  that  compartmentalized  
CSF  populations  can  be  detected  during  primary  infection  (132,  284),  suggesting  that  
compartmentalization  can  occur  early  and  in  the  absence  of  overt  neurological  symptoms.    
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Intermediate  levels  of  compartmentalization  have  been  associated  with  either  an  
asymptomatic  state  or  less  severe  forms  of  HAND  (132,  284),  while  extensive  CSF  
compartmentalization  has  been  shown  to  be  a  strong  indicator  of  pathogenesis  contributing  
to  HAD  (82,  132,  225,  239,  258,  313).    Compartmentalized  variants  have  also  been  detected  in  
the  brains  of  HAD  subjects  at  autopsy  (82,  83,  119,  225,  247,  262,  322).  
 
Compartmentalization versus clonal amplification 
Two  types  of  CNS  compartmentalization  have  been  observed.    The  first  involves  the  
independent  replication  of  a  viral  population  within  the  CNS,  or  significant  
compartmentalization,  characterized  by  high  diversity  and  indicative  of  a  prolonged  period  
of  isolated  replication.    These  more  complex  populations  can  enter  cells  using  low  levels  of  
CD4  and  are  presumably  replicating  in  macrophages  and/or  microglia  (283).    The  second  
form  of  CNS  compartmentalization  is  characterized  by  the  rapid  expansion  of  identical  or  
nearly  identical  variants,  generating  a  population  of  low  complexity  and  indicating  recent  
expansion  within  the  CNS.    This  less  complex  method  of  compartmentalization,  or  clonal  
amplification,  is  comprised  of  virus  that  requires  high  levels  of  CD4  for  entry,  presumably  
replicating  in  CD4+  T  cells  within  the  CNS.  
Clonal  amplification  has  been  detected  during  primary  infection  as  well  as  during  
chronic  HIV-­‐‑1  infection  (283,  284),  almost  exclusively  within  compartments  such  as  the  CNS  
as  it  is  detected  infrequently  in  the  blood  (241).    The  exact  source  of  clonally  amplified  virus  
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is  uncertain.    Clonal  amplification  is  often  associated  with  CSF  pleocytosis  indicative  of  an  
inflammatory  response,  potentially  providing  a  cellular  target  that  can  support  rapid  
expansion  of  an  HIV-­‐‑1  variant.    This  clonally  amplified  variant  may  have  only  recently  been  
transported  into  and  expanded  by  CD4+  T  cells  within  the  CNS,  or  the  influx  of  CD4+  T  cells  
may  support  the  rapid  expansion  of  a  compartmentalized  CNS  variant  already  replicating  
independently  within  the  CNS.      
 
HIV-1 compartmentalization in other biological compartments 
There  is  growing  interest  in  compartmentalization  in  other  biological  compartments  
besides  the  CNS.    Sexual  transmission  is  the  most  common  mode  of  HIV-­‐‑1  transmission  and  
HIV-­‐‑1  is  detected  in  the  male  genital  tract  (MGT)  seminal  plasma  as  well  as  in  the  female  
genital  tract  (FGT)  mucus  early  during  infection,  indicating  that  there  is  a  mechanism  for  
introducing  virus  into  genital  tract  secretions  (141,  241,  324).    One  study  analyzing  the  viral  
dynamics  between  the  peripheral  blood  and  semen  found  that  in  addition  to  the  direct  
import  of  virus  from  the  periphery,  resulting  in  genetically  similar  populations  between  the  
two  compartments,  clonal  amplification  as  well  as  significant  compartmentalization  could  
be  observed  within  the  seminal  tract  (11).    Separate  studies  analyzing  the  genetic  
relationship  between  virus  isolated  from  the  periphery  and  virus  isolated  from  cervical  
lavages  have  observed  both  clonal  amplification  and  significant  compartmentalization  
within  the  female  genital  tract  (Dukhovlinova  et  al.,  in  preparation)  (293).      
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While  still  controversial  due  to  the  lack  of  HIV-­‐‑1  receptor  and  coreceptor  expression  
on  REC,  studies  have  suggested  compartmentalization  can  occur  within  the  kidney  in  HIV-­‐‑1  
infected  patients  with  HIVAN  (39,  191).    HIV-­‐‑1  RNA  and  proviral  DNA  have  also  been  
detected  in  liver  biopsies  from  persons  with  HIV-­‐‑1  infection  (48,  77).  There  has  recently  
been  some  preliminary  evidence  to  suggest  that  compartmentalized  HIV-­‐‑1  populations  can  
be  detected  in  the  liver  of  infected  individuals,  suggesting  adaptation  to  the  liver  as  an  
isolated  compartment  for  HIV-­‐‑1  replication  (27).      
  
Compartmentalization and SIV 
Nonhuman  primate/Simian  immunodeficiency  virus  (SIV)  models  are  powerful  tools  
to  study  the  pathogenesis  of  HIV-­‐‑1,  including  compartmentalization.    Infections  using  
certain  strains  of  SIV  can  result  in  CNS  disorders,  such  as  viral  meningitis  and  encephalitis,  
and  the  Rhesus  macaque/SIV  model  of  CNS  infection  enables  sampling  of  CSF  throughout  
the  course  of  infection  and  allows  rapid  sampling  and  tissue  preservation  at  autopsy,  
thereby  removing  the  limitations  of  human/HIV-­‐‑1  infections  (46,  316).    Studies  have  
reported  SIV  infection  of  macrophage/microglia  in  the  CNS  (161,  339)  and  SIV  RNA/DNA  
has  been  isolated  from  both  CSF  and  brain  tissue  of  infected  macaques  (60,  267),  indicating  
that  SIV  infection  of  local  cells  in  the  CNS  occurs  during  the  course  of  infection.    
A  previous  study  analyzing  the  dynamics  of  SIV  populations  in  the  blood  and  CSF  
showed  that  discordant  CSF  populations  could  be  observed  in  SIVsm  E660  rhesus  macaque  
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infections  (130).    Additionally,  this  discordance  in  population  dynamics  was  associated  with  
elevated  MCP-­‐‑1  levels  and  increased  numbers  of  infiltrating  perivascular  macrophages,  a  
common  feature  of  SIV-­‐‑  and  HIV-­‐‑1-­‐‑associated  neurological  disease  (116,  166,  339,  346).    In  
contrast,  uninfected  macaques  or  macaques  with  concordant  viral  populations  between  the  
two  compartments  had  little  to  no  increase  in  MCP-­‐‑1  levels  or  infiltration  of  inflammatory  
cells  compared  to  baseline  levels.    Overall,  with  similar  population  dynamics  observed  in  
SIV  infection,  the  SIV  model  could  potentially  be  used  to  better  understand  CNS  disease  
over  the  full  course  of  infection.      
 
CNS compartmentalization: T cell versus macrophage tropism 
Within  the  periphery,  HIV-­‐‑1  decays  rapidly  following  initiation  of  HAART  (86,  142,  
234,  285,  331),  indicating  replication  in  a  short-­‐‑lived  cell  type,  such  as  CD4+  T  cells.    Within  
the  CNS,  some  virus  also  decays  rapidly  following  the  initiation  of  therapy,  while  others  
exhibit  a  slow  decay,  indicating  replication  in  a  long-­‐‑lived  cell  type  such  as  macrophages  
(86,  127,  131,  285).    This  rapid  decay  of  virus  (i.e.  T  cell  tropism)  has  been  observed  in  the  
CSF  of  asymptomatic  subjects,  while  genetically  compartmentalized  T  cell-­‐‑tropic  and  
macrophage-­‐‑tropic  HIV-­‐‑1  populations  have  been  shown  to  be  associated  with  neurological  
complications,  such  as  HAD,  in  adults  (283,  285).      
Therefore,  compartmentalized  HIV-­‐‑1  populations  within  the  CNS  can  be  either  
CCR5  (R5)-­‐‑using  T  cell-­‐‑tropic  or  macrophage-­‐‑tropic  (38,  118,  163,  237,  283).    Macrophage-­‐‑
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tropic  HIV-­‐‑1  variants  are  characterized  by  the  ability  to  infect  cells  with  low  CD4  surface  
expression  (119,  262,  322)  and  are  poorly  represented  in  the  blood  (241,  283).    Additionally,  
while  the  transmitted  variant  is  predominantly  R5-­‐‑tropic,  macrophage-­‐‑tropic  variants  are  
not  transmitted  (7,  148,  171,  223,  273).  
  
SIGNIFICANCE AND OBJECTIVES 
  
HIV-­‐‑1  infection  of  the  CNS  can  occur  shortly  after  transmission  (70,  238,  308),  and  
genetically  distinct,  compartmentalized  populations  have  been  detected  in  the  CSF  of  
infected  individuals  throughout  the  course  of  infection,  most  strongly  associated  with  HAD  
(132,  258).    Without  therapy  approximately  one-­‐‑third  of  those  infected  will  eventually  
progress  to  HAD  (31,  116).    While  cART  has  markedly  reduced  the  incidence  of  HAD,  the  
prevalence  of  milder  HAND  has  increased  despite  treatment  (10,  96).    Independent  
replication  in  the  CNS  may  also  represent  a  distinct  reservoir  from  that  found  in  the  blood  
and  lymphoid  tissue.    We  do  not  know  the  time  course  of  the  virologic  events  that  lead  to  
these  features,  or  the  extent  to  which  these  long-­‐‑term  outcomes  are  predicted  by  the  initial  
aspects  of  virus-­‐‑host  interaction.    The  main  objective  of  this  dissertation  is  to  characterize  
the  viral  genetic  determinants  associated  with  CNS  compartmentalization  early  following  
transmission,  since  developments  at  this  time  may  determine  the  subsequent  course  of  
neurocognitive  impairment  or  reservoir  establishment  within  the  CNS.      
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Several  areas  required  further  examination  to  expand  our  understanding  of  early  
CNS  pathogenesis.    First,  information  on  the  genetic  and  phenotypic  characteristics  of  HIV-­‐‑1  
within  the  CNS  of  infants  and  young  children  is  scarce.    Second,  while  extensive  research  
has  been  conducted  on  HIV-­‐‑1  subtype  B  CNS  infections,  little  is  known  about  CNS  
compartmentalization  of  HIV-­‐‑1  subtype  C  (the  most  common  subtype  worldwide)  or  the  
ability  of  HIV-­‐‑1  subtype  C  populations  to  evolve  to  use  low  levels  of  CD4  for  entry.    Third,  
while  studies  have  shown  that  HIV-­‐‑1  compartmentalization  can  occur  during  primary  
infection,  these  studies  were  limited  by  sample  size  and/or  by  the  use  of  less  sensitive  
approaches  to  study  compartmentalization:  thus,  a  more  comprehensive  analysis  is  needed.    
Finally,  studies  have  begun  to  examine  compartmentalization  in  an  SIV  model,  but  a  larger  
sample  size  and  more  sensitive  approaches  to  analyze  compartmentalization  are  needed  to  
make  more  generalizable  conclusions  regarding  the  viral  population  dynamics  in  the  CSF  
and  blood  during  SIV  infection.  
Overall,  using  tools  such  as  compartmentalization  and  entry  tropism  that  have  
helped  define  the  more  severe  stages  of  HIV-­‐‑1  neurological  involvement,  we  have  expanded  
our  understanding  of  the  subtype  B  and  C  virus/host  interactions  early  in  disease.    
Additionally,  this  examination  involved  three  subject  populations,  children,  adults,  and  
rhesus  macaques,  allowing  us  to  more  thoroughly  examine  the  viral  genetic  determinants  
associated  with  CNS  compartmentalization.        
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CHAPTER II. CENTRAL NERVOUS SYSTEM COMPARTMENTALIZATION OF 






HIV-­‐‑1  subtype  B  replication  in  the  CNS  can  occur  in  CD4+  T  cells  or  
macrophages/microglia  in  adults.    However,  little  is  known  about  CNS  infection  in  children  
or  the  ability  of  subtype  C  HIV-­‐‑1  to  evolve  macrophage-­‐‑tropic  variants.    In  this  study,  we  
examined  HIV-­‐‑1  variants  in  ART-­‐‑naïve  children  aged  three  years  or  younger  to  determine  
viral  genotypes  and  phenotypes  associated  with  HIV-­‐‑1  subtype  C  pediatric  CNS  infection.    
We  examined  HIV-­‐‑1  subtype  C  populations  in  blood  and  CSF  of  43  Malawian  children  with  
neurodevelopmental  delay  or  acute  neurological  symptoms.    Using  single  genome  
amplification  (SGA)  and  phylogenetic  analysis  of  the  full-­‐‑length  env  gene,  we  defined  four  
states:  equilibrated  virus  in  blood  and  CSF  (n=20,  47%),  intermediate  compartmentalization  
(n=11,  25%),  and  two  distinct  types  of  compartmentalized  CSF  virus  (n=12,  28%).    Older  age  
and  a  higher  CSF/blood  viral  load  ratio  were  associated  with  compartmentalization,  
                                                                                                              
1  This  chapter  previously  appeared  as  an  article  in  the  journal  PLoS  Pathogens.    The  original  citation  is  a  follows:  
C.B.  Sturdevant,  A.  Dow,  C.B.  Jabara,  S.B.  Joseph,  G.  Schnell,  N.  Takamune,  M.  Mallewa,  R.S.  Heyderman,  A.  
Van  Rie,  and  R.  Swanstrom.  Central  Nervous  System  Compartmentalization  of  HIV-­‐‑1  Subtype  C  Variants  Early  
and  Late  in  Infection  in  Young  Children.  PLoS  Pathog,  2012.  8(12):  p.  e1003094.    Athor  conributions  are  as  
follows:  conceived  and  designed  the  experiments,  CBS  AD  CBJ  SBJ  GS  MM  RSH  AVR  RS;  performed  the  
experiments,  CBS  AD  CBJ  SBJ  GS  NT  MM  RSH;  analyzed  the  data,  CBS  AD  CBJ  SBJ  GS  NT  MM  RSH  AVR  RS;  
wrote  the  paper,  CBS  AD  CBJ  SBJ  GS  NT  MM  RSH  AVR  RS.  
  
  51  
consistent  with  independent  replication  in  the  CNS.    Cell  tropism  was  assessed  using  
pseudotyped  reporter  viruses  to  enter  a  cell  line  on  which  CD4  and  CCR5  receptor  
expression  can  be  differentially  induced.    In  a  subset  of  compartmentalized  cases  (n=2,  17%),  
the  CNS  virus  was  able  to  infect  cells  with  low  CD4  surface  expression,  a  hallmark  of  
macrophage-­‐‑tropic  viruses,  and  intermediate  compartmentalization  early  was  associated  
with  an  intermediate  CD4  entry  phenotype.    Transmission  of  multiple  variants  was  
observed  for  5  children;  in  several  cases,  one  variant  was  sequestered  within  the  CNS,  
consistent  with  early  stochastic  colonization  of  the  CNS  by  virus.    Thus  we  hypothesize  two  
pathways  to  compartmentalization:  early  stochastic  sequestration  in  the  CNS  of  one  of  
multiple  variants  transmitted  from  mother  to  child,  and  emergence  of  compartmentalized  
variants  later  in  infection,  on  average  at  age  13.5  months,  and  becoming  fully  apparent  in  
the  CSF  by  age  18  months.    Overall,  compartmentalized  viral  replication  in  the  CNS  




Genetically  compartmentalized  human  immunodeficiency  virus  type  1  (HIV-­‐‑1)  
subtype  B  populations  can  be  variably  detected  in  the  cerebrospinal  fluid  (CSF)  of  adults.    
Compartmentalization  is  indicative  of  local  CNS  replication,  and  late  in  disease  is  linked  to  
HIV-­‐‑associated  dementia  (HAD).    Compartmentalized  viral  populations  can  comprise  either  
CCR5-­‐‑using  T  cell-­‐‑tropic  or  macrophage-­‐‑tropic  virus.    Little  is  known  about  CNS  infection  
in  children  or  the  ability  of  subtype  C  HIV-­‐‑1  to  evolve  macrophage-­‐‑tropic  variants.    We  
examined  viral  populations  in  the  blood  and  CSF  of  HIV-­‐‑1  subtype  C-­‐‑infected  children.    We  
found  an  intermediate  level  of  compartmentalization  in  about  half  of  the  children  under  18  
months  of  age.    About  50%  of  children  older  than  18  months  had  clearly  compartmentalized  
virus  in  the  CSF/CNS,  and  in  some  cases  CSF  virus  evolved  a  low  CD4  entry  phenotype.    In  
some  of  the  children  two  variants  were  transmitted  from  the  mother.    In  several  of  these  
cases  one  of  the  transmitted  viruses  was  replicating  in  the  CNS  while  the  other  was  found  
predominantly  in  the  blood/periphery.    Our  results  suggest  that  compartmentalized  
CSF/CNS  populations  can  be  detected  in  up  to  50%  of  children  by  year  three,  either  





Human  immunodeficiency  virus  type  1  (HIV-­‐‑1)  infection  of  the  central  nervous  
system  (CNS)  can  occur  shortly  after  transmission,  and  compartmentalized  HIV-­‐‑1  variants,  
genetically  distinct  from  the  virus  in  the  blood,  can  be  detected  in  the  cerebrospinal  fluid  
(CSF)  in  some  individuals  throughout  the  course  of  infection.    Detection  of  
compartmentalized  CSF  viral  populations  during  primary  infection  suggests  that  
compartmentalization  can  occur  early  in  the  absence  of  overt  neurological  symptoms  (284).    
Extensive  compartmentalization  of  HIV-­‐‑1  has  been  shown  to  be  a  strong  indicator  of  HIV-­‐‑1  
neuropathogenesis  contributing  to  HIV-­‐‑1-­‐‑associated  dementia  (HAD)  (82,  132,  225,  258),  
while  intermediate  levels  of  compartmentalization  are  associated  with  either  an  
asymptomatic  state  or  less  severe  forms  of  HIV-­‐‑1-­‐‑associated  neurological  disease  (132,  284).    
Although  a  longitudinal  link  has  not  been  made,  these  results  raise  the  possibility  that  early  
detection  of  compartmentalized  CSF  variants  may  identify  subjects  with  a  higher  risk  of  
developing  HIV-­‐‑1-­‐‑associated  neurological  complications.    
Compartmentalized  HIV-­‐‑1  subtype  B  CNS  populations  can  be  either  CCR5  (R5)-­‐‑
using  T  cell-­‐‑tropic  or  macrophage-­‐‑tropic  (38,  118,  163,  237,  283).    Macrophage-­‐‑tropic  HIV-­‐‑1  
variants  are  characterized  by  the  ability  to  infect  cells  with  low  CD4  surface  expression  (119,  
262,  322),  are  poorly  represented  in  the  blood  (283),  are  not  transmitted  (7,  273),  and  decay  
slowly  following  initiation  of  highly  active  antiretroviral  therapy  (HAART)  (127,  285),  
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unlike  the  rapid  decay  of  virus  replicating  in  activated  CD4+  T  cells  within  the  blood  (142,  
285,  331).    While  extensive  research  has  been  conducted  on  HIV-­‐‑1  subtype  B  CNS  infections,  
little  is  known  about  CNS  compartmentalization  of  HIV-­‐‑1  subtype  C  (the  most  common  
subtype  worldwide)  or  the  ability  of  HIV-­‐‑1  subtype  C  to  evolve  to  use  low  levels  of  CD4  for  
entry.    Previous  studies  have  reported  significant  differences  in  the  subtype  B  and  C  
envelope  glycoproteins  and  suggested  that  subtype  C  may  be  less  neuropathogenic  than  
subtype  B  (251,  257,  278).    Additional  studies  on  HIV-­‐‑1  subtype  C  CNS  infections  are  needed  
to  improve  our  knowledge  on  HIV-­‐‑1  subtype  C  pathogenesis,  CNS  compartmentalization  
and  entry  tropism.    
Information  on  the  genetic  and  phenotypic  characteristics  of  HIV-­‐‑1  within  the  CNS  
of  infants  and  young  children  is  scarce.    HIV-­‐‑1  CNS  disease  is  often  an  AIDS-­‐‑defining  illness  
in  children  (104,  327,  329),  and  this  implies  that  early  infection  of  the  CNS  may  be  important  
in  the  pathogenesis  of  HIV-­‐‑1  infection  in  infants  (327).    Understanding  the  dynamics  of  
pediatric  HIV-­‐‑1  CNS  replication  is  thus  of  critical  importance.    We  examined  HIV-­‐‑1  variants  
in  43  ART-­‐‑naïve  Malawian  children  aged  three  years  or  younger  to  determine  the  viral  
genotypes  and  phenotypes  associated  with  HIV-­‐‑1  subtype  C  pediatric  CNS  infection.    We  
observed  intermediate,  minor  compartmentalization  in  25%  and  distinct,  
compartmentalized  CSF  variants  in  28%  of  children.    Older  age  and  a  higher  CSF/blood  viral  
load  ratio  were  associated  with  CNS  compartmentalization,  with  genetic  evidence  
suggesting  outgrowth  of  the  compartmentalized  variant  starting  at  around  13  months  of  
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age.    Transmission  of  multiple  variants  had  occurred  in  5  children,  of  which  4  had  one  
variant  sequestered  within  the  CNS,  consistent  with  early  stochastic  colonization  of  the  CNS  
by  the  virus.    Finally,  we  showed  that  genetically  compartmentalized  R5  virus  with  the  
ability  to  infect  cells  with  low  CD4  surface  expression,  a  hallmark  of  macrophage-­‐‑tropic  
viruses,  can  evolve  in  HIV-­‐‑1  subtype  C  CNS  infection  in  young  children,  although  this  was  
not  common  in  the  first  three  years  of  life.    Overall  we  found  that  by  3  years  of  age,  50%  of  





We  examined  viral  populations  in  paired  peripheral  blood  and  CSF  samples  
collected  from  43  HIV-­‐‑infected  Malawian  children  presenting  with  either  
neurodevelopmental  delay  or  acute  neurologic  symptoms  (neurodevelopmental  delay  will  
be  examined  in  a  separate  study).    Subjects  were  infected  with  HIV-­‐‑1  subtype  C,  were  ART  
naïve,  and  ranged  in  age  from  3  to  35  months.    Blood  viral  loads  ranged  from  4,344  to  
>80,000,000  copies/mL.  and  CSF  viral  loads  ranged  from  56  to  4,745,000  copies/mL.    The  
virological  characteristics  for  each  subject  are  summarized  in  Table  1.    Infection  is  assumed  
to  be  by  a  vertical  route  but  the  fractions  infected  prepartum,  intrapartum,  or  postpartum  
are  not  known.    To  asses  HIV-­‐‑1  genetic  compartmentalization,  cDNA  templates  were  
generated  from  extracted  blood  and  CSF  viral  RNA  and  used  in  single  genome  
amplification  (SGA)  of  the  full-­‐‑length  viral  env  gene  (3,  158,  228,  272,  297).    A  mean  of  19  
amplicons  were  analyzed  per  sample.    The  sequence  of  the  entire  env  gene  was  determined  
for  each  amplicon  and  phylogenetic  analysis  was  completed.  
Compartmentalization  was  assessed  visually  and  statistically  using  the  Slatkin-­‐‑
Maddison  test  (298).    CNS  compartmentalization  was  defined  by  a  Slatkin-­‐‑Maddison  P  
value  <0.05  and  a  genetically  distinct  CSF  population  with  a  bootstrap  value  ≥40;  we  used  a  
relatively  low  bootstrap  value  in  this  exploratory  analysis  because  of  the  overall  low  
  57  
diversity  of  the  viral  population  in  these  children.    Intermediate  populations  were  defined  
by  a  Slatkin-­‐‑Maddison  P  value  >0.05  but  with  visual  evidence  of  a  minor  CSF  subpopulation  
of  ≥  4  CSF  amplicons  and  a  bootstrap  value  ≥  40.    Equilibrated  populations  were  defined  by  
a  Slatkin-­‐‑Maddison  P  value  >0.05  and  no  evidence  of  a  minor  or  major  CSF  population  
(Table  1).      
Phylogenetic  trees  were  also  examined  for  clonal  amplification.    Clonally  amplified  
lineages  were  defined  as  having  short  branch  lengths  in  the  neighbor-­‐‑joining  phylogenetic  
tree  with  bootstrap  values  ≥  99  and  a  clade  of  ≥  3  variants.    These  lineages  signify  the  recent  
amplification  of  identical  or  nearly  identical  variants.  
  
Relationship of viral populations in blood and CSF 
Twenty  out  of  43  subjects  (46%)  had  equilibrated  viral  populations  in  their  blood  and  
CSF  (Table  1  and  Figure  1A).    For  these  subjects,  sequences  from  the  two  compartments  
were  well  mixed  and  the  CSF  sequences  were  not  genetically  distinct  from  those  of  the  
blood.    Two  of  these  subjects  did,  however,  display  evidence  of  minor  clonal  amplification  
in  the  CSF.    
In  11  out  of  43  subjects  (26%),  an  intermediate  condition  existed  where  the  peripheral  
blood  and  CSF  HIV-­‐‑1  populations  were  not  uniformly  equilibrated  and  contained  a  minor  
CSF  subpopulation  (Table  1  and  Figure  1B).    Six  of  these  intermediate  subjects  displayed  
evidence  of  clonal  amplification.    We  hypothesize  that  the  minor  CSF  population  may  
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indicate  a  precursor  population  within  the  CNS  with  the  potential  to  expand  into  a  
compartmentalized  population  as  infection  progresses  (see  relationship  with  age  below).  
Significant  genetic  compartmentalization  was  detected  between  the  blood  and  CSF  
populations  in  12  out  of  43  subjects  (28%)  (Table  1  and  Figure  1C)  indicating  the  presence  of  
an  independent,  autonomously  replicating  viral  population  within  the  CNS.    In  these  
subjects,  the  virus  in  the  CSF  was  genetically  distinct  from  the  virus  in  the  blood.    In  5  
compartmentalized  subjects,  evidence  of  clonal  amplification  was  observed.    Therefore,  
within  the  first  three  years  of  HIV-­‐‑1  subtype  C  pediatric  infection,  significant  genetic  
compartmentalization  can  be  observed.  
  
Compartmentalization is significantly related to older age and a higher 
CSF/blood viral load ratio 
Relationships  between  subject  characteristics  and  compartmentalization  were  
assessed  using  the  Mann-­‐‑Whitney  test.    Older  children  were  more  likely  to  have  
compartmentalized  CSF  variants  when  compared  to  equilibrated  (P=0.05)  and  intermediate  
subjects  (P=0.005)  (Figure  2A).    As  the  majority  of  vertical  transmission  occurs  early,  either  
in  utero,  at  delivery  or  during  the  first  months  of  breast  feeding  (4),  older  age  provides  a  
longer  period  of  time  for  viral  variants  to  become  established  within  the  CSF.    No  
relationship  was  observed  between  the  blood  and  CSF  viral  loads  and  subject  classifications  
(Figure  3).    However,  a  higher  CSF/blood  viral  load  ratio  was  significantly  related  to  
compartmentalization  when  compared  to  equilibrated  (P=0.02)  or  intermediate  subjects  
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(P=0.001)  (Figure  2B),  consistent  with  the  occurrence  of  local  replication  and  expansion  of  
viral  populations  within  the  CNS  independent  from  the  peripheral  blood.    Thus,  
compartmentalization  most  often  appears  subsequent  to  transmission  and  is  associated  with  
a  higher  CSF/blood  viral  load  ratio,  representing  virus  produced  locally  in  the  CNS.  
  
Evolutionary history of viral populations within the first three years of life 
Bayesian  Evolutionary  Analysis  by  Sampling  Trees  (BEAST)  (78)  was  used  to  
estimate  the  time  to  most  recent  common  ancestor  (TMRCA)  of  the  entire  viral  populations  
and  the  compartmentalized  populations  (Table  1).    For  the  majority  of  the  subjects,  
transmission  was  predicted  to  have  occurred  at  birth  ±  6  months,  as  shown  by  the  good  
concordance  between  the  TMRCA  and  the  age  of  the  child  at  the  time  of  sampling  (Figure  
4A).    For  5  subjects,  the  predicted  TMRCA  was  substantially  higher  than  the  age  of  the  child,  
which,  based  on  further  analysis  (discussed  below),  was  probably  due  to  multiple  
transmitted  viruses.  
As  the  majority  of  subjects  were  probably  infected  at  or  around  the  time  of  birth,  we  
were  able  to  depict  the  occurrence  of  compartmentalization  as  a  function  of  time  (Figure  4B).    
Before  age  18  months,  the  populations  in  half  the  children  were  equilibrated,  with  more  
intermediate  populations  than  compartmentalized  in  the  remaining  half.    After  age  18  
months,  about  half  of  the  children  continued  to  have  equilibrated  populations  while  in  the  
remainder,  compartmentalized  populations  were  now  much  more  prevalent  than  
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intermediate  populations.    These  data  further  support  a  potential  transition  over  time  in  
one-­‐‑half  of  the  children  to  increasing  CNS  compartmentalization  in  the  absence  of  
antiretroviral  therapy.    
  
Evidence of multiple transmitted variants 
For  5  subjects  for  whom  the  predicted  TMRCA  was  substantially  greater  than  the  
age  of  the  subject  (Figure  4A),  further  analysis  revealed  the  presence  of  multiple  transmitted  
viruses  (Table  1).    For  one  compartmentalized  subject  (3002;  age  5  months),  phylogenetic  
analysis  revealed  a  deep  bifurcation  separating  two  distinct  viral  populations,  one  
comprised  almost  exclusively  of  CSF  variants,  and  the  other  comprised  primarily  of  blood  
variants  (Figure  5A).    Sequence  analysis  demonstrated  that  the  viral  populations  were  
genetically  distinct  and  had  minimal  recombination  (Figure  5B).    The  overall  TMRCA  was  
52  months,  while  the  TMRCAs  for  the  distinct  plasma  and  CSF  populations  were  6  and  8  
months,  respectively.    Together,  these  results  indicate  that  the  mother  likely  transmitted  two  
genetically  distinct  viruses  to  the  child,  and  one  variant  was  sequestered  within  the  CNS  
while  the  other  was  maintained  within  the  periphery.    A  multiple  variant  transmission  
event  was  observed  in  one  additional  compartmentalized  subject  (Figure  6),  two  
intermediate  subjects  (Figure  7  and  8)  as  well  as  one  equilibrated  subject  (Figure  9).    For  the  
compartmentalized  and  intermediate  subjects,  one  virus  was  sequestered  within  the  CNS.    
For  the  equilibrated  subject,  both  transmitted  variants  expanded  within  the  blood  and  CSF.    
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These  data  suggest  that  some  variants  can  get  selectively  established  in  the  CNS  early  after  
transmission.  
  
Evolution of CSF viruses to infect cells with low levels of CD4 surface 
expression 
Macrophage  tropism  of  HIV-­‐‑1  is  associated  with  the  ability  to  infect  cells  expressing  
low  levels  of  CD4  (119,  262,  322),  while  R5  T  cell-­‐‑tropic  viruses  infect  these  cells  very  poorly  
and  require  high  levels  of  CD4  to  enter  cells  (142,  331).    However,  different  preparations  of  
macrophages  vary  significantly  in  their  ability  to  be  infected  due  to  differing  levels  of  CD4  
in  separate  preparations  of  monocyte-­‐‑derived  macrophages  (MDM)  (Joseph  et  al.,  in  
preparation).    To  avoid  this  confounding  variability,  we  have  turned  to  a  cell  line  that  has  
regulatable  levels  of  CD4  and  CCR5,  i.e.  293-­‐‑Affinofile  cells  (151).    Entry  phenotype  was  
assessed  by  measuring  the  ability  of  pseudotyped  reporter  viruses  to  enter  cells  expressing  
either  high  or  low  levels  of  CD4.    Viruses  pseudotyped  with  Env  proteins  derived  from  
virus  in  equilibrated  subjects  were  only  able  to  infect  Affinofile  cells  with  high  CD4  surface  
expression  and  were  considered  R5  T  cell-­‐‑tropic  (Figure  10A).    Viruses  pseudotyped  with  
Env  proteins  derived  from  virus  in  intermediate  subjects  were  also  only  able  to  infect  cells  
expressing  high  levels  of  CD4  which  we  infer  defines  R5  T  cell  tropism  (Figure  10B).    A  
partially  evolved  entry  phenotype  was  observed  in  subjects  4007  and  4013,  where  CSF  
variants  were  able  to  infect  cells  with  low  CD4  at  modest  levels,  potentially  identifying  a  
precursor  population  to  the  low  CD4  entry  phenotype.    Examples  of  viruses  with  a  low  CD4  
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entry  phenotype  were  observed  in  two  compartmentalized  subjects  (4049  and  4058)  (Figure  
10C).    For  both  of  these  subjects,  only  the  Env-­‐‑pseudotyped  viruses  derived  from  the  
compartmentalized  CSF  population,  not  virus  from  the  blood,  were  able  to  infect  cells  with  
low  CD4  surface  expression.    These  results  indicate  that  subtype  C  HIV-­‐‑1  viruses  with  a  low  
CD4  entry  phenotype  can  be  detected  in  the  CSF  of  children,  but  this  is  not  a  common  
occurrence  within  the  first  three  years.    Thus,  we  hypothesize  that  in  most  children  
replication  in  the  CNS  is  sustained  by  growth  in  T  cells,  while  in  a  subset  (10-­‐‑20%  of  
children  with  CNS  compartmentalized  virus)  the  virus  evolves  to  replicate  in  cells  with  low  




Our  study  design  involves  cross-­‐‑sectional  sampling  and  thus  has  several  limitations,  
especially  with  regard  to  inferring  temporal  relationship.    However,  there  is  a  wide  
distribution  of  ages  of  the  subjects  within  the  enrollment  criteria  allowing  us  to  compare  
between  different  age  groups  and  to  draw  correlations  based  on  age.    Also,  the  virus  carries  
the  history  of  longitudinal  evolution  in  its  sequence,  thus  allowing  us  to  infer  dates  of  
bottlenecks  in  the  history  of  viral  replication.    While  cross-­‐‑sectional  analyses  are  inherently  
limited,  we  have  some  basis  for  suggesting  temporal  relationships  in  the  observed  
phenomenon.    Based  on  our  results  we  hypothesize  four  distinct  states  to  describe  the  
relationship  between  virus  in  the  CSF/CNS  and  virus  in  the  blood/periphery.    The  first  state  
has  no  genetic  evidence  for  HIV-­‐‑1  replication  in  the  CNS,  wherein  the  only  virus  detected  in  
the  CSF  is  genetically  similar  to  that  in  the  blood  and  is  typically  present  at  1%  or  lower  of  
the  level  in  the  blood,  possibly  due  to  some  import  or  spill  pathway  from  the  blood  into  the  
CSF.    The  second  state  occurs  prior  to  18  months  of  age  and  involves  minor  
compartmentalization  of  the  CSF  viral  population,  suggesting  some  local  replication  in  the  
CSF/CNS  but  not  to  a  level  where  the  viral  load  increases  in  the  CSF.    In  10-­‐‑20%  of  these  
children  there  is  evidence  for  the  initial  evolution  of  virus  that  can  use  lower  levels  of  CD4,  
potentially  on  a  path  to  becoming  macrophage-­‐‑tropic.    The  third  state  occurs  in  about  half  of  
the  children  older  than  18  months  of  age,  and  in  this  state  the  viral  population  in  the  CSF  
  64  
shows  strong  evidence  of  genetic  compartmentalization,  indicative  of  local  replication  and  
evolution  within  the  CNS.    This  is  also  accompanied  by  a  higher  relative  viral  load  in  the  
CSF  due  to  the  local  production  of  virus  well  above  the  low  level  that  is  imported  from  the  
periphery.    In  about  10-­‐‑20%  of  the  children  with  compartmentalized  virus  in  the  CSF,  we  
identified  variants  that  had  evolved  to  use  low  levels  of  CD4,  which  we  presume  indicates  
that  the  virus  was  now  growing  in  macrophages  and/or  microglia  within  the  CNS.    The  
fourth  state  involves  multiple  variant  transmissions  from  mother  to  infant  of  which  one  
variant  preferentially  replicates  in  the  CNS  and  another  replicates  in  the  periphery.    As  HIV-­‐‑
1  replication  in  the  CNS  can  contribute  to  neurological  disease,  further  research  should  
determine  whether  the  ability  to  detect  different  states  of  CSF  viral  populations  within  the  
CNS  of  young  children  could  guide  strategies  to  monitor  and  prevent  neurodevelopmental  
disorders  in  HIV-­‐‑infected  children.  
Vertically  transmitted  viruses  are  often  highly  homogeneous,  representing  infection  
seeded  by  a  single  variant  and  characterized  by  low  diversity  (5,  210,  264,  279).    We  
identified  five  infants  who  appeared  to  be  infected  with  multiple  variants,  with  the  viral  
populations  in  the  remaining  infants  having  a  phylogenetic  age  consistent  with  the  age  of  
the  infant,  which  we  assume  indicates  infection  with  a  single  variant.    Surprisingly,  in  four  
of  the  five  infants  infected  with  multiple  variants,  one  of  the  variants  was  largely  
sequestered  in  the  CNS/CSF.    For  this  to  occur,  either  one  of  the  transmitted  variants  had  a  
selective  tropism  for  the  CNS,  or  infection  of  the  CNS  was  a  low  probability  event  
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influenced  by  the  chance  introduction  of  a  founder  virus.    Alternatively,  since  the  CNS  is  a  
somewhat  immune-­‐‑privileged  site,  the  absence  of  the  sequestered  virus  in  the  periphery  
may  be  due  to  selection  by  maternal  antibodies  or  the  initial  infant  immune  response  in  that  
compartment.    All  of  the  env  genes  tested  from  three  of  these  subjects  (3002,  3017,  and  4002;  
see  Figure  10)  showed  that  the  pseudotyped  viruses  required  high  levels  of  CD4  to  enter  
cells,  i.e.  were  R5  T  cell-­‐‑tropic.    In  our  previous  work  we  found  multiple  variants  in  
approximately  30%  of  infants  infected  vertically  (264),  which  is  not  substantially  different  
from  the  number  found  here.    The  sequestration  of  virus  in  the  CNS  shortly  after  
transmission  suggests  that  inferring  the  number  of  transmitted  variants  based  on  the  
complexity  of  virus  in  the  blood  may  result  in  an  underestimate  of  the  frequency  of  
transmission  of  multiple  variants.  
We  can  infer  several  other  features  of  compartmentalization  by  comparing  the  age  of  
the  infant  to  the  inferred  age  of  the  viral  population  using  BEAST  for  those  infants  infected  
with  a  single  variant.    In  the  remaining  10  infants  with  compartmentalization  who  were  
infected  with  a  single  variant,  the  age  of  the  CSF/CNS  compartmentalized  viral  population  
was  significantly  less  than  the  age  of  the  entire  viral  population  when  compared  to  the  age  
of  the  infant  (P=0.002;  Wilcoxon  signed  rank  test).    In  these  cases  it  appears  that  
compartmentalization  is  established  after  the  initial  stages  of  infection,  with  the  
compartmentalized  virus  emerging  on  average  at  13.5  months  but  with  outgrowth  in  the  
CNS  only  becoming  apparent  in  the  CSF  approximately  18  months  after  birth.    Thus  we  can  
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identify  two  distinct  pathways  to  compartmentalization:  early  sequestration  of  a  transmitted  
virus  in  the  CNS,  or  the  later  establishment  of  independently  replicating  virus  that  
originates  in  the  periphery.    The  compartmentalized  lineage  in  the  intermediate  group  
appeared  earlier  after  birth  (mean  5.1  months)  compared  to  the  compartmentalized  lineage  
in  the  compartmentalized  group  (mean  13.5  months)  (P=0.008;  Mann-­‐‑Whitney  test).    This  
may  be  an  indication  that  the  intermediate  state  represents  susceptibility  to  viral  replication  
in  the  CNS  but  that  there  is  a  subsequent  bottleneck  that  defines  the  CNS  population.  
Genetically  compartmentalized  R5  T  cell-­‐‑tropic  and  macrophage-­‐‑tropic  HIV-­‐‑1  
subtype  B  populations  have  been  shown  to  be  associated  with  neurological  complications  in  
adults  (283).    The  macrophage-­‐‑tropic  populations  were  genetically  diverse,  representing  
established  CNS  infections,  while  the  R5  T  cell-­‐‑tropic  populations  were  clonally  amplified  
and  associated  with  pleocytosis  (283).    Macrophage-­‐‑tropic  HIV-­‐‑1  variants  are  generally  
characterized  by  the  ability  to  infect  cells  with  low  CD4  surface  expression  (119,  262,  322).    
However,  infection  using  MDM  from  healthy  donors  is  highly  variable,  and  the  variability  
is  correlated  with  different  levels  of  CD4  (Joseph  et  al.,  in  preparation).    For  this  reason,  it  is  
more  quantitative  to  use  a  cell  line  where  the  levels  of  CD4  are  regulatable  and  
reproducible.    Thus  we  have  used  Affinofile  cells  (151)  as  a  surrogate  for  the  entry  
phenotype  of  viruses  able  to  use  low  levels  of  CD4  versus  those  requiring  high  levels  of  
CD4.    Our  results  demonstrated  that  compartmentalized  R5  T  cell-­‐‑tropic  and  what  we  infer  
to  be  macrophage-­‐‑tropic  populations  can  also  be  found  in  the  CSF  of  children  infected  with  
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HIV-­‐‑1  subtype  C.    A  partial  entry  phenotype  was  observed  in  two  intermediate  subjects;  we  
hypothesize  that  this  is  evidence  for  the  initial  evolution  of  virus  that  can  use  lower  levels  of  
CD4,  potentially  on  a  path  to  becoming  macrophage-­‐‑tropic.    
Viral  replication  in  the  CNS  results  in  the  local  production  of  inflammatory  and  
neuronal  destruction  molecules  such  as  monocyte  chemoattractant  protein  (MCP-­‐‑1),  
neopterin,  IP-­‐‑10,  and  neurofilament  light  subunit  (NFL).    Production  of  these  inflammatory  
markers  has  been  observed  in  animal  models  (130,  184)  and  has  been  linked  to  HIV-­‐‑1-­‐‑
associated  neurocognitive  damage  in  adults  (58,  85,  129).    The  potential  for  long  term  
neurocognitive  damage  in  children  as  a  result  of  HIV-­‐‑1-­‐‑associated  production  of  
inflammatory  markers  within  the  CNS,  our  findings  of  compartmentalized  viral  replication  
with  viral  lineage  established  at  13.5  months  on  average,  and  the  ability  of  a  transmitted  
variant  to  become  sequestered  in  the  CNS  shortly  after  transmission  adds  further  
justification  to  the  policy  of  early  initiation  of  antiretroviral  treatment  in  children,  in  this  
case  as  part  of  an  effort  to  prevent  the  establishment  of  compartmentalized  viral  
populations  that  may  contribute  to  neurological  complications.    
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MATERIALS AND METHODS 
  
Study subject population 
The  study  was  approved  by  the  Institutional  Review  Boards  of  the  University  of  
North  Carolina  at  Chapel  Hill  and  the  University  of  Malawi  College  of  Medicine  in  
Blantyre.    Permission  to  participate  in  the  research  study  was  obtained  for  all  children  
through  written  informed  consent  by  the  caregiver.    All  subjects  included  in  this  study  were  
HIV-­‐‑1  subtype  C-­‐‑infected  children  between  3  and  35  months  of  age.    HIV-­‐‑1  infection  was  
verified  at  time  of  enrollment  by  a  positive  PCR  for  HIV  DNA/RNA  if  <18  months  of  age  or  
two  positive  rapid  HIV  antibody  tests  after  age  18  months.    Samples  were  collected  at  a  one  
pre-­‐‑HAART  baseline  visit  for  all  subjects.    CSF  and  blood  plasma  samples  were  used  for  
viral  genetic  compartmentalization  and  env  protein  phenotypic  analyses.    Blood  plasma  and  
CSF  HIV-­‐‑1  viral  loads  (copies/mL)  were  determined  by  the  UNC  Chapel  Hill  Center  for  
AIDS  Research  Virology  Core.  
  
Single genome amplification 
Subtype  C  HIV-­‐‑1  RNA  was  isolated  from  blood  plasma  and  CSF  samples  as  
previously  described  (285).    Briefly,  viral  RNA  was  isolated  from  blood  plasma  and  CSF  
samples  (140  µμL)  using  the  QIAmp  Viral  RNA  Mini  kit  (Qiagen).    Prior  to  RNA  isolation,  all  
blood  plasma  and  CSF  samples  were  pelleted  (0.1–0.5  mL)  by  centrifugation  at  25,000xg  for  
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1.5  hours  at  4oC  to  increase  template  number  and  improve  sampling.    Purified  viral  RNA  
(10-­‐‑50  µμl)  was  reverse  transcribed  using  Superscript  III  Reverse  transcriptase  (Invitrogen)  
and  an  oligo-­‐‑d(T)  primer  according  to  the  manufacturer’s  instructions.    Single  genome  
amplification  (SGA)  of  the  full-­‐‑length  HIV-­‐‑1  env  gene  through  the  3’  LTR  U3  end  was  
conducted  as  previously  described  (272).    Briefly,  cDNA  was  endpoint  diluted  and  nested  
PCR  was  completed  using  Platinum  Taq  High  Fidelity  polymerase  (Invitrogen)  and  the  
primers  Vif1  (272)  and  2.R3.B6R  (5'ʹ-­‐‑TGAAGCACTCAAGGCAAGCTTTATTGAGGC-­‐‑3'ʹ;  nt  
9607  to  9636),  and  EnvA  (272)  and  Low2c  (5'ʹ-­‐‑TGAGGCTTAAGCAGTGGGTTCC-­‐‑3'ʹ;  nt  9591  
to  9612),  were  used  for  the  first  and  second  rounds  of  PCR,  respectively.    PCR  amplicons  
were  sequenced  from  the  start  of  env  through  env  gp41,  gp160  end  (HXB2  numbering  of  
positions  6110-­‐‑8833).    Chromatograms  with  double  peaks,  indicating  amplification  from  
more  than  one  cDNA  template,  as  well  as  sequences  with  frameshift  mutations  resulting  in  
premature  stop  codons,  were  excluded  from  analysis.  
  
Phylogenetic analysis of env viral sequences 
DNA  sequences  alignments  of  env  genes  were  performed  using  ClustalW  (323).    
Sequences  for  each  subject  were  codon  aligned  (MEGA  4.0)  and  phylogenetic  trees  were  
generated  using  neighbor-­‐‑joining  method  (MEGA  4.0)  (319).    Compartmentalization  of  viral  
sequences  was  assessed  using  the  Slatkin-­‐‑Maddison  test  (298)  available  through  HyPhy  




A  Bayesian  Markov  Chain  Monte  Carlo  (MCMC)  approach,  as  implemented  in  
BEAST  v.1.6.1  (78),  estimated  TMRCA  for  each  patient  sample.      A  substitution  rate  of  
3.5x10-­‐‑5  substitutions/site/generation  was  fixed  under  a  strict  clock  model,  as  determined  by  
calculation  of  inter-­‐‑patient  percent  difference  in  the  plasma  nucleotide  sequence.    The  HKY  
nucleotide  substitution  model  had  estimated  base  frequencies  and  a  gamma-­‐‑distributed  rate  
heterogeneity  (4  gamma  categories).    A  coalescent  Bayesian  Skyline  tree  prior  with  a  
Piecewise-­‐‑constant  skyline  model  was  used  (4  groups).    The  MCMC  algorithm  was  run  for  
30  million  generations,  logging  every  1000  and  with  a  10%  burn-­‐‑in.    The  results  from  at  least  
two  independent  runs  were  combined,  and  the  effective  sample  size  for  all  estimates  was  
>200.    A  generation  time  of  1.5  days  was  used  for  estimation  of  time  to  the  MRCA  (190).  
  
Construction of HIV-1 env clones 
SGA  amplicons,  selected  based  on  the  subject’s  phylogenetic  tree  structure,  were  re-­‐‑
amplified  from  the  first-­‐‑round  nested  PCR  product  using  the  Phusion  hot  start  high-­‐‑fidelity  
DNA  polymerase  (Finnzymes)  and  the  primers  EnvAClon  (5'ʹ  
CACCGGCTTAGGCATCTCCTGTGGCAGGAAGAA-­‐‑3'ʹ;  nt  5950-­‐‑5982)  and  EnvN  (272)  
following  the  manufacturer’s  instructions.    HIV-­‐‑1  env  amplicons  were  then  gel  purified  
using  the  Qiagen  gel  extraction  kit  (QIagen).    Purified  HIV-­‐‑1  env  genes  (50ng)  were  cloned  
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into  the  pcDNA3.1D/V5-­‐‑His-­‐‑TOPO  expression  vector  (invitrogen)  using  the  pcDNA  3.1  
directional  TOPO  expression  kit  (Invitrogen)  and  the  entire  cloning  reaction  (6  µμl)  was  
transformed  into  MAX  Efficiency  Stbl2  competent  cells  (50  µμl)  as  per  the  manufacturer’s  
instructions.    Bacterial  colonies  were  screened  for  correct  insertion  of  the  HIV-­‐‑1  env  gene  
using  colony  PCR,  and  DNA  was  extracted  from  3-­‐‑6  positive  colonies  using  the  Qiaprep  
spin  miniprep  kit  (Qiagen).  
  
Cells 
293T  cells  were  cultured  in  Dulbecco’s  modified  Eagle  medium  (DMEM)  
supplemented  with  10%  fetal  bovine  serum  (FBS)  and  100  mg/ml  of  penicillin  and  
streptomycin.    293-­‐‑Affinofile  cells  (151)  were  maintained  in  DMEM  supplemented  with  10%  
dialyzed  FBS  (12–14  kD  dialyzed;  Atlanta  Biologicals)  and  50  mg/ml  blasticidin  (D10F/B).    
The  Affinofile  cell  line  was  generously  provided  by  Dr.  Ben-­‐‑Hur  Lee.    
  
Env-pseudotyped viruses 
Each  Env-­‐‑pseudotyped  luciferase  reporter  virus  was  generated  using  the  Fugene  6  
transfection  reagent  and  protocol  (Roche)  to  co-­‐‑transfect  293T  cells  with  an  env  expression  
vector  and  the  pNL4-­‐‑3.LucR-­‐‑E-­‐‑  HIV-­‐‑1  backbone  (obtained  from  the  NIH  AIDS  Research  and  
Reference  Reagent  Program,  Division  of  AIDS,  NIAID,  NIH).    Prior  to  transfection,  293T  
cells  were  seeded  at  a  density  of  4.8  x  105  cells/well  in  6-­‐‑well  tissue  culture  plates  coated  
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with  10%  poly-­‐‑L-­‐‑lysine.    Transfection  medium  was  replaced  five  hours  post-­‐‑transfection  
with  fresh  culture  medium  and  the  cells  were  incubated  at  37oC  for  48  hours,  after  which  
viral  supernatants  were  filtered  with  0.45  µμM  filters  (Millipore)  and  stored  at  -­‐‑80oC.  
  
293-Affinofile cellular surface xxpression of CD4 and CCR5 
293-­‐‑Affinofile  cell  (151)  CD4  and  CCR5  receptor  expression  was  induced  with  
doxycycline  (doxy;  Invitrogen)  and  ponasterone  A  (ponA;  Invitrogen),  respectively,  and  
induced  as  previously  described  (285).    Briefly,  cells  were  induced  with  doxy  (0  ng/ml  or  6  
ng/ml)  and  ponA  (5  µμM)  for  18-­‐‑24  hours  at  37oC  and  receptor  expression  was  measured  
using  quantitative  fluorescence-­‐‑activated  cytometry  (qFACS)  following  staining  with  either  
phycoerythin  (PE)-­‐‑conjugated  anti-­‐‑human  CD4  antibody  (clone  Q4120,  BD  Biosciences)  or  
PE-­‐‑conjugated  mouse  anti-­‐‑human  CCR5  antibody  (clone  2D7,  BD  Biosciences).    CD4  and  
CCR5  receptor  levels  were  quantified  using  QuantiBRITE  beads  (BD  Biosciences).  
  
Single-cycle infection of 293-Affinofile cells 
Env-­‐‑pseudotyped  luciferase  reporter  viruses  were  first  titered  in  triplicate  in  a  96-­‐‑
well  plate  format  on  293-­‐‑Affinofile  cells  (151)  expressing  the  maximum  induction  levels  for  
both  CD4  (6  ng/ml  doxy)  and  CCR5  (5  µμM  ponA)  surface  expression  as  previously  
described  (285).    In  order  to  ensure  that  each  infection  assay  was  performed  within  the  
linear  range,  we  used  the  volume  of  each  virus  needed  to  produce  800,000  relative  light  
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units  (RLUs)  when  used  to  infect  Affinofile  cells  expressing  the  highest  levels  of  CD4  and  
CCR5.    Two  days  prior  to  infection,  96-­‐‑well,  black  tissue  culture  plates  were  coated  with  
10%  poly-­‐‑L-­‐‑lysine  and  then  seeded  with  293-­‐‑Affinofile  cells  at  a  density  of  1.85  x  104  
cells/well.    18-­‐‑24  hours  later,  expression  of  CD4  and  CCR5  was  induced  at  two  conditions  in  
triplicate:  CD4high/CCR5high  (6  ng/ml  doxy  and  5  µμM  ponA,  respectively)  and  CD4low/CCR5high  
(0  ng/ml  doxy  and  5  µμM  ponA).    18  to  24  hours  later,  the  induction  medium  was  removed  
and  gently  replaced  with  100  µμl  of  fresh,  warmed  culture  medium  containing  env-­‐‑
pseudotyped  virus.    The  infection  plates  were  spinoculated  (222)  at  2,000  rpm  for  2  hours  at  
37oC,  and  then  incubated  for  an  additional  48  hours  at  37oC.    Infection  medium  was  then  
removed,  the  cells  were  lysed,  and  luciferase  activity  was  assayed  using  the  luciferase  assay  
system  (Promega).  
  
Nucleotide sequence accession numbers 
The  HIV-­‐‑1  env  nucleotide  sequences  determined  in  this  study  have  been  deposited  in  




Table  1:  Subject  population  virologic  and  phylogenetic  characteristics  
3006 35 5.92 3.01 0.001 0 0.158 Eq 14 1 N/A
3032 4 6.79 4.64 0.007 0 0.379 Eq 3 1 N/A
3036 6 6.36 3.42 0.001 0 0.168 Eq 7 1 N/A
3040 15 5.47 3.84 0.024 0 0.023f Eq 4 1 N/A
4001 22 5.48 3.22 0.006 0 0.458 Eq 18 1 N/A
4014 15 7.01 5.08 0.012 0 0.349 Eq 12 1 N/A
4015 22 6.19 4.25 0.011 0 0.476 Eq 19 1 N/A
4016 10 >7.90 6.68 N/A 0 0.458 Eq 6 1 N/A
4026 13 6.6 5.51 0.081 0 0.981 Eq 8 1 N/A
4029 9 5.79 3.42 0.004 0 0.17 Eq, Amp 8 1 N/A
4032 32 5.23 3.71 0.031 0 0.578 Eq, Amp 29 1 N/A
4037 12 6.23 3.18 0.001 0 0.821 Eq 15 1 N/A
4038 16 6.4 4.05 0.004 0 0.771 Eq 11 1 N/A
4039 3 5.7 1.75 0 0 0.203 Eq 7 1 N/A
4041 5 4.85 4.55 0.497 0 0.259 Eq 6 1 N/A
4045 20 6.77 4.74 0.009 0 0.062 Eq 19 1 N/A
4046 16 6.39 4.95 0.036 0 0.943 Eq 15 1 N/A
4055 9 6.67 4.46 0.006 22 0.139 Eq 71 2 *
4056 22 6.36 4.02 0.005 0 0.501 Eq 16 1 N/A
4059 28 5.57 4.59 0.105 0 0.269 Eq 32 1 N/A
3017 5 7.04 4.83 0.006 38 0.091 Inter 24 2 *
3037 8 6.82 4.54 0.005 39 0.095 Inter, Amp 6 1 4
4007 16 5.79 3.72 0.008 33 0.179 Inter, Amp 24 1 16
4008 16 6.43 4.58 0.014 41 0.082 Inter 18 1 14
4009 14 6.23 3.85 0.004 25 0.21 Inter 10 1 8
4013 6 5.57 3.48 0.008 28 0.0001g Inter, Amp 7 1 4
4028 17 5.7 3.72 0.01 40 0.157 Inter 6 1 5
4034 21 6.36 4.27 0.008 67 0.171 Inter 15 1 8
4036 12 6.71 3.82 0.001 75 0.068 Inter 4 1 4
4048 18 5.61 2.94 0.002 39 0.448 Inter, Amp 53 >2 *
4060 12 6.66 3.78 0.001 24 0.282 Inter 19 1 13
3002 5 6.48 5.07 0.039 71 0.008 Comp 57 2 8
3009 17 3.64 3.35 0.512 68 <0.0001 Comp 22 1 6
4002 21 5.99 4.15 0.015 45 0.001 Comp 19 1 12
4004 34 5.87 4.97 0.126 95 <0.0001 Comp, Amp 52, 47j ≥3 52, 24
4017 28 6.02 4.64 0.041 74 0.0001 Comp 26 1 19
4027 35 5.53 3.47 0.009 73 0.0002 Comp, Amp 21 1 7
4030 17 5.84 4.67 0.067 90 <0.0001 Comp 15 1 10
4031 26 4.76 2.8 0.011 67 0.001 Comp 11 1 5
4049 18 7.08 6.32 0.174 94 <0.0001 Comp 16 1 9
4050 23 6.01 3.98 0.009 65 0.024 Comp 17 1 12
4058 20 5.52 4.13 0.041 40 <0.0001 Comp, Amp 18 1 5








VL             
Plasmaa
VL               
CSFbSubject ID Age (mo) VL ratio
c % Compd P Valuee CSF comparth
    
a,bVL,  viral  load;  HIV-­‐‑1  RNA  (log10  copies/ml)  
cCSF/blood  VL  ratio  
dThe  percent  of  CSF  env  sequences  that  were  compartmentalized  (comp.)  for  each  subject.    
CSF  env   sequences  were  considered  compartmentalized  when  ≥4  sequences  were  found  
within  the  same  clade  and  bootstrap  values  ≥40  were  observed.    
eP  values  used  to  measure  genetic  compartmentalization  between  the  blood  plasma  and  
CSF   HIV-­‐‑1   populations   were   obtained   using   the   Slatkin-­‐‑Maddison   test   for   gene   flow  
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between   populations   (298).      A   P   value   <0.05   indicated   statistically   significant   genetic  
compartmentalization.  
fP   value   <0.05   was   obtained   for   subject   3040,   but   visual   assessment   of   the   neighbor-­‐‑
joining   tree   structure   indicated   the   presence   of   an   additional  HIV-­‐‑1   population  within  
the  blood  plasma  that  was  largely  absent  from  the  CSF.    
gP  value  <0.05  was  obtained  for  subject  4013,  but  visual  assessment  of  neighbor-­‐‑joining  
tree  structure  indicated  significant  compartmentalization  was  not  present.  
hHIV-­‐‑1   population   characteristics   in   the   CSF   compartment   (compart).      Eq,   equilibrated  
blood  plasma   and  CSF  populations;   Inter   (Intermediate),   a  minor   subpopulation  of   the  
CSF  was  compartmentalized;  Comp,  significant  compartmentalization  in  the  CSF;  Amp,  
clonal  amplification  of  ≥3  variants  detected  in  the  CSF;  N/A,  not  applicable  when  the  CSF  
viral  load  was  too  low  to  obtain  enough  CSF  env  sequences.  
iThe  time  to  most  recent  common  ancestor  (TMRCA)  analyzed  by  Bayesian  Evolutionary  
Analysis  by  Sampling  Trees  (BEAST)  (78).    
jFor  patient  4004,  ≥3  transmitted  variants  observed:  the  first  variant  evolved  at  52  months;  
the  second  and  third  variants  evolved  at  47  months.  
kNumber  of  variants  transmitted.  
lTMRCA   for   compartmentalized   (Comp)   population   for   intermediate   and  
compartmentalized   subjects.      Equilibrated   subjects   were   not   analyzed   (N/A).      When  





































































































Figure  1:  HIV-­‐‑1  blood  and  CSF  populations  in  infected  children  can  be  well  equilibrated,  
intermediate  or  compartmentalized    
Neighbor-­‐‑joining  phylogenetic  trees.  env  sequences  from  the  CSF  are  labeled  with  solid  
blue  circles  and  env  sequences  from  the  blood  plasma  are  labeled  with  solid  red  triangles.    
Bootstrap   values   ≥40   are   indicated   (*)   at   the   appropriate   nodes.      Genetic   distance   is  
indicated   at   the   bottom   of   each   figure   (0.001)   and   indicates   the   number   of   nucleotide  
substitutions   per   site   between   env   sequences.      Compartmentalized   populations   are  
indicated   by   open   circle.      Clonal   amplification   is   indicated   by   solid   bar.      (A)   One  
representative   subject   with   well   equilibrated   blood   plasma   and   CSF   populations.      (B)  
Two   subjects   demonstrating   an   intermediate   condition   between   the   blood   plasma   and  
CSF   viral   population.      (C)   Two   subjects   demonstrating   the   presence   of   a   statistically  
significant   compartmentalized   population   within   the   CSF   relative   to   the   blood,   as  




P = 0.63 P = 0.005
P = 0.05
P = 0.43 P = 0.001
P = 0.02
  
Figure  2:  Older  age  and  a  higher  CSF/blood  viral  load  ratio  are  strong  determining  factors  
for  compartmentalization  
Relationships   between   clinical   characteristics   and   genetic   compartmentalization   were  
assessed  using   the  Mann-­‐‑Whitney  test   in  GraphPad  Prism  4.     Horizontal  bars  represent  
median  values.    A  P  value  <0.05  was  considered  statistically  significant.    (A)  Comparisons  
between   age   of   the   subjects   and   compartmentalization.      (B)   Comparisons   between   the  






































































Figure  3:  No  relationship  between  viral  load  and  subject  classification    
Relationships   between   blood   or   CSF   viral   loads   and   virological   classifications   were  
assessed  using   the  Mann-­‐‑Whitney  test   in  GraphPad  Prism  4.     Horizontal  bars  represent  
median   values.      (A)   Comparisons   between   blood   viral   load   and   CSF   compartment  
classification   (Eq,   equilibrated;   Inter,   Intermediate;   Comp,   compartmentalized.)      (B)  
Comparisons   between   blood   viral   load   and   TMRCA   classification.      (C)   Comparisons  















Figure  4:  Evolutionary  history  of  HIV-­‐‑1  populations  within  the  first  three  years  of  
pediatric  CNS  infection    
Age  and  TMRCA  comparisons  over  the  first  three  years  of  life.    (A)  Relationship  between  
age   of   subjects   and   TMRCA   of   plasma   population   determined   by   BEAST   (78).    
Concordance  of  age  and  TMRCA  indicated  by  dotted  line.    TMRCA  outliers  are  indicated  
by   open   circle;   equilibrated,   subject   4055;   intermediate,   subjects   3017   and   4048;  
compartmentalized,  subjects  3002  and  4004.      (B)  Pie  charts  grouping  the  children  by  age  























































































































Figure  5:  Evidence  of  multiple  transmission  events  during  pediatric  HIV-­‐‑1  subtype  C  
infection    
Phylogenetic   and   sequence   analysis   of   plasma   and  CSF  HIV-­‐‑1   populations   for   subject  
3002.      (A)  Neighbor-­‐‑joining   tree.      Sequences   from   the  CSF   are   labeled  with   solid   blue  
circles,  and  plasma  sequences  (PL)  are  labeled  with  solid  red  triangles.    Bootstrap  values  
≥40  are  indicated  (*)  at  the  appropriate  nodes.    Genetic  distance  is  scaled  at  the  bottom  of  
the  figure  (0.001)  and  indicates  the  number  of  nucleotide  substitutions  per  site  between  
env  sequences.    The  subject’s  age  is  noted,  as  well  as  the  overall  TMRCA  and  the  TMRCA  
of   the   two   transmitted   viruses.      The  CNS   sequestered  population   is   represented  by   an  
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open   black   circle.      (B)   Highlighter   plot   of   aligned   env   plasma   and   CSF   sequences,  
generated   at  www.hiv.lanl.gov.      The  HXB2  nucleotide  position  number   is   indicated   on  
the  x  axis,  and  the  sequence  identifier  is  indicated  on  the  y  axis.    Nucleotide  changes  are  
indicated  by  the  following  ticks  on  the  highlighter  plot:  A,  green;  T,  red;  G,  orange;  and  










































































Figure  6:  Compartmentalized  subject  4004  exhibiting  three  or  more  transmitted  viruses    
Phylogenetic   and   sequence   analysis   of   plasma   and  CSF  HIV-­‐‑1   populations   for   subject  
4004.    (A)  Neighbor-­‐‑joining  tree.    CSF  sequences  are  labeled  with  solid  blue  circles,  and  
plasma   sequences   (PL)   are   labeled   with   solid   red   triangles.      Bootstrap   values   ≥40   are  
indicated   (*)   at   the   appropriate   nodes.     Genetic   distance   is   scaled   at   the   bottom   of   the  
figure  (0.001)  and  indicates  the  number  of  nucleotide  substitutions  per  site  between  env  
sequences.      The   subject’s   age   is   noted,   as  well   as   the   TMRCA   for   the   transmitted   and  
compartmentalized  populations.     The  CNS  sequestered  population  is  represented  by  an  
open   black   circle.      (B)   Highlighter   plot   of   aligned   env   plasma   and   CSF   sequences,  
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generated  at  www.hiv.lanl.gov.     The  HXB2  base  number   is   indicated  on   the  x   axis,   and  
the   sequence   identifier   is   indicated   on   the   y   axis.      Base   changes   are   indicated   by   the  
following   ticks   on   the   highlighter   plot:   A,   green;   T,   red;   G,   orange;   and   C,   blue.    
Sequestered  populations   resulting   from   the   transmitted  viruses   are   separated  by  heavy  
black   lines.     One  variant  was   sequestered  within   the  CSF   (top)   and  additional  variants  
were  established  within  the  blood  (middle).     Another  variant  was  also  isolated  from  the  




























































Figure  7:  Intermediate  subject  3017  exhibiting  two  transmitted  viruses    
Phylogenetic   and   sequence   analysis   of   plasma   and  CSF  HIV-­‐‑1   populations   for   subject  
3017.      (A)  Neighbor-­‐‑joining   tree.      Sequences   from   the  CSF   are   labeled  with   solid   blue  
circles,  and  plasma  sequences  (PL)  are  labeled  with  solid  red  triangles.    Bootstrap  values  
≥40  are  indicated  (*)  at  the  appropriate  nodes.    Genetic  distance  is  scaled  at  the  bottom  of  
the  figure  (0.001)  and  indicates  the  number  of  nucleotide  substitutions  per  site  between  
env   sequences.     The  subject’s  age   is  noted,  as  well  as   the  overall  TMRCA.     BEAST  was  
unable  to  assign  a  TMRCA  to  the  internal  nodes  due  to  recombination  in  the  population.    
The  CNS  sequestered  population  is  represented  by  an  open  black  circle.  (B)  Highlighter  
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plot   of   aligned   env   plasma   and   CSF   sequences,   generated   at   www.hiv.lanl.gov.      The  
highlighter   plot   characteristics   are   the   same   as   those   stated   in   Figure   6.      Subject   was  
likely  infected  with  two  viral  variants  during  transmission.     The  two  sequences  that  are  
closest   to   the   parental   strains   are   PL_14   (top)   and   CSF_3   (bottom),   and   recombination  
between  the  transmitted  viruses  appears  to  account  for  much  of  the  env  genetic  diversity  
detected   in   both   the   plasma   and   CSF   populations.      The   transmitted   CSF   variant   was  
maintained   within   the   CNS,   generating   a   minor   CSF   population   with   small   local  
























































































































Figure  8:  Intermediate  subject  4048  exhibiting  greater  than  two  transmitted  viruses    
Phylogenetic   and   sequence   analysis   of   plasma   and  CSF  HIV-­‐‑1   populations   for   subject  
4048.      (A)  Neighbor-­‐‑joining   tree.      Sequences   from   the  CSF   are   labeled  with   solid   blue  
circles,  and  plasma  sequences  (PL)  are  labeled  with  solid  red  triangles.    Bootstrap  values  
≥40  are   indicated   (*)   at   the  appropriate  nodes.     The  phylogenetic   tree   characteristics  are  
the  same  as  those  stated  in  Figure  7.    (B)  Highlighter  plot  of  aligned  env  plasma  and  CSF  
sequences,   generated   at   www.hiv.lanl.gov.      The   highlighter   plot   characteristics   are   the  
same  as  those  stated  in  Figure  6.    Several  unique  motifs  were  observed  around  1000  base  
pairs   (top),   indicating   that   there   were   potentially   greater   than   2   transmitted   viruses.    
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Recombination  between  the   transmitted  viruses  appears   to  account  for  much  of   the  env  
genetic  diversity  detected  in  both  the  plasma  and  CSF  populations.    The  transmitted  CSF  
variant  was  maintained  within  the  CNS,  generating  a  minor  CSF  population  with  small  




































































Figure  9:  Equilibrated  subject  4055  exhibiting  two  transmitted  viruses  
    Phylogenetic  and  sequence  analysis  of  plasma  and  CSF  HIV-­‐‑1  populations   for   subject  
4055.      (A)  Neighbor-­‐‑joining   tree.      Sequences   from   the  CSF   are   labeled  with   solid   blue  
circles,  and  plasma  sequences  (PL)  are  labeled  with  solid  red  triangles.    Bootstrap  values  
≥40  are  indicated  (*)  at  the  appropriate  nodes.    Genetic  distance  is  scaled  at  the  bottom  of  
the  figure  (0.001)  and  indicates  the  number  of  nucleotide  substitutions  per  site  between  
env  sequences.    The  subject’s  age  is  noted,  as  well  as  the  overall  TMRCA.    (B)  Highlighter  
plot   of   aligned   env   plasma   and   CSF   sequences,   generated   at   www.hiv.lanl.gov.      The  
highlighter   plot   characteristics   are   the   same   as   those   stated   in   Figure   6.      Subject   was  
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likely   infected   with   2   viral   variants   during   transmission.      The   two   sequences   that   are  
likely  closet  to  the  parental  strains  are  CSF_16  and  PL_4,  and  recombination  between  the  
transmitted  viruses  appears  to  account  for  much  of  the  env  genetic  diversity  detected  in  
both  the  plasma  and  CSF  populations.     Both  variants  were  maintained  within  the  blood  
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Figure  10:  Compartmentalized  HIV-­‐‑1  CSF  populations  in  children  can  have  a  low  CD4  
entry  phenotype    
Single-­‐‑cycle  infection  of  HIV-­‐‑1  Env-­‐‑pseudotyped  reporter  viruses  on  CD4lowCCR5high  293-­‐‑
Affinofile   cells   (151).   Receptor   expression   was   measured   as   follows:   CD4low   =   1,702  
receptors/cell,  CD4high  =  63,387  receptors/cell,  CCR5high  =  26,117  receptors/cell.    The  data  are  
averaged   from   triplicate   wells   for   each   of   2   to   3   env   clones   that   were   generated   per  
indicated  amplicon.    Amplicons  were  selected  for  cloning  to  represent  different  portions  
of  the  phylogenetic  tree.    Panels  show  infection  results  for:  (A)  equilibrated  subjects;  (B)  
intermediate;   and   (C)   compartmentalized   subjects.      Selected   HIV-­‐‑1   env   sequences   are  
indicated   by   a   black   square   followed   by   the   env   name   on   neighbor   joining   trees   for  
several  subjects  (Figure  1).  
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Figure  11:  No  contamination  was  observed  between  subjects    
Neighbor-­‐‑joining   phylogenetic   tree   (radial   topology).      env   sequences   from   the  CSF   are  
labeled  with  solid  blue  circles  and  env  sequences  from  the  blood  plasma  are  labeled  with  
solid  red  triangles.    Genetic  distance  is  indicated  at  the  bottom  of  the  figure  and  indicates  
the  number  of  nucleotide  substitutions  per  site  between  env  sequences.    Each  subject  ID  
is  indicated.  
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CHAPTER III. COMPARTMENTALIZED REPLICATION OF R5 T CELL-TROPIC 





Compartmentalized  HIV-­‐‑1  replication  within  the  central  nervous  system  (CNS)  
likely  provides  a  foundation  for  neurocognitive  impairment  and  a  potentially  important  
tissue  reservoir.    The  timing  of  emergence  and  character  of  this  local  CNS  replication  has  not  
yet  been  defined  in  a  population  of  subjects.    We  examined  the  frequency  of  elevated  HIV-­‐‑1  
RNA  concentration  in  the  CSF,  the  nature  of  the  CSF  viral  population  compared  to  the  
blood,  and  the  presence  of  a  cellular  inflammatory  response  (with  the  potential  to  bring  
infected  cells  into  the  CNS)  using  paired  cerebrospinal  fluid  (CSF)  and  blood  samples  
obtained  over  the  first  two  years  of  subtype  B  infection  from  72  ART-­‐‑naïve  subjects.    Using  
single  genome  amplification  (SGA)  and  phylodynamics  analysis  of  the  full-­‐‑length  env  gene,  
we  compared  CSF  and  blood  viral  populations  in  33  out  of  the  72  subjects.    Independent  
replication  of  HIV-­‐‑1  in  the  CNS  (compartmentalization)  was  detected  in  12%  of  sample  
pairs,  predominantly  after  four  months  of  infection.    In  subjects  with  longitudinal  sampling,  
35%  showed  evidence  of  CNS  viral  replication  or  pleocytosis/inflammation  in  at  least  one  
                                                                                                              
2	  C.B.  Sturdevant,  G.  Schnell,  R.W.  Price,  R.  Swanstrom,  and  S.  Spudich.    The  data  presented  in  this  chapter  are  
currently  submitted  to  a  peer-­‐‑reviewed  journal.    Author  contributions  are  as  follows:  conceived  and  designed  
the  experiments,  CBS  GS  RWP  RS  SS;  performed  the  experiments,  CBS  GS;  analyzed  the  data,  CBS  GS  RWP  RS  
SS;  wrote  the  paper,  CBS  GS  RWP  RS  SS.  
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time  point,  and  in  approximately  20%  of  subjects  we  observed  evolving  CSF/CNS  
compartmentalized  viral  replication  and/or  a  marked  CSF  inflammatory  response  at  
multiple  time  points  suggesting  an  ongoing  or  recurrent  impact  of  the  infection  in  the  CNS.    
Two  subjects  had  one  of  two  transmitted  lineages  (or  their  recombinant)  largely  sequestered  
within  the  CNS  shortly  after  transmission,  indicating  an  additional  mechanism  for  
establishing  early  independent  CNS  replication.    Transmitted  variants  were  R5  T  cell-­‐‑tropic  
and  were  selected  to  use  high  levels  of  CD4  for  entry.    Overall,  examination  of  the  
relationships  between  CSF  viral  populations,  blood  and  CSF  HIV-­‐‑1  RNA  concentrations,  
and  inflammatory  responses  suggested  four  distinct  states  of  viral  population  dynamics,  





Early  HIV-­‐‑1  CNS  replication  likely  provides  a  foundation  for  brain  injury  and  a  
potentially  important  tissue  reservoir.    To  explore  the  character  and  timing  of  emergence  of  
early  HIV-­‐‑1  CNS  replication,  we  examined  paired  cerebrospinal  fluid  (CSF)  and  blood  
samples  from  72  ART-­‐‑naïve  adults,  with  one-­‐‑half  having  longitudinal  samples,  during  the  
first  two  years  following  HIV-­‐‑1  infection.    In  a  cross  sectional  analysis  over  the  first  two  
years  of  infection,  15-­‐‑25%  of  subjects  had  evidence  of  either  local  viral  replication  in  the  
CNS,  defined  by  the  presence  of  CSF  compartmentalization,  or  a  robust  inflammatory  
response,  and  in  approximately  20%  of  subjects  this  CNS  involvement  persisted  over  time.    
In  some  subjects,  one  of  two  transmitted  viruses  replicated  predominantly  within  the  CNS,  
providing  insight  into  how  HIV-­‐‑1  can  establish  independently  replicating  populations  early  
in  different  parts  of  the  body.    Based  on  their  entry  phenotype,  all  viruses  were  selected  for  
replication  in  CD4+  T  cells,  although  this  phenotype  was  slightly  altered  in  the  
compartmentalized  virus.    Overall,  we  suggest  four  states  to  model  the  nature  of  HIV-­‐‑1  CNS  






While  HIV-­‐‑1  can  be  detected  in  both  the  cerebrospinal  fluid  (CSF)  and  brain  tissue  
during  the  weeks  after  initial  exposure  (70,  89,  238,  284,  308,  318,  326),  it  is  unknown  when  
the  virus  actually  begins  replicating  independently  in  the  central  nervous  system  (CNS).    
Independent  viral  replication  within  the  CNS  has  two  important  implications.    First,  HIV-­‐‑1  
replication  can  lead  to  CNS  dysfunction  and  injury,  and  while  combination  antiretroviral  
therapy  (cART)  has  markedly  reduced  the  incidence  of  HIV-­‐‑associated  dementia  (HAD),  the  
prevalence  of  milder  HIV-­‐‑associated  neurological  disorders  (HAND)  has  increased  (10,  96)  
in  the  cART  era.    Second,  independent  CNS  replication  may  also  provide  a  reservoir  distinct  
from  that  found  in  CD4+  T  cells  in  the  blood  and  lymphoid  tissue.    We  do  not  know  the  time  
course  of  the  virologic  events  that  lead  to  neurological  dysfunction  and  the  potential  
establishment  of  a  CNS  reservoir,  or  the  extent  to  which  these  long-­‐‑term  outcomes  are  
predicted  by  the  initial  aspects  of  virus-­‐‑host  interaction.  
While  extensive  independent,  or  compartmentalized,  CSF/CNS  replication  is  
associated  with  severe  HIV-­‐‑1  clinical  CNS  dysfunction  (82,  132,  225,  238,  285),  genetically  
distinct  virus  can  be  detected  in  the  CNS  throughout  the  course  of  infection  (132,  284).    Thus  
far,  two  types  of  compartmentalization  have  been  defined:  one  in  which  a  few  variants  are  
rapidly  expanded  giving  a  CSF  viral  population  of  low  complexity  (clonal  amplification)  
consisting  of  variants  that  require  high  levels  of  CD4  for  entry  (R5  T  cell-­‐‑tropic).    The  second  
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type  is  characterized  by  a  complex  CSF  viral  population  consisting  of  variants  that  can  enter  
cells  expressing  low  levels  of  CD4  (macrophage-­‐‑tropic),  indicative  of  a  more  prolonged  
period  of  isolated  replication  and  evolution  of  the  entry  phenotype.    Additionally,  we  have  
recently  shown  that  after  vertical  transmission  to  children,  CNS  compartmentalization  can  
be  established  via  two  mechanisms:  the  early  sequestration  of  one  of  multiple  transmitted  
variants  in  the  CNS,  or  the  later  establishment  of  compartmentalized  CNS  virus  originating  
from  the  periphery  (317).    In  a  previous  study,  we  demonstrated  CSF  HIV-­‐‑1  
compartmentalization  in  human  subjects  during  the  first  year  of  HIV-­‐‑1  infection  in  adults  
(284).    However,  that  study  only  examined  viral  population  sequences  from  CSF  and  plasma  
in  a  small  number  of  subjects  (eight),  limiting  the  generalizability  of  our  findings.    
Furthermore,  the  previous  study  had  sparse  assessment  of  longitudinal  samples,  and  
included  no  analysis  of  sources  of  compartmentalized  HIV-­‐‑1  within  the  CSF.          
For  the  current  study,  we  used  single  genome  amplification  (SGA)  and  phylogenetic  
analysis  to  assess  viral  populations  in  the  CSF  in  the  presence  and  absence  of  cellular  
inflammation  (i.e.  pleocytosis)  in  cross-­‐‑sectional  and  often  longitudinal  paired  blood  plasma  
and  CSF  samples  obtained  during  the  first  two  years  of  HIV-­‐‑infection  in  ART-­‐‑naïve  subjects.    
We  also  extended  our  analytical  approach  to  include  Bayesian  Evolutionary  Analysis  by  
Sampling  Trees  (BEAST)  to  assess  time  to  most  recent  common  ancestor  (TMRCA)  of  CSF  
and  blood  HIV-­‐‑1  populations  (78),  and  we  assessed  the  entry  phenotypes  of  selected  clones.    
Based  upon  a  complex  interplay  between  HIV-­‐‑1  RNA  concentration,  viral  
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compartmentalization,  and  CSF  white  blood  cell  (WBC)  count,  we  suggest  at  least  four  
different  patterns  to  characterize  the  relationship  between  virus  in  the  blood  and  virus  in  
the  CSF/CNS  during  the  early  period  after  infection.    The  current  study  considerably  
enhances  the  generalizability  of  our  results  and  provides  an  unprecedented  view  of  the  




Study population and analysis parameters 
We  analyzed  the  HIV-­‐‑1  RNA  concentrations  in  paired  blood  plasma  and  CSF  
samples  collected  from  72  adult  subjects  enrolled  in  an  observational  neurological  study  of  
primary  HIV-­‐‑1  infection,  defined  as  within  one  year  of  initial  infection.    All  subjects  were  
infected  with  HIV-­‐‑1  subtype  B  and  were  ART-­‐‑naïve  at  all  study  intervals,  except  for  one  
subject,  9018,  who  was  treated  with  tenofovir,  emtricitabine,  and  atazanavir  between  the  
first  and  second  analyzed  time  points.    Paired  follow-­‐‑up  samples  were  assessed  for  37  
subjects  with  longitudinal  samples  available  within  the  initial  two  years  post  infection  (p.i.).    
In  total,  144  paired  samples  were  available  for  analysis.    Baseline  demographic  and  clinical  
characteristics  at  enrollment  for  the  entire  cohort  (n=72)  and  for  the  subset  that  had  
sufficient  CSF  viral  RNA  concentrations  (defined  as  greater  than  1,000  copies  of  viral  
RNA/ml)  to  allow  adequate  sampling  of  the  viral  population  via  SGA  (n=33)  are  shown  in  
Table  2.    For  the  33  subjects  whose  samples  were  analyzed  by  SGA,  a  total  of  55  blood  
plasma/CSF  sample  pairs  were  analyzed  including  the  longitudinal  samples  (Table  3;  three  
time  points  and  one  time  point  beyond  2  years  p.i.  were  analyzed  for  subject  9018  and  9040,  
respectively,  but  were  not  included  in  any  overall  population  analysis.)  
Following  SGA  and  phylogenetic  analysis,  compartmentalization  was  assessed  
visually  and  statistically  using  the  Slatkin-­‐‑Maddison  test  (298)  (a  P  value  <  0.05  was  
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considered  significant),  and  three  CNS  phylogenetic  states  were  defined  (Figure  12):  i)  
equilibrated,  with  similar  populations  between  the  blood  and  CSF,  with  no  evidence  of  
independent  CNS  replication  (Figure  12A);  ii)  intermediate,  with  a  minor  genetically  distinct  
but  not  statistically  significant  CSF  population  (Figure  12B);  and  iii)  compartmentalized,  with  
a  genetically  distinct  and  statistically  significant  CSF  population  that  differed  from  the  
population  in  the  blood  (Figure  12C).    In  our  analyses,  compartmentalized  populations  
typically  included  clonally  amplified  variants  often  with  more  genetically  diverse  variants  
(Figure  12C,  Sub.  9040),  and  sometimes  with  the  presence  of  recombinants  between  two  
clonally  amplified  variants  (Figure  12C,  Sub.  9096).    Table  3  shows  the  clinical  and  virologic  
assessment  for  each  subject  who  had  at  least  one  time  point  analyzed  by  SGA,  and  Table  4  
shows  this  information  for  the  39  subjects  who  had  no  time  points  analyzed  by  SGA.  
We  also  considered  what  role  cellular  inflammation  (pleocytosis)  might  play  in  
determining  both  the  HIV-­‐‑1  RNA  concentrations  and  the  nature  of  the  viral  population  in  
the  CSF,  specifically  whether  an  equilibrated  population  might  exist  with  higher  CSF  HIV-­‐‑1  
RNA  concentrations  due  to  an  influx  of  cells,  including  infected  cells,  during  an  
inflammatory  response.    For  our  analyses,  we  chose  a  cut-­‐‑off  of  10  WBC/µμl  to  define  a  state  
of  CSF  pleocytosis,  as  this  is  two-­‐‑times  the  published  normal  values  of  CSF  WBC  (0  to  5  
cells/µμl)  (97)  ensuring  that  the  measured  pleocytosis  was  a  robust  marker  for  an  
inflammatory  response.  
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Approximately two-thirds of subjects have low CSF viral RNA concentrations 
during the first two years of infection 
In  order  to  assess  temporal  patterns  of  CNS  viral  replication  and  inflammation,  we  
treated  all  144  paired  samples  from  the  72  subjects  as  independent  observations  (a  limitation  
of  the  analysis  but  one  that  allowed  us  to  categorize  the  samples  by  time  post  infection).    We  
divided  the  samples  into  the  following  three  windows:  acute,  0-­‐‑4  months  p.i.;  early,  5-­‐‑12  
months  p.i.;  or  established,  13-­‐‑24  months  p.i..    The  choice  of  these  times  also  allowed  us  to  
bin  the  data  into  groups  with  reasonable  sample  sizes.    Regardless  of  length  of  time  since  
HIV-­‐‑1  infection,  the  CSF  viral  RNA  concentration  was  less  than  1,000  copies/ml  in  
approximately  two-­‐‑thirds  of  samples  (Figure  13A),  suggestive  of  little  local  production  of  
virus  in  the  CNS.    Analysis  of  the  viral  populations  in  the  remaining  samples  showed  that  in  
19-­‐‑30%  of  the  paired  samples  the  viral  population  in  the  CSF  was  similar  to  the  viral  
population  in  the  blood  (i.e.  equilibrated),  and  pleocytosis  was  detected  in  the  CSF  of  one-­‐‑
third  to  one-­‐‑half  of  the  samples  with  these  equilibrated  populations  (Figure  13A).    
Compartmentalized  or  intermediate  viral  populations  were  detected  largely  after  the  first  4  
months,  in  20%  of  samples  in  the  early  group  (total  n=70)  and  6%  of  the  established  group  
(total  n=30).    However,  samples  in  which  pleocytosis  was  detected  were  significantly  less  
likely  to  have  viral  RNA  levels  in  the  CSF  of  less  than  1,000  copies/ml  compared  to  the  total  
group  of  samples  (Figure  13B;  and  see  below).    
We  next  assessed  factors  associated  with  the  CSF  viral  load.    We  first  examined  
subjects  without  evidence  of  inflammation  (i.e.  no  pleocytosis)  and  either  low  viral  load  in  
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the  CSF  (less  than  1,000  copies/ml)  or  an  equilibrated  population  as  evidence  of  no  sustained  
local  replication.    In  these  subjects  the  HIV-­‐‑1  RNA  concentration  in  the  CSF  was  
proportionally  1-­‐‑2%  of  the  level  in  the  blood  (Spearman’s  rank  correlation  coefficient  =  0.48,  
P<0.0001)  (Figure  13C).    We  could  not  determine  whether  this  proportional  relationship  was  
maintained  for  those  samples  in  which  the  CSF  viral  load  was  undetectable  (<50  copies/ml),  
although  there  was  a  trend  for  these  samples  to  be  from  subjects  with  low  plasma  HIV-­‐‑1  
RNA  concentrations  (Figure  13C).  
  
Pleocytosis can be associated with elevated viral load in the CSF and an influx 
of virus from the blood 
Pleocytosis  was  detected  in  36%  of  all  subjects  (Table  3  and  4).    When  pleocytosis  
was  detected,  the  HIV-­‐‑1  RNA  concentration  was  twice  as  likely  (64%,  Figure  13B)  to  be  
above  1,000  copies/ml  in  the  CSF  compared  to  the  overall  population  (two-­‐‑thirds  below  
1,000  copies/ml;  Figure  13A).    Additionally,  when  pleocytosis  was  present  and  the  CSF  viral  
load  was  high  enough  for  SGA  analysis,  the  viral  populations  were  most  often  equilibrated  
(Figure  13D,  open  circles),  with  a  CSF  viral  load  that  was  significantly  higher  than  for  
equilibrated  populations  without  pleocytosis  (P=0.0006,  Mann-­‐‑Whitney  Test)  (Figure  13D).    
This  suggests  that  the  influx  of  infected  CD4+  T  cells  associated  with  pleocytosis  brings  
virus  into  the  CSF/CNS  from  the  blood.    There  was  a  trend  toward  increased  CSF:blood  
albumin  ratio  (a  marker  for  reduced  blood-­‐‑brain  barrier  integrity)  in  the  presence  of  
pleocytosis,  which  could  contribute  to  an  influx  of  virus  (Table  3).    However,  there  was  a  
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similar  (and  statistically  significant)  increase  in  CSF:blood  albumin  ratio  in  the  
compartmentalized  subjects  that  did  not  account  for  the  increase  in  CSF  HIV-­‐‑1  RNA  
concentration  compared  to  the  samples  with  equilibrated  populations  without  pleocytosis  
(Figure  13D;  see  below),  which  was  instead  due  to  local  virus  production.    These  data  
suggest  that  increased  viral  burden  in  the  CNS  can  result  from  two  factors:  independent  
CNS  replication,  generating  compartmentalized  CSF  populations,  or  an  influx  of  infected  
cells  as  the  result  of  the  inflammatory  response  of  pleocytosis,  producing  a  viral  population  
in  the  CSF  that  is  similar  to  that  in  the  blood.    It  is  possible  that  much  of  the  pleocytosis  seen  
in  these  subjects  is  in  response  to  HIV-­‐‑1  replication  in  the  CNS  where  the  influx  of  infected  
cells  from  the  blood  produces  elevated  levels  of  virus  that  obscure  the  detection  of  a  lower  
level  of  the  locally  produced  and  compartmentalized  virus  responsible  for  inducing  the  
inflammation.    Other  agents  that  induce  pleocytosis  should  have  a  similar  effect  on  viral  
load  in  the  CSF  and  this  was  seen  in  an  incident  of  neurosyphilis  in  subject  9018  when  
sampled  at  day  687  p.i.  (Table  3).    However,  we  note  that  pleocytosis  is  not  always  
associated  with  higher  viral  load  (Figure  13B,  13D),  indicating  a  more  complex  and  perhaps  
dynamic  relationship  between  pleocytosis  and  viral  load.  
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Compartmentalized viral populations early are associated with higher CSF 
viral loads, and local replication and/or inflammation can persist or reoccur 
over time 
Little  evidence  for  local  CNS  replication  (intermediate  or  compartmentalized  
populations)  was  detected  until  after  4  months  of  infection  (Figure  13A),  suggesting  that  
detectable  CNS-­‐‑compartmentalized  populations  are  present  at  greater  frequency  with  a  
longer  time  since  HIV-­‐‑1  exposure.    As  noted  above,  CSF  samples  with  compartmentalized  
populations  had  elevated  viral  RNA  loads  when  compared  to  the  samples  with  only  
equilibrated  populations  in  the  absence  of  pleocytosis  (Figure  13D),  consistent  with  local  
production  of  virus  with  the  detection  of  compartmentalization.    However,  those  samples  
with  an  intermediate  population  did  not  have  a  significantly  elevated  viral  RNA  load,  
consistent  with  the  local  production  representing  only  a  fraction  of  the  virus  present  (Figure  
13D).  
We  were  interested  in  examining  whether  these  markers  of  local  replication  and  
inflammation  persisted  over  time.    As  noted  above,  in  our  cross  sectional  analysis  74-­‐‑87%  of  
samples  have  a  CSF  viral  RNA  concentration  less  than  1,000  copies/ml  or  an  equilibrated  
population  with  little  to  no  pleocytosis  (Figure  13A);  however  this  underestimates  the  
probability  of  having  evidence  of  viral  replication  in  the  CNS  within  the  first  two  years.    In  
this  analysis  we  interpret  equilibrated  populations  with  pleocytosis/inflammation  as  an  
indirect  marker  of  local  viral  replication,  i.e.  the  inflammatory  response  to  local  viral  
replication.    Of  the  37  subjects  with  longitudinal  sampling,  17  (46%)  had  low  CSF  viral  loads  
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at  all  sampling  time  points  (Table  4),  and  7  (19%)  had  only  low  CSF  viral  loads  or  
equilibrated  populations  with  minimal  to  no  pleocytosis  at  all  time  points  (Figure  14A).    
Conversely,  35%  of  subjects  (13  out  of  37)  showed  evidence  of  pleocytosis  and/or  
compartmentalized  viral  replication  in  at  least  one  time  point  within  the  initial  two-­‐‑year  
period  (Figure  14B).    Furthermore,  22%  (8  out  of  37)  had  one  of  these  states  in  at  least  two  
time  points  (Figure  14B,  subjects  below  dotted  line).    Thus  approximately  35%  of  subjects  
with  longitudinal  sampling  showed  evidence  of  viral  replication  in  the  CNS  in  at  least  one  
time  point,  and  20%  of  subjects  in  the  first  two  years  of  infection  showed  evidence  of  viral  
replication  and/or  inflammation  within  the  CNS  over  an  extended  period  of  time.    Finally,  if  
the  initial  sample  showed  evidence  of  compartmentalization  or  an  equilibrated  population  
with  pleocytosis,  there  was  a  high  probability  that  at  least  one  subsequent  sample  was  in  
one  of  these  states  compared  to  those  subjects  where  the  initial  sample  was  not  in  one  of  
these  states  (P=0.001).  
  
Genetic evidence for the persistence of HIV-1 CNS replication 
In  two  subjects,  9040  and  9021,  a  compartmentalized  CNS  population  was  observed  
at  enrollment  and  for  all  analyzed  longitudinal  time  points,  spanning  a  period  of  753  and  
201  days  p.i.,  respectively  (one  time  point  beyond  2  years  p.i.  was  analyzed  for  subject  9040  
but  was  not  included  in  any  overall  population  analysis).    Further  analysis  of  these  subjects  
identified  distinct  trends  of  how  HIV-­‐‑1  becomes  established  in  the  CNS.      
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One  pattern  was  seen  in  the  viral  evolution  in  subject  9040  (Figure  15A).    In  this  case  
a  clonally  amplified  population  present  at  the  initial  time  point  (day  165)  was  replaced  with  
a  second  clonally  amplified  variant  at  day  352,  but  the  sampling  included  a  recombinant  
between  the  first  and  second  clonally  amplified  variants.    Several  recombinants  between  
these  two  early  populations  were  maintained  through  day  644  (with  a  subsequent  time  
point  showing  an  equilibrated  population).    Using  BEAST  analysis  to  estimate  number  of  
generations  of  the  viral  population,  the  time  to  most  recent  common  ancestor  (TMRCA)  of  
the  blood  population  at  the  initial  time  point  was  estimated  to  be  209  days,  reasonably  
consistent  with  the  reported  date  of  transmission  (165  days  prior  to  sampling).    We  also  
estimated  that  the  initial  clonally  amplified  CSF  population  was  established  33  days  prior  to  
sampling  (approximately  170  days  after  transmission),  followed  by  a  subsequent  clonal  
amplification  event  and  recombination  between  the  two  lineages.    These  data  showed  the  
early  establishment  of  a  lineage  within  the  CNS  that  persisted  over  a  period  of  at  least  2  
years.    To  our  knowledge,  this  was  the  first  study  to  show  the  maintenance  and  evolution  of  
a  compartmentalized  viral  population  within  the  CNS  over  a  long  duration  of  time  starting  
during  early  infection.  
A  second  trend  was  seen  for  subject  9021  (Figure  15B).    Again,  the  reported  date  of  
transmission,  140  days  prior  to  the  first  sampling  date,  was  reasonably  close  to  the  
transmission  bottleneck  estimated  using  BEAST  at  159  days  prior  to  sampling.    In  this  
subject  one  clonally  amplified  lineage  was  detected  in  the  CSF  at  the  first  sampling  time  
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point  with  an  estimated  age  of  102  days,  or  starting  57  days  post  infection.    This  lineage  was  
not  present  at  the  second  sampling  time  point  (at  341  days)  but  was  replaced  by  a  different  
clonally  amplified  variant  with  an  estimated  age  of  55  days.    Thus  for  this  subject  we  
observed  a  permissive  environment  for  viral  replication  in  which  variants  are  successively  
and  independently  amplified  within  the  CNS.  
  
Timing of introduction of HIV-1 into the CNS 
We  detected  intermediate  compartmentalization  as  early  as  58  days  p.i.  while  
compartmentalized  CNS  populations  were  not  detected  until  after  four  months  of  infection  
(Figure  13A).    Using  BEAST  to  estimate  the  time  to  most  recent  common  ancestor  (TMRCA)  
we  were  able  to  show  that  often  these  CSF  populations  were  established  much  earlier.    Nine  
subjects  (14  samples)  had  an  intermediate  or  compartmentalized  CSF  population  detected  
between  5-­‐‑12  months  post  infection  (Figure  13A);  five  of  these  subjects  had  an  initial  
clonally  amplified  CSF  population.    When  we  determined  the  estimated  TMRCAs  of  these  
CSF  populations,  we  could  date  all  but  one  of  the  early  clonal  amplification  events  as  
starting  around  two  months  after  infection  (Subjects  7146,  9018,  9021,  and  9044;  Table  3).    
These  data  show  that  the  CNS  compartment  is  permissive  for  HIV-­‐‑1  replication  in  at  least  a  
subset  of  subjects  from  very  early  times  after  infection.  
We  have  recently  shown  that  after  vertical  transmission  to  children,  CNS  
compartmentalization  can  be  established  early  via  the  sequestration  of  one  of  multiple  
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transmitted  variants  in  the  CNS  (317).    When  we  reanalyzed  data  from  a  previously  
described  subject  (7146,  Figure  15C)  (284)  using  BEAST,  we  showed  that  the  phenomenon  of  
transmission  of  two  variants  with  one  sequestered  in  the  CSF/CNS  shortly  after  
transmission  also  occurs  in  adults.    In  this  case  the  two  transmitted  variants  diverged  from  
each  other  in  the  donor  (BEAST-­‐‑estimated  TMRCA  of  965  days  but  with  a  reported  
transmission  date  of  156  days  prior  to  sampling)  while  the  transmitted  variants  diversified  
in  the  recipient.    One  lineage  that  was  present  in  both  the  blood  and  CSF  went  through  a  
bottleneck  (presumably  the  transmission  bottleneck)  at  134  days  prior  to  sampling,  again  
consistent  with  the  reported  transmission  date  of  156  days  prior  to  sampling.    The  other  
variant  was  sequestered  in  the  CNS  with  an  estimated  bottleneck  of  85  days,  appearing  
early  as  a  clonally  amplified  variant.    In  addition,  a  series  of  recombinants  between  these  
two  lineages  appeared  in  both  the  blood  and  CSF  over  time.    This  additional  mechanism  for  
establishing  a  compartmentalized  viral  population  within  the  CNS  early  following  
transmission  was  also  observed  for  subject  9018  (Table  3).  
 
All transmitted variants are R5 T cell-tropic and are predominantly selected to 
use high levels of CD4 for entry  
Macrophage-­‐‑tropic  HIV-­‐‑1  variants  can  infect  cells  expressing  low  levels  of  CD4  
while  R5  T  cell-­‐‑tropic  viruses  are  selected  for  replication  in  cells  with  high  levels  of  CD4  for  
entry  (8,  79,  80,  119,  193,  230,  262,  322).    Macrophage-­‐‑tropic  HIV-­‐‑1  is  seen  most  reliably  as  a  
compartmentalized  CSF/CNS  population  in  a  subset  of  individuals  with  HAD.    To  further  
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our  understanding  of  viral  characteristics  in  the  CNS  early  during  infection,  we  analyzed  
the  entry  phenotype  of  viruses  isolated  from  our  adult  primary  infection  cohort.    Affinofile  
cells,  on  which  CD4  and  CCR5  surface  expression  can  be  differentially  induced  (151),  are  a  
more  reproducible  model  for  entry  tropism  analysis  compared  to  primary  cells  (154).    We  
assessed  entry  phenotypes  by  measuring  the  ability  of  pseudotyped  reporter  viruses  to  
enter  Affinofile  cells  expressing  either  high  or  low  levels  of  CD4.    Viruses  pseudotyped  with  
Env  proteins  derived  from  24  subjects,  representing  all  phylogenetic  states  and  a  wide  range  
of  days  p.i.,  were  only  able  to  infect  Affinofile  cells  expressing  CCR5  and  high  levels  of  CD4  
and  were  considered  R5  T  cell-­‐‑tropic  (Figure  16A-­‐‑C).    However,  the  CSF/CNS  
compartmentalized  viruses  showed  a  statistically  significant  small  enhancement  for  entry  at  
low  CD4  compared  to  the  CSF/CNS  equilibrated  viruses  (P=0.0004,  Figure  16C),  suggestive  
of  a  distinctive  replication  environment  (discussed  below).    Thus,  we  conclude  that  in  most  
adults  early  after  infection,  replication  in  the  CNS,  including  compartmentalized,  
independent  replication,  is  dominated  by  viruses  that  have  been  selected  for  replication  in  T  
cells.    Additionally,  these  data  reinforce  the  growing  evidence  that  macrophage-­‐‑tropic  




Independent  HIV-­‐‑1  replication  in  the  CNS  has  been  associated  with  neurological  
disorders  (132,  258,  283)  and  may  represent  a  distinct  reservoir  from  that  found  in  the  blood  
and  lymphoid  tissue  (6,  243).    We  examined  the  virologic  characteristics  associated  with  
early  CNS  infection  through  analysis  of  paired  cross-­‐‑sectional  and  longitudinal  blood  
plasma  and  CSF  samples  from  a  large  cohort  of  72  ART-­‐‑naïve  subjects  infected  with  HIV-­‐‑1  
for  less  than  two  years.    Our  current  study  significantly  builds  upon  a  previous  preliminary  
study  by  our  group  (284),  enabling  us  to  propose  a  model  with  four  distinct  states  to  
describe  the  relationship  between  viral  populations  in  the  CSF/CNS  and  viral  populations  
within  the  peripheral  blood  during  early  HIV-­‐‑1  infection.    These  states  are  based  upon  
details  revealed  by  the  current  study  on  mechanisms  of  establishment  of  viral  
compartmentalization  within  the  CNS,  relationships  between  cellular  inflammation,  HIV  
RNA  levels  and  phylogenetic  state,  and  insight  into  longitudinal  maintenance  and  evolution  
of  compartmentalization.    
The  first  state  (Figure  17A)  was  observed  in  subjects  with  little  evidence  of  CNS  
replication  or  pleocytosis,  with  CSF  HIV-­‐‑1  RNA  concentrations  proportionally  1-­‐‑2%  of  the  
viral  load  in  the  periphery  (Figure  13B).    In  many  of  these  subjects,  the  CSF  HIV-­‐‑1  RNA  
level  was  very  low,  below  the  limit  of  detection  of  standard  assays.    Minimal  CSF  viral  
burden  has  been  observed  in  a  prior  report  on  a  portion  of  this  primary  infection  cohort  
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(308).    With  little  or  no  pleocytosis,  HIV-­‐‑1  is  likely  entering  the  CSF/CNS  at  low  levels  via  
incomplete  partitioning  of  virus  at  the  blood-­‐‑brain  barrier,  or  low  level  trafficking  of  
immune  cells,  including  small  numbers  of  infected  CD4+  T  cells.    In  this  circumstance  the  
viral  population  is  very  similar  to  the  population  in  the  blood.    It  is  possible  that  some  HIV-­‐‑
1  is  replicating  independently  in  the  CNS  at  low  levels  in  these  subjects,  but  we  were  not  
able  to  detect  these  putative  genetic  variants  above  the  low  level  background  of  virus  
recently  imported  from  the  periphery  into  the  CSF/CNS.    An  argument  in  favor  of  even  this  
low  level  viremia  in  the  CSF  being  the  result  of  T  cell  trafficking  is  the  observation  that  in  
neuro-­‐‑asymptomatic  subjects  with  CD4+  T  cells  below  50  cells/ul  in  the  blood  the  viral  load  
in  the  CSF  is  on  average  lower  than  in  subjects  with  higher  CD4+  T  cell  counts  (248,  309).  
In  a  second  state  (Figure  17B),  we  observed  a  relationship  between  equilibrated  viral  
populations  with  elevated  viral  load  and  high  levels  of  pleocytosis  (Figure  13C).    These  
equilibrated  populations  were  most  likely  the  result  of  the  release  of  virus  from  increased  
numbers  of  infected  CD4+  T  cells  trafficking  from  the  periphery  into  the  CNS  in  response  to  
HIV-­‐‑1  replication  or  another  inflammatory  condition  (e.g.  neurosyphilis).    Thus,  while  low  
levels  of  local  CNS  replication  may  have  been  occurring,  the  virus  imported  from  the  
periphery  by  infected  CD4+  T  cells  dominated  the  population  as  it  raised  the  CSF  HIV-­‐‑1  
RNA  concentration  by  release  of  virus.    If  the  inflammatory  immune  response  was  
successful,  pleocytosis  might  eventually  result  in  low  CSF  viral  loads,  a  condition  observed  
in  a  small  subset  of  subjects  with  pleocytosis  but  very  low  levels  of  virus  in  the  CSF  (Table  
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4).    Pleocytosis  was  also  observed  in  several  subjects  with  an  intermediate  viral  population  
phenotype  and  half  of  the  subjects  with  compartmentalized  viral  populations  (Figure  13D),  
suggesting  pleocytosis  may  result  in  dynamic  changes  in  the  viral  population  in  the  CSF.    
An  association  between  equilibrated  compartments  and  high  pleocytosis  was  also  observed  
in  a  previous  study  analyzing  four  HIV-­‐‑1  infected  subjects  during  therapy  interruption  
(299).      
In  a  third  state  (Figure  17C),  we  observed  clonally  amplified  CSF  populations  of  low  
complexity  (Figures  12  and  15)  representing  the  recent  expansion  of  identical  or  nearly  
identical  variants  that  required  high  levels  of  CD4  for  entry  (R5  T  cell-­‐‑tropic;  Figure  16).    
High  levels  of  pleocytosis  were  observed  in  approximately  half  of  the  subjects  with  clonally  
amplified  CSF  populations,  making  it  possible  that  the  influx  of  activated  CD4+  T  cells  may  
also  have  provided  cellular  targets  for  further  transient  amplification  of  a  CSF  variant.    We  
(11)  (Dukhovlinova  et  al.,  in  preparation)  and  others  (44,  159,  293)  have  observed  clonal  
amplification  in  the  genital  tract  as  well  as  in  the  CSF  both  early  (284,  317)  and  later  times  in  
infection  (283).    Clonal  amplification  appears  to  be  a  distinct  type  of  virus-­‐‑host  interaction  
where  infection  of  a  population  of  CD4+  T  cells  in  a  compartment  is  a  low  probability  event  
and  when  it  occurs  there  is  transient  rapid  expansion  of  the  viral  population.      The  detection  
of  clonally  amplified  populations  in  the  CSF  within  the  first  year  of  infection  has  allowed  us  
to  estimate  the  establishment  of  these  populations  within  the  CNS  to  within  the  first  2-­‐‑6  
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months  (Table  3,  Figure  15),  and  such  amplified  populations  were  detected  in  8%  of  subjects  
in  this  study  within  the  first  year.  
In  the  final  state,  we  observed  more  genetically  complex  compartmentalized  viral  
replication  within  the  CSF/CNS  (Figure  17D)  indicative  of  persistent  replication  beyond  a  
single  clonal  amplification  event.    In  an  effort  to  get  a  more  complete  view  of  the  interaction  
of  the  virus  within  the  CNS  at  these  early  times  of  infection  we  have  interpreted  the  
presence  of  persistent  replication  in  the  CNS  based  on  four  criteria:    i)  sequential  clonal  
amplification  events  that  indicated  a  permissive  CNS  environment  for  viral  replication  
(Figure  15B);  ii)  overlapping  clonal  amplification  events  that  gave  rise  to  compartmentalized  
recombinants  showing  continuous  replication  between  the  sampled  time  points  (Figure  
15A);  iii)  intermittent  compartmentalization  and  pleocytosis  suggesting  an  inflammatory  
immune  response  to  ongoing  replication  (Figure  14B);  and  iv)  sequestration  of  a  transmitted  
variant  within  the  CNS  (Figure  15C).    Collectively  these  markers  defined  approximately  
35%  of  subjects  in  the  first  two  years  as  having  evidence  of  viral  replication  in  the  CNS  in  at  
least  one  time  point,  and  20%  having  evidence  of  replication  and/or  inflammation  at  
multiple  time  points  within  this  period.    This  suggests  that  the  CNS  compartment  is  
permissive  for  HIV-­‐‑1  replication  in  at  least  a  subset  of  subjects  from  a  very  early  period  after  
infection.  
Entry  tropism  analysis  revealed  that  all  compartmentalized  variants  required  high  
levels  of  CD4  for  entry.    It  is  now  widely  described  in  the  literature  that  macrophage-­‐‑tropic  
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variants  utilize  low  levels  of  CD4  for  entry  (8,  79,  80,  119,  193,  230,  262,  322),  are  not  
transmitted,  and  that  the  transmitted  virus  is  R5  T  cell-­‐‑tropic  (8,  148,  158,  171,  223,  230,  241,  
273,  335),  an  understanding  further  supported  by  our  phenotypic  analysis  (Figure  16).    Our  
finding  that  the  viruses  involved  in  this  early  persistent  CNS  replication  were  adapted  to  
replication  in  CD4+  T  cells  is  distinct  from  previous  studies  of  individuals  with  HAD  where  
genetically  complex  compartmentalized  CSF  populations  that  had  been  replicating  as  an  
isolated  population  had  evolved  to  replicate  in  macrophages/microglia  (283).    Thus,  
adaptation  to  use  low  levels  of  CD4  for  entry,  a  hallmark  of  macrophage  tropism,  is  not  a  
feature  of  the  transmitted  virus  and  does  not  evolve  during  the  early  stages  of  CNS  infection  
in  adults,  at  least  as  reflected  in  the  compartmentalized  virus  detected  in  the  CSF.      
However,  we  do  note  that  the  compartmentalized  viruses  from  the  CSF  show  a  statistically  
significant  increase  in  the  ability  to  enter  cells  with  low  levels  of  CD4  compared  to  CSF  virus  
from  equilibrated  subjects  (Figure  16C).    One  explanation  for  this  small  difference  is  that  the  
virus  in  the  CNS  is  carrying  out  at  least  a  portion  of  its  replication  in  a  cell  with  low  levels  of  
CD4  which  allows  for  at  least  a  low  level  of  selection  for  a  low  CD4  entry  phenotype.  
Despite  limitations  of  generalizing  CSF  findings  to  those  of  the  CNS  more  broadly,  
our  studies  have  used  the  best  methods  available  in  living  humans  to  assess  HIV-­‐‑1  
populations  derived  from  the  CNS  in  a  unique  cohort  of  subjects  enrolled  during  primary  
HIV-­‐‑1  infection.    Our  results  show  that  in  cross  sectional  analysis  over  the  first  two  years  of  
HIV-­‐‑1  infection,  35%  of  subjects  have  evidence  of  either  local  viral  replication  in  the  CNS  or  
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a  robust  inflammatory  response,  and  that  in  approximately  20%  of  subjects  this  CNS  
involvement  can  persist  over  time.    We  have  found  that  the  viral  population  in  the  CSF  is  
dynamic  as  the  result  of  local  replication  and/or  the  influx  of  virus  in  infected  CD4+  T  cells  
as  part  of  an  inflammatory  response.    This  early  viral  replication  in  a  subset  of  subjects  may  
represent  an  inability  to  protect  the  CNS  from  infection,  potentially  leading  to  HAND  later  
in  infection,  and  may  also  define  a  distinct  reservoir  of  infected  cells  within  the  body.    
Longitudinal  follow-­‐‑up  of  these  subjects  to  examine  the  long-­‐‑term  impact  of  the  presence  of  
early  active  HIV-­‐‑1  replication  in  the  CNS  will  help  to  define  the  significance  of  these  
findings  for  clinical  neurologic  disease  outcomes  and  compartmentalized  viral  reservoirs  in  
the  setting  of  HIV-­‐‑1. 
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MATERIALS AND METHODS 
 
Ethics statement 
The  study  was  approved  by  the  Institutional  Review  Boards  at  UCSF,  Yale  
University,  and  the  University  of  North  Carolina.    All  study  participants  were  adults.    
Written  informed  consent  was  obtained  from  all  participants.      
  
Study design 
We  assessed  samples  obtained  through  an  observational  longitudinal  neurological  
study  of  primary  HIV-­‐‑1  infection  to  determine  viral  characteristics  associated  with  early  
HIV-­‐‑1  CNS  infection.    Subjects  were  referred  from  the  community  and  were  eligible  if  they  
met  prospectively  determined  criteria  for  laboratory  confirmation  of  primary  HIV-­‐‑1  
infection,  as  previously  described  (284).    Blood  and  CSF  samples  were  collected  at  
enrollment,  six  weeks,  and  every  six  months  thereafter.    This  analysis  included  samples  
obtained  up  to  two  years  post-­‐‑infection  from  subjects  enrolled  prior  to  4/1/2012.    CSF  and  
plasma  HIV-­‐‑1  RNA  concentrations  were  determined  as  described  (284);  paired  samples  
were  selected  for  further  SGA  analysis  if  CSF  HIV-­‐‑1  RNA  was  greater  than1,000  copies/ml  
(to  ensure  adequate  sampling).    Primary  study  endpoints  included  SGA  of  HIV-­‐‑1  env  for  
viral  genetic  compartmentalization  and  phenotypic  analyses,  CSF  and  blood  HIV-­‐‑1  RNA  
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concentrations,  measures  of  CSF  cellular  inflammatory  response  (white  blood  count,  WBC)  
and  blood  brain  barrier  disruption  (CSF:plasma  albumin  ratio).      
      
Single genome amplification 
Viral  RNA  was  isolated  as  previously  described  (284).    Briefly,  RNA  was  isolated  
from  samples  (140  µμL)  with  viral  loads  >10,000  copies/ml  using  the  QIAmp  Viral  RNA  Mini  
kit  (Qiagen).    To  increase  template  number,  samples  with  viral  loads  <10,000  copies/ml  were  
first  pelleted  via  ultracentrifugation.    cDNA  was  generated  using  an  oligo-­‐‑d(T)  primer.    
Single  genome  amplification/template  endpoint  dilution  PCR  (158)  of  the  env  gene  through  
the  3’  LTR  U3  end  was  conducted  using  the  cDNA  as  template  as  previously  described  (284,  
317).    Sequences  for  full-­‐‑length  env  were  generated  (samples  analyzed  previously  were  
sequenced  from  the  start  of  V1  through  the  ectodomain  of  gp41  (284)).    
  
Phylogenetic analysis of env viral sequences 
Phylogenetic  analysis  was  conducted  as  previously  described  (317).    In  brief,  DNA  
sequences  were  aligned  (ClustalW)  (323),  codon  aligned  (MEGA  4.0),  and  phylogenetic  trees  
were  generated  (neighbor-­‐‑joining  method,  MEGA  4.0  (319)).    Phylogenetic  states  were  
determined  by  visual  assessment  and  statistically  evaluated  using  the  Slatkin-­‐‑Maddison  (S-­‐‑
M)  test  (298)  as  previously  described  (317).    Phylogenetic  states  included:  
compartmentalization,  genetically  distinct  and  statistically  significant  CSF  population  (S-­‐‑M  
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P  value  <  0.05);  intermediate,  minor  but  not  statistically  significant  CSF  population  of  ≥  4  
CSF  variants  (S-­‐‑M  P  value  >  0.05);  and  equilibrated,  no  evidence  of  a  minor  or  major  CSF  
population  (S-­‐‑M  P  value  >  0.05).    If  discrepancies  existed  between  visual  and  statistically  
observation,  further  analysis  of  sequence  diversity  and  phylogenetic  tree  structure  was  
used.    Low  bootstrap  values  were  used  (≥35)  because  of  the  overall  low  diversity  of  the  viral  
populations  early  after  infection.    Clonally  amplified  lineages  (short  branch  lengths  with  
bootstrap  values  ≥  99  and  a  clade  of  ≥  3  variants)  were  also  identified.  
  
Bayesian analysis 
A  Bayesian  Markov  Chain  Monte  Carlo  (MCMC)  approach  using  BEAST  v.1.6.1  (78)  
estimated  the  TMRCA  for  each  viral  population.      A  substitution  rate  of  1.5x10-­‐‑5  
substitutions/site/generation  and  standard  deviation  of  3.0x10-­‐‑6  were  fixed  under  a  
lognormal  relaxed  clock  (uncorrelated)  model.    The  rate  was  calculated  via  tip  dating,  using  
a  consensus  sequence  (set  as  day  0),  and  the  estimated  days  post  infection.    The  HKY  
nucleotide  substitution  model  had  estimated  base  frequencies  and  a  gamma-­‐‑distributed  rate  
heterogeneity  (4  gamma  categories).    A  coalescent  Bayesian  Skyline  tree  prior  with  a  
Piecewise-­‐‑constant  skyline  model  was  used  (10  groups).    The  MCMC  algorithm  was  run  for  
30  million  generations,  logging  every  1000  and  with  a  10%  burn-­‐‑in.    The  results  from  at  least  
two  independent  runs  were  combined,  and  the  effective  sample  size  for  all  estimates  was  
>200.    A  generation  time  of  1.0  day  was  used.  
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Construction of HIV-1 env clones 
Full  length  HIV-­‐‑1  env  genes  were  re-­‐‑amplified  from  the  first-­‐‑round  SGA  products  as  
previously  described  (283).    The  PCR  product  was  cloned  into  the  pcDNA3.1D/V5-­‐‑His-­‐‑




293T  cells  were  cultured  in  Dulbecco’s  modified  Eagle  medium  (DMEM)  
supplemented  with  10%  fetal  bovine  serum  (FBS)  and  100  mg/ml  of  penicillin  and  
streptomycin.    293-­‐‑Affinofile  cells  (151),  generously  provided  by  Dr.  Ben-­‐‑Hur  Lee,  were  
maintained  in  DMEM  supplemented  with  10%  dialyzed  FBS  (12–14  kD  dialyzed;  Atlanta  
Biologicals)  and  50  mg/ml  blasticidin  (D10F/B).  
  
Env-pseudotyped viruses 
Env-­‐‑pseudotyped  luciferase  reporter  viruses  were  generated  as  previously  described  
(317).    Briefly,  293T  cells  were  cotransfected  with  an  env  expression  vector  and  the  pNL4-­‐‑
3.LucR-­‐‑E-­‐‑  HIV-­‐‑1  backbone  (obtained  from  the  NIH  AIDS  Research  and  Reference  Reagent  
Program,  Division  of  AIDS,  NIAID,  NIH)  using  the  Fugene  6  transfection  reagent  and  
protocol  (Roche).    Transfection  medium  was  replaced  with  fresh  culture  medium  five  hours  
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post-­‐‑transfection  and  the  cells  were  incubated  at  37oC  for  48  hours,  after  which  viral  
supernatants  were  filtered  with  0.45  µμM  filters  (Millipore)  and  stored  at  -­‐‑80oC.  
  
293-Affinofile cellular surface expression of CD4 and CCR5 
293-­‐‑Affinofile  cell  (151)  CD4  and  CCR5  receptor  expression  was  induced  with  
doxycycline  (doxy;  Invitrogen)  and  ponasterone  A  (ponA;  Invitrogen),  respectively,  as  
previously  described  (317).    Briefly,  cells  were  induced  at  two  conditions:  CD4high/CCR5high  
(6  ng/ml  doxy  and  5  µμM  ponA,  respectively)  and  CD4low/CCR5high  (0  ng/ml  doxy  and  5  µμM  
ponA).    CD4  and  CCR5  receptor  expression  was  measured  using  quantitative  fluorescence-­‐‑
activated  cytometry  (qFACS)  following  staining  with  either  phycoerythin  (PE)-­‐‑conjugated  
anti-­‐‑human  CD4  antibody  (clone  Q4120,  BD  Biosciences)  or  PE-­‐‑conjugated  mouse  anti-­‐‑
human  CCR5  antibody  (clone  2D7,  BD  Biosciences),  and  surface  levels  were  calculated  
using  QuantiBRITE  beads  (BD  Biosciences).  
  
Single-cycle infection of 293-Affinofile cells 
As  described  previously  (317),  Env-­‐‑pseudotyped  luciferase  reporter  viruses  were  
first  titered  on  293-­‐‑Affinofile  cells  (151)  expressing  CD4high/CCR5high.    For  viral  infections,  
black  tissue  culture  plates  (96  wells)  were  coated  with  10%  poly-­‐‑L-­‐‑lysine  and  seeded  with  
293-­‐‑Affinofile  cells  (1.85  x  104  cells/well).    Eighteen  to  24  hours  later,  expression  of  CD4  and  
CCR5  was  induced  at  CD4high/CCR5high  and  CD4low/CCR5high.    Eighteen  to  24  hours  later,  the  
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induction  medium  was  removed  and  replaced  with  100  µμl  of  fresh,  warmed  culture  medium  
containing  Env-­‐‑pseudotyped  virus.    The  plates  were  spinoculated  (222)  at  2,000  rpm  for  2  
hours  at  37oC,  and  incubated  for  48  hours  at  37oC.    Infection  medium  was  removed,  cells  
were  lysed,  and  luciferase  activity  was  assayed  using  the  luciferase  assay  system  (Promega).  
  
Statistical analysis 
Compartmentalization  was  assessed  statistically  using  the  Slatkin-­‐‑Maddison  test  for  
gene  flow  (298).    Differences  between  groups  were  examined  for  statistical  significance  
using  the  Mann-­‐‑Whitney  Test.    Correlations  employed  Spearman’s  rank  correlation  





Table  2:  Background  demographic  and  clinical  characteristics  of  study  participants  at  
baseline    
Entire PHI cohort                  
(n=72)
Subjects analyzed by SGA 
(n=33)a
Sex, % male 98.6 97
Age, y 36 (28-43) 36 (31-44)
Days post infection 106  (73-158) 128 (76-173)
CD4+ T cells (cells/µl) 567 (411-732) 488 (361-714)
plasma HIV-1 RNA (log10 copies/ml) 4.66 (4.09-5.08) 5.06 (4.72-5.58)
CSF HIV-1 RNA (log10 copies/ml) 2.62 (1.74-3.32) 3.37 (2.97-3.82)
CSF WBC (cells/µl) 6.0 (3.0-10.8) 7.0 (4.0-12.0)
CSF/plasma albumin ratio 5.0 (4.0-6.8) 5.2 (3.7-6.8) 	  	  
NOTE.  Values  shown  are  medians  (interquartile  ranges)  except  where  noted  
aSubjects  with  sufficient  viral  RNA  loads   in   the  CSF   (>1,000  copies  of  viral  RNA/ml;   to  
ensure  adequate   sampling)   for   further  SGA  analysis   at  one  or  more   time  points  within  
the  first  two  years.  
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Table  3:  Subject  population  virologic,  clinical  and  phylogenetic  characteristics    
7146 156 5.63 5.23 0.392 552 86 14.35 Cp, Ap 0.022 965* 85
177 5.34 4.4 0.115 476 97 14.35 Eq 0.162   
203 5.01 4.41 0.252 310 53 7.12 Cp, Ap 0.006  
9001 308 5.29 3.07 0.006 573 4 3.5 Eq 0.648 378  
399 4.87 3.61 0.055 575 5 4.33 Eq 0.967 456  
9002 275 4.65 3.66 0.102 539 8 7.35 In 0.828 296 43
338 4.57 4.08 0.323 501 14 9.61 In, Ap 0.16 309 76
9003 375 4.56 3.18 0.041 521 4 3.19 Eq 0.867 1292*
9006 153 4.44 3.11 0.047 435 8 4.64 Eq 0.842 167
340 4.82 3.21 0.025 453 6 3.75 Eq 0.331 493
9007 149 5.37 2.63 0.002 256 4 10.85 Eq 0.999 307
406 4.47 3.59 0.132 292 4 6.87 In 0.038 231 117
9015 77 5.41 3.33 0.008 474 6 7.4 Eq 0.377 153  
9016 409 5.06 3.38 0.021 344 0 4.2 Eq 0.279 390  
691 4.94 3.12 0.015 237 5 4.3 Eq 0.533 592
9018 200 5.61 4.57 0.093 350 11 6.45 Cp, Ap 0.104 2277* 140
687 4.8 4.47 0.471 491 119m 9.29 Eq 0.257   
876 4.65 4.55 0.805 425 71 11.84 Eq 0.601  
1073 4.95 3.99 0.109 453 14 7.97 Cp, Ap 0.022  
1180 4.98 4.61 0.43 505 17 5.34 Cp, Ap <0.0001
9019 100 4.69 3.14 0.028 750 13 5.58 Eq 0.1173 82
9020 240 4.59 3.45 0.073 368 10 6.95 Cp 0.002 608* 246
9021 140 4.82 3.37 0.036 441 8 4.89 Cp 0.002 159 102
341 5.8 4.01 0.016 446 71 5.21 Ap 0.003 314 55
9024 222 4.75 4.29 0.348 974 12 5.74 Eq 0.315 196  
405 4.63 3.73 0.125 732 5 4.34 Eq 0.697 379  
596 4.4 4.01 0.407 600 10 5.58 Eq 0.735 1045
9025 50 5 4.18 0.15 752 7 3.91 Eq N/A 49  
9027 234 4.84 3 0.015 402 6 6.17 In 0.328 236 115
425 4.76 3.39 0.043 375 5 6.11 Eq 0.973 775  
9036 223 4.48 3.11 0.042 610 4 6.07 Eq 0.298 386
9037 46 5.71 3.43 0.005 884 26 6.35 Eq N/A 52
9039 36 5.57 4.3 0.054 539 53 9.31 Eq 0.465 89  
9040 165 4.22 3.79 0.37 705 4 7.67 Ap <0.0001 209 33
352 4.88 3.15 0.019 664 3 9.19 Cp, Ap <0.0001 262 131
644 5.34 3.64 0.02 484 2 8.15 Cp 0.001 553 321
918 5.44 3.37 0.009 279 4 8.33 Eq 0.39
9044 128 4.82 3.49 0.047 533 20 4.3 In, Ap 0.011 124 50
190 5.08 3.98 0.079 583 30 4.01 Eq, Ap 0.776 307
9045 54 4.75 3.1 0.022 542 9 4.46 Eq, Ap 0.292 214
9048 58 5.21 3.1 0.008 456 11 7.52 In 0.258 131 73
9055 106 5.38 3.51 0.013 619 12 6.42 Eq 0.028 83
9058 110 5.18 3.66 0.03 237 4 2.44 Eq 0.249 398
9062 103 4.88 3.43 0.035 420 16 4.09 Eq 0.24 89  
9063 86 5.06 3.01 0.009 558 4 3.38 Eq 0.548 565*
9071 128 5.59 3.93 0.022 279 6 4.31 Eq 0.815 124  
177 5.64 4.08 0.028 468 13 4.3 Eq 0.994 147  
9073 75 5.68 4.01 0.021 297 42 2.07 Eq 0.954 765*
9076 185 5.66 3.85 0.015 111 4 4.09 Eg 0.989 257
9082 106 4.9 3.94 0.11 421 32 2.14 Eq 0.948 91
9083 151 5.37 3.72 0.022 352 7 3.55 Eq 0.941 374  
344 5.31 3.55 0.017 389 3 5.48 Eq 0.39 754  
9096 271 5.58 3.77 0.015 666 3 2.68 In 0.027 649 253
348 4.39 3.53 0.138 743 9 3.02 Cp, Ap <0.0001 707 337

























aTime  point(s)  beyond  2  years  p.i.  analyzed  for  subject  9018  and  9040  were  not  included  
in  any  overall  population  analyses.    
bEstimated  
c,dVL,  viral  load;  HIV-­‐‑1  RNA  (log10  copies/ml)  
eCSF/blood  viral  load  rati.  
fCells/µμl  
gCSF  white  blood  cell  (WBC)  count,  cell/µμl  
hCSF/plasma  albumin  ratio  
iHIV-­‐‑1   population   characteristics   in   the   CSF   compartment   (compart).      Eq,   equilibrated  
blood  plasma  and  CSF  populations;  In  (Intermediate),  a  minor  subpopulation  of  the  CSF  
was   compartmentalized;   Cp,   significant   compartmentalization   in   the   CSF;   Ap,   clonal  
amplification  of  ≥3  variants  detected  in  the  CSF.  
jP  values  used   to  measure  genetic  compartmentalization  between  the  blood  plasma  and  
CSF  HIV-­‐‑1   populations  were   obtained   using   the   Slatkin-­‐‑Maddison   (S-­‐‑M)   test   for   gene  
flow  between  populations  (298).    A  P  value  <0.05  indicated  statistically  significant  genetic  
compartmentalization.      When   very   low   sequence   diversity   was   present,   a   Slatkin-­‐‑
Maddison  P  valued  could  not  be  accurately  determined  (N/A).  
kTMRCA  of  the  entire  viral  population,  analyzed  by  BEAST  (78).    An  asterisk  (*)  indicates  
transmission  of  >  1  variant.    
lTMRCA   for   the   compartmentalized   (Comp)   CSF   population   for   intermediate   and  
compartmentalized  subjects.    
mPatient  9018  diagnosed  with  neurosyphilis  at  indicated  date.    
  
  124  
Table  4:  Virologic  and  clinical  characteristics  for  subjects  not  analyzed  by  SGA  
Subject                           
IDa
Days                     
p.i.b
VL                          
Plasmac
VL                    
CSFd CD4




9004 123 3.97 1.69 587 2 4.16
9005 89 2.98 1.69 656 5 2.02
139 3.32 1.69 627 3 2.29
9008 148 2.92 1.69 758 1 4.31
203 3.89 1.69 715 0 4.69
9010 237 3.01 2.31 497 11 5.55
302 3.51 1.69 538 6 3.79
439 2.87 1.69 242 3 5.38
547 4.24 1.81 175 5 5.29
9012 106 4.87 2.60 601 8 11.09
162 5.58 2.89 627 7 11.86
293 5.03 2.69 544 7 10.37
475 4.86 2.47 544 8 10.44
9017 50 4.24 2.18 361 14 4.51
9023 82 4.94 2.58 305 0 10.14
9026 46 4.70 2.62 317 6 6.84
9029 376 4.10 2.95 410 1 6.43
418 4.02 2.33 520 1 5.45
9030 304 4.10 2.05 447 2 5.40
409 3.94 2.65 501 8 5.96
9034 54 3.89 1.69 854 3 4.47
98 3.51 2.08 787 3 4.29
9035 51 4.46 1.75 576 2 4.96
9038 92 1.69 1.69 1234 6 7.38
155 1.69 1.69 1399 4 6.71
289 1.69 1.69 1497 2 7.53
484 1.69 1.69 1251 6 7.77
714 1.69 1.69 898 0 7.96
9042 42 4.24 1.85 854 2 4.79
9043 102 3.50 1.69 1143 4 12.07
185 3.61 1.69 1076 6 10.05
295 4.08 2.09 891 6 10.88
9046 74 2.83 1.69 596 30 12.71
9047 91 4.35 1.56 586 1 7.39
9049 176 3.64 1.86 735 9 3.62
258 4.33 2.20 655 6 3.39
385 4.29 2.18 574 20 3.33
559 4.02 1.63 630 2 3.35
686 4.45 2.46 589 3 2.77
9051 150 4.72 2.46 412 2 5.14   
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9052 75 2.86 1.69 686 7 6.54
143 3.59 1.69 839 5 5.52
325 2.18 1.38 823 4 5.88
523 3.14 2.71 777 15 5.30
9053 72 4.08 1.69 1608 6 4.13
9054 153 3.80 1.69 601 3 5.34
9056 45 4.38 2.54 518 22 5.54
89 4.16 2.80 522 9 4.61
237 3.93 2.49 567 9 3.76
9060 133 4.69 2.88 584 6 5.21
9064 52 3.95 2.56 798 11 5.77
9065 225 4.46 2.64 441 2 3.00
9067 54 4.17 1.88 598 1 2.42
114 3.16 1.69 951 2 2.50
259 3.31 1.69 590 2 2.19
432 4.21 2.18 724 0 3.51
9069 136 5.09 2.77 452 12 3.98
242 4.97 2.68 472 25 3.71
9070 316 3.28 1.69 377 1 2.85
360 3.52 1.90 386 4 2.84
442 3.59 2.12 323 3 2.93
9072 250 4.90 2.99 740 1 3.22
9078 127 3.90 1.69 493 3 9.05
9079 127 4.33 2.79 641 17 7.26
9084 61 4.60 2.61 858 5 3.40
110 3.74 1.86 627 12 4.35
9085 139 4.43 2.21 590 4 4.08
9090 333 4.37 2.83 384 7 3.04
9091 78 4.80 1.80 657 3 8.68
132 4.89 1.78 557 3 10.50
9094 20 5.01 1.74 617 3 3.78
9095 77 5.57 2.30 772 1 4.48
9099 100 4.63 2.17 259 3 4.85
  
aTime  point(s)  beyond  2  years  p.i.  analyzed  for  subject  9018  and  9040  were  not  included  
in  any  overall  population  analyses.    
bEstimated.  
c,dVL,  viral  load;  HIV-­‐‑1  RNA  (log10  copies/ml).  
eCells/µμl.  
fCSF  white  blood  cell  (WBC)  count,  cell/µμl.  
gCSF/plasma  albumin  ratio.  
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Figure  12:  HIV-­‐‑1  blood  and  CSF  populations  early  during  infection  can  be  equilibrated,  
intermediate  or  compartmentalized  
Neighbor-­‐‑joining  phylogenetic  trees  depicting  sequence  relationships  from  subjects  with  
(A)   equilibrated,   (B)   intermediate   and   (C)   compartmentalized   viral   populations.      env  
sequences   from   the   CSF   (blue   circles)   and   blood   plasma   (red   triangles)   are   shown.    
Bootstrap   values   ≥35   are   included   (*)   at   the   appropriate   nodes.      Genetic   distance   is  
indicated  at  the  bottom  of  each  figure  (0.001,  number  of  nucleotide  substitutions  per  site  
between  env   sequences).      Independent  CNS  populations  are  noted  by  an  open   circle   at  
the   appropriate   node   and   a   dashed   (intermediate)   or   solid   (compartmentalized)   blue  
bracket.      Clonal   amplification   is   indicated   by   a   solid   black   bar.
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Figure  13:  Correlates  of  CSF  HIV-­‐‑1  RNA  levels,  CNS  inflammation,  and  CNS  
phylogenetic  state  
(A)  Pie  charts  grouping  the  samples  by  days  p.i.  and  showing  the  percentage  of  samples  
in  each  phylogenetic  state  as  a  function  of  time:  0-­‐‑4  months  (‘acute’),  5-­‐‑12  months  (‘early’),  
and  13-­‐‑24  (‘established’).    States  represented  include:  Not  Analyzed  by  SGA,  due  to  CSF  
viral  load  <1,000  copies/ml;  Equilibrated  (-­‐‑),  CSF  WBC  <10  cells/µμl;  Equilibrated  (+),  CSF  
WBC  ≥10  cells/µμl;  Intermediate;  and  Compartmentalized.    We  used  a  cut-­‐‑off  of  10  WBC/µμl  
to  define  a  state  of  substantial  CSF  pleocytosis  because  this  is  two-­‐‑times  the  upper  limit  
of  normal  value  of  CSF  WBC  (0  to  5  cells/µμl)  (97)  ensuring  that  the  measured  pleocytosis  
was  a  robust  marker  for  an  inflammatory  response.    (B)  Pie  chart  showing  the  percent  of  
samples  in  each  phylogenetic  state  exhibiting  substantial  CSF  pleocytosis  (CSF  WBC  ≥10  
cells/µμl).      (C)  Relationship  between  plasma  and  CSF  HIV-­‐‑1  RNA  concentrations  for  not  
analyzed   samples   with   minimal   pleocytosis   (NA(-­‐‑);   CSF   WBC   <10   cells/µμl)   and  
equilibrated   samples   with   minimal   pleocytosis   (Eq   (-­‐‑);   CSF   WBC   <10   cells/µμl).    
Spearman’s   rank   correlation   coefficient   and   P-­‐‑value   are   indicated.      Samples   with  
undetectable  CSF  HIV-­‐‑1  RNA  (<50  copies/ml;  limit  of  detection)  were  not  included  in  the  
correlation   analysis.      (D)   Relationship   between   CSF   viral   loads   for   equilibrated   with  
minimal  pleocytosis   (Eq(-­‐‑);  CSF  WBC  <10  cells/µμl);   intermediate   (Int);  equilibrated  with  
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marked   pleocytosis   (Eq(+);   CSF   WBC   ≥10   cells/µμl);   and   compartmentalized   (Comp)  
samples.      Significant  P   values   (Mann-­‐‑Whitney   Test)   comparing   relationships   between  
groups   are   indicated.      Samples   with   evidence   of   marked   pleocytosis   (CSF   WBC   ≥10  
cells/µμl)  are  indicated  using  open  circles,  while  samples  with  minimal  to  no  pleocytosis  
are  indicated  by  solid  circles.    
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Figure  14:  An  assessment  of  the  viral  populations  in  the  two  compartments  
longitudinally      
Examination   of   longitudinal   relationships   early   during   infection   for   20   subjects   with  
multiple   time  points  where   at   least   one   time  point  was   analyzed   for   viral   populations.    
This   group  did   not   differ   significantly   from   the   17   subjects  with   longitudinal   samples  
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available  but  not  analyzed  (due  to  low  CSF  viral  load)  in  the  average  number  of  samples  
per  person  or   the   time  span  covered   (not   shown).     Within   individual   subjects,   the  days  
post   infection  for  each  sample  is   indicated  using  circles,  which  represent   the  following:  
open  light  blue  circle,  sample  not  analyzed  due  to  CSF  viral  load  (VL)  <  1,000  copies/ml  
(NA   (low   CSF   VL));   open   royal   blue   circle;   sample   not   analyzed   but   CSF   VL   >   1,000  
copies/ml   (NA   (high  CSF  VL));   closed  dark  blue   circle,   equilibrated  with  minimal  CSF  
pleocytosis   (CSF  WBC   <10   cells/µμl)   (Equilibrated   (-­‐‑));   closed   pink   circle,   intermediate;  
closed   orange   circle   equilibrated  with  marked  CSF   pleocytosis   (CSF  WBC   ≥10   cells/µμl)  
(Equilibrated   (+));   and   closed   red   circle,   compartmentalized.      (A)   Subjects   with   all  
analyzed   time   points   equilibrated  with  minimal   to   no   pleocytosis   and   remaining   time  
points   not   analyzed.   (B)   Subjects   with   pleocytosis,   an   intermediate   phenotype,   or  
compartmentalization   in   one   time   point   (above   dotted   line)   and   subjects   with  
pleocytosis,   an   intermediate   phenotype,   or   compartmentalization   in   at   least   two   time  
points   (below   dotted   line).      In   every   subject   but   9002,   the   intermediate   (I)   or  
compartmentalized   (C)   viral   sequence   population   changed   between   sampling   time  

















































































Figure  15:  Compartmentalization  can  persist  and  evolve  independently  within  the  CSF  
over  time  
Neighbor-­‐‑joining   phylogenetic   trees   showing   how   compartmentalization   can:   (A)   be  
persistent   with   multiple   clonal   expansions   allowing   recombination;   (B)   consist   of  
sequential  transient  clonal  expansions;  and  (C)  be  established  with  a  transmitted  variant.    
env  sequences  from  the  CSF  are  labeled  with  circles  (C,  colors  designated  in  figure)  and  
env  sequences  from  the  blood  plasma  are  labeled  with  triangles  (P,  colors  designated  in  
figure).      Days   p.i.   are   noted.      Bootstrap   values   ≥50   are   indicated   (*)   at   the   appropriate  
nodes   to  highlight   the  more   significant  branch  points.     Genetic  distance   is   indicated  at  
the   top   of   each   phylogenetic   tree   (0.001,   number   of   nucleotide   substitutions   per   site  
between   env   sequences.)      Compartmentalized   populations   are   indicated   at   the  
appropriate  node  by  an  open  circle  and  emphasized  using  a  blue  bar.    BEAST-­‐‑generated  
TMRCAs   of   the   entire   viral   population   are   noted   adjacent   to   the   subject   ID,   and   the  
TMRCAs   of   the   different   compartmentalized   linages   (subject   9040   and   9021)   and  

















































Figure  16:  All  viruses  required  high  levels  of  CD4  for  entry,  indicative  of  selection  for  
replication  in  CD4+  T  cells      
Single-­‐‑cycle  infection  of  HIV-­‐‑1  Env-­‐‑pseudotyped  reporter  viruses  on  CD4lowCCR5high  293-­‐‑
Affinofile   cells   (151).      Receptor   expression   was   measured   as   follows:   CD4low   =   972  
receptors/cell,  CD4high  =  72,041  receptors/cell,  CCR5high  =  15,636  receptors/cell.    The  data  are  
averaged   from   triplicate   wells   for   each   of   2   to   3   env   clones   that   were   generated   per  
indicated  amplicon.    Amplicons  were  selected  for  cloning  to  represent  different  portions  
of  the  phylogenetic  tree.     Panels  show  infection  results  for  a  subset  of:  (A)  equilibrated;  
(B)   intermediate;   and   (C)   compartmentalized   subjects.      Longitudinal   time   points   are  
indicated  (T1,  T2,  T3,  etc.)  and  samples  with  marked  pleocytosis  are  noted  (*).  
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Figure  17:  Four  states  can  define  the  relationship  between  virus  in  the  CSF/CNS  and  
blood  early  during  infection      
Blood   and   CSF/CNS   compartments   are   indicated.      Blood   plasma   viral   variants   are  
represented  by  the  red  virus  particles;  and  CNS  viral  variants  are  represented  by  the  blue  
virus  particles.     CD4+  T  cells  are  represented  by  open  circles.     Arrows  indicate  direction  
of  virus  movement  between  compartments.      (A)  State  with  a  CSF  HIV-­‐‑1  RNA  level  1-­‐‑2%  
of   the   viral   load   in   the   blood   and   defined   by  minimal   to   no   local   CNS   replication   or  
inflammation,   resulting   in   an   equilibrated   state   between   the   two   compartments   (when  
CSF  viral   load  high  enough   for   analysis).     Transparent   infected  CD4+  T   cell   represents  
potential  local  CNS  replication  that  may  be  obscured  by  the  import  of  virus  into  the  CNS  
from  the  periphery.      (B)  State  of  equilibration  between  CSF  and  blood  accompanied  by  
high   levels   of   pleocytosis,   potentially   caused   by   local   CNS   replication.      Transparent  
infected  CD4+  T   cell   represents   potential   local   CNS   replication   likely   obscured   by   the  
high  levels  of  virus  secreted  by  the  infiltrating  CD4+  T  cells.    (C)  State  of  CSF/CNS  clonal  
amplification  of  identical  or  nearly  identical  variants  within  CD4+  T  cells.    These  clonally  
amplified  populations  are  characterized  by  low  diversity,  signified  by  all  CSF  viruses  in  
a   single   shade   of   blue.      (D)   State   of   genetically   complex,   compartmentalized   viral  
replication   within   CD4+   T   cells   in   the   CSF/CNS   indicative   of   persistent   replication  
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beyond   a   single   clonal   amplification   event;   this   complexity   is   signified   by   CNS   viral  
variants  in  multiple  shades  of  blue.  
  135  
CHAPTER IV. COMPARTMENTALIZED SIMIAN IMMUNODEFICIENCY VIRUS 
POPULATIONS OBSERVED IN THE CEREBROSPINAL FLUID OF RHESUS 




Human  Immunodeficiency  virus  type-­‐‑1  (HIV-­‐‑1)  infection  of  the  CNS  can  lead  to  the  
development  of  various  HIV-­‐‑1-­‐‑associated  neurological  disorders  (HAND),  often  occurring  
with  the  presence  of  genetically  distinct  compartmentalized  CSF  populations.    Nonhuman  
primate/Simian  Immunodeficiency  Virus  (SIV)  models  are  powerful  tools  to  study  the  
neuropathogenesis  of  HIV-­‐‑1  as  macaques  can  be  examined  longitudinally  and  both  CSF  and  
brain  tissue  can  be  analyzed.    Using  heteroduplex  tracking  assay  (HTA),  single  genome  
amplification  (SGA)  and  phylogenetic  analysis  of  the  full-­‐‑length  env  gene,  we  examined  
viral  sequences  in  paired  peripheral  blood  and  CSF  collected  over  the  full  course  of  infection  
from  9  rhesus  macaques  infected  with  either  SIVsm  E660  or  SIVsm  E543.    We  observed  slow  
disease  progression  in  4  macaques,  rapid  disease  progression  in  1  macaque,  and  average  
disease  progression  in  4  macaques.    The  macaque  with  rapid  disease  progression  exhibited  
equilibrated  viral  populations  within  the  blood  and  CSF.    In  contrast,  the  4  macaques  with  
                                                                                                              
3CB  Sturdevant  and  R  Swanstrom.    Author  contributions  are  as  follows:  conceived  and  designed  the  





normal  disease  progression  all  had  compartmentalized  CSF  populations,  ranging  from  28%  
to  100%  of  all  CSF  variants  being  compartmentalized.    Clonally  amplified  CSF  variants  were  
also  observed  in  one  macaque,  comprising  most  of  the  compartmentalized  CSF  population.    
Overall,  our  results  show  that  compartmentalized  viral  populations  can  be  observed  in  SIV  
CNS  infection,  providing  further  evidence  that  the  SIV  model  could  potentially  be  used  to  




Human  immunodeficiency  virus  type  1  (HIV-­‐‑1)  appears  in  the  central  nervous  
system  (CNS)  shortly  after  transmission,  with  the  detection  of  HIV-­‐‑1  in  both  the  
cerebrospinal;  fluid  (CSF)  and  brain  tissue  during  the  weeks  after  initial  exposure  (70,  89,  
238,  284,  308,  318),  although  it  is  not  clear  if  the  virus  detected  is  actually  replicating  in  the  
CNS.    In  the  absence  of  therapy  approximately  one-­‐‑third  of  those  infected  will  eventually  
progress  to  HIV-­‐‑1-­‐‑associated  dementia  (HAD)  (31,  116).    While  highly  active  antiretroviral  
therapy  (HAART)  has  markedly  reduced  the  incidence  of  HAD,  the  prevalence  of  milder  
HIV-­‐‑associated  neurological  disorders  (HAND),  including  asymptomatic  HIV-­‐‑associated  
neurocognitive  disorders  (ANI)  and  minor  neurocognitive  disorders  (MND),  appear  to  have  
increased  despite  treatment  (10,  96)  and  affect  quality  of  life  for  infected  individuals  (269).    
We  do  not  know  the  time  course  of  the  virologic  events  (i.e.  viral  replication,  inflammation,  
etc.)  that  lead  to  these  disorders  or  the  extent  to  which  these  long-­‐‑term  outcomes  are  
predicted  by  the  initial  aspects  of  virus-­‐‑host  interaction.  
In  the  CSF  of  patients  with  HAD  it  is  often  possible  to  detect  CSF  viral  populations  
that  are  undergoing  independent,  or  compartmentalized  replication  (82,  132,  225,  238,  285).    
Compartmentalization  of  CSF  variants  has  been  observed  in  neurologically  asymptomatic  
primary  infection  (130,  284).    Additionally,  clonally  amplified  linages,  defined  as  a  group  of  
identical  or  nearly  identical  viral  genomes  recently  expanded  within  the  CSF,  have  also  been  
detected,  differing  from  compartmentalized  populations  in  their  low  level  of  complexity  
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(283).  While  a  significant  body  of  knowledge  has  been  accumulated,  studies  on  HIV-­‐‑1  CNS  
infections  are  limited  in  several  ways.    First  of  all,  studies  analyzing  population  dynamics  
within  the  CNS  rely  on  sampling  of  the  CSF,  as  direct  sampling  of  brain  tissue  is  typically  
available  only  once,  at  autopsy  or  biopsy.    Additionally,  the  CSF  turns  over  rapidly  and  can  
incorporate  virus  from  various  regions  of  the  brain  and  blood;  therefore  determining  the  
region  of  the  brain  where  HIV-­‐‑1  replication  and  compartmentalization  is  occurring  is  not  
possible  through  sampling  the  CSF.    These  factors,  paired  with  a  lack  of  follow-­‐‑up  in  patient  
cohorts  and  the  influence  of  HAART  on  CNS  viral  replication,  makes  analyses  of  viral  
dynamics  in  the  brain  over  the  full  course  of  disease  extremely  difficult.      
Nonhuman  primate/Simian  immunodeficiency  virus  (SIV)  models  are  powerful  tools  
to  study  the  pathogenesis  of  HIV-­‐‑1.    Infections  using  certain  strains  of  SIV  can  result  in  CNS  
disorders,  such  as  viral  meningitis  and  encephalitis,  and  the  Rhesus  macaque/SIV  model  of  
CNS  infection  enables  sampling  of  CSF  throughout  infection  and  allows  rapid  sampling  and  
tissue  preservation  at  autopsy,  removing  the  limitations  of  human/HIV-­‐‑1  infections  (46,  
316).    SIVsm  E660  infection  recapitulates  many  aspects  of  the  typical  disease  course  in  
humans,  including  the  viral  population  dynamics  in  the  blood,  receptor  and  coreceptor  
usage,  and  the  severity  and  incidence  of  CNS  disease,  causing  a  dementia-­‐‑like  illness  in  one  
out  of  three  macaques  (140,  150).    Previous  work  by  our  group  showed  that  discordant  CSF  
populations  could  be  observed  in  SIVsm  E660  rhesus  macaque  infections  (130).    
Additionally,  through  cytokine  analysis  and  staining  of  brain  tissue,  the  authors  provided  
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preliminary  evidence  suggesting  that  the  viral  population  dynamics  between  the  blood  and  
CSF  may  be  associated  with  different  neurological  outcomes.  
As  the  previous  SIV  study  only  analyzed  three  macaques  (130),  a  larger  sample  size  
is  needed  to  make  generalizable  conclusions  regarding  the  viral  population  dynamics  in  the  
CSF  and  blood  during  SIV  infection.    If  the  phenotypes  observed  in  HIV-­‐‑1  CNS  infection  are  
mirrored  in  rhesus  macaques,  SIV  infections  in  macaques  could  provide  an  animal  model  
system  for  studying  CNS  infections,  allowing  us  to  explore  beyond  our  limitations  in  
human  hosts.    We  analyzed  paired  peripheral  blood  and  CSF  over  the  full  course  of  
infection  from  nine  infected  rhesus  macaques.    The  macaques  were  infected  with  either  
SIVsm  E660  or  SIVsm  E543  and  samples  were  collected  at  consistent  intervals  until  end  
stage  disease  (around  forty  weeks  for  the  majority  of  the  macaques).    In  four  of  the  
macaques,  we  observed  slow  disease  progression,  characterized  by  viral  loads  in  the  blood  
and  CSF  too  low  for  analysis.    In  striking  contrast,  we  observed  rapid  disease  progression  in  
one  macaque  that  was  euthanized  at  eight  weeks  post  infection  (p.i.)  and  exhibited  
equilibrated  blood  plasma  and  CSF  viral  populations.    In  the  remaining  four  macaques,  
disease  progression  was  normal,  and  we  observed  significantly  compartmentalized  CSF  
populations  at  week  forty  in  all  four  macaques.    Clonally  amplified  lineages  were  observed  
in  one  macaque.    Overall,  our  results  showed  that  compartmentalized  viral  populations  
could  be  observed  in  SIV  CNS  infection,  providing  further  evidence  that  the  SIV  model  





We  examined  viral  populations  in  paired  peripheral  blood  and  CSF  samples  
collected  from  9  rhesus  macaques  over  the  full  curse  of  SIV  infection  (determined  by  end-­‐‑
stage  disease).    Three  macaques  were  infected  with  50  ID50  doses  SIVsm  E660,  an  inoculum  
containing  several  viral  populations  (139),  and  six  macaques  were  infected  with  SIVsm  
E543,  a  pathogenic  molecular  clone  (137).    Specimens  were  collected  every  2  weeks  for  
approximately  the  first  3  months  and  then  approximately  every  4  weeks  until  end-­‐‑stage  
disease  and  euthanasia.    All  but  1  macaque  was  examined  through  at  least  week  40;  
macaque  21602  had  rapid  disease  progression  and  was  euthanized  at  week  8.    Blood  plasma  
viral  loads  were  only  known  for  week  0,  2,  4,  6,  8,  12,  16  and  24  for  all  macaques  (Figure  18),  
and  CSF  viral  loads  were  not  measured.    
In  order  to  determine  whether  the  viral  loads  in  the  blood  plasma  and  CSF  within  
the  macaques  over  the  full  course  of  infection  were  high  enough  for  analysis,  HTAs  were  
first  completed  analyzing  the  specimens  collected  for  all  macaques  from  week  0  through  
week  40,  when  available.    HTA  results  showed  that  macaque  21740  and  21908  had  viral  
loads  below  our  limit  of  detection  in  both  the  plasma  and  CSF  (data  not  shown).    As  the  
plasma  viral  loads  were  low  at  several  earlier  time  points  (Figure  18),  this  result  was  not  
surprising.    It  is  possible  that  these  macaques  were  not  infected  following  inoculation.    
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Macaques  21739  and  21861  had  detectable  viral  loads  within  the  plasma,  supported  by  the  
available  plasma  viral  load  data  (Figure  18),  but  within  the  CSF  the  viral  loads  were  too  low  
for  HTA  analysis  (data  not  shown).    Thus,  we  observed  slow  (or  no)  disease  progression  in  
macaques  21740,  21908,  21739,  and  21861,  characterized  by  low  to  undetectable  viral  loads  in  
the  plasma  and/or  CSF,  and  as  a  result,  we  did  not  proceed  with  these  4  macaques.    
Detectable  plasma  and  CSF  viral  loads  were  measured  within  the  plasma  and  CSF  of  5  
macaques:  2  SIVsm  E660  infected  macaques  (21602  and  21783)  and  3  SIVsm  E543  infected  
macaques  (21775,  21787,  and  21789).    For  macaque  21602,  we  observed  rapid  disease  
progression,  supported  by  very  high  plasma  viral  loads  (Figure  18),  resulting  in  the  
macaque  being  euthanized  at  8  weeks  post  infection  (p.i.).    In  the  remaining  4  macaques,  
disease  progression  appeared  typical  for  infection  with  this  strain  of  SIV.    Virologic  
characteristics  for  each  macaque  are  listed  in  Table  5.  
 
Detection of discordant blood and CSF viral populations within macaques 
using HTA 
We  used  HTA  targeting  the  V1/V2  hypervariable  region  of  env  to  initially  screen  the  
viral  population  dynamics  between  the  peripheral  blood  and  CSF  in  the  5  macaques  with  
detectable  viral  loads  within  both  compartments.    While  limited  in  its  scope,  HTA  analysis  
enabled  us  to  analyze  the  viral  diversity  within  the  blood  and  CSF  through  co-­‐‑visualization  
of  genetic  variants  comprising  at  least  3%  of  the  total  population  (72,  73,  217,  254).    
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Additionally,  as  V1/V2  is  highly  diverse,  this  region  provides  a  sensitive  target  for  
identifying  distinct,  coexisting  genetic  subpopulations  within  the  two  compartments.  
For  macaque  21602  (euthanized  at  week  8  p.i.),  viral  populations  within  the  plasma  
and  CSF  were  concordant  for  all  time  points  (Figure  19A).    As  disease  progression  was  rapid  
in  this  macaque,  it  was  not  surprising  that  the  viral  populations  within  the  blood  and  CSF  
appeared  genetically  similar,  as  there  was  no  time  for  vial  populations  to  become  
established  within  the  CNS  and  expand  independently  over  time.    For  the  remaining  4  
macaques  in  which  disease  progression  appeared  normal,  concordant  viral  populations  
between  the  blood  and  CSF  were  observed  until  week  10  to  week  18  (Figure  19B-­‐‑E).    For  
these  macaques  the  viral  populations  within  the  blood  and  CSF  began  to  diverge  between  3  
and  5  months  p.i.,  evidenced  by  the  unique  HTA  banding  patterns  observed  within  the  two  
compartments.    For  the  duration  of  infection  (through  week  40),  the  banding  patterns  
remained  diverse  within  all  4  macaques.    However,  due  to  the  high  degree  of  complexity  
within  the  two  compartments,  additional  phylogenetic  tools  were  necessary  to  further  
explore  the  population  dynamics  between  the  blood  plasma  and  CSF.    Overall,  it  appears  as  
if  all  macaques,  with  the  exception  of  21602,  contain  discordant  populations  within  the  
blood  and  CSF,  identifying  potentially  compartmentalized  CSF  variants.    Blood  and  CSF  
populations  were  concordant  in  macaque  21602;  therefore,  these  compartments  are  likely  
equilibrated.    HTA  results  are  summarized  in  Table  5.  
  143  
Compartmentalized CSF populations observed in SIVsm E660 and E543 
infected macaques 
To  assess  SIV  genetic  compartmentalization,  cDNA  templates  were  generated  from  
extracted  blood  and  CSF  viral  RNA  and  used  in  single  genome  amplification  (SGA)  of  the  
full-­‐‑length  env  gene  (3,  158,  228,  272,  297)  for  one  early  and  one  late  time  point  for  all  5  
macaques.    The  sequence  of  the  entire  env  gene  was  determined  for  each  amplicon  and  
phylogenetic  analysis  was  completed.    Following  phylogenetic  analysis,  two  CNS  
phylogenetic  states  were  defined:  compartmentalization,  defined  by  a  genetically  distinct  
and  statistically  significant  CSF  population  (Slatkin-­‐‑Maddison  P  value  >  0.05  and  a  
genetically  distinct  CSF  population  with  a  bootstrap  value  ≥50);  and  equilibrated,  defined  by  
no  evidence  of  an  independent  replication  within  the  CNS  (Slatkin-­‐‑Maddison  P  value  >  0.05  
and  no  evidence  of  a  minor  or  major  CSF  population).    Phylogenetic  trees  were  also  
examined  for  clonally  amplified  lineages,  signifying  the  recent  amplification  of  identical  or  
nearly  identical  variants.    
SGA  analysis  of  macaque  21602  supported  our  HTA  analysis;  the  viral  populations  
at  all  time  points  within  the  blood  and  CSF  were  equilibrated,  with  no  evidence  of  
independent  replication  occurring  within  the  CSF  (Figure  20A).    In  contrast,  genetically  
distinct  compartmentalized  populations  were  observed  within  the  CSF  of  the  remaining  
SIVsm  E660  macaque  21783  (Figure  20B)  as  well  as  all  SIVsm  E543  macaques  (Figure  21A-­‐‑
C).    While  all  macaques  had  statistically  significant  compartmentalized  CSF  populations,  
based  on  visual  observation  and  the  Slatkin-­‐‑Maddison  test,  the  most  striking  example  of  
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CNS  compartmentalization  was  observed  in  macaque  21789  (Figure  21C)  in  which  100%  of  
the  CSF  variants  grouped  independently  from  the  blood.    Clonal  amplification  of  a  CSF  
variant  was  only  observed  in  one  SIVsm  E543  macaque,  21775.    Phylogenetic  results  are  





Nonhuman  primate/Simian  immunodeficiency  virus  (SIV)  models  are  powerful  tools  
to  study  the  neuropathogenesis  of  HIV-­‐‑1  as  SIV  infections  often  recapitulate  the  HIV-­‐‑1  
disease  process  in  the  CNS.    Additionally,  CSF  samples  can  be  collected  longitudinally  over  
the  full  course  of  infection  and  brain  tissue  can  be  preserved  at  autopsy  quickly  after  
euthanasia,  limitations  of  studying  HIV-­‐‑1  CNS  infections  in  humans.    If  the  phenotypes  
observed  in  HIV-­‐‑1  CNS  infection  are  also  observed  in  rhesus  macaques,  such  as  the  
observation  of  compartmentalized  CSF  populations,  SIV  infections  in  macaques  could  
provide  an  animal  model  system  for  studying  CNS  infections,  allowing  us  to  explore  
beyond  our  limitations  in  human  hosts.      
In  our  study,  we  analyzed  the  viral  dynamics  between  the  blood  plasma  and  CSF  
over  the  full  course  of  infection  in  three  SIVsm  E660  and  six  SIVsm  E543  infected  rhesus  
macaques.    Out  of  the  nine  macaques,  we  observed  slow  (or  no)  disease  progression  in  four  
macaques,  rapid  disease  progression  in  one  macaque,  and  average  disease  progression  in  
four  macaques.    In  the  one  macaque  with  rapid  disease  progression,  HTA  and  SGA  analysis  
showed  that  over  the  eight-­‐‑week  period  prior  to  euthanasia,  the  viral  populations  within  the  
blood  and  CSF  were  well  equilibrated  between  the  two  compartments.    In  contrast,  in  all  
macaques  with  average  disease  progression,  compartmentalized  CSF  populations  were  
observed,  ranging  from  28%  to  100%  of  the  CSF  variants  being  compartmentalized.    
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Clonally  amplified  CSF  variants  were  also  observed  in  one  macaque,  comprising  most  of  the  
compartmentalized  CSF  population.    Overall,  our  results  show  that  compartmentalized  viral  
populations  can  be  observed  in  SIV  CNS  infection,  providing  further  evidence  that  the  SIV  
model  could  potentially  be  used  to  better  understand  CNS  disease  over  the  full  course  of  
infection.      
Complex  equilibrated  populations  between  the  blood  and  CSF  were  observed  early  
in  the  four  macaques  with  normal  disease  progression,  suggesting  that  the  CSF  
compartment  is  readily  accessible  to  SIVsm  E660  and  SIVsm  E543  variants  replicating  in  the  
periphery.    As  variants  become  established  within  the  CNS,  differences  in  immune  selective  
pressures,  entry  tropism,  and  viral  replication  kinetics  likely  occur,  resulting  in  different  
population  dynamics  between  the  periphery  and  CSF.    Discordant  viral  populations  were  
observed  as  early  as  10  weeks  post  infection  and  continued  throughout  the  full  course  of  
infection,  with  compartmentalized  viral  populations  observed  in  the  CSF  at  40  weeks  post  
infection.    While  all  compartmentalized  populations  were  statistically  significant  in  the  
macaques,  the  nature  of  the  compartmentalization  varied.    For  one  macaque  (21775,  Figure  
21A),  the  distinct  CSF  population  was  comprised  primarily  of  a  clonally  amplified  lineage.    
Clonal  amplification  has  been  observed  in  HIV-­‐‑1  subtype  B  and  C  CNS  infections  in  adults  
(283,  284)  and  children  (317),  and  has  also  been  observed  in  analysis  of  the  male  (11)  and  
female  (Dukhovlinova  et  al.,  in  preparation)  reproductive  tract,  indicating  the  potential  for  
clonal  amplification  to  occur  in  privileged  compartments.    Two  
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Figure  20B  and  21787,  Figure  21B)  had  compartmentalized  populations  within  the  CSF  
making  up  56%  and  28%  of  all  CSF  variants  sampled,  indicating  that  there  was  still  some  
spillover  between  virus  in  the  blood  into  the  CSF  occurring  at  the  same  time  independent  
viral  replication  was  occurring  in  the  CNS.    In  contrast,  for  macaque  21789  (Figure  21C),  
100%  of  the  CSF  variants  sampled  were  replicating  in  the  CNS,  indicating  that  any  spillover  
occurring  from  the  blood  into  the  CNS  was  being  obscured  by  the  significant  independent  
replication  within  the  CNS.  
As  distinct  CNS  phylogenetic  states  may  indicate  differences  in  SIV-­‐‑associated  
neurological  involvement,  further  analysis  would  be  valuable  to  determine  if  a  relationship  
existed  between  compartmentalization  and  neurological  biomarkers  in  the  rhesus  
macaques.    Viral  replication  in  the  CNS  results  in  the  local  production  of  inflammatory  and  
neuronal  destruction  molecules  such  as  monocyte  chemoattractant  protein  (MCP-­‐‑1),  
neopterin,  IP-­‐‑10,  and  neurofilament  light  subunit  (NFL).    Production  of  these  inflammatory  
markers  has  been  observed  in  animal  models  (130,  184)  and  has  been  linked  to  HIV-­‐‑1-­‐‑
associated  neurocognitive  damage  in  adults  (58,  85,  129).    In  a  previous  study  (130),  a  
correlation  was  observed  between  the  proinflammatory  cytokine  MCP-­‐‑1  and  discordant  
populations  within  the  blood  and  CSF  (determined  by  HTA),  with  elevated  levels  of  MCP-­‐‑1  
at  end-­‐‑stage  disease  observed  only  when  discordant  viral  populations  were  observed.    
Understanding  the  integrity  of  the  blood-­‐‑brain  barrier  (BBB)  in  the  infected  rhesus  
macaques,  through  markers  such  as  albumin,  would  also  be  valuable,  especially  in  macaque  
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21602  which  had  rapid  disease  progression,  resulting  in  the  macaque  being  euthanized  at  
week  8  p.i.    21602  had  equilibrated  viral  populations  between  the  blood  and  CSF  
compartments,  an  expected  result  as  the  short  duration  of  infection  provided  minimal  time  
for  an  independent  population  to  become  established  within  the  CNS.    Rapid  disease  
progression  in  this  macaque  may  have  resulted  in  a  breakdown  of  the  BBB,  increasing  the  
spillover  of  virus  from  the  blood  into  the  CSF,  again  maintaining  the  genetic  similarity  
between  the  blood  plasma  and  CSF.      
Unlike  in  humans,  where  direct  sampling  of  brain  tissue  is  available  only  once  (at  
biopsy  or  autopsy),  a  significant  advantage  of  the  non-­‐‑human  primate  model  is  the  ability  to  
sample  any  region  of  the  brain  throughout  the  course  of  infection.    Previous  work  from  our  
lab  studying  the  dynamics  of  SIV  populations  within  the  blood  and  CSF  of  SIVsm  E660  
macaques  (130)  analyzed  the  trafficking  of  monocytes  and  macrophages  into  the  brain,  a  
common  feature  of  SIV-­‐‑  and  HIV-­‐‑1-­‐‑associated  neurological  disease  (116,  166,  339,  346).    The  
authors  stained  paraffin-­‐‑embedded  sections  of  the  caudate  nucleus  and  overlying  frontal  
cortex  with  an  antibody  to  CD68,  which  specifically  stains  macrophages,  and  counted  
stained  cells  in  the  cortex,  subcortical  white  matter,  and  caudate.    While  little  to  no  staining  
was  observed  in  macaques  with  concordant,  or  equilibrated,  CSF  and  blood  populations,  a  
moderate  number  of  CD68+  cells  were  observed  in  the  macaque  with  discordant,  or  
compartmentalized,  CSF  and  blood  populations,  with  the  most  intense  staining  localized  to  
the  caudate  and  subcortical  white  matter,  regions  often  afflicted  in  patients  with  HAD  (15,  
  149  
122).  Paraffin-­‐‑embedded  sections  were  collected  from  various  regions  of  the  brain  for  all  
rhesus  macaques  studied  in  this  analysis.    Regions  sampled  varied  between  macaques  but  
included:  choroid  plexus,  caudate  nucleus,  cortex  (white  matter),  cerebellum  (white  matter),  
thalamus,  brainstem,  frontal  lobe,  spinal  cord,  occipital  lobe,  pons,  pituitary,  and  midbrain.    
While  three  macaques  was  not  a  sufficient  sample  size  to  fully  determine  the  relationship  
between  independent  viral  replication  in  the  CSF  and  infiltration  of  macrophages,  our  study  
provides  additional  macaques  to  increase  the  sample  size  of  the  previous  study  and  help  
determine  if  this  correlation  is  more  generalizable  to  SIV  CNS  infection.      
Overall,  we  provide  evidence  that  genetically  distinct,  compartmentalized  CSF  
populations  are  found  during  both  SIVsm  E660  and  SIVsm  E543  infections  in  macaques,  
similar  to  what  is  observed  in  HIV-­‐‑1  infection  in  humans.    While  HIV-­‐‑1  CSF  
compartmentalization  has  been  observed  is  relation  to  a  spectrum  of  neurological  disorders,  
from  asymptomatic  primary  infection  to  HAD,  a  longitudinal  link  has  not  yet  been  made.    
Therefore,  understanding  any  relationships  between  CSF  compartmentalization  and  SIV-­‐‑
associated  neurological  disorders  would  further  our  understanding  of  both  SIV  and  HIV-­‐‑1  
neuropathogenesis  and  help  determine  if  detection  of  compartmentalized  CSF  variants  may  
identify  subjects  with  a  higher  risk  of  developing  HIV-­‐‑1-­‐‑associated  neurological  
complications.    
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MATERIALS AND METHODS 
  
Viruses, animals, and specimen collection 
The  SIVsm  E660  (139)  and  SIVsm  E543  (137)  challenge  inoculums  were  previously  
isolated.    Nine  rhesus  macaques  were  infected  as  previously  described  (130).    Briefly,  
macaques  were  challenged  intravenously  (iv)  via  the  sapheneous  vein  with  ~50  ID50U  of  
either  SIVsm  E660  (21602,  21739,  21783)  or  SIVsm  E543  (21740,  21775,  21787,  21789,  21861,  
and  21906)  (i.e.  50  times  the  50%  macaque  infection  does.)    Blood  plasma  and  CSF  were  
collected  (on  the  same  day)  before  challenge,  every  two  weeks  for  approximately  the  first  
three  months  of  infection,  and  every  four  weeks  thereafter,  up  to  week  74,  or  end-­‐‑stage  
disease.    Macaques  were  euthanized  at  end-­‐‑stage  disease,  determined  by  severe  weight  loss,  
diarrhea  and/or  wasting.    No  CSF  obtained  via  a  traumatic  lumbar  puncture  (i.e.  with  risk  of  
blood  contamination)  was  used.    Blood,  CSF  and  brain  tissue  was  harvested  at  autopsy  and  
immediately  fixed  and  frozen.    All  animal  care  was  preformed  at  Columbus,  Ohio,  
Children’s  Research  Institute  in  accordance  with  institution  guidelines.      
  
Viral RNA isolation 
SIVsm  E660  and  SIVsm  E543  RNA  was  isolated  from  blood  plasma  and  CSF  samples  
as  previously  described  for  extraction  of  HIV-­‐‑1  (285).    Briefly,  in  order  to  increase  template  
number  and  improve  sampling,  0.2-­‐‑0.5  mL  of  blood  plasma  and  CSF  samples  were  first  
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pelleted  via  ultracentrifugation  at  25,000xg  for  1.5  hours  at  4oC.    Following  centrifugation,  
all  but  140  µμL  of  the  blood  plasma  and  CSF  supernatant  was  removed  and  stored  at  -­‐‑80oC  
for  biomarker  analysis.    All  virus  pellets  were  then  re-­‐‑suspended  in  the  remaining  140  µμL  
and  viral  RNA  was  isolated  from  blood  plasma  and  CSF  samples  using  the  QIAmp  Viral  
RNA  Mini  kit  (Qiagen).      
  
RT-PCR and HTA analysis 
RT-­‐‑PCR  targeting  the  V1/V2  region  of  env,  and  V1/V2  env  HTA  were  preformed  as  
previously  described  (266).    Briefly,  10  µμl  of  isolated  RNA  was  used  in  a  RT-­‐‑PCR  reaction  
targeting  V1/V2  using  the  one-­‐‑step  RT-­‐‑PCR  kit  (Qiagen)  according  to  the  manufacturer’s  
instructions.    Generated  RT-­‐‑PCR  products  were  then  analyzed  by  HTA  using  a  single-­‐‑
stranded,  35S-­‐‑labeled  V1/V2  DNA  probe  based  on  the  SIVsm  H4  molecular  clone  (130,  138,  
266).    In  order  to  increase  our  confidence  in  the  generated  banding  patterns  and  validate  
sampling  quality,  we  completed  two  independent  RT-­‐‑PCR  and  HTA  analyses  for  each  blood  
plasma  and  CSF  specimen.    Only  results  with  reproducible  banding  patterns  were  used  in  
this  study.      
  
Single genome amplification 
After  viral  RNA  extraction,  10  µμl  of  viral  RNA  was  reverse  transcribed  using  
Superscript  III  Reverse  transcriptase  (Invitrogen)  and  an  oligo-­‐‑d(T)  primer  according  to  the  
  152  
manufacturer’s  instructions.    Single  genome  amplification  (SGA)  of  the  full-­‐‑length  HIV-­‐‑1  
env  gene  through  the  end  of  gp41,  gp160  was  conducted  as  previously  described  (272).    
Briefly,  cDNA  was  endpoint  diluted  and  nested  PCR  was  completed  using  Platinum  Taq  
High  Fidelity  polymerase  (Invitrogen)  and  the  primers  SIVoutF  (5'-­‐
CTCAGAATTGGCAGTCAATATCACAG-­‐3';	  nt	  6129-­‐6148)	  and  SIVoutR  (5'-­‐
TGTCTCTTGACCACATCCAACAGCT-­‐3';	  nt	  9478-­‐9499),  and  SIVinF  (5'-­‐
ATCACAGAGGCTTTTGATGCTTGG-­‐3';	  nt	  6307-­‐6327)	  and  SIVinR  (5'-­‐
GTTGCTGTTGCTGCACTATCCCAGC-­‐3';	  nt	  9437-­‐9459)  were  used  for  the  first  and  second  rounds  of  
PCR,  respectively.    Full-­‐‑length  env  PCR  amplicons  were  then  bi-­‐‑directionally  sequenced  (nt  
6530-­‐‑9341)  and  analyzed.    Chromatograms  with  double  peaks,  indicating  amplification  from  
more  than  one  cDNA  template,  as  well  as  sequences  with  frameshift  mutations  resulting  in  
premature  stop  codons,  were  excluded  from  analysis.  
  
Phylogenetic analysis of env viral sequences 
DNA  sequences  alignments  of  env  genes  were  performed  using  ClustalW  (323).    
Sequences  for  each  subject  were  codon  aligned  (MEGA  4.0)  and  phylogenetic  trees  were  
generated  using  neighbor-­‐‑joining  method  (MEGA  4.0)  (319).    Compartmentalization  of  viral  
sequences  was  assessed  visually  based  on  the  phylogenetic  tree  structure,  as  well  as  
statistically  using  the  Slatkin-­‐‑Maddison  test  for  gene  flow  (298)  available  through  HyPhy  
(244)  using  10,000  permutations.  
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21602 E660 rapid Concordant Eq 0 0.1
21739 E660 slow N/A N/A N/A N/A
21783 E660 normal discordant Comp 56 <0.0001
21740 E543 slow N/A N/A N/A N/A
21775 E543 normal discordant Comp,'Amp 32 0.006
21787 E543 normal discordant Comp 28 0.003
21789 E543 normal discordant Comp 100 <0.0001
21861 E543 slow N/A N/A N/A N/A
21908 E543 slow N/A N/A N/A N/A   
aDisease  progression  based  on  plasma  viral  RNA  load.  
bSIV   population   characteristics   in   the   CSF   compartment   (Compart).      Eq,   equilibrated  
blood  plasma  and  CSF  populations;  Comp,  significant  compartmentalization  in  the  CSF;  
Amp,  clonal  amplification  of  ≥3  variants  detected  in  the  CSF;  N/A,  not  applicable  when  
the   plasma   and/or   CSF   viral   load   was   too   low   to   obtain   enough   CSF   env   sequences  
(determined  by  HTA  analysis).  
  cThe  percent  of  CSF  env  sequences  that  were  compartmentalized  (Comp)  for  each  subject.    
CSF  env   sequences  were  considered  compartmentalized  when  ≥4  sequences  were  found  
within  the  same  clade  and  bootstrap  values  ≥50  were  observed.    
dP  values  used  to  measure  genetic  compartmentalization  between  the  blood  plasma  and  
CSF  HIV-­‐‑1   populations  were   obtained   using   the   Slatkin-­‐‑Maddison   (S-­‐‑M)   test   for   gene  
flow  between  populations  (298).    A  P  value  <0.05  indicated  statistically  significant  genetic  
compartmentalization  in  the  CSF.  
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Figure  18:  Plasma  viral  RNA  copies/mL  indicate  various  types  of  disease  progression  
Plasma  viral  RNA  load  (log  copies/mL)  for  all  9  rhesus  macaques  on  week  0,  2,  4,  6,  8,  12,  
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Figure  19:  HTA  analysis  over  the  full  course  of  infection  shows  discordant  viral  
populations  
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Longitudinal  V1/V2  HTA  analysis  of  SIVsm  E660  and  SIVsm  E543   in   the  blood  plasma  
and  CSF  of  9  infected  rhesus  macaques  over  the  full  course  of  infection  (week  2  through  
week  40,  when  available).     The  macaque  IDs  are  indicated  above  the  HTA  gel  image,  as  














































Figure  20:  Equilibrated  and  compartmentalized  populations  observed  SIVsmE660  
infection  
Neighbor-­‐‑joining   phylogenetic   trees   from   two   SIVsm   E660   infected   macaques.   env  
sequences  from  the  CSF  are  labeled  with  circles  (C,  colors  designated  in  figure)  and  env  
sequences   from   the   blood   plasma   are   labeled   with   triangles   (P,   colors   designated   in  
figure).     Weeks   p.i.   for   each  macaque   are   noted   adjacent   to   the   corresponding   symbol.    
Bootstrap   values   ≥50   are   indicated   (*)   at   the   appropriate   nodes.      Genetic   distance   is  
indicated   at   the   bottom   of   each   figure   (0.001)   and   indicates   the   number   of   nucleotide  
substitutions   per   site   between   env   sequences.      Compartmentalized   populations   are  
indicated   by   open   black   circle   and   solid   blue   bar.      (A)   Macaque   21602   with   well  
equilibrated  blood  plasma  and  CSF  populations.      (B)  Macaque  21783  demonstrating  the  
presence   of   a   statistically   significant   compartmentalized   population   within   the   CSF  






















































Figure  21:  Significant  compartmentalization  observed  in  SIVsm  E543  infections  
Neighbor-­‐‑joining   phylogenetic   trees   from   three   SIVsm   E543   infected   macaques.   env  
sequences  from  the  CSF  are  labeled  with  circles  (C,  colors  designated  in  figure)  and  env  
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sequences   from   the   blood   plasma   are   labeled   with   triangles   (P,   colors   designated   in  
figure).     Weeks   p.i.   for   each  macaque   are   noted   adjacent   to   the   corresponding   symbol.    
Bootstrap   values   ≥50   are   indicated   (*)   at   the   appropriate   nodes.      Genetic   distance   is  
indicated   at   the   bottom   of   each   figure   (0.001)   and   indicates   the   number   of   nucleotide  
substitutions   per   site   between   env   sequences.      Compartmentalized   populations   are  
indicated  by  open  black  circle  and  solid  blue  bar.     Clonal  amplification   is   indicated  by  
solid  black  bar.    (A)  Macaque  21775  (B)  21787  and  (C)  21789  demonstrating  the  presence  of  
a   statistically   significant   compartmentalized   population  within   the   CSF   relative   to   the  






CHAPTER V.  DISCUSSION AND FUTURE DIRECTIONS 
  
The  main  objective  for  this  dissertation  was  to  discern  the  viral  characteristics  
associated  with  early  CNS  infection  prior  to  the  initiation  of  therapy.    In  Chapters  Two  and  
Three,  using  sensitive  techniques  such  as  single  genome  amplification,  sequence,  and  
phylogenetic  analysis  of  the  full  length  viral  env  gene,  I  assessed  HIV-­‐‑1  genetic  
compartmentalization  between  viral  populations  in  the  peripheral  blood  and  CSF  early  
following  transmission  in  two  ART-­‐‑naïve  patient  cohorts:  Malawian  children  three  years  of  
age  or  younger  (Chapter  Two);  and  adults  infected  for  less  than  two  years  (Chapter  Three).    
I  was  also  able  to  examine  the  generation  of  compartmentalization  in  SIV-­‐‑infected  macaques  
in  Chapter  Four,  expanding  on  our  understanding  of  primate  models  as  tools  to  study  HIV-­‐‑
1  CNS  infection.  
In  Chapter  Two  I  showed  that  CNS  compartmentalization  could  occur  in  the  CSF  of  
HIV-­‐‑1  subtype  C  infected  young  children  in  Malawi,  with  a  significant  relationship  
observed  between  older  age  and  compartmentalization.    I  showed  in  Chapter  Three  that  
compartmentalized  CSF  populations  could  be  observed  early  in  infected  adults,  with  
significant  compartmentalization  present  with  a  longer  time  since  HIV-­‐‑1  exposure.    My  
results  indicate  that  a  longer  time  since  transmission  provides  a  greater  opportunity  for  the  
establishment  of  independent  replication  within  the  CNS,  although  this  was  happening  
within  the  time  frame  of  the  first  one  to  three  years.    More  extensive  longitudinal  studies  
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will  be  necessary  to  examine  how  compartmentalization  evolves  over  time  and  whether  
early  CNS  replication  influences  later  neurological  outcomes.    
Longitudinal  samples  were  available  for  the  adult  primary  infection  study,  enabling  
us  to  examine  CSF  viral  population  dynamics  within  individual  subjects  over  a  period  of  up  
to  two  years.    We  were  able  to  show  that  roughly  20%  of  subjects  in  the  first  two  years  of  
infection  displayed  evidence  of  supporting  viral  replication  within  the  CNS  over  an  
extended  period  of  time,  evidenced  by  intermediate  CSF  compartmentalization,  significant  
CSF  compartmentalization,  or  equilibration  in  the  presence  of  marked  CSF  pleocytosis,  
suggesting  that  the  CNS  was  a  favorable  environment  for  viral  replication  in  these  subjects.    
In  one  subject  (9040)  we  saw  that  compartmentalization  can  be  maintained  and  evolve  
independently  within  the  CNS  over  a  long  period  of  time,  demonstrating  the  dynamic  
nature  of  HIV-­‐‑1  infection  in  the  CNS  early  after  transmission.    To  my  knowledge,  this  is  the  
first  study  to  show  the  maintenance  and  evolution  of  a  compartmentalized  viral  population  
within  the  CNS  over  a  long  duration  of  time  during  primary  infection.        
The  observation  of  significant  compartmentalization  early  following  both  vertical  
and  horizontal  transmission  adds  further  justification  to  the  policy  of  prompt  initiation  of  
antiretroviral  treatment,  especially  in  children.    Early  pediatric  infection  can  have  a  
significant  impact  on  brain  development  and  the  achievement  and  maintenance  of  
developmental  milestones  (327);  therefore  early  therapy  initiation  in  children  to  prevent  
neurologically  harmful  viral  replication  is  crucial.    In  adults,  extensive  independent  HIV-­‐‑1  
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CNS  replication  has  been  linked  to  neurological  complications  such  as  HAD  (132,  258,  285),  
and  as  HIV-­‐‑1  can  persist  in  the  CNS  during  therapy  (243,  287),  the  CNS  provides  a  potential  
immune-­‐‑privileged  reservoir  for  HIV-­‐‑1.    Therefore,  detection  of  compartmentalized  CSF  
variants  during  primary  HIV-­‐‑1  infection  may  identify  subjects  vulnerable  to  developing  
HIV-­‐‑1  associated  neurological  problems  later  in  infection.  
In  previous  compartmentalization  studies,  only  two  CNS  states  were  defined:  
compartmentalized  and  equilibrated.    During  my  analyses,  we  determined  that  a  more  
stringent  classification  was  necessary  to  allow  for  an  intermediate  state  defined  by  minor  
local  CNS  replication.    This  enabled  us  to  more  rigorously  describe  the  viral  dynamics  
between  the  peripheral  blood  and  CSF.    Children  with  an  intermediate  state  were  younger  
than  children  with  significant  compartmentalization.    Additionally,  in  adults,  an  
intermediate  state  was  observed  as  early  as  58  days  post  infection  while  significant  
compartmentalization  was  not  observed  until  later.    I  hypothesize  that  this  intermediate  
state  may  in  some  subjects  be  a  precursor  state  to  significant  local  CNS  replication.    If  true,  
the  intermediate  state  may  identify  subjects  at  risk  of  developing  significant  CNS  replication  
and/or  neurological  complications  as  infection  progresses.    To  understand  whether  such  an  
association  exists,  HIV  researchers  will  need  to  follow  subjects  from  the  early  stages  of  
primary  infection  through  the  chronic  stages  of  disease.  
In  this  dissertation  I  also  expanded  on  our  understanding  of  CNS  
compartmentalization  versus  clonal  amplification.    In  previous  studies,  clonal  amplification  
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and  compartmentalization  in  the  CSF  were  considered  separate  phenomena.    
Compartmentalization  consisted  of  complex  CSF  populations  indicative  of  more  prolonged  
period  of  isolated  replication,  while  clonal  amplification  represented  the  recent  expansion  of  
identical  or  nearly  identical  CSF  populations  of  low  complexity.    Uniquely,  in  my  adult  
cohort,  compartmentalized  CSF  populations  most  often  consisted  of  one  or  more  clonally  
amplified  lineages  with  the  outgrowth  of  recombinants  that  persisted  within  the  CNS.    Only  
in  rare  cases  was  CSF  compartmentalization  exclusively  a  complex  population  with  no  
clonally  amplified  variants,  or  clonal  amplification  exclusively  an  expansion  of  a  single  or  
small  number  of  variants  without  the  generation  of  recombinants  within  the  CNS.    These  
observations  also  help  to  more  stringently  define  the  CNS  condition  during  primary  
infection,  and  may  be  useful  in  future  studies  examining  relationships  between  CNS  
phylogenetic  states  and  neurocognitive  condition.  
I  also  described  our  use  of  the  phylogenetic  tool  BEAST  (78)  to  further  characterize  
early  CNS  infection.    In  Chapter  Two,  BEAST  was  used  to  approximate  the  timing  of  
infection  in  our  pediatric  cohort  and  was  central  to  our  discovery  that  some  children  were  
infected  with  more  than  one  variant.    More  importantly  for  our  objectives,  in  the  majority  of  
these  multiple  variant  transmission  events,  one  of  the  transmitted  variants  was  sequestered  
within  the  CNS,  with  minimal  to  no  recombination  occurring  with  virus  replicating  within  
the  periphery,  generating  two  distinct  viral  linages.    When  we  applied  BEAST  analysis  to  
our  adult  cohort  in  Chapter  Three,  we  found  that  multiple  variant  transmission  events  were  
  164  
also  observed  in  horizontal  transmission,  with  the  sequestration  of  one  transmitted  variant,  
or  its  recombinant,  within  the  CNS  also  observed.    Further  studies  are  needed  to  understand  
the  host  or  virus  characteristics  that  enabled  the  transmitted  variants  to  be  partitioned  in  
such  a  manner.      
In  the  children  and  adults  infected  with  a  single  variant,  we  were  able  to  use  BEAST  
to  determine  when  during  the  course  of  infection  a  compartmentalized  population  was  
established  within  the  CNS.    This  analysis,  together  with  our  examination  of  multiple  
variant  transmission  events,  enabled  us  to  define  two  distinct  pathways  to  
compartmentalization:  the  early  sequestration  of  a  transmitted  virus  in  the  CNS;  and  the  
later  establishment  of  an  independently  replicating  population  within  the  CNS  that  
originated  from  the  periphery.    
Another  objective  of  Chapters  Two  and  Three  was  exploring  the  entry  phenotypes  of  
virus  isolated  early  following  transmission.    It  is  now  widely  described  in  the  literature  that  
macrophage-­‐‑tropic  variants  are  not  transmitted  and  that  the  transmitted  virus  is  R5  T  cell-­‐‑
tropic  (8,  148,  158,  171,  223,  230,  273,  280,  335,  345),  an  understanding  further  supported  by  
my  phylogenetic  analysis  in  Chapter  Three.    This  result  was  somewhat  surprising  for  
subject  9040  in  whom  we  observed  the  maintenance  and  evolution  of  a  single  CSF/CNS  
population  over  a  period  of  1.6  years,  a  viral  population  we  hypothesized  would  have  
adapted  to  grow  within  long-­‐‑lived  cells  within  the  CNS  such  as  macrophages  and/or  
microglia.    Nonetheless,  no  virus  was  able  to  enter  cells  expressing  low  levels  of  CD4  (a  
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surrogate  phenotypic  marker  for  macrophage  tropism),  indicating  that  low  CD4  utilization  
is  acquired  later  during  chronic  infection.  
While  the  CD4  utilization  of  subtype  B  HIV-­‐‑1  has  been  previously  described  (283),  
we  did  not  know  whether  this  was  subtype  specific  or  a  characteristic  of  other  HIV-­‐‑1  
subtypes  such  as  subtype  C.    In  our  pediatric  study,  we  observed  low  CD4  utilization  in  a  
small  percentage  of  both  compartmentalized  and  intermediate  subjects.  This  low  CD4  usage  
was  only  observed  in  the  CSF  compartmentalized  populations,  indicating  a  compartment-­‐‑
specific  adaption.    Additionally,  one  of  the  subjects  was  only  six  months  old,  suggesting  that  
in  children,  this  evolution  can  occur  early  within  CSF/CNS  viral  populations.    To  my  
knowledge,  this  is  the  first  study  to  report  the  detection  of  macrophage-­‐‑tropic  HIV-­‐‑1  
subtype  C  variants.      
Overall,  to  summarize  my  results  from  the  pediatric  cohort,  we  defined  four  states  to  
describe  the  relationship  between  virus  in  the  CNS  and  virus  in  the  periphery  in  these  
young  children,  shown  on  a  time  scale  in  Figure  22  and  described  in  detail  in  Chapter  Two.    
The  four  states  are,  in  brief;  no  genetic  evidence  for  HIV-­‐‑1  replication  in  the  CNS  
(Equilibrated);  minor  compartmentalization  of  a  CNS  viral  population  in  younger  children  
(Intermediate);  strong  evidence  of  genetic  compartmentalization  in  the  CNS  of  older  
children  (Compartmentalized);  and  multiple  variant  transmission  from  mother  to  infant  
resulting  in  one  virus  established  within  the  CNS  shortly  after  transmission  and  a  second  
within  the  periphery  (Sequestration).  
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Unique  to  our  adult  cohort,  we  examined  the  contribution  of  pleocytosis  to  the  CNS  
phylogenetic  state  and  hypothesized  a  complex  relationship  that  could  impact  various  
phylogenetic  states.    Overall,  to  summarize  our  results,  we  defined  four  states  to  define  the  
relationship  between  CNS  viral  load,  pleocytosis,  and  CNS  phylogenetic  state,  described  in  
detail  in  Chapter  Three  (Figure  17).      In  brief,  the  four  states  are;  CSF  viral  load  
proportionally  1-­‐‑2%  the  plasma  viral  load  with  an  equilibrated  CNS  state  and  minimal  CSF  
pleocytosis  (when  the  CSF  viral  load  was  high  enough  for  analysis);  an  equilibrated  CNS  
state  with  high  levels  of  CSF  pleocytosis;  clonal  amplification  of  CSF  populations  of  low  
complexity;  and  genetically  complex  compartmentalized  CSF  populations  indicative  of  
persistent  replication  beyond  a  single  clonal  amplification  event.  
SIV/Rhesus  macaque  models  of  infection  provide  a  unique  opportunity  to  study  
HIV-­‐‑1  CNS  infections  as  macaques  can  be  observed  and  samples  extracted  throughout  the  
duration  of  infection.    Additionally,  brain  tissue  can  be  rapidly  harvested  and  analyzed  in  a  
macaque  study,  removing  a  crucial  limitation  of  studying  CNS  infections  in  humans.    In  
Chapter  Four  I  added  to  the  growing  body  of  literature  of  SIV  CNS  infections  by  exploring  
the  viral  dynamics  between  the  peripheral  blood  and  CNS  in  macaques  over  the  duration  of  
infection.    Overall,  our  results  show  that  compartmentalized  viral  populations  can  be  
observed  in  SIV  CNS  infection,  providing  further  evidence  that  the  SIV  model  could  
potentially  be  used  to  better  understand  HIV-­‐‑1  CNS  disease  and  virus-­‐‑host  interaction.  
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Future  studies  are  needed  to  examine  what  causes  a  transmitted  variant  to  become  
selectively  established  within  the  CNS  shortly  after  transmission.    Previous  studies  have  
reported  that  brain  adapted  HIV-­‐‑1  envelopes  have  enhanced  sensitivity  to  neutralizing  
antibodies  (Nabs)  (81,  192,  306).    While  this  neutralization  sensitivity  is  often  discussed  in  
relation  to  macrophage  tropism  (e.g.  a  more  open/exposed  CD4  binding  pocket),  
transmitted  variants  likely  respond  differently  to  the  immune  system’s  selective  pressures  
and  could  partition  in  different  compartments  based  on  this  distinction.    The  CNS  is  an  
immune-­‐‑privileged  site  where  antibodies  are  not  common.    This  creates  an  environment  
favorable  for  a  neutralization  sensitive  transmitted  variant  compared  to  a  neutralization  
resistant  transmitted  variant  that  can  expand  within  the  periphery.    In  both  patient  cohorts,  I  
could  examine  the  neutralization  sensitivity  of  HIV-­‐‑1  envelopes  from  sequestered  CNS  
lineages  compared  to  lineages  replicating  in  the  periphery  using  either  heterologous  
antibodies,  targeting  areas  such  as  the  CD4  binding  pocket,  or  autologous  antibodies  from  
the  serum.      
While  there  is  no  consensus  on  the  role  maternal  antibodies  play  in  MTCT,  some  
studies  have  shown  that  MTCT  resulted  in  the  selection  for  variants  resistant  to  maternal  
antibodies,  suggesting  a  protective  role  for  these  antibodies  within  the  infant  (30,  167).    This  
passive  maternal  immunity  increases  while  the  infant  is  in  utero  and  is  maintained  through  
breastfeeding.    My  observation  that  variants  can  be  sequestered  within  the  CNS  following  
transmission  in  children  leads  me  to  hypothesize  that  this  may  be  due  to  different  
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sensitivities  to  maternal  antibodies  present  at  the  time  of  transmission.    Further  analysis  of  
mother-­‐‑infant  transmission  pairs  would  be  required  to  explore  this  hypothesis,  a  limitation  
of  the  current  pediatric  study.      
I  could  also  examine  the  number  of  encoded  N-­‐‑linked  glycosylation  sites  on  Env  in  
the  various  transmitted  variants  as  glycosylation  provides  a  potential  glycan  shield  for  
immune  evasion  (312).    Studies  have  shown  that  both  horizontally  and  vertically  
transmitted  variants  generally  have  shorter  variable  regions  and  fewer  glycosylation  sites  
(57,  76,  271,  274,  275).    A  recent  study  by  our  group  concluded  that  the  presence  of  many  
glycosylation  sites  on  the  transmitted/founder  virus  is  variable  and  that  the  absence  of  
glycosylation  sites  may  make  a  virus  vulnerable  to  Env-­‐‑specific  antibodies  (241).    Different  
degrees  of  glycosylation  among  the  transmitted  variants  could  influence  antibody  resistance  
and  cause  a  Nab  sensitive  variant  to  become  established  within  the  CNS.    There  are  
approximately  thirty  glycosylation  sites  spanning  both  the  conserved  and  variable  regions  
of  the  extracellular  domain  of  Env,  providing  various  sites  for  analysis  using  tools  such  as  
N-­‐‑Glycosite  (www.hiv.lanl.gov).    Comparing  glycosylation  sites  in  my  pediatric  cohort,  
especially  since  maternal  serum  is  not  available,  may  hint  at  a  susceptibility/resistance  to  
maternal  antibodies  that  could  influence  an  antibody  sensitive  variant  to  be  maintained  in  
the  immune-­‐‑privileged  CNS.            
Replication  and  fitness  differences  could  also  be  assessed  as  this  may  influence  the  
partitioning  I  observed.    To  do  so,  full-­‐‑length  replication  competent  clones  would  need  to  be  
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generated  from  the  CNS  and  blood  lineages.    I  could  then  examine  the  relative  fitness  of  the  
two  transmitted  variants  in  competition  experiments.    While  the  generation  of  full-­‐‑length  
HIV-­‐‑1  clones  is  extremely  difficult,  this  experiment  would  enable  us  to  look  beyond  
differences  in  envelope  to  explain  why  a  variant  could  so  quickly  become  established  within  
the  CNS  but  is  largely  absence  within  the  periphery.  Competition  experiments  and  an  
analysis  of  the  kinetics  of  virus  replication  and  spread  could  also  be  used  to  examine  T  cell-­‐‑
tropic  versus  macrophage-­‐‑tropic  virus  from  my  pediatric  cohort  to  determine  if  there  is  a  
fitness  consequence  to  acquiring  macrophage  tropism.    If  macrophage-­‐‑tropic  virus  had  
reduced  fitness  compared  to  T-­‐‑cell  tropic  virus  from  the  same  subject,  this  could  potentially  
explain  the  CNS  compartmentalization,  as  the  virus  in  the  CNS  is  not  exposed  to  the  same  
degree  of  immune  surveillance  as  variants  replicating  in  T  cells  within  the  periphery.    
The  previously  discussed  analyses  (neutralization  sensitivity,  number  of  
glycosylation  sites,  fitness,  etc.)  could  also  be  applied  to  examine  the  intermediate  CD4  
utilization  phenotype  observed  in  the  pediatric  cohort.    These  viruses  did  not  have  a  
capacity  to  use  low  densities  of  CD4  comparable  to  our  macrophage-­‐‑tropic  control  virus,  but  
they  did  enter  cells  with  low  levels  of  CD4  with  greater  efficiency  than  our  T  cell-­‐‑tropic  
control  viruses.    Therefore,  a  more  detailed  examination  is  needed  to  determine  if  this  is  in  
fact  a  unique  phenotype  or  should  be  considered  macrophage-­‐‑tropic.    Additionally,  an  
interesting  result  of  our  Affinofile  assay  in  my  adult  cohort  was  that  there  was  some  low  
level  variability  in  the  percent  of  infection  in  CSF  variants  from  compartmentalized  subjects  
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compared  to  equilibrated  or  intermediate  subjects  and/or  all  plasma  variants.    Further  
studies  are  needed  to  determine  if  a  more  open  envelope  conformation,  neutralization  
sensitivity,  co-­‐‑receptor  usage,  etc.,  can  explain  this  variability  that  is  only  observed  in  
compartmentalized  CSF  variants.      
I  find  it  intriguing  that  HIV-­‐‑1  subtype  C  evolved  to  use  low  levels  of  CD4  in  less  
than  two  years  of  infection  within  children,  but  HIV-­‐‑1  subtype  B  did  not  within  two  years  of  
infection  in  adults.    This  may  be  due  to  the  different  CNS  cell  populations  present  in  the  
developing  brain  compared  to  the  mature  brain,  which  could  provide  additional  cell  
populations  vulnerable  to  infection  by  HIV-­‐‑1.    For  example,  amoeboid  (or  activated)  
microglia  are  absent  in  the  adult  brain  but  are  present  at  a  higher  frequency  in  the  
developing  brain  where  they  act  as  scavenger  cells,  removing  debris  and  apoptotic  cells  that  
result  from  normal  brain  development  (110,  126,  260).    Also,  children  have  higher  viral  loads  
compared  to  adults  and  are  likely  to  be  more  immunodeficient  even  during  the  early  stages  
of  infection.    Overall,  we  cannot  conclude  from  our  pediatric  study  that  HIV-­‐‑1  subtype  C  
can  acquire  the  ability  to  utilize  low  levels  of  CD4  early  in  infection,  as  pediatric  infections  
are  very  distinct  from  infections  in  adults.    Therefore,  there  is  still  a  need  to  explore  the  
evolution  of  macrophage  tropism  in  subtype  C  infected  adults.    Only  after  CD4  utilization  is  
observed  in  similar  patient  cohorts  can  we  suggest  whether  this  is  a  subtype  specific  
adaptation  or  the  result  of  infection  in  two  very  distinct  hosts.      
  171  
In  equilibrated  subjects  and  subjects  with  lower  CSF  viral  loads,  we  claim  that  there  
is  little  to  no  replication  occurring  within  the  CNS.    Additionally,  in  subjects  with  high  
levels  of  CSF  pleocytosis,  the  virus  secreted  by  the  infiltrating  CD4+  T  cells  obscures  any  
potential  low-­‐‑level  local  CNS  replication,  resulting  in  equilibration  between  the  
compartments.    Newer,  more  sensitive  phylogenetic  tools,  such  as  deep  sequencing  
technology,  could  be  utilized  to  determine  whether  potentially  important,  low  frequency  
variants  are  present  in  the  CNS  early  in  infection.    These  next-­‐‑generation  sequencing  
techniques  provide  a  rapid  approach  for  characterizing  complex  and  rapidly  evolving  viral  
quasispecies.    As  local  CNS  replication  has  been  linked  with  neurological  complications,  
understanding  the  extent  of  CNS  compartmentalization  and  the  timing  of  establishment  in  
the  CNS  could  be  better  explored  using  these  more  sensitive  phylogenetic  techniques.  
In  contrast  to  analyzing  a  specific  region  of  HIV-­‐‑1,  in  our  case  env,  a  whole  genome  
deep  sequencing  technique  has  recently  been  described  that  is  able  to  rapidly  and  
sensitively  sequence  across  the  whole  HIV-­‐‑1  genome  for  population-­‐‑scale  genetic  analyses  
(136).    When  applied  to  longitudinal  samples,  this  technique  allows  for  characterization  of  
the  earliest  signs  of  immune  adaptation  and  identification  of  early,  low  frequency  escape  
variants.    If  we  applied  this  new  technique  to  our  analyses  comparing  blood  and  CNS  
variants,  we  could  analyze  subjects  with  various  phylogenetic  states  to  determine  whether  
these  states  (e.g.  equilibration  versus  an  early  sequestration  and/or  compartmentalization)  
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are  influenced  by  early  viral  adaptations,  or  a  lack  thereof,  not  detected  by  conventional  
sequencing  approaches.      
An  examination  of  whether  the  presence  of  early  CNS  replication  begins  the  process  
towards  neurological  compromise  should  also  correspond  to  a  parallel  examination  of  
whether  a  lack  of  early  CNS  viral  burden  influences  the  long-­‐‑term  trajectory  of  CNS  HIV-­‐‑1.    
This  analysis  would  help  us  determine  if  an  early  CNS  state  predicts  later  CNS  compromise  
or  is  merely  a  snapshot  of  what  is  occurring  in  the  brain  at  a  point  in  time  but  does  not  
predict  later  neurological  complications.    Further  studies  will  be  necessary,  beginning  when  
a  subject  is  in  the  earliest  stages  of  acute  infection  and  continuing  longitudinally,  to  explore  
what  is  occurring  in  the  situation  where  the  viral  load  in  the  CSF  is  low  despite  a  high  
plasma  viral  load,  a  condition  observed  in  some  subjects  in  my  adult  study.    This  phenotype  
has  been  observed  in  other  acute  infection  studies  (308).      
Altered  concentrations  of  CSF  biomarkers,  such  as  NFL,  neopterin,  MCP-­‐‑1,  and  IP-­‐‑10  
have  been  associated  with  neurodegenerative  processes  (58,  85,  129,  232),  and  while  these  
biomarkers  have  been  associated  with  CNS  inflammation  and  the  development  of  
neurological  disorders  in  chronic  and  late  stage  HIV-­‐‑1  infection,  their  effects  in  pre-­‐‑
symptomatic  primary  infection  have  also  been  described  (308).    Supernatants  were  stored  
for  all  analyzed  samples  from  my  pediatric,  adult,  and  macaque  studies.    An  analysis  of  
biomarkers  is  a  crucial  next  step  in  the  examination  of  early  CNS  infections,  as  there  is  still  a  
need  to  determine  the  state  of  BBB  integrity  in  subjects  early  and  whether  there  is  an  
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association  between  compartmentalization  and  abnormal  biomarker  concentrations  early  
that  could  lead  to  neurological  complications.    
During  HIV-­‐‑1  infection  in  humans,  analysis  of  brain  tissue  is  possible  once,  at  
autopsy  or  biopsy.    Therefore,  we  rely  heavily  on  the  CSF  to  study  HIV-­‐‑1  CNS  infection.    
Currently  there  is  minimal  understanding  of  where  in  the  brain  HIV-­‐‑1  replication  is  
occurring,  but  this  is  of  critical  importance  as  the  region  of  infection  will  likely  influence  the  
degree  of  neurological  damage  and,  subsequently,  neurological  disease.    In  my  SIV/rhesus  
macaque  study,  paraffin-­‐‑embedded  sections  of  various  regions  of  the  brain  are  available  for  
analysis.    Several  studies  of  other  neurotropic  viruses  (19,  49,  211,  330)  as  well  as  SIV  (51,  74)  
have  been  able  to  detect  viral  nucleic  acid  in  tissue  using  in  situ  hybridization  techniques.    In  
my  rhesus  macaque  study  I  could  examine  viral  nuclei  acid  in  formalin-­‐‑fixed  paraffin  
embedded  sections  of  the  brain  by  in  situ  hybridization  using  cloned  and  radiolabeled  
complementary  DNA  viral  gene  specific  probes  (riboprobes).    As  the  rhesus  macaques  in  
my  study  had  varying  degrees  of  disease  progression  and  phylogenetic  states,  I  could  
explore  whether  the  location  of  viral  replication  in  the  CNS  is  related  to  disease  progression  
and/or  the  presence/absence  of  compartmentalization.    Additionally,  an  understanding  of  
where  SIV  replication  is  occurring  in  the  brains  of  infected  macaques  could  guide  further  
studies  exploring  HIV-­‐‑1  replication  in  humans.    
Neurological  complications  continue  to  persist  despite  treatment  and  eradication  of  
potential  HIV-­‐‑1  reservoirs,  such  as  in  the  CNS,  is  one  of  several  critical  steps  towards  a  cure  
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for  HIV.    Our  understanding  of  the  extent  of  HIV-­‐‑1  replication  in  the  brain  and  the  
consequences  of  such  replication  is  ever  expanding,  but  much  about  this  process  is  still  
unknown,  especially  in  the  arena  of  how  early  CNS  involvement  impacts  later  neurological  
outcomes.    Future  longitudinal  studies  are  imperative  to  understand  the  evolutionary  
events  leading  to  significant  CNS  viral  burden,  and  whether  local  replication  early  predicts  
neurological  complications  later  during  infection.    Recent  technological  advances  such  as  
deep  sequencing  provide  an  opportunity  to  explore  CNS  viral  populations  with  greater  
sensitivity  than  was  possible  previously.    Additionally,  a  more  thorough  understanding  of  
what  characteristics,  such  as  neutralization  sensitivity  or  glycosylation,  result  in  a  
transmitted  variant  or  compartmentalized  population  being  better  suited  for  replication  in  
the  CNS  would  help  drive  future  therapeutic  applications  in  both  children  and  adults  











Figure  22:  Four  states  to  describe  the  relationship  between  virus  in  the  CNS  and  virus  in  
the  periphery  in  young  children  
Blood   and   CSF/CNS   compartments   are   indicated   as   well   as   time   post   vertical  
transmission.    Blood  plasma  viral  variants  are  represented  by  the  red  virus  particles;  and  
CNS   viral   variants   are   represented   by   the   blue   virus   particles.      CD4+   T   cells   are  
represented   by   open   circles   and   macrophages   by   irregularly   shaped   cells.      Arrows  
indicate  direction  of  virus  movement  between  and  within  compartments.    The  following  
states  are  depicted:    
EQUILIBRATED:  State  with  no  genetic  evidence  for  HIV-­‐‑1  replication  in  the  CNS.    
INTERMEDIATE:      State   that   occurs   prior   to   18   months   of   age   and   involves   minor  
compartmentalization  of   the  CSF  viral  population,   suggesting   some   local   replication   in  
the  CSF/CNS.    Some  evidence  for  the  initial  evolution  of  virus  that  can  use  lower  levels  
of   CD4,   potentially   on   a   path   to   becoming   macrophage-­‐‑tropic.  
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COMPARTMENTALIZED:  State   that  occurs   in  about  half  of   the  children  older   than  18  
months  of  age,  and  in  this  state  the  viral  population  in  the  CSF  shows  strong  evidence  of  
genetic   compartmentalization,   indicative   of   local   replication   and   evolution   within   the  
CNS.      Evidence   of   variants   that   had   evolved   to   use   low   levels   of   CD4      are   observed,  
presumably  now  growing  in  macrophages  and/or  microglia  within  the  CNS.    
SEQUESTRATION:   State   that   involves   multiple   variant   transmissions   from  mother   to  
infant  of  which  one  variant  preferentially  replicates  in  the  CNS  and  another  replicates  in  
the  periphery.    
  177  
REFERENCES 
1.   Abbott,  N.  J.,  L.  Ronnback,  and  E.  Hansson.  2006.  Astrocyte-­‐‑endothelial  interactions  
at  the  blood-­‐‑brain  barrier.  Nature  reviews.  Neuroscience  7:41-­‐‑53.  
  
2.   Abdulle,  S.,  A.  Mellgren,  B.  J.  Brew,  P.  Cinque,  L.  Hagberg,  R.  W.  Price,  L.  
Rosengren,  and  M.  Gisslen.  2007.  CSF  neurofilament  protein  (NFL)  -­‐‑-­‐‑  a  marker  of  
active  HIV-­‐‑related  neurodegeneration.  Journal  of  neurology  254:1026-­‐‑1032.  
  
3.   Abrahams,  M.  R.,  J.  A.  Anderson,  E.  E.  Giorgi,  C.  Seoighe,  K.  Mlisana,  L.  H.  Ping,  
G.  S.  Athreya,  F.  K.  Treurnicht,  B.  F.  Keele,  N.  Wood,  J.  F.  Salazar-­‐‑Gonzalez,  T.  
Bhattacharya,  H.  Chu,  I.  Hoffman,  S.  Galvin,  C.  Mapanje,  P.  Kazembe,  R.  Thebus,  
S.  Fiscus,  W.  Hide,  M.  S.  Cohen,  S.  A.  Karim,  B.  F.  Haynes,  G.  M.  Shaw,  B.  H.  
Hahn,  B.  T.  Korber,  R.  Swanstrom,  and  C.  Williamson.  2009.  Quantitating  the  
multiplicity  of  infection  with  human  immunodeficiency  virus  type  1  subtype  C  
reveals  a  non-­‐‑poisson  distribution  of  transmitted  variants.  J  Virol  83:3556-­‐‑3567.  
  
4.   Ahmad,  N.  2005.  The  vertical  transmission  of  human  immunodeficiency  virus  type  
1:  molecular  and  biological  properties  of  the  virus.  Crit  Rev  Clin  Lab  Sci  42:1-­‐‑34.  
  
5.   Ahmad,  N.,  B.  M.  Baroudy,  R.  C.  Baker,  and  C.  Chappey.  1995.  Genetic  analysis  of  
human  immunodeficiency  virus  type  1  envelope  V3  region  isolates  from  mothers  
and  infants  after  perinatal  transmission.  J  Virol  69:1001-­‐‑1012.  
  
6.   Alexaki,  A.,  Y.  Liu,  and  B.  Wigdahl.  2008.  Cellular  reservoirs  of  HIV-­‐‑1  and  their  role  
in  viral  persistence.  Curr  HIV  Res  6:388-­‐‑400.  
  
7.   Alexander,  M.,  R.  Lynch,  J.  Mulenga,  S.  Allen,  C.  A.  Derdeyn,  and  E.  Hunter.  
Donor  and  recipient  envs  from  heterosexual  human  immunodeficiency  virus  
subtype  C  transmission  pairs  require  high  receptor  levels  for  entry.  J  Virol  84:4100-­‐‑
4104.  
  
8.   Alexander,  M.,  R.  Lynch,  J.  Mulenga,  S.  Allen,  C.  A.  Derdeyn,  and  E.  Hunter.  2010.  
Donor  and  recipient  envs  from  heterosexual  human  immunodeficiency  virus  
subtype  C  transmission  pairs  require  high  receptor  levels  for  entry.  J  Virol  84:4100-­‐‑
4104.  
  
9.   Allan,  J.  S.,  J.  E.  Coligan,  F.  Barin,  M.  F.  McLane,  J.  G.  Sodroski,  C.  A.  Rosen,  W.  A.  
Haseltine,  T.  H.  Lee,  and  M.  Essex.  1985.  Major  glycoprotein  antigens  that  induce  
antibodies  in  AIDS  patients  are  encoded  by  HTLV-­‐‑III.  Science  228:1091-­‐‑1094.  
  178  
  
10.   Ances,  B.  M.,  and  R.  J.  Ellis.  2007.  Dementia  and  neurocognitive  disorders  due  to  
HIV-­‐‑1  infection.  Seminars  in  neurology  27:86-­‐‑92.  
  
11.   Anderson,  J.  A.,  L.  H.  Ping,  O.  Dibben,  C.  B.  Jabara,  L.  Arney,  L.  Kincer,  Y.  Tang,  
M.  Hobbs,  I.  Hoffman,  P.  Kazembe,  C.  D.  Jones,  P.  Borrow,  S.  Fiscus,  M.  S.  Cohen,  
and  R.  Swanstrom.  2010.  HIV-­‐‑1  Populations  in  Semen  Arise  through  Multiple  
Mechanisms.  PLoS  Pathog  6:e1001053.  
  
12.   Anton,  P.  A.,  J.  Elliott,  M.  A.  Poles,  I.  M.  McGowan,  J.  Matud,  L.  E.  Hultin,  K.  
Grovit-­‐‑Ferbas,  C.  R.  Mackay,  I.  S.  Y.  Chen,  and  J.  V.  Giorgi.  2000.  Enhanced  levels  
of  functional  HIV-­‐‑1  co-­‐‑receptors  on  human  mucosal  T  cells  demonstrated  using  
intestinal  biopsy  tissue.  AIDS  14:1761-­‐‑1765.  
  
13.   Armulik,  A.,  G.  Genove,  M.  Mae,  M.  H.  Nisancioglu,  E.  Wallgard,  C.  Niaudet,  L.  
He,  J.  Norlin,  P.  Lindblom,  K.  Strittmatter,  B.  R.  Johansson,  and  C.  Betsholtz.  2010.  
Pericytes  regulate  the  blood-­‐‑brain  barrier.  Nature  468:557-­‐‑561.  
  
14.   Augenbraun,  M.  H.,  and  W.  M.  McCormack.  1994.  Sexually  transmitted  diseases  in  
HIV-­‐‑infected  persons.  Infectious  disease  clinics  of  North  America  8:439-­‐‑448.  
  
15.   Aylward,  E.  H.,  J.  D.  Henderer,  J.  C.  McArthur,  P.  D.  Brettschneider,  G.  J.  Harris,  P.  
E.  Barta,  and  G.  D.  Pearlson.  1993.  Reduced  basal  ganglia  volume  in  HIV-­‐‑1-­‐‑
associated  dementia:  results  from  quantitative  neuroimaging.  Neurology  43:2099-­‐‑
2104.  
  
16.   Balin,  B.  J.,  R.  D.  Broadwell,  M.  Salcman,  and  M.  el-­‐‑Kalliny.  1986.  Avenues  for  
entry  of  peripherally  administered  protein  to  the  central  nervous  system  in  mouse,  
rat,  and  squirrel  monkey.  The  Journal  of  comparative  neurology  251:260-­‐‑280.  
  
17.   Banks,  W.  A.  2005.  The  blood-­‐‑brain  barrier:  its  stucture  and  function,  p.  107-­‐‑113.  In  
H.  E.  Gendelman,  I.  Grant,  I.  P.  Everall,  S.  A.  Lipton,  and  S.  Swindells  (ed.),  The  
Neurology  of  AIDS,  vol.  2nd  Edition.  Oxford  University  Press,  New  York.  
  
18.   Banks,  W.  A.,  E.  O.  Freed,  K.  M.  Wolf,  S.  M.  Robinson,  M.  Franko,  and  V.  B.  
Kumar.  2001.  Transport  of  human  immunodeficiency  virus  type  1  pseudoviruses  
across  the  blood-­‐‑brain  barrier:  role  of  envelope  proteins  and  adsorptive  endocytosis.  
J  Virol  75:4681-­‐‑4691.  
  
  179  
19.   Barnett,  E.  M.,  M.  D.  Cassell,  and  S.  Perlman.  1993.  Two  neurotropic  viruses,  herpes  
simplex  virus  type  1  and  mouse  hepatitis  virus,  spread  along  different  neural  
pathways  from  the  main  olfactory  bulb.  Neuroscience  57:1007-­‐‑1025.  
  
20.   Bedima,  R.  J.,  Skiest,  D.J.  2009.  Cryptoccosis  and  Other  Fungal  Infcetions  of  the  
Central  Nervous  System,  p.  347-­‐‑361.  In  K.  Goodkin,  Shapshak,  P.,  Verma,  A.  (ed.),  
The  Spectrum  of  Neuro-­‐‑AIDS  Disorders:  Pathophysiology,  Diagnosis,  and  
Treatment.  ASM  Press,  Washington,  DC.  
  
21.   Bellizzi,  A.,  E.  Anzivino,  D.  M.  Rodio,  A.  T.  Palamara,  L.  Nencioni,  and  V.  
Pietropaolo.  2013.  New  Insights  on  Human  Polyomavirus  JC  and  Pathogenesis  of  
Progressive  Multifocal  Leukoencephalopathy.  Clinical  &  developmental  
immunology  2013:839719.  
  
22.   Belman,  A.  L.  2009.  Pediatric  Neuro-­‐‑AIDS,  p.  455-­‐‑471.  In  K.  Goodkin,  P.  Shapshak,  
and  A.  Verma  (ed.),  The  Spectrum  of  Neuro-­‐‑AIDS  Disorders:  Pathophysiology,  
Diagnosis,  and  Treatment,  vol.  1.  ASM  Press,  Washington,  DC.  
  
23.   Belman,  A.  L.,  G.  Diamond,  D.  Dickson,  D.  Horoupian,  J.  Llena,  G.  Lantos,  and  A.  
Rubinstein.  1988.  Pediatric  acquired  immunodeficiency  syndrome.  Neurologic  
syndromes.  Am  J  Dis  Child  142:29-­‐‑35.  
  
24.   Beral,  V.,  T.  Peterman,  R.  Berkelman,  and  H.  Jaffe.  1991.  AIDS-­‐‑associated  non-­‐‑
Hodgkin  lymphoma.  Lancet  337:805-­‐‑809.  
  
25.   Berger,  J.  R.,  Cohen,  B.A.  2005.  Opportunistic  infections  of  the  nervous  system  in  
AIDS,  p.  485-­‐‑529.  In  H.  E.  Gendelman,  Grant,  I.,  Everall,  I.P.,  Lipton,  S.A.,  Swindells,  
S.  (ed.),  The  Neurology  of  AIDS,  vol.  2nd  Edition.  Oxford  University  Press,  New  
York.  
  
26.   Bhaskaran,  K.,  C.  Mussini,  A.  Antinori,  A.  S.  Walker,  M.  Dorrucci,  C.  Sabin,  A.  
Phillips,  K.  Porter,  and  C.  Collaboration.  2008.  Changes  in  the  incidence  and  
predictors  of  human  immunodeficiency  virus-­‐‑associated  dementia  in  the  era  of  
highly  active  antiretroviral  therapy.  Annals  of  neurology  63:213-­‐‑221.  
27.   Blackard,  J.  T.,  G.  Ma,  C.  M.  Martin,  S.  D.  Rouster,  M.  T.  Shata,  and  K.  E.  Sherman.  
2011.  HIV  variability  in  the  liver  and  evidence  of  possible  compartmentalization.  
AIDS  Res  Hum  Retroviruses  27:1117-­‐‑1126.  
  
28.   Blanche,  S.,  M.  L.  Newell,  M.  J.  Mayaux,  D.  T.  Dunn,  J.  P.  Teglas,  C.  Rouzioux,  and  
C.  S.  Peckham.  1997.  Morbidity  and  mortality  in  European  children  vertically  
  180  
infected  by  HIV-­‐‑1.  The  French  Pediatric  HIV  Infection  Study  Group  and  European  
Collaborative  Study.  J  Acquir  Immune  Defic  Syndr  Hum  Retrovirol  14:442-­‐‑450.  
  
29.   Blennow,  K.,  H.  Hampel,  M.  Weiner,  and  H.  Zetterberg.  2010.  Cerebrospinal  fluid  
and  plasma  biomarkers  in  Alzheimer  disease.  Nature  reviews.  Neurology  6:131-­‐‑144.  
  
30.   Blish,  C.  A.,  W.  M.  Blay,  N.  L.  Haigwood,  and  J.  Overbaugh.  2007.  Transmission  of  
HIV-­‐‑1  in  the  face  of  neutralizing  antibodies.  Curr  HIV  Res  5:578-­‐‑587.  
  
31.   Boisse,  L.,  M.  J.  Gill,  and  C.  Power.  2008.  HIV  infection  of  the  central  nervous  
system:  clinical  features  and  neuropathogenesis.  Neurologic  clinics  26:799-­‐‑819,  x.  
  
32.   Borrow,  P.,  H.  Lewicki,  B.  H.  Hahn,  G.  M.  Shaw,  and  M.  B.  Oldstone.  1994.  Virus-­‐‑
specific  CD8+  cytotoxic  T-­‐‑lymphocyte  activity  associated  with  control  of  viremia  in  
primary  human  immunodeficiency  virus  type  1  infection.  J  Virol  68:6103-­‐‑6110.  
  
33.   Boven,  L.  A.,  J.  Middel,  E.  C.  Breij,  D.  Schotte,  J.  Verhoef,  C.  Soderland,  and  H.  S.  
Nottet.  2000.  Interactions  between  HIV-­‐‑infected  monocyte-­‐‑derived  macrophages  and  
human  brain  microvascular  endothelial  cells  result  in  increased  expression  of  CC  
chemokines.  J  Neurovirol  6:382-­‐‑389.  
  
34.   Brenchley,  J.  M.,  T.  W.  Schacker,  L.  E.  Ruff,  D.  A.  Price,  J.  H.  Taylor,  G.  J.  Beilman,  
P.  L.  Nguyen,  A.  Khoruts,  M.  Larson,  A.  T.  Haase,  and  D.  C.  Douek.  2004.  CD4+  T  
cell  depletion  during  all  stages  of  HIV  disease  occurs  predominantly  in  the  
gastrointestinal  tract.  The  Journal  of  experimental  medicine  200:749-­‐‑759.  
  
35.   Broadwell,  R.  D.,  and  M.  V.  Sofroniew.  1993.  Serum  proteins  bypass  the  blood-­‐‑
brain  fluid  barriers  for  extracellular  entry  to  the  central  nervous  system.  
Experimental  neurology  120:245-­‐‑263.  
  
36.   Brooks,  B.  R.,  and  D.  L.  Walker.  1984.  Progressive  multifocal  leukoencephalopathy.  
Neurologic  clinics  2:299-­‐‑313.  
  
37.   Brown,  K.  V.,  and  D.  J.  Skiest.  2009.  Toxoplasmosis  of  the  Central  Nervous  System,  
p.  313-­‐‑329.  In  K.  Goodkin,  P.  Shapshak,  and  A.  Verma  (ed.),  The  Spectrum  of  Neuro-­‐‑
AIDS  Disorders:  Pathophysiology,  Diagnosis,  and  Treatment,  vol.  1.  ASM  Press,  
Washington,  DC.  
  
38.   Brown,  R.  J.,  P.  J.  Peters,  C.  Caron,  M.  P.  Gonzalez-­‐‑Perez,  L.  Stones,  C.  
Ankghuambom,  K.  Pondei,  C.  P.  McClure,  G.  Alemnji,  S.  Taylor,  P.  M.  Sharp,  P.  
  181  
R.  Clapham,  and  J.  K.  Ball.  2011.  Intercompartmental  recombination  of  HIV-­‐‑1  
contributes  to  env  intrahost  diversity  and  modulates  viral  tropism  and  sensitivity  to  
entry  inhibitors.  J  Virol  85:6024-­‐‑6037.  
  
39.   Bruggeman,  L.  A.,  M.  D.  Ross,  N.  Tanji,  A.  Cara,  S.  Dikman,  R.  E.  Gordon,  G.  C.  
Burns,  V.  D.  D'ʹAgati,  J.  A.  Winston,  M.  E.  Klotman,  and  P.  E.  Klotman.  2000.  Renal  
epithelium  is  a  previously  unrecognized  site  of  HIV-­‐‑1  infection.  Journal  of  the  
American  Society  of  Nephrology  :  JASN  11:2079-­‐‑2087.  
  
40.   Budka,  H.  1986.  Multinucleated  giant  cells  in  brain:  a  hallmark  of  the  acquired  
immune  deficiency  syndrome  (AIDS).  Acta  neuropathologica  69:253-­‐‑258.  
  
41.   Budka,  H.  2005.  The  neuropathology  of  HIV-­‐‑associated  brain  disease,  p.  375-­‐‑391.  In  
H.  E.  Gendelman,  I.  Grant,  I.  P.  Everall,  S.  A.  Lipton,  and  S.  Swindells  (ed.),  The  
Neurology  of  AIDS.  Oxford  University  Press,  New  York.  
  
42.   Budka,  H.,  G.  Costanzi,  S.  Cristina,  A.  Lechi,  C.  Parravicini,  R.  Trabattoni,  and  L.  
Vago.  1987.  Brain  pathology  induced  by  infection  with  the  human  
immunodeficiency  virus  (HIV).  A  histological,  immunocytochemical,  and  electron  
microscopical  study  of  100  autopsy  cases.  Acta  neuropathologica  75:185-­‐‑198.  
  
43.   Budka,  H.,  C.  A.  Wiley,  P.  Kleihues,  J.  Artigas,  A.  K.  Asbury,  E.  S.  Cho,  D.  R.  
Cornblath,  M.  C.  Dal  Canto,  U.  DeGirolami,  D.  Dickson,  and  et  al.  1991.  HIV-­‐‑
associated  disease  of  the  nervous  system:  review  of  nomenclature  and  proposal  for  
neuropathology-­‐‑based  terminology.  Brain  pathology  1:143-­‐‑152.  
  
44.   Bull,  M.  E.,  L.  M.  Heath,  J.  L.  McKernan-­‐‑Mullin,  K.  M.  Kraft,  L.  Acevedo,  J.  E.  
Hitti,  S.  E.  Cohn,  K.  A.  Tapia,  S.  E.  Holte,  J.  A.  Dragavon,  R.  W.  Coombs,  J.  I.  
Mullins,  and  L.  M.  Frenkel.  2013.  Human  immunodeficiency  viruses  appear  
compartmentalized  to  the  female  genital  tract  in  cross-­‐‑sectional  analyses  but  genital  
lineages  do  not  persist  over  time.  J  Infect  Dis  207:1206-­‐‑1215.  
  
45.   Burkala,  E.,  J.  T.  West,  J.  He,  C.  K.  Petito,  and  C.  Wood.  2005.  The  choroid  plexus  
and  viral  entry  into  the  brain,  p.  163-­‐‑171.  In  H.  E.  Gendelman,  I.  Grant,  I.  P.  Everall,  
S.  A.  Lipton,  and  S.  Swindells  (ed.),  The  Neurology  of  AIDS.  Oxford  University  
Press,  New  York.  
  
46.   Burudi,  E.  M.,  and  H.  S.  Fox.  2001.  Simian  immunodeficiency  virus  model  of  HIV-­‐‑
induced  central  nervous  system  dysfunction.  Advances  in  virus  research  56:435-­‐‑468.  
  
  182  
47.   Caldwell,  R.  L.,  B.  S.  Egan,  and  V.  L.  Shepherd.  2000.  HIV-­‐‑1  Tat  represses  
transcription  from  the  mannose  receptor  promoter.  J  Immunol  165:7035-­‐‑7041.  
  
48.   Cao,  Y.  Z.,  D.  Dieterich,  P.  A.  Thomas,  Y.  X.  Huang,  M.  Mirabile,  and  D.  D.  Ho.  
1992.  Identification  and  quantitation  of  HIV-­‐‑1  in  the  liver  of  patients  with  AIDS.  
AIDS  6:65-­‐‑70.  
  
49.   Carbone,  K.  M.,  T.  R.  Moench,  and  W.  I.  Lipkin.  1991.  Borna  disease  virus  replicates  
in  astrocytes,  Schwann  cells  and  ependymal  cells  in  persistently  infected  rats:  
location  of  viral  genomic  and  messenger  RNAs  by  in  situ  hybridization.  Journal  of  
neuropathology  and  experimental  neurology  50:205-­‐‑214.  
  
50.   Cesarman,  E.,  Y.  Chang,  P.  S.  Moore,  J.  W.  Said,  and  D.  M.  Knowles.  1995.  Kaposi'ʹs  
sarcoma-­‐‑associated  herpesvirus-­‐‑like  DNA  sequences  in  AIDS-­‐‑related  body-­‐‑cavity-­‐‑
based  lymphomas.  The  New  England  journal  of  medicine  332:1186-­‐‑1191.  
  
51.   Chakrabarti,  L.,  M.  Hurtrel,  M.  A.  Maire,  R.  Vazeux,  D.  Dormont,  L.  Montagnier,  
and  B.  Hurtrel.  1991.  Early  viral  replication  in  the  brain  of  SIV-­‐‑infected  rhesus  
monkeys.  The  American  journal  of  pathology  139:1273-­‐‑1280.  
  
52.   Chan,  D.  C.,  D.  Fass,  J.  M.  Berger,  and  P.  S.  Kim.  1997.  Core  structure  of  gp41  from  
the  HIV  envelope  glycoprotein.  Cell  89:263-­‐‑273.  
  
53.   Chang,  H.  C.,  F.  Samaniego,  B.  C.  Nair,  L.  Buonaguro,  and  B.  Ensoli.  1997.  HIV-­‐‑1  
Tat  protein  exits  from  cells  via  a  leaderless  secretory  pathway  and  binds  to  
extracellular  matrix-­‐‑associated  heparan  sulfate  proteoglycans  through  its  basic  
region.  AIDS  11:1421-­‐‑1431.  
  
54.   Chang,  Y.,  E.  Cesarman,  M.  S.  Pessin,  F.  Lee,  J.  Culpepper,  D.  M.  Knowles,  and  P.  
S.  Moore.  1994.  Identification  of  herpesvirus-­‐‑like  DNA  sequences  in  AIDS-­‐‑
associated  Kaposi'ʹs  sarcoma.  Science  266:1865-­‐‑1869.  
  
55.   Chen,  P.,  B.  K.  Chen,  A.  Mosoian,  T.  Hays,  M.  J.  Ross,  P.  E.  Klotman,  and  M.  E.  
Klotman.  2011.  Virological  synapses  allow  HIV-­‐‑1  uptake  and  gene  expression  in  
renal  tubular  epithelial  cells.  Journal  of  the  American  Society  of  Nephrology  :  JASN  
22:496-­‐‑507.  
  
56.   Choe,  H.,  M.  Farzan,  Y.  Sun,  N.  Sullivan,  B.  Rollins,  P.  D.  Ponath,  L.  Wu,  C.  R.  
Mackay,  G.  LaRosa,  W.  Newman,  N.  Gerard,  C.  Gerard,  and  J.  Sodroski.  1996.  The  
  183  
beta-­‐‑chemokine  receptors  CCR3  and  CCR5  facilitate  infection  by  primary  HIV-­‐‑1  
isolates.  Cell  85:1135-­‐‑1148.  
  
57.   Chohan,  B.,  D.  Lang,  M.  Sagar,  B.  Korber,  L.  Lavreys,  B.  Richardson,  and  J.  
Overbaugh.  2005.  Selection  for  human  immunodeficiency  virus  type  1  envelope  
glycosylation  variants  with  shorter  V1-­‐‑V2  loop  sequences  occurs  during  
transmission  of  certain  genetic  subtypes  and  may  impact  viral  RNA  levels.  J  Virol  
79:6528-­‐‑6531.  
  
58.   Cinque,  P.,  A.  Bestetti,  R.  Marenzi,  S.  Sala,  M.  Gisslen,  L.  Hagberg,  and  R.  W.  
Price.  2005.  Cerebrospinal  fluid  interferon-­‐‑gamma-­‐‑inducible  protein  10  (IP-­‐‑10,  
CXCL10)  in  HIV-­‐‑1  infection.  J  Neuroimmunol  168:154-­‐‑163.  
  
59.   Civitello,  L.  2003.  Neurologic  aspects  of  HIV  infection  in  infants  and  children:  
therapeutic  approaches  and  outcome.  Curr  Neurol  Neurosci  Rep  3:120-­‐‑128.  
  
60.   Clements,  J.  E.,  T.  Babas,  J.  L.  Mankowski,  K.  Suryanarayana,  M.  Piatak,  Jr.,  P.  M.  
Tarwater,  J.  D.  Lifson,  and  M.  C.  Zink.  2002.  The  central  nervous  system  as  a  
reservoir  for  simian  immunodeficiency  virus  (SIV):  steady-­‐‑state  levels  of  SIV  DNA  in  
brain  from  acute  through  asymptomatic  infection.  J  Infect  Dis  186:905-­‐‑913.  
  
61.   Cohen,  M.  S.,  C.  L.  Gay,  M.  P.  Busch,  and  F.  M.  Hecht.  2010.  The  detection  of  acute  
HIV  infection.  J  Infect  Dis  202  Suppl  2:S270-­‐‑277.  
  
62.   Collins,  K.  L.,  B.  K.  Chen,  S.  A.  Kalams,  B.  D.  Walker,  and  D.  Baltimore.  1998.  HIV-­‐‑
1  Nef  protein  protects  infected  primary  cells  against  killing  by  cytotoxic  T  
lymphocytes.  Nature  391:397-­‐‑401.  
  
63.   Couderc,  T.,  T.  Barzu,  F.  Horaud,  and  R.  Crainic.  1990.  Poliovirus  permissivity  and  
specific  receptor  expression  on  human  endothelial  cells.  Virology  174:95-­‐‑102.  
  
64.   Crowe,  S.,  J.  Mills,  and  M.  S.  McGrath.  1987.  Quantitative  
immunocytofluorographic  analysis  of  CD4  surface  antigen  expression  and  HIV  
infection  of  human  peripheral  blood  monocyte/macrophages.  AIDS  Res  Hum  
Retroviruses  3:135-­‐‑145.  
  
65.   Cullen,  B.  R.  1998.  Retroviruses  as  model  systems  for  the  study  of  nuclear  RNA  
export  pathways.  Virology  249:203-­‐‑210.  
  
  184  
66.   Daar,  E.  S.,  S.  Little,  J.  Pitt,  J.  Santangelo,  P.  Ho,  N.  Harawa,  P.  Kerndt,  J.  V.  Glorgi,  
J.  Bai,  P.  Gaut,  D.  D.  Richman,  S.  Mandel,  S.  Nichols,  and  H.  I.  V.  I.  R.  N.  Los  
Angeles  County  Primary.  2001.  Diagnosis  of  primary  HIV-­‐‑1  infection.  Los  Angeles  
County  Primary  HIV  Infection  Recruitment  Network.  Ann  Intern  Med  134:25-­‐‑29.  
  
67.   Dalgleish,  A.  G.,  P.  C.  Beverley,  P.  R.  Clapham,  D.  H.  Crawford,  M.  F.  Greaves,  
and  R.  A.  Weiss.  1984.  The  CD4  (T4)  antigen  is  an  essential  component  of  the  
receptor  for  the  AIDS  retrovirus.  Nature  312:763-­‐‑767.  
  
68.   Dallasta,  L.  M.,  L.  A.  Pisarov,  J.  E.  Esplen,  J.  V.  Werley,  A.  V.  Moses,  J.  A.  Nelson,  
and  C.  L.  Achim.  1999.  Blood-­‐‑brain  barrier  tight  junction  disruption  in  human  
immunodeficiency  virus-­‐‑1  encephalitis.  The  American  journal  of  pathology  155:1915-­‐‑
1927.  
  
69.   Dandekar,  S.  2007.  Pathogenesis  of  HIV  in  the  gastrointestinal  tract.  Current  
HIV/AIDS  reports  4:10-­‐‑15.  
  
70.   Davis,  L.  E.,  B.  L.  Hjelle,  V.  E.  Miller,  D.  L.  Palmer,  A.  L.  Llewellyn,  T.  L.  Merlin,  S.  
A.  Young,  R.  G.  Mills,  W.  Wachsman,  and  C.  A.  Wiley.  1992.  Early  viral  brain  
invasion  in  iatrogenic  human  immunodeficiency  virus  infection.  Neurology  42:1736-­‐‑
1739.  
  
71.   Dean,  M.,  L.  P.  Jacobson,  G.  McFarlane,  J.  B.  Margolick,  F.  J.  Jenkins,  O.  M.  
Howard,  H.  F.  Dong,  J.  J.  Goedert,  S.  Buchbinder,  E.  Gomperts,  D.  Vlahov,  J.  J.  
Oppenheim,  S.  J.  O'ʹBrien,  and  M.  Carrington.  1999.  Reduced  risk  of  AIDS  
lymphoma  in  individuals  heterozygous  for  the  CCR5-­‐‑delta32  mutation.  Cancer  
research  59:3561-­‐‑3564.  
  
72.   Delwart,  E.  L.,  H.  W.  Sheppard,  B.  D.  Walker,  J.  Goudsmit,  and  J.  I.  Mullins.  1994.  
Human  immunodeficiency  virus  type  1  evolution  in  vivo  tracked  by  DNA  
heteroduplex  mobility  assays.  J  Virol  68:6672-­‐‑6683.  
  
73.   Delwart,  E.  L.,  E.  G.  Shpaer,  J.  Louwagie,  F.  E.  McCutchan,  M.  Grez,  H.  Rubsamen-­‐‑
Waigmann,  and  J.  I.  Mullins.  1993.  Genetic  relationships  determined  by  a  DNA  
heteroduplex  mobility  assay:  analysis  of  HIV-­‐‑1  env  genes.  Science  262:1257-­‐‑1261.  
  
74.   Demuth,  M.,  S.  Czub,  U.  Sauer,  E.  Koutsilieri,  P.  Haaft,  J.  Heeney,  C.  Stahl-­‐‑
Hennig,  V.  ter  Meulen,  and  S.  Sopper.  2000.  Relationship  between  viral  load  in  
blood,  cerebrospinal  fluid,  brain  tissue  and  isolated  microglia  with  neurological  
disease  in  macaques  infected  with  different  strains  of  SIV.  J  Neurovirol  6:187-­‐‑201.  
  185  
  
75.   Deng,  H.,  R.  Liu,  W.  Ellmeier,  S.  Choe,  D.  Unutmaz,  M.  Burkhart,  P.  Di  Marzio,  S.  
Marmon,  R.  E.  Sutton,  C.  M.  Hill,  C.  B.  Davis,  S.  C.  Peiper,  T.  J.  Schall,  D.  R.  
Littman,  and  N.  R.  Landau.  1996.  Identification  of  a  major  co-­‐‑receptor  for  primary  
isolates  of  HIV-­‐‑1.  Nature  381:661-­‐‑666.  
  
76.   Derdeyn,  C.  A.,  J.  M.  Decker,  F.  Bibollet-­‐‑Ruche,  J.  L.  Mokili,  M.  Muldoon,  S.  A.  
Denham,  M.  L.  Heil,  F.  Kasolo,  R.  Musonda,  B.  H.  Hahn,  G.  M.  Shaw,  B.  T.  Korber,  
S.  Allen,  and  E.  Hunter.  2004.  Envelope-­‐‑constrained  neutralization-­‐‑sensitive  HIV-­‐‑1  
after  heterosexual  transmission.  Science  303:2019-­‐‑2022.  
  
77.   Donaldson,  Y.  K.,  J.  E.  Bell,  J.  W.  Ironside,  R.  P.  Brettle,  J.  R.  Robertson,  A.  
Busuttil,  and  P.  Simmonds.  1994.  Redistribution  of  HIV  outside  the  lymphoid  
system  with  onset  of  AIDS.  Lancet  343:383-­‐‑385.  
  
78.   Drummond,  A.  J.,  and  A.  Rambaut.  2007.  BEAST:  Bayesian  evolutionary  analysis  by  
sampling  trees.  BMC  Evol  Biol  7:214  
  
79.   Duenas-­‐‑Decamp,  M.  J.,  P.  J.  Peters,  D.  Burton,  and  P.  R.  Clapham.  2009.  
Determinants  flanking  the  CD4  binding  loop  modulate  macrophage  tropism  of  
human  immunodeficiency  virus  type  1  R5  envelopes.  J  Virol  83:2575-­‐‑2583.  
  
80.   Dunfee,  R.,  E.  R.  Thomas,  P.  R.  Gorry,  J.  Wang,  P.  Ancuta,  and  D.  Gabuzda.  2006.  
Mechanisms  of  HIV-­‐‑1  neurotropism.  Curr  HIV  Res  4:267-­‐‑278.  
  
81.   Dunfee,  R.  L.,  E.  R.  Thomas,  and  D.  Gabuzda.  2009.  Enhanced  macrophage  tropism  
of  HIV  in  brain  and  lymphoid  tissues  is  associated  with  sensitivity  to  the  broadly  
neutralizing  CD4  binding  site  antibody  b12.  Retrovirology  6:69.  
  
82.   Dunfee,  R.  L.,  E.  R.  Thomas,  P.  R.  Gorry,  J.  Wang,  J.  Taylor,  K.  Kunstman,  S.  M.  
Wolinsky,  and  D.  Gabuzda.  2006.  The  HIV  Env  variant  N283  enhances  macrophage  
tropism  and  is  associated  with  brain  infection  and  dementia.  Proc  Natl  Acad  Sci  U  S  
A  103:15160-­‐‑15165.  
  
83.   Dunfee,  R.  L.,  E.  R.  Thomas,  J.  Wang,  K.  Kunstman,  S.  M.  Wolinsky,  and  D.  
Gabuzda.  2007.  Loss  of  the  N-­‐‑linked  glycosylation  site  at  position  386  in  the  HIV  




84.   Earl,  P.  L.,  B.  Moss,  and  R.  W.  Doms.  1991.  Folding,  interaction  with  GRP78-­‐‑BiP,  
assembly,  and  transport  of  the  human  immunodeficiency  virus  type  1  envelope  
protein.  J  Virol  65:2047-­‐‑2055.  
  
85.   Eden,  A.,  R.  W.  Price,  S.  Spudich,  D.  Fuchs,  L.  Hagberg,  and  M.  Gisslen.  2007.  
Immune  activation  of  the  central  nervous  system  is  still  present  after  >4  years  of  
effective  highly  active  antiretroviral  therapy.  J  Infect  Dis  196:1779-­‐‑1783.  
  
86.   Ellis,  R.  J.,  A.  C.  Gamst,  E.  Capparelli,  S.  A.  Spector,  K.  Hsia,  T.  Wolfson,  I.  
Abramson,  I.  Grant,  and  J.  A.  McCutchan.  2000.  Cerebrospinal  fluid  HIV  RNA  
originates  from  both  local  CNS  and  systemic  sources.  Neurology  54:927-­‐‑936.  
  
87.   Engelhardt,  B.  2006.  Molecular  mechanisms  involved  in  T  cell  migration  across  the  
blood-­‐‑brain  barrier.  Journal  of  neural  transmission  113:477-­‐‑485.  
  
88.   Englund,  J.  A.,  C.  J.  Baker,  C.  Raskino,  R.  E.  McKinney,  M.  H.  Lifschitz,  B.  Petrie,  
M.  G.  Fowler,  J.  D.  Connor,  H.  Mendez,  K.  O'ʹDonnell,  and  D.  W.  Wara.  1996.  
Clinical  and  laboratory  characteristics  of  a  large  cohort  of  symptomatic,  human  
immunodeficiency  virus-­‐‑infected  infants  and  children.  AIDS  Clinical  Trials  Group  
Protocol  152  Study  Team.  Pediatr  Infect  Dis  J  15:1025-­‐‑1036.  
  
89.   Enting,  R.  H.,  J.  M.  Prins,  S.  Jurriaans,  K.  Brinkman,  P.  Portegies,  and  J.  M.  Lange.  
2001.  Concentrations  of  human  immunodeficiency  virus  type  1  (HIV-­‐‑1)  RNA  in  
cerebrospinal  fluid  after  antiretroviral  treatment  initiated  during  primary  HIV-­‐‑1  
infection.  Clinical  infectious  diseases  :  an  official  publication  of  the  Infectious  
Diseases  Society  of  America  32:1095-­‐‑1099.  
  
90.   Eugenin,  E.  A.,  and  J.  W.  Berman.  2005.  Mechanisms  of  viral  entry  through  the  
blood-­‐‑brain  barrier,  p.  147-­‐‑154.  In  H.  E.  Gendelman,  I.  Grant,  I.  P.  Everall,  S.  A.  
Lipton,  and  S.  Swindells  (ed.),  The  Neurology  of  AIDS.  Oxford  University  Press,  
New  York.  
  
91.   Farina,  C.,  F.  Aloisi,  and  E.  Meinl.  2007.  Astrocytes  are  active  players  in  cerebral  
innate  immunity.  Trends  in  immunology  28:138-­‐‑145.  
  
92.   Fauci,  A.  S.,  and  R.  C.  Desrosiers.  1997.  Pathogenesis  of  HIV  and  SIV.  In  J.  M.  Coffin,  
S.  H.  Hughes,  and  H.  E.  Varmus  (ed.),  Retroviruses.  Cold  Spring  Harbor  Laboratory  
Press,  Cold  Spring  Harbor,  New  york.  
  
  187  
93.   Feng,  Y.,  C.  C.  Broder,  P.  E.  Kennedy,  and  E.  A.  Berger.  1996.  HIV-­‐‑1  entry  cofactor:  
functional  cDNA  cloning  of  a  seven-­‐‑transmembrane,  G  protein-­‐‑coupled  receptor.  
Science  272:872-­‐‑877.  
  
94.   Fennie,  C.,  and  L.  A.  Lasky.  1989.  Model  for  intracellular  folding  of  the  human  
immunodeficiency  virus  type  1  gp120.  J  Virol  63:639-­‐‑646.  
  
95.   Finke,  S.,  and  K.  K.  Conzelmann.  2005.  Replication  strategies  of  rabies  virus.  Virus  
research  111:120-­‐‑131.  
  
96.   Fischer-­‐‑Smith,  T.,  and  J.  Rappaport.  2005.  Evolving  paradigms  in  the  pathogenesis  
of  HIV-­‐‑1-­‐‑associated  dementia.  Expert  reviews  in  molecular  medicine  7:1-­‐‑26.  
  
97.   Fishman,  R.  A.  1992.  Cerebrospinal  fluid  in  diseases  of  the  nervous  system,  2nd  ed.  
W.  B.  Saunders  Company,  Philadelphia,  PA.  
  
98.   Forthal,  D.  N.,  G.  Landucci,  J.  Bream,  L.  P.  Jacobson,  T.  B.  Phan,  and  B.  Montoya.  
2007.  FcgammaRIIa  genotype  predicts  progression  of  HIV  infection.  J  Immunol  
179:7916-­‐‑7923.  
  
99.   Fournier,  J.  G.,  M.  Tardieu,  P.  Lebon,  O.  Robain,  G.  Ponsot,  S.  Rozenblatt,  and  M.  
Bouteille.  1985.  Detection  of  measles  virus  RNA  in  lymphocytes  from  peripheral-­‐‑
blood  and  brain  perivascular  infiltrates  of  patients  with  subacute  sclerosing  
panencephalitis.  The  New  England  journal  of  medicine  313:910-­‐‑915.  
  
100.   Franzen,  B.,  K.  Duvefelt,  C.  Jonsson,  B.  Engelhardt,  J.  Ottervald,  M.  Wickman,  Y.  
Yang,  and  I.  Schuppe-­‐‑Koistinen.  2003.  Gene  and  protein  expression  profiling  of  
human  cerebral  endothelial  cells  activated  with  tumor  necrosis  factor-­‐‑alpha.  Brain  
research.  Molecular  brain  research  115:130-­‐‑146.  
  
101.   Freed,  E.  O.,  and  M.  A.  Martin.  2007.  HIVs  and  Their  Replication,  p.  2108-­‐‑2179.  In  D.  
M.  H.  Knipe,  P.M.  (ed.),  Fields  Virology,  vol.  5th  ed.  Wolters  Kluwer  
Health/Lippincott  Williams  &  Wilkins,  Philadelphia.  
  
102.   Fuentes,  M.  E.,  S.  K.  Durham,  M.  R.  Swerdel,  A.  C.  Lewin,  D.  S.  Barton,  J.  R.  
Megill,  R.  Bravo,  and  S.  A.  Lira.  1995.  Controlled  recruitment  of  monocytes  and  
macrophages  to  specific  organs  through  transgenic  expression  of  monocyte  
chemoattractant  protein-­‐‑1.  J  Immunol  155:5769-­‐‑5776.  
  
  188  
103.   Furuta,  R.  A.,  C.  T.  Wild,  Y.  Weng,  and  C.  D.  Weiss.  1998.  Capture  of  an  early  
fusion-­‐‑active  conformation  of  HIV-­‐‑1  gp41.  Nature  structural  biology  5:276-­‐‑279.  
  
104.   Gabuzda,  D.  H.,  and  M.  S.  Hirsch.  1987.  Neurologic  manifestations  of  infection  with  
human  immunodeficiency  virus.  Clinical  features  and  pathogenesis.  Ann  Intern  Med  
107:383-­‐‑391.  
  
105.   Garcia,  J.  V.,  and  A.  D.  Miller.  1991.  Serine  phosphorylation-­‐‑independent  
downregulation  of  cell-­‐‑surface  CD4  by  nef.  Nature  350:508-­‐‑511.  
  
106.   Garcia-­‐‑Samaniego,  J.,  V.  Soriano,  J.  Castilla,  R.  Bravo,  A.  Moreno,  J.  Carbo,  A.  
Iniguez,  J.  Gonzalez,  and  F.  Munoz.  1997.  Influence  of  hepatitis  C  virus  genotypes  
and  HIV  infection  on  histological  severity  of  chronic  hepatitis  C.  The  Hepatitis/HIV  
Spanish  Study  Group.  The  American  journal  of  gastroenterology  92:1130-­‐‑1134.  
  
107.   Gasper-­‐‑Smith,  N.,  D.  M.  Crossman,  J.  F.  Whitesides,  N.  Mensali,  J.  S.  Ottinger,  S.  
G.  Plonk,  M.  A.  Moody,  G.  Ferrari,  K.  J.  Weinhold,  S.  E.  Miller,  C.  F.  Reich,  3rd,  L.  
Qin,  S.  G.  Self,  G.  M.  Shaw,  T.  N.  Denny,  L.  E.  Jones,  D.  S.  Pisetsky,  and  B.  F.  
Haynes.  2008.  Induction  of  plasma  (TRAIL),  TNFR-­‐‑2,  Fas  ligand,  and  plasma  
microparticles  after  human  immunodeficiency  virus  type  1  (HIV-­‐‑1)  transmission:  
implications  for  HIV-­‐‑1  vaccine  design.  J  Virol  82:7700-­‐‑7710.  
  
108.   Gaulton,  G.  N.,  J.  V.  Scobie,  and  M.  Rosenzweig.  1997.  HIV-­‐‑1  and  the  thymus.  
AIDS  11:403-­‐‑414.  
  
109.   Gee,  J.  R.,  and  J.  N.  Keller.  2005.  Astrocytes:  regulation  of  brain  homeostasis  via  
apolipoprotein  E.  The  international  journal  of  biochemistry  &  cell  biology  37:1145-­‐‑
1150.  
  
110.   Gehrmann,  J.,  Y.  Matsumoto,  and  G.  W.  Kreutzberg.  1995.  Microglia:  intrinsic  
immuneffector  cell  of  the  brain.  Brain  research.  Brain  research  reviews  20:269-­‐‑287.  
  
111.   Genovese,  G.,  S.  J.  Tonna,  A.  U.  Knob,  G.  B.  Appel,  A.  Katz,  A.  J.  Bernhardy,  A.  W.  
Needham,  R.  Lazarus,  and  M.  R.  Pollak.  2010.  A  risk  allele  for  focal  segmental  
glomerulosclerosis  in  African  Americans  is  located  within  a  region  containing  
APOL1  and  MYH9.  Kidney  international  78:698-­‐‑704.  
  
112.   Ghiso,  J.,  and  B.  Frangione.  2002.  Amyloidosis  and  Alzheimer'ʹs  disease.  Advanced  
drug  delivery  reviews  54:1539-­‐‑1551.  
  
  189  
113.   Gisslen,  M.,  J.  Krut,  U.  Andreasson,  K.  Blennow,  P.  Cinque,  B.  J.  Brew,  S.  Spudich,  
L.  Hagberg,  L.  Rosengren,  R.  W.  Price,  and  H.  Zetterberg.  2009.  Amyloid  and  tau  
cerebrospinal  fluid  biomarkers  in  HIV  infection.  BMC  neurology  9:63.  
  
114.   Gisslen,  M.,  L.  Rosengren,  L.  Hagberg,  S.  G.  Deeks,  and  R.  W.  Price.  2005.  
Cerebrospinal  fluid  signs  of  neuronal  damage  after  antiretroviral  treatment  
interruption  in  HIV-­‐‑1  infection.  AIDS  Res  Ther  2:6.  
  
115.   Goff,  S.  P.  2007.  Retroviridae:  The  Retroviruses  and  Their  Replication,  p.  2001-­‐‑2069.  
In  D.  M.  H.  Knipe,  P.M.  (ed.),  Fields  Virology,  vol.  5th  ed.  Wolters  Kluwer  
Health/Lippincott  Williams  &  Wilkins,  Philadelphia.  
  
116.   Gonzalez-­‐‑Scarano,  F.,  and  J.  Martin-­‐‑Garcia.  2005.  The  neuropathogenesis  of  AIDS.  
Nat  Rev  Immunol  5:69-­‐‑81.  
  
117.   Goodkin,  K.,  A.  Aronoow,  G.  Baldwin,  R.  Molina,  W.  Zheng,  and  W.  D.  Hardy.  
2009.  HIV-­‐‑1-­‐‑Associated  Neurocognitive  Disorders  in  the  HAART  Era,  p.  3-­‐‑27.  In  K.  
Goodkin,  P.  Shapshak,  and  A.  Verma  (ed.),  The  Spectrum  of  Neuro-­‐‑AIDS  Disorders:  
Pathophysiology,  Diagnosis,  and  Treatment,  vol.  1.  ASM  Press,  Washington,  DC.  
  
118.   Gorry,  P.  R.,  G.  Bristol,  J.  A.  Zack,  K.  Ritola,  R.  Swanstrom,  C.  J.  Birch,  J.  E.  Bell,  N.  
Bannert,  K.  Crawford,  H.  Wang,  D.  Schols,  E.  De  Clercq,  K.  Kunstman,  S.  M.  
Wolinsky,  and  D.  Gabuzda.  2001.  Macrophage  tropism  of  human  
immunodeficiency  virus  type  1  isolates  from  brain  and  lymphoid  tissues  predicts  
neurotropism  independent  of  coreceptor  specificity.  J  Virol  75:10073-­‐‑10089.  
  
119.   Gorry,  P.  R.,  J.  Taylor,  G.  H.  Holm,  A.  Mehle,  T.  Morgan,  M.  Cayabyab,  M.  Farzan,  
H.  Wang,  J.  E.  Bell,  K.  Kunstman,  J.  P.  Moore,  S.  M.  Wolinsky,  and  D.  Gabuzda.  
2002.  Increased  CCR5  affinity  and  reduced  CCR5/CD4  dependence  of  a  
neurovirulent  primary  human  immunodeficiency  virus  type  1  isolate.  J  Virol  
76:6277-­‐‑6292.  
  
120.   Granovsky,  M.  O.,  H.  L.  Minkoff,  B.  H.  Tess,  D.  Waters,  A.  Hatzakis,  D.  E.  Devoid,  
S.  H.  Landesman,  A.  Rubinstein,  A.  M.  Di  Bisceglie,  and  J.  J.  Goedert.  1998.  
Hepatitis  C  virus  infection  in  the  mothers  and  infants  cohort  study.  Pediatrics  
102:355-­‐‑359.  
  
121.   Grant,  I.,  N.  Sacktor,  and  J.  McArthur.  2005.  HIV  neurocognitive  disorders,  p.  357-­‐‑
373.  In  H.  E.  Gendelman,  I.  Grant,  I.  P.  Everall,  S.  A.  Lipton,  and  S.  Swindells  (ed.),  
The  Neurology  of  AIDS,  vol.  2nd  Edition.  Oxford  University  Press,  New  York.  
  190  
  
122.   Gray,  F.,  H.  Adle-­‐‑Biassette,  F.  Chretien,  G.  Lorin  de  la  Grandmaison,  G.  Force,  and  
C.  Keohane.  2001.  Neuropathology  and  neurodegeneration  in  human  
immunodeficiency  virus  infection.  Pathogenesis  of  HIV-­‐‑induced  lesions  of  the  brain,  
correlations  with  HIV-­‐‑associated  disorders  and  modifications  according  to  
treatments.  Clinical  neuropathology  20:146-­‐‑155.  
  
123.   Griffin,  D.  E.  2003.  Immune  responses  to  RNA-­‐‑virus  infections  of  the  CNS.  Nat  Rev  
Immunol  3:493-­‐‑502.  
  
124.   Griffiths,  P.  2004.  Cytomegalovirus  infection  of  the  central  nervous  system.  Herpes  :  
the  journal  of  the  IHMF  11  Suppl  2:95A-­‐‑104A.  
  
125.   Guadalupe,  M.,  S.  Sankaran,  M.  D.  George,  E.  Reay,  D.  Verhoeven,  B.  L.  Shacklett,  
J.  Flamm,  J.  Wegelin,  T.  Prindiville,  and  S.  Dandekar.  2006.  Viral  suppression  and  
immune  restoration  in  the  gastrointestinal  mucosa  of  human  immunodeficiency  
virus  type  1-­‐‑infected  patients  initiating  therapy  during  primary  or  chronic  infection.  
J  Virol  80:8236-­‐‑8247.  
126.   Guillemin,  G.  J.,  and  B.  J.  Brew.  2004.  Microglia,  macrophages,  perivascular  
macrophages,  and  pericytes:  a  review  of  function  and  identification.  Journal  of  
leukocyte  biology  75:388-­‐‑397.  
  
127.   Haas,  D.  W.,  L.  A.  Clough,  B.  W.  Johnson,  V.  L.  Harris,  P.  Spearman,  G.  R.  
Wilkinson,  C.  V.  Fletcher,  S.  Fiscus,  S.  Raffanti,  R.  Donlon,  J.  McKinsey,  J.  
Nicotera,  D.  Schmidt,  R.  E.  Shoup,  R.  E.  Kates,  R.  M.  Lloyd,  Jr.,  and  B.  Larder.  2000.  
Evidence  of  a  source  of  HIV  type  1  within  the  central  nervous  system  by  
ultraintensive  sampling  of  cerebrospinal  fluid  and  plasma.  AIDS  Res  Hum  
Retroviruses  16:1491-­‐‑1502.  
  
128.   Haase,  A.  T.  1986.  Pathogenesis  of  lentivirus  infections.  Nature  322:130-­‐‑136.  
  
129.   Hagberg,  L.,  P.  Cinque,  M.  Gisslen,  B.  J.  Brew,  S.  Spudich,  A.  Bestetti,  R.  W.  Price,  
and  D.  Fuchs.  2010.  Cerebrospinal  fluid  neopterin:  an  informative  biomarker  of  
central  nervous  system  immune  activation  in  HIV-­‐‑1  infection.  AIDS  Res  Ther  7:15.  
  
130.   Harrington,  P.  R.,  M.  J.  Connell,  R.  B.  Meeker,  P.  R.  Johnson,  and  R.  Swanstrom.  
2007.  Dynamics  of  simian  immunodeficiency  virus  populations  in  blood  and  
cerebrospinal  fluid  over  the  full  course  of  infection.  J  Infect  Dis  196:1058-­‐‑1067.  
  
  191  
131.   Harrington,  P.  R.,  D.  W.  Haas,  K.  Ritola,  and  R.  Swanstrom.  2005.  
Compartmentalized  human  immunodeficiency  virus  type  1  present  in  cerebrospinal  
fluid  is  produced  by  short-­‐‑lived  cells.  J  Virol  79:7959-­‐‑7966.  
  
132.   Harrington,  P.  R.,  G.  Schnell,  S.  L.  Letendre,  K.  Ritola,  K.  Robertson,  C.  Hall,  C.  L.  
Burch,  C.  B.  Jabara,  D.  T.  Moore,  R.  J.  Ellis,  R.  W.  Price,  and  R.  Swanstrom.  2009.  
Cross-­‐‑sectional  characterization  of  HIV-­‐‑1  env  compartmentalization  in  cerebrospinal  
fluid  over  the  full  disease  course.  Aids  23:907-­‐‑915.  
  
133.   He,  J.  C.,  M.  Husain,  M.  Sunamoto,  V.  D.  D'ʹAgati,  M.  E.  Klotman,  R.  Iyengar,  and  
P.  E.  Klotman.  2004.  Nef  stimulates  proliferation  of  glomerular  podocytes  through  
activation  of  Src-­‐‑dependent  Stat3  and  MAPK1,2  pathways.  The  Journal  of  clinical  
investigation  114:643-­‐‑651.  
  
134.   Heaton,  R.  K.,  D.  R.  Franklin,  R.  J.  Ellis,  J.  A.  McCutchan,  S.  L.  Letendre,  S.  
Leblanc,  S.  H.  Corkran,  N.  A.  Duarte,  D.  B.  Clifford,  S.  P.  Woods,  A.  C.  Collier,  C.  
M.  Marra,  S.  Morgello,  M.  R.  Mindt,  M.  J.  Taylor,  T.  D.  Marcotte,  J.  H.  Atkinson,  T.  
Wolfson,  B.  B.  Gelman,  J.  C.  McArthur,  D.  M.  Simpson,  I.  Abramson,  A.  Gamst,  C.  
Fennema-­‐‑Notestine,  T.  L.  Jernigan,  J.  Wong,  and  I.  Grant.  2011.  HIV-­‐‑associated  
neurocognitive  disorders  before  and  during  the  era  of  combination  antiretroviral  
therapy:  differences  in  rates,  nature,  and  predictors.  J  Neurovirol  17:3-­‐‑16.  
  
135.   Heaton,  R.  K.,  T.  D.  Marcotte,  M.  R.  Mindt,  J.  Sadek,  D.  J.  Moore,  H.  Bentley,  J.  A.  
McCutchan,  C.  Reicks,  and  I.  Grant.  2004.  The  impact  of  HIV-­‐‑associated  
neuropsychological  impairment  on  everyday  functioning.  J  Int  Neuropsychol  Soc  
10:317-­‐‑331.  
  
136.   Henn,  M.  R.,  C.  L.  Boutwell,  P.  Charlebois,  N.  J.  Lennon,  K.  A.  Power,  A.  R.  
Macalalad,  A.  M.  Berlin,  C.  M.  Malboeuf,  E.  M.  Ryan,  S.  Gnerre,  M.  C.  Zody,  R.  L.  
Erlich,  L.  M.  Green,  A.  Berical,  Y.  Wang,  M.  Casali,  H.  Streeck,  A.  K.  Bloom,  T.  
Dudek,  D.  Tully,  R.  Newman,  K.  L.  Axten,  A.  D.  Gladden,  L.  Battis,  M.  Kemper,  Q.  
Zeng,  T.  P.  Shea,  S.  Gujja,  C.  Zedlack,  O.  Gasser,  C.  Brander,  C.  Hess,  H.  F.  
Gunthard,  Z.  L.  Brumme,  C.  J.  Brumme,  S.  Bazner,  J.  Rychert,  J.  P.  Tinsley,  K.  H.  
Mayer,  E.  Rosenberg,  F.  Pereyra,  J.  Z.  Levin,  S.  K.  Young,  H.  Jessen,  M.  Altfeld,  B.  
W.  Birren,  B.  D.  Walker,  and  T.  M.  Allen.  2012.  Whole  genome  deep  sequencing  of  
HIV-­‐‑1  reveals  the  impact  of  early  minor  variants  upon  immune  recognition  during  
acute  infection.  PLoS  Pathog  8:e1002529.  
  
  192  
137.   Hirsch,  V.,  D.  Adger-­‐‑Johnson,  B.  Campbell,  S.  Goldstein,  C.  Brown,  W.  R.  Elkins,  
and  D.  C.  Montefiori.  1997.  A  molecularly  cloned,  pathogenic,  neutralization-­‐‑
resistant  simian  immunodeficiency  virus,  SIVsmE543-­‐‑3.  J  Virol  71:1608-­‐‑1620.  
  
138.   Hirsch,  V.  M.,  R.  A.  Olmsted,  M.  Murphey-­‐‑Corb,  R.  H.  Purcell,  and  P.  R.  Johnson.  
1989.  An  African  primate  lentivirus  (SIVsm)  closely  related  to  HIV-­‐‑2.  Nature  
339:389-­‐‑392.  
  
139.   Hirsch,  V.  M.,  P.  M.  Zack,  and  P.  R.  Johnson.  1990.  Molecular  characterization  of  
SIV  in  tissues  from  experimentally  infected  macaques.  Journal  of  medical  
primatology  19:287-­‐‑294.  
  
140.   Hirsch,  V.  M.,  P.  M.  Zack,  A.  P.  Vogel,  and  P.  R.  Johnson.  1991.  Simian  
immunodeficiency  virus  infection  of  macaques:  end-­‐‑stage  disease  is  characterized  by  
widespread  distribution  of  proviral  DNA  in  tissues.  J  Infect  Dis  163:976-­‐‑988.  
  
141.   Hladik,  F.,  and  T.  J.  Hope.  2009.  HIV  infection  of  the  genital  mucosa  in  women.  
Current  HIV/AIDS  reports  6:20-­‐‑28.  
  
142.   Ho,  D.  D.,  A.  U.  Neumann,  A.  S.  Perelson,  W.  Chen,  J.  M.  Leonard,  and  M.  
Markowitz.  1995.  Rapid  turnover  of  plasma  virions  and  CD4  lymphocytes  in  HIV-­‐‑1  
infection.  Nature  373:123-­‐‑126.  
  
143.   Huang,  C.  C.,  M.  Tang,  M.  Y.  Zhang,  S.  Majeed,  E.  Montabana,  R.  L.  Stanfield,  D.  
S.  Dimitrov,  B.  Korber,  J.  Sodroski,  I.  A.  Wilson,  R.  Wyatt,  and  P.  D.  Kwong.  2005.  
Structure  of  a  V3-­‐‑containing  HIV-­‐‑1  gp120  core.  Science  310:1025-­‐‑1028.  
  
144.   Hudson,  L.,  J.  Liu,  A.  Nath,  M.  Jones,  R.  Raghavan,  O.  Narayan,  D.  Male,  and  I.  
Everall.  2000.  Detection  of  the  human  immunodeficiency  virus  regulatory  protein  tat  
in  CNS  tissues.  J  Neurovirol  6:145-­‐‑155.  
  
145.   Hunter,  C.  A.,  and  J.  S.  Remington.  1994.  Immunopathogenesis  of  toxoplasmic  
encephalitis.  J  Infect  Dis  170:1057-­‐‑1067.  
  
146.   Husain,  M.,  V.  D.  D'ʹAgati,  J.  C.  He,  M.  E.  Klotman,  and  P.  E.  Klotman.  2005.  HIV-­‐‑1  
Nef  induces  dedifferentiation  of  podocytes  in  vivo:  a  characteristic  feature  of  
HIVAN.  AIDS  19:1975-­‐‑1980.  
  
147.   Husain,  M.,  G.  L.  Gusella,  M.  E.  Klotman,  I.  H.  Gelman,  M.  D.  Ross,  E.  J.  Schwartz,  
A.  Cara,  and  P.  E.  Klotman.  2002.  HIV-­‐‑1  Nef  induces  proliferation  and  anchorage-­‐‑
  193  
independent  growth  in  podocytes.  Journal  of  the  American  Society  of  Nephrology  :  
JASN  13:1806-­‐‑1815.  
  
148.   Isaacman-­‐‑Beck,  J.,  E.  A.  Hermann,  Y.  Yi,  S.  J.  Ratcliffe,  J.  Mulenga,  S.  Allen,  E.  
Hunter,  C.  A.  Derdeyn,  and  R.  G.  Collman.  2009.  Heterosexual  transmission  of  
human  immunodeficiency  virus  type  1  subtype  C:  Macrophage  tropism,  alternative  
coreceptor  use,  and  the  molecular  anatomy  of  CCR5  utilization.  J  Virol  83:8208-­‐‑8220.  
  
149.   Jevtovic,  D.,  V.  Vanovac,  M.  Veselinovic,  D.  Salemovic,  J.  Ranin,  and  E.  Stefanova.  
2009.  The  incidence  of  and  risk  factors  for  HIV-­‐‑associated  cognitive-­‐‑motor  complex  
among  patients  on  HAART.  Biomedicine  &  pharmacotherapy  =  Biomedecine  &  
pharmacotherapie  63:561-­‐‑565.  
  
150.   Johnson,  P.  R.,  and  V.  M.  Hirsch.  1991.  Pathogenesis  of  AIDS:  the  non-­‐‑human  
primate  model.  AIDS  5  Suppl  2:S43-­‐‑48.  
  
151.   Johnston,  S.  H.,  M.  A.  Lobritz,  S.  Nguyen,  K.  Lassen,  S.  Delair,  F.  Posta,  Y.  J.  
Bryson,  E.  J.  Arts,  T.  Chou,  and  B.  Lee.  2009.  A  quantitative  affinity-­‐‑profiling  system  
that  reveals  distinct  CD4/CCR5  usage  patterns  among  human  immunodeficiency  
virus  type  1  and  simian  immunodeficiency  virus  strains.  J  Virol  83:11016-­‐‑11026.  
  
152.   Jones,  M.  V.,  J.  E.  Bell,  and  A.  Nath.  2000.  Immunolocalization  of  HIV  envelope  
gp120  in  HIV  encephalitis  with  dementia.  AIDS  14:2709-­‐‑2713.  
  
153.   Jordan-­‐‑Sciutto,  K.  L.,  and  C.  Akay.  2009.  Cell  Cycle  Proteins  and  the  Pathogenesis  of  
HIV-­‐‑1  Encephalitis  in  the  HAART  Era,  p.  231-­‐‑244.  In  K.  Goodkin,  P.  Shapshak,  and  
A.  Verma  (ed.),  The  Spectrum  of  Neuro-­‐‑AIDS  Disorders:  Pathophysiology,  
Diagnosis,  and  Treatment,  vol.  1.  ASM  Press,  Washington,  DC.  
  
154.   Joseph,  S.  B.,  K.  T.  Arrildt,  A.  E.  Swanstrom,  G.  Schnell,  B.  Lee,  J.  A.  Hoxie,  and  R.  
Swanstrom.  2013.  Quantification  of  Entry  Phenotypes  of  Macrophage-­‐‑Tropic  HIV-­‐‑1  
Across  a  Wide  Range  of  CD4  Densities.  J  Virol.  
  
155.   Jowett,  J.  B.,  V.  Planelles,  B.  Poon,  N.  P.  Shah,  M.  L.  Chen,  and  I.  S.  Chen.  1995.  The  
human  immunodeficiency  virus  type  1  vpr  gene  arrests  infected  T  cells  in  the  G2  +  M  
phase  of  the  cell  cycle.  J  Virol  69:6304-­‐‑6313.  
  
156.   Kaplan,  A.  H.,  M.  Manchester,  and  R.  Swanstrom.  1994.  The  activity  of  the  protease  
of  human  immunodeficiency  virus  type  1  is  initiated  at  the  membrane  of  infected  
  194  
cells  before  the  release  of  viral  proteins  and  is  required  for  release  to  occur  with  
maximum  efficiency.  J  Virol  68:6782-­‐‑6786.  
  
157.   Kaplan,  J.  E.,  D.  Hanson,  M.  S.  Dworkin,  T.  Frederick,  J.  Bertolli,  M.  L.  Lindegren,  
S.  Holmberg,  and  J.  L.  Jones.  2000.  Epidemiology  of  human  immunodeficiency  
virus-­‐‑associated  opportunistic  infections  in  the  United  States  in  the  era  of  highly  
active  antiretroviral  therapy.  Clinical  infectious  diseases  :  an  official  publication  of  
the  Infectious  Diseases  Society  of  America  30  Suppl  1:S5-­‐‑14.  
  
158.   Keele,  B.  F.,  E.  E.  Giorgi,  J.  F.  Salazar-­‐‑Gonzalez,  J.  M.  Decker,  K.  T.  Pham,  M.  G.  
Salazar,  C.  Sun,  T.  Grayson,  S.  Wang,  H.  Li,  X.  Wei,  C.  Jiang,  J.  L.  Kirchherr,  F.  
Gao,  J.  A.  Anderson,  L.  H.  Ping,  R.  Swanstrom,  G.  D.  Tomaras,  W.  A.  Blattner,  P.  
A.  Goepfert,  J.  M.  Kilby,  M.  S.  Saag,  E.  L.  Delwart,  M.  P.  Busch,  M.  S.  Cohen,  D.  C.  
Montefiori,  B.  F.  Haynes,  B.  Gaschen,  G.  S.  Athreya,  H.  Y.  Lee,  N.  Wood,  C.  
Seoighe,  A.  S.  Perelson,  T.  Bhattacharya,  B.  T.  Korber,  B.  H.  Hahn,  and  G.  M.  
Shaw.  2008.  Identification  and  characterization  of  transmitted  and  early  founder  
virus  envelopes  in  primary  HIV-­‐‑1  infection.  Proc  Natl  Acad  Sci  U  S  A  105:7552-­‐‑7557.  
  
159.   Kemal,  K.  S.,  B.  Foley,  H.  Burger,  K.  Anastos,  H.  Minkoff,  C.  Kitchen,  S.  M.  
Philpott,  W.  Gao,  E.  Robison,  S.  Holman,  C.  Dehner,  S.  Beck,  W.  A.  Meyer,  3rd,  A.  
Landay,  A.  Kovacs,  J.  Bremer,  and  B.  Weiser.  2003.  HIV-­‐‑1  in  genital  tract  and  
plasma  of  women:  compartmentalization  of  viral  sequences,  coreceptor  usage,  and  
glycosylation.  Proc  Natl  Acad  Sci  U  S  A  100:12972-­‐‑12977.  
  
160.   Kim,  J.  H.,  J.  H.  Kim,  J.  A.  Park,  S.  W.  Lee,  W.  J.  Kim,  Y.  S.  Yu,  and  K.  W.  Kim.  2006.  
Blood-­‐‑neural  barrier:  intercellular  communication  at  glio-­‐‑vascular  interface.  Journal  
of  biochemistry  and  molecular  biology  39:339-­‐‑345.  
  
161.   Kitagawa,  M.,  A.  A.  Lackner,  D.  J.  Martfeld,  M.  B.  Gardner,  and  S.  Dandekar.  1991.  
Simian  immunodeficiency  virus  infection  of  macaque  bone  marrow  macrophages  
correlates  with  disease  progression  in  vivo.  The  American  journal  of  pathology  
138:921-­‐‑930.  
  
162.   Klein,  R.  S.,  C.  A.  Harris,  C.  B.  Small,  B.  Moll,  M.  Lesser,  and  G.  H.  Friedland.  
1984.  Oral  candidiasis  in  high-­‐‑risk  patients  as  the  initial  manifestation  of  the  
acquired  immunodeficiency  syndrome.  The  New  England  journal  of  medicine  
311:354-­‐‑358.  
  
163.   Koenig,  S.,  H.  E.  Gendelman,  J.  M.  Orenstein,  M.  C.  Dal  Canto,  G.  H.  
Pezeshkpour,  M.  Yungbluth,  F.  Janotta,  A.  Aksamit,  M.  A.  Martin,  and  A.  S.  Fauci.  
  195  
1986.  Detection  of  AIDS  virus  in  macrophages  in  brain  tissue  from  AIDS  patients  
with  encephalopathy.  Science  233:1089-­‐‑1093.  
  
164.   Korber,  B.  T.,  K.  J.  Kunstman,  B.  K.  Patterson,  M.  Furtado,  M.  M.  McEvilly,  R.  
Levy,  and  S.  M.  Wolinsky.  1994.  Genetic  differences  between  blood-­‐‑  and  brain-­‐‑
derived  viral  sequences  from  human  immunodeficiency  virus  type  1-­‐‑infected  
patients:  evidence  of  conserved  elements  in  the  V3  region  of  the  envelope  protein  of  
brain-­‐‑derived  sequences.  J  Virol  68:7467-­‐‑7481.  
  
165.   Kwong,  P.  D.,  R.  Wyatt,  J.  Robinson,  R.  W.  Sweet,  J.  Sodroski,  and  W.  A.  
Hendrickson.  1998.  Structure  of  an  HIV  gp120  envelope  glycoprotein  in  complex  
with  the  CD4  receptor  and  a  neutralizing  human  antibody.  Nature  393:648-­‐‑659.  
  
166.   Lane,  J.  H.,  V.  G.  Sasseville,  M.  O.  Smith,  P.  Vogel,  D.  R.  Pauley,  M.  P.  Heyes,  and  
A.  A.  Lackner.  1996.  Neuroinvasion  by  simian  immunodeficiency  virus  coincides  
with  increased  numbers  of  perivascular  macrophages/microglia  and  intrathecal  
immune  activation.  J  Neurovirol  2:423-­‐‑432.  
  
167.   Lathey,  J.  L.,  J.  Tsou,  K.  Brinker,  K.  Hsia,  W.  A.  Meyer,  3rd,  and  S.  A.  Spector.  1999.  
Lack  of  autologous  neutralizing  antibody  to  human  immunodeficiency  virus  type  1  
(HIV-­‐‑1)  and  macrophage  tropism  are  associated  with  mother-­‐‑to-­‐‑infant  transmission.  
J  Infect  Dis  180:344-­‐‑350.  
  
168.   Lavanchy,  D.  2009.  The  global  burden  of  hepatitis  C.  Liver  international  :  official  
journal  of  the  International  Association  for  the  Study  of  the  Liver  29  Suppl  1:74-­‐‑81.  
  
169.   Lee,  B.,  M.  Sharron,  L.  J.  Montaner,  D.  Weissman,  and  R.  W.  Doms.  1999.  
Quantification  of  CD4,  CCR5,  and  CXCR4  levels  on  lymphocyte  subsets,  dendritic  
cells,  and  differentially  conditioned  monocyte-­‐‑derived  macrophages.  Proc  Natl  Acad  
Sci  U  S  A  96:5215-­‐‑5220.  
  
170.   Levy,  J.  A.  2007.  HIV  and  the  Pathogenesis  of  AIDS,  vol.  Third  Edition.  ASM  Press,  
Washington,  DC.  
  
171.   Li,  H.,  K.  J.  Bar,  S.  Wang,  J.  M.  Decker,  Y.  Chen,  C.  Sun,  J.  F.  Salazar-­‐‑Gonzalez,  M.  
G.  Salazar,  G.  H.  Learn,  C.  J.  Morgan,  J.  E.  Schumacher,  P.  Hraber,  E.  E.  Giorgi,  T.  
Bhattacharya,  B.  T.  Korber,  A.  S.  Perelson,  J.  J.  Eron,  M.  S.  Cohen,  C.  B.  Hicks,  B.  F.  
Haynes,  M.  Markowitz,  B.  F.  Keele,  B.  H.  Hahn,  and  G.  M.  Shaw.  2010.  High  




172.   Li,  Q.,  P.  J.  Skinner,  S.  J.  Ha,  L.  Duan,  T.  L.  Mattila,  A.  Hage,  C.  White,  D.  L.  
Barber,  L.  O'ʹMara,  P.  J.  Southern,  C.  S.  Reilly,  J.  V.  Carlis,  C.  J.  Miller,  R.  Ahmed,  
and  A.  T.  Haase.  2009.  Visualizing  antigen-­‐‑specific  and  infected  cells  in  situ  predicts  
outcomes  in  early  viral  infection.  Science  323:1726-­‐‑1729.  
  
173.   Liang,  C.,  and  M.  A.  Wainberg.  2002.  The  role  of  Tat  in  HIV-­‐‑1  replication:  an  
activator  and/or  a  suppressor?  AIDS  reviews  4:41-­‐‑49.  
  
174.   Lindback,  S.,  A.  C.  Karlsson,  J.  Mittler,  A.  Blaxhult,  M.  Carlsson,  G.  Briheim,  A.  
Sonnerborg,  and  H.  Gaines.  2000.  Viral  dynamics  in  primary  HIV-­‐‑1  infection.  
Karolinska  Institutet  Primary  HIV  Infection  Study  Group.  Aids  14:2283-­‐‑2291.  
  
175.   Lindback,  S.,  R.  Thorstensson,  A.  C.  Karlsson,  M.  von  Sydow,  L.  Flamholc,  A.  
Blaxhult,  A.  Sonnerborg,  G.  Biberfeld,  and  H.  Gaines.  2000.  Diagnosis  of  primary  
HIV-­‐‑1  infection  and  duration  of  follow-­‐‑up  after  HIV  exposure.  Karolinska  Institute  
Primary  HIV  Infection  Study  Group.  Aids  14:2333-­‐‑2339.  
  
176.   Liu,  X.,  M.  Jana,  S.  Dasgupta,  S.  Koka,  J.  He,  C.  Wood,  and  K.  Pahan.  2002.  Human  
immunodeficiency  virus  type  1  (HIV-­‐‑1)  tat  induces  nitric-­‐‑oxide  synthase  in  human  
astroglia.  The  Journal  of  biological  chemistry  277:39312-­‐‑39319.  
  
177.   Lobato,  M.  N.,  M.  B.  Caldwell,  P.  Ng,  and  M.  J.  Oxtoby.  1995.  Encephalopathy  in  
children  with  perinatally  acquired  human  immunodeficiency  virus  infection.  
Pediatric  Spectrum  of  Disease  Clinical  Consortium.  J  Pediatr  126:710-­‐‑715.  
  
178.   Lossinsky,  A.  S.,  A.  W.  Vorbrodt,  and  H.  M.  Wisniewski.  1983.  Ultracytochemical  
studies  of  vesicular  and  canalicular  transport  structures  in  the  injured  mammalian  
blood-­‐‑brain  barrier.  Acta  neuropathologica  61:239-­‐‑245.  
  
179.   Lu,  T.  C.,  J.  C.  He,  Z.  H.  Wang,  X.  Feng,  T.  Fukumi-­‐‑Tominaga,  N.  Chen,  J.  Xu,  R.  
Iyengar,  and  P.  E.  Klotman.  2008.  HIV-­‐‑1  Nef  disrupts  the  podocyte  actin  
cytoskeleton  by  interacting  with  diaphanous  interacting  protein.  The  Journal  of  
biological  chemistry  283:8173-­‐‑8182.  
  
180.   Luban,  J.,  K.  L.  Bossolt,  E.  K.  Franke,  G.  V.  Kalpana,  and  S.  P.  Goff.  1993.  Human  




181.   Lyter,  D.  W.,  J.  Bryant,  R.  Thackeray,  C.  R.  Rinaldo,  and  L.  A.  Kingsley.  1995.  
Incidence  of  human  immunodeficiency  virus-­‐‑related  and  nonrelated  malignancies  in  
a  large  cohort  of  homosexual  men.  Journal  of  clinical  oncology  :  official  journal  of  the  
American  Society  of  Clinical  Oncology  13:2540-­‐‑2546.  
  
182.   MacMahon,  E.  M.,  J.  D.  Glass,  S.  D.  Hayward,  R.  B.  Mann,  P.  S.  Becker,  P.  
Charache,  J.  C.  McArthur,  and  R.  F.  Ambinder.  1991.  Epstein-­‐‑Barr  virus  in  AIDS-­‐‑
related  primary  central  nervous  system  lymphoma.  Lancet  338:969-­‐‑973.  
  
183.   Maggi,  F.,  M.  Giorgi,  C.  Fornai,  A.  Morrica,  M.  L.  Vatteroni,  M.  Pistello,  G.  
Siciliano,  A.  Nuccorini,  and  M.  Bendinelli.  1999.  Detection  and  quasispecies  
analysis  of  hepatitis  C  virus  in  the  cerebrospinal  fluid  of  infected  patients.  J  
Neurovirol  5:319-­‐‑323.  
184.   Mankowski,  J.  L.,  S.  E.  Queen,  J.  E.  Clements,  and  M.  C.  Zink.  2004.  Cerebrospinal  
fluid  markers  that  predict  SIV  CNS  disease.  J  Neuroimmunol  157:66-­‐‑70.  
  
185.   Mao,  Y.,  L.  Wang,  C.  Gu,  A.  Herschhorn,  A.  Desormeaux,  A.  Finzi,  S.  H.  Xiang,  and  
J.  G.  Sodroski.  2013.  Molecular  architecture  of  the  uncleaved  HIV-­‐‑1  envelope  
glycoprotein  trimer.  Proc  Natl  Acad  Sci  U  S  A.  
  
186.   Marcello,  A.,  M.  Zoppe,  and  M.  Giacca.  2001.  Multiple  modes  of  transcriptional  
regulation  by  the  HIV-­‐‑1  Tat  transactivator.  IUBMB  life  51:175-­‐‑181.  
  
187.   Marin,  M.,  K.  M.  Rose,  S.  L.  Kozak,  and  D.  Kabat.  2003.  HIV-­‐‑1  Vif  protein  binds  the  
editing  enzyme  APOBEC3G  and  induces  its  degradation.  Nat  Med  9:1398-­‐‑1403.  
  
188.   Marine-­‐‑Barjoan,  E.,  A.  Berrebi,  V.  Giordanengo,  S.  F.  Favre,  H.  Haas,  M.  Moreigne,  
J.  Izopet,  J.  Tricoire,  A.  Tran,  C.  Pradier,  and  A.  Bongain.  2007.  HCV/HIV  co-­‐‑
infection,  HCV  viral  load  and  mode  of  delivery:  risk  factors  for  mother-­‐‑to-­‐‑child  
transmission  of  hepatitis  C  virus?  AIDS  21:1811-­‐‑1815.  
  
189.   Mark,  K.  S.,  and  D.  W.  Miller.  1999.  Increased  permeability  of  primary  cultured  
brain  microvessel  endothelial  cell  monolayers  following  TNF-­‐‑alpha  exposure.  Life  
Sci  64:1941-­‐‑1953.  
  
190.   Markowitz,  M.,  M.  Louie,  A.  Hurley,  E.  Sun,  M.  Di  Mascio,  A.  S.  Perelson,  and  D.  
D.  Ho.  2003.  A  novel  antiviral  intervention  results  in  more  accurate  assessment  of  
human  immunodeficiency  virus  type  1  replication  dynamics  and  T-­‐‑cell  decay  in  
vivo.  J  Virol  77:5037-­‐‑5038.  
  
  198  
191.   Marras,  D.,  L.  A.  Bruggeman,  F.  Gao,  N.  Tanji,  M.  M.  Mansukhani,  A.  Cara,  M.  D.  
Ross,  G.  L.  Gusella,  G.  Benson,  V.  D.  D'ʹAgati,  B.  H.  Hahn,  M.  E.  Klotman,  and  P.  E.  
Klotman.  2002.  Replication  and  compartmentalization  of  HIV-­‐‑1  in  kidney  epithelium  
of  patients  with  HIV-­‐‑associated  nephropathy.  Nat  Med  8:522-­‐‑526.  
  
192.   Martin,  J.,  C.  C.  LaBranche,  and  F.  Gonzalez-­‐‑Scarano.  2001.  Differential  CD4/CCR5  
utilization,  gp120  conformation,  and  neutralization  sensitivity  between  envelopes  
from  a  microglia-­‐‑adapted  human  immunodeficiency  virus  type  1  and  its  parental  
isolate.  J  Virol  75:3568-­‐‑3580.  
  
193.   Martin-­‐‑Garcia,  J.,  W.  Cao,  A.  Varela-­‐‑Rohena,  M.  L.  Plassmeyer,  and  F.  Gonzalez-­‐‑
Scarano.  2006.  HIV-­‐‑1  tropism  for  the  central  nervous  system:  Brain-­‐‑derived  envelope  
glycoproteins  with  lower  CD4  dependence  and  reduced  sensitivity  to  a  fusion  
inhibitor.  Virology  346:169-­‐‑179.  
  
194.   Mattapallil,  J.  J.,  D.  C.  Douek,  B.  Hill,  Y.  Nishimura,  M.  Martin,  and  M.  Roederer.  
2005.  Massive  infection  and  loss  of  memory  CD4+  T  cells  in  multiple  tissues  during  
acute  SIV  infection.  Nature  434:1093-­‐‑1097.  
  
195.   Mayhan,  W.  G.,  and  D.  D.  Heistad.  1985.  Permeability  of  blood-­‐‑brain  barrier  to  
various  sized  molecules.  The  American  journal  of  physiology  248:H712-­‐‑718.  
  
196.   McCarthy,  G.  M.  1992.  Host  factors  associated  with  HIV-­‐‑related  oral  candidiasis.  A  
review.  Oral  surgery,  oral  medicine,  and  oral  pathology  73:181-­‐‑186.  
  
197.   McCarthy,  G.  M.,  I.  D.  Mackie,  J.  Koval,  H.  S.  Sandhu,  and  T.  D.  Daley.  1991.  
Factors  associated  with  increased  frequency  of  HIV-­‐‑related  oral  candidiasis.  Journal  
of  oral  pathology  &  medicine  :  official  publication  of  the  International  Association  of  
Oral  Pathologists  and  the  American  Academy  of  Oral  Pathology  20:332-­‐‑336.  
  
198.   McGowan,  I.,  J.  Elliott,  M.  Fuerst,  P.  Taing,  J.  Boscardin,  M.  Poles,  and  P.  Anton.  
2004.  Increased  HIV-­‐‑1  mucosal  replication  is  associated  with  generalized  mucosal  
cytokine  activation.  Journal  of  acquired  immune  deficiency  syndromes  37:1228-­‐‑1236.  
  
199.   McKeating,  J.  A.,  A.  McKnight,  and  J.  P.  Moore.  1991.  Differential  loss  of  envelope  
glycoprotein  gp120  from  virions  of  human  immunodeficiency  virus  type  1  isolates:  
effects  on  infectivity  and  neutralization.  J  Virol  65:852-­‐‑860.  
  
200.   McKendall,  R.  R.,  Tselis,  A.  2009.  Basic  and  Clinical  Aspects  of  Human  
Cytomegalovirus  infection,  p.  331-­‐‑346.  In  K.  Goodkin,  Shapshak,  P.,  Verma,  A.  (ed.),  
  199  
The  Spectrum  of  Neuro-­‐‑AIDS  Disorders:  Pathophysiology,  Diagnosis,  and  
Treatment.  ASM  Press,  Washington,  DC.  
  
201.   McMichael,  A.  J.,  P.  Borrow,  G.  D.  Tomaras,  N.  Goonetilleke,  and  B.  F.  Haynes.  
2010.  The  immune  response  during  acute  HIV-­‐‑1  infection:  clues  for  vaccine  
development.  Nat  Rev  Immunol  10:11-­‐‑23.  
  
202.   Medapalli,  R.  K.,  J.  C.  He,  and  P.  E.  Klotman.  2011.  HIV-­‐‑associated  nephropathy:  
pathogenesis.  Current  opinion  in  nephrology  and  hypertension  20:306-­‐‑311.  
  
203.   Melikyan,  G.  B.,  R.  M.  Markosyan,  H.  Hemmati,  M.  K.  Delmedico,  D.  M.  Lambert,  
and  F.  S.  Cohen.  2000.  Evidence  that  the  transition  of  HIV-­‐‑1  gp41  into  a  six-­‐‑helix  
bundle,  not  the  bundle  configuration,  induces  membrane  fusion.  The  Journal  of  cell  
biology  151:413-­‐‑423.  
  
204.   Miller,  D.  W.  2005.  The  blood-­‐‑brain  barrier  as  an  immunocompetent  organ,  p.  115-­‐‑
124.  In  H.  E.  Gendelman,  I.  Grant,  I.  P.  Everall,  S.  A.  Lipton,  and  S.  Swindells  (ed.),  
The  Neurology  of  AIDS,  vol.  2nd  Edition.  Oxford  University  Press,  New  York.  
  
205.   Mintz,  M.  1994.  Clinical  comparison  of  adult  and  pediatric  NeuroAIDS.  Advances  in  
neuroimmunology  4:207-­‐‑221.  
  
206.   Morris,  A.,  and  K.  A.  Norris.  2012.  Colonization  by  Pneumocystis  jirovecii  and  its  
role  in  disease.  Clinical  microbiology  reviews  25:297-­‐‑317.  
  
207.   Morsica,  G.,  M.  T.  Bernardi,  R.  Novati,  C.  Uberti  Foppa,  A.  Castagna,  and  A.  
Lazzarin.  1997.  Detection  of  hepatitis  C  virus  genomic  sequences  in  the  cerebrospinal  
fluid  of  HIV-­‐‑infected  patients.  Journal  of  medical  virology  53:252-­‐‑254.  
  
208.   Moses,  A.  V.,  F.  E.  Bloom,  C.  D.  Pauza,  and  J.  A.  Nelson.  1993.  Human  
immunodeficiency  virus  infection  of  human  brain  capillary  endothelial  cells  occurs  
via  a  CD4/galactosylceramide-­‐‑independent  mechanism.  Proc  Natl  Acad  Sci  U  S  A  
90:10474-­‐‑10478.  
  
209.   Moulard,  M.,  and  E.  Decroly.  2000.  Maturation  of  HIV  envelope  glycoprotein  
precursors  by  cellular  endoproteases.  Biochimica  et  biophysica  acta  1469:121-­‐‑132.  
  
210.   Mulder-­‐‑Kampinga,  G.  A.,  A.  Simonon,  C.  L.  Kuiken,  J.  Dekker,  H.  J.  Scherpbier,  P.  
van  de  Perre,  K.  Boer,  and  J.  Goudsmit.  1995.  Similarity  in  env  and  gag  genes  
between  genomic  RNAs  of  human  immunodeficiency  virus  type  1  (HIV-­‐‑1)  from  
  200  
mother  and  infant  is  unrelated  to  time  of  HIV-­‐‑1  RNA  positivity  in  the  child.  J  Virol  
69:2285-­‐‑2296.  
  
211.   Nakamura,  S.,  W.  W.  Tourtellotte,  and  P.  Shapshak.  1987.  [The  detection  of  viral  
nucleic  acid  sequences  in  paraffin-­‐‑embedded  subacute  sclerosing  panencephalitis  
(SSPE)  and  progressive  multifocal  leukoencephalopathy  (PML)  brain  tissues  by  in  
situ  hybridization].  No  to  shinkei  =  Brain  and  nerve  39:725-­‐‑731.  
  
212.   Nath,  A.  2002.  Human  immunodeficiency  virus  (HIV)  proteins  in  neuropathogenesis  
of  HIV  dementia.  J  Infect  Dis  186  Suppl  2:S193-­‐‑198.  
  
213.   Navia,  B.  A.,  E.  S.  Cho,  C.  K.  Petito,  and  R.  W.  Price.  1986.  The  AIDS  dementia  
complex:  II.  Neuropathology.  Annals  of  neurology  19:525-­‐‑535.  
  
214.   Navia,  B.  A.,  B.  D.  Jordan,  and  R.  W.  Price.  1986.  The  AIDS  dementia  complex:  I.  
Clinical  features.  Annals  of  neurology  19:517-­‐‑524.  
  
215.   Neil,  S.  J.,  T.  Zang,  and  P.  D.  Bieniasz.  2008.  Tetherin  inhibits  retrovirus  release  and  
is  antagonized  by  HIV-­‐‑1  Vpu.  Nature  451:425-­‐‑430.  
  
216.   Nelson,  B.  H.  2004.  IL-­‐‑2,  regulatory  T  cells,  and  tolerance.  J  Immunol  172:3983-­‐‑3988.  
  
217.   Nelson,  J.  A.,  S.  A.  Fiscus,  and  R.  Swanstrom.  1997.  Evolutionary  variants  of  the  
human  immunodeficiency  virus  type  1  V3  region  characterized  by  using  a  
heteroduplex  tracking  assay.  J  Virol  71:8750-­‐‑8758.  
  
218.   Norgren,  N.,  P.  Sundstrom,  A.  Svenningsson,  L.  Rosengren,  T.  Stigbrand,  and  M.  
Gunnarsson.  2004.  Neurofilament  and  glial  fibrillary  acidic  protein  in  multiple  
sclerosis.  Neurology  63:1586-­‐‑1590.  
  
219.   Nottet,  H.  S.  1999.  Interactions  between  macrophages  and  brain  microvascular  
endothelial  cells:  role  in  pathogenesis  of  HIV-­‐‑1  infection  and  blood  -­‐‑  brain  barrier  
function.  J  Neurovirol  5:659-­‐‑669.  
  
220.   Nottet,  H.  S.,  M.  Jett,  C.  R.  Flanagan,  Q.  H.  Zhai,  Y.  Persidsky,  A.  Rizzino,  E.  W.  
Bernton,  P.  Genis,  T.  Baldwin,  J.  Schwartz,  and  et  al.  1995.  A  regulatory  role  for  
astrocytes  in  HIV-­‐‑1  encephalitis.  An  overexpression  of  eicosanoids,  platelet-­‐‑
activating  factor,  and  tumor  necrosis  factor-­‐‑alpha  by  activated  HIV-­‐‑1-­‐‑infected  
monocytes  is  attenuated  by  primary  human  astrocytes.  J  Immunol  154:3567-­‐‑3581.  
  
  201  
221.   Nuovo,  G.  J.,  and  M.  L.  Alfieri.  1996.  AIDS  dementia  is  associated  with  massive,  
activated  HIV-­‐‑1  infection  and  concomitant  expression  of  several  cytokines.  
Molecular  medicine  2:358-­‐‑366.  
  
222.   O'ʹDoherty,  U.,  W.  J.  Swiggard,  and  M.  H.  Malim.  2000.  Human  immunodeficiency  
virus  type  1  spinoculation  enhances  infection  through  virus  binding.  J  Virol  
74:10074-­‐‑10080.  
  
223.   Ochsenbauer,  C.,  T.  G.  Edmonds,  H.  Ding,  B.  F.  Keele,  J.  Decker,  M.  G.  Salazar,  J.  
F.  Salazar-­‐‑Gonzalez,  R.  Shattock,  B.  F.  Haynes,  G.  M.  Shaw,  B.  H.  Hahn,  and  J.  C.  
Kappes.  2012.  Generation  of  transmitted/founder  HIV-­‐‑1  infectious  molecular  clones  
and  characterization  of  their  replication  capacity  in  CD4  T  lymphocytes  and  
monocyte-­‐‑derived  macrophages.  J  Virol  86:2715-­‐‑2728.  
  
224.   Oh,  S.  K.,  W.  W.  Cruikshank,  J.  Raina,  G.  C.  Blanchard,  W.  H.  Adler,  J.  Walker,  
and  H.  Kornfeld.  1992.  Identification  of  HIV-­‐‑1  envelope  glycoprotein  in  the  serum  of  
AIDS  and  ARC  patients.  Journal  of  acquired  immune  deficiency  syndromes  5:251-­‐‑
256.  
  
225.   Ohagen,  A.,  A.  Devitt,  K.  J.  Kunstman,  P.  R.  Gorry,  P.  P.  Rose,  B.  Korber,  J.  Taylor,  
R.  Levy,  R.  L.  Murphy,  S.  M.  Wolinsky,  and  D.  Gabuzda.  2003.  Genetic  and  
functional  analysis  of  full-­‐‑length  human  immunodeficiency  virus  type  1  env  genes  
derived  from  brain  and  blood  of  patients  with  AIDS.  J  Virol  77:12336-­‐‑12345.  
  
226.   Oyaizu,  N.,  N.  Chirmule,  V.  S.  Kalyanaraman,  W.  W.  Hall,  R.  Pahwa,  M.  Shuster,  
and  S.  Pahwa.  1990.  Human  immunodeficiency  virus  type  1  envelope  glycoprotein  
gp120  produces  immune  defects  in  CD4+  T  lymphocytes  by  inhibiting  interleukin  2  
mRNA.  Proc  Natl  Acad  Sci  U  S  A  87:2379-­‐‑2383.  
  
227.   Palella,  F.  J.,  Jr.,  K.  M.  Delaney,  A.  C.  Moorman,  M.  O.  Loveless,  J.  Fuhrer,  G.  A.  
Satten,  D.  J.  Aschman,  and  S.  D.  Holmberg.  1998.  Declining  morbidity  and  
mortality  among  patients  with  advanced  human  immunodeficiency  virus  infection.  
HIV  Outpatient  Study  Investigators.  The  New  England  journal  of  medicine  338:853-­‐‑
860.  
  
228.   Palmer,  S.,  A.  P.  Wiegand,  F.  Maldarelli,  H.  Bazmi,  J.  M.  Mican,  M.  Polis,  R.  L.  
Dewar,  A.  Planta,  S.  Liu,  J.  A.  Metcalf,  J.  W.  Mellors,  and  J.  M.  Coffin.  2003.  New  
real-­‐‑time  reverse  transcriptase-­‐‑initiated  PCR  assay  with  single-­‐‑copy  sensitivity  for  




229.   Pantaleo,  G.,  J.  F.  Demarest,  H.  Soudeyns,  C.  Graziosi,  F.  Denis,  J.  W.  Adelsberger,  
P.  Borrow,  M.  S.  Saag,  G.  M.  Shaw,  R.  P.  Sekaly,  and  et  al.  1994.  Major  expansion  of  
CD8+  T  cells  with  a  predominant  V  beta  usage  during  the  primary  immune  response  
to  HIV.  Nature  370:463-­‐‑467.  
  
230.   Parrish,  N.  F.,  C.  B.  Wilen,  L.  B.  Banks,  S.  S.  Iyer,  J.  M.  Pfaff,  J.  F.  Salazar-­‐‑Gonzalez,  
M.  G.  Salazar,  J.  M.  Decker,  E.  H.  Parrish,  A.  Berg,  J.  Hopper,  B.  Hora,  A.  Kumar,  T.  
Mahlokozera,  S.  Yuan,  C.  Coleman,  M.  Vermeulen,  H.  Ding,  C.  Ochsenbauer,  J.  C.  
Tilton,  S.  R.  Permar,  J.  C.  Kappes,  M.  R.  Betts,  M.  P.  Busch,  F.  Gao,  D.  Montefiori,  
B.  F.  Haynes,  G.  M.  Shaw,  B.  H.  Hahn,  and  R.  W.  Doms.  2012.  Transmitted/founder  
and  chronic  subtype  C  HIV-­‐‑1  use  CD4  and  CCR5  receptors  with  equal  efficiency  and  
are  not  inhibited  by  blocking  the  integrin  alpha4beta7.  PLoS  Pathog  8:e1002686.  
  
231.   Pelkmans,  L.,  J.  Kartenbeck,  and  A.  Helenius.  2001.  Caveolar  endocytosis  of  simian  
virus  40  reveals  a  new  two-­‐‑step  vesicular-­‐‑transport  pathway  to  the  ER.  Nature  cell  
biology  3:473-­‐‑483.  
  
232.   Peluso,  M.  J.,  D.  J.  Meyerhoff,  R.  W.  Price,  J.  Peterson,  E.  Lee,  A.  C.  Young,  R.  
Walter,  D.  Fuchs,  B.  J.  Brew,  P.  Cinque,  K.  Robertson,  L.  Hagberg,  H.  Zetterberg,  
M.  Gisslen,  and  S.  Spudich.  2013.  Cerebrospinal  Fluid  and  Neuroimaging  
Biomarker  Abnormalities  Suggest  Early  Neurological  Injury  in  a  Subset  of  
Individuals  During  Primary  HIV  Infection.  J  Infect  Dis  207:1703-­‐‑1712.  
  
233.   Peluso,  R.,  A.  Haase,  L.  Stowring,  M.  Edwards,  and  P.  Ventura.  1985.  A  Trojan  
Horse  mechanism  for  the  spread  of  visna  virus  in  monocytes.  Virology  147:231-­‐‑236.  
  
234.   Perelson,  A.  S.,  A.  U.  Neumann,  M.  Markowitz,  J.  M.  Leonard,  and  D.  D.  Ho.  1996.  
HIV-­‐‑1  dynamics  in  vivo:  virion  clearance  rate,  infected  cell  life-­‐‑span,  and  viral  
generation  time.  Science  271:1582-­‐‑1586.  
  
235.   Perrella,  O.,  P.  B.  Carrieri,  D.  Guarnaccia,  and  M.  Soscia.  1992.  Cerebrospinal  fluid  
cytokines  in  AIDS  dementia  complex.  Journal  of  neurology  239:387-­‐‑388.  
  
236.   Persidsky,  Y.,  J.  Limoges,  J.  Rasmussen,  J.  Zheng,  A.  Gearing,  and  H.  E.  
Gendelman.  2001.  Reduction  in  glial  immunity  and  neuropathology  by  a  PAF  
antagonist  and  an  MMP  and  TNFalpha  inhibitor  in  SCID  mice  with  HIV-­‐‑1  
encephalitis.  J  Neuroimmunol  114:57-­‐‑68.  
  
  203  
237.   Peters,  P.  J.,  J.  Bhattacharya,  S.  Hibbitts,  M.  T.  Dittmar,  G.  Simmons,  J.  Bell,  P.  
Simmonds,  and  P.  R.  Clapham.  2004.  Biological  analysis  of  human  
immunodeficiency  virus  type  1  R5  envelopes  amplified  from  brain  and  lymph  node  
tissues  of  AIDS  patients  with  neuropathology  reveals  two  distinct  tropism  
phenotypes  and  identifies  envelopes  in  the  brain  that  confer  an  enhanced  tropism  
and  fusigenicity  for  macrophages.  J  Virol  78:6915-­‐‑6926.  
  
238.   Pilcher,  C.  D.,  D.  C.  Shugars,  S.  A.  Fiscus,  W.  C.  Miller,  P.  Menezes,  J.  Giner,  B.  
Dean,  K.  Robertson,  C.  E.  Hart,  J.  L.  Lennox,  J.  J.  Eron,  Jr.,  and  C.  B.  Hicks.  2001.  
HIV  in  body  fluids  during  primary  HIV  infection:  implications  for  pathogenesis,  
treatment  and  public  health.  AIDS  15:837-­‐‑845.  
  
239.   Pillai,  S.  K.,  S.  L.  Pond,  Y.  Liu,  B.  M.  Good,  M.  C.  Strain,  R.  J.  Ellis,  S.  Letendre,  D.  
M.  Smith,  H.  F.  Gunthard,  I.  Grant,  T.  D.  Marcotte,  J.  A.  McCutchan,  D.  D.  
Richman,  and  J.  K.  Wong.  2006.  Genetic  attributes  of  cerebrospinal  fluid-­‐‑derived  
HIV-­‐‑1  env.  Brain  :  a  journal  of  neurology  129:1872-­‐‑1883.  
  
240.   Piller,  S.  C.,  P.  Jans,  P.  W.  Gage,  and  D.  A.  Jans.  1998.  Extracellular  HIV-­‐‑1  virus  
protein  R  causes  a  large  inward  current  and  cell  death  in  cultured  hippocampal  
neurons:  implications  for  AIDS  pathology.  Proc  Natl  Acad  Sci  U  S  A  95:4595-­‐‑4600.  
  
241.   Ping,  L.  H.,  S.  B.  Joseph,  J.  A.  Anderson,  M.  R.  Abrahams,  J.  F.  Salazar-­‐‑Gonzalez,  L.  
P.  Kincer,  F.  K.  Treurnicht,  L.  Arney,  S.  Ojeda,  M.  Zhang,  J.  Keys,  E.  L.  Potter,  H.  
Chu,  P.  Moore,  M.  Salazar-­‐‑Gonzalez,  S.  Iyer,  C.  Jabara,  J.  Kirchherr,  C.  Mapanje,  
N.  Ngandu,  C.  Seoighe,  I.  Hoffman,  F.  Gao,  Y.  Tang,  C.  Labranche,  B.  Lee,  A.  
Saville,  M.  Vermeulen,  S.  Fiscus,  L.  Morris,  S.  Abdool  Karim,  B.  F.  Haynes,  G.  M.  
Shaw,  B.  T.  Korber,  B.  H.  Hahn,  M.  S.  Cohen,  D.  Montefiori,  C.  Williamson,  R.  
Swanstrom,  and  C.  A.  I.  S.  t.  C.  f.  H.  I.  V.  A.  V.  I.  C.  for  the.  2013.  Comparison  of  
Viral  Env  Proteins  From  Acute  and  Chronic  Infections  of  Subtype  C  Human  
Immunodeficiency  Virus  Type  1  Identifies  Differences  In  Glycosylation  and  CCR5  
Utilization  and  Suggests  A  New  Strategy  For  Immunogen  Design.  J  Virol.  
  
242.   Poland,  S.  D.,  G.  P.  Rice,  and  G.  A.  Dekaban.  1995.  HIV-­‐‑1  infection  of  human  brain-­‐‑
derived  microvascular  endothelial  cells  in  vitro.  J  Acquir  Immune  Defic  Syndr  Hum  
Retrovirol  8:437-­‐‑445.  
243.   Pomerantz,  R.  J.  2003.  Reservoirs,  sanctuaries,  and  residual  disease:  the  hiding  spots  
of  HIV-­‐‑1.  HIV  Clin  Trials  4:137-­‐‑143.  
  
244.   Pond,  S.  L.,  S.  D.  Frost,  and  S.  V.  Muse.  2005.  HyPhy:  hypothesis  testing  using  
phylogenies.  Bioinformatics  21:676-­‐‑679.  
  204  
  
245.   Popov,  S.,  M.  Rexach,  G.  Zybarth,  N.  Reiling,  M.  A.  Lee,  L.  Ratner,  C.  M.  Lane,  M.  
S.  Moore,  G.  Blobel,  and  M.  Bukrinsky.  1998.  Viral  protein  R  regulates  nuclear  
import  of  the  HIV-­‐‑1  pre-­‐‑integration  complex.  The  EMBO  journal  17:909-­‐‑917.  
  
246.   Posavad,  C.  M.,  D.  M.  Koelle,  M.  F.  Shaughnessy,  and  L.  Corey.  1997.  Severe  
genital  herpes  infections  in  HIV-­‐‑infected  individuals  with  impaired  herpes  simplex  
virus-­‐‑specific  CD8+  cytotoxic  T  lymphocyte  responses.  Proc  Natl  Acad  Sci  U  S  A  
94:10289-­‐‑10294.  
  
247.   Power,  C.,  J.  C.  McArthur,  R.  T.  Johnson,  D.  E.  Griffin,  J.  D.  Glass,  S.  Perryman,  
and  B.  Chesebro.  1994.  Demented  and  nondemented  patients  with  AIDS  differ  in  
brain-­‐‑derived  human  immunodeficiency  virus  type  1  envelope  sequences.  J  Virol  
68:4643-­‐‑4649.  
  
248.   Price,  R.  W.,  J.  Peterson,  D.  Fuchs,  T.  E.  Angel,  H.  Zetterberg,  L.  Hagberg,  S.  
Spudich,  R.  D.  Smith,  J.  M.  Jacobs,  J.  N.  Brown,  and  M.  Gisslen.  2013.  Approach  to  
Cerebrospinal  Fluid  (CSF)  Biomarker  Discovery  and  Evaluation  in  HIV  Infection.  J  
Neuroimmune  Pharmacol  8:1147-­‐‑1158.  
  
249.   Rabkin,  C.  S.,  Q.  Yang,  J.  J.  Goedert,  G.  Nguyen,  H.  Mitsuya,  and  S.  Sei.  1999.  
Chemokine  and  chemokine  receptor  gene  variants  and  risk  of  non-­‐‑Hodgkin'ʹs  
lymphoma  in  human  immunodeficiency  virus-­‐‑1-­‐‑infected  individuals.  Blood  93:1838-­‐‑
1842.  
  
250.   Radkowski,  M.,  Nasseri,  J.,  Laskus,  T.  2009.  Hepatitis  C  Virus:  Variability,  
Extrahepatic  Replication,  and  Neuroinvasion,  p.  295-­‐‑311.  In  K.  Goodkin,  Shapshak,  
P.,  Verma,  A.  (ed.),  The  Spectrum  of  Neuro-­‐‑AIDS  Disorders:  Pathophysiology,  
Diagnosis,  and  Treatment,  vol.  1.  ASM  Press,  Washington,  DC.  
  
251.   Rao,  V.  R.,  A.  R.  Sas,  E.  A.  Eugenin,  N.  B.  Siddappa,  H.  Bimonte-­‐‑Nelson,  J.  W.  
Berman,  U.  Ranga,  W.  R.  Tyor,  and  V.  R.  Prasad.  2008.  HIV-­‐‑1  clade-­‐‑specific  
differences  in  the  induction  of  neuropathogenesis.  J  Neurosci  28:10010-­‐‑10016.  
252.   Reef,  S.  E.,  and  K.  H.  Mayer.  1995.  Opportunistic  candidal  infections  in  patients  
infected  with  human  immunodeficiency  virus:  prevention  issues  and  priorities.  
Clinical  infectious  diseases  :  an  official  publication  of  the  Infectious  Diseases  Society  
of  America  21  Suppl  1:S99-­‐‑102.  
  
  205  
253.   Renold,  C.,  A.  Sugar,  J.  P.  Chave,  L.  Perrin,  J.  Delavelle,  G.  Pizzolato,  P.  Burkhard,  
V.  Gabriel,  and  B.  Hirschel.  1992.  Toxoplasma  encephalitis  in  patients  with  the  
acquired  immunodeficiency  syndrome.  Medicine  71:224-­‐‑239.  
  
254.   Resch,  W.,  N.  Parkin,  E.  L.  Stuelke,  T.  Watkins,  and  R.  Swanstrom.  2001.  A  
multiple-­‐‑site-­‐‑specific  heteroduplex  tracking  assay  as  a  tool  for  the  study  of  viral  
population  dynamics.  Proc  Natl  Acad  Sci  U  S  A  98:176-­‐‑181.  
  
255.   Richardson,  E.  P.,  Jr.  1988.  Progressive  multifocal  leukoencephalopathy  30  years  
later.  The  New  England  journal  of  medicine  318:315-­‐‑317.  
  
256.   Ridzon,  R.,  K.  Gallagher,  C.  Ciesielski,  M.  B.  Ginsberg,  B.  J.  Robertson,  C.  C.  Luo,  
and  A.  DeMaria,  Jr.  1997.  Simultaneous  transmission  of  human  immunodeficiency  
virus  and  hepatitis  C  virus  from  a  needle-­‐‑stick  injury.  The  New  England  journal  of  
medicine  336:919-­‐‑922.  
  
257.   Riedel,  D.,  M.  Ghate,  M.  Nene,  R.  Paranjape,  S.  Mehendale,  R.  Bollinger,  N.  
Sacktor,  J.  McArthur,  and  A.  Nath.  2006.  Screening  for  human  immunodeficiency  
virus  (HIV)  dementia  in  an  HIV  clade  C-­‐‑infected  population  in  India.  J  Neurovirol  
12:34-­‐‑38.  
  
258.   Ritola,  K.,  K.  Robertson,  S.  A.  Fiscus,  C.  Hall,  and  R.  Swanstrom.  2005.  Increased  
human  immunodeficiency  virus  type  1  (HIV-­‐‑1)  env  compartmentalization  in  the  
presence  of  HIV-­‐‑1-­‐‑associated  dementia.  J  Virol  79:10830-­‐‑10834.  
  
259.   Robey,  W.  G.,  B.  Safai,  S.  Oroszlan,  L.  O.  Arthur,  M.  A.  Gonda,  R.  C.  Gallo,  and  P.  
J.  Fischinger.  1985.  Characterization  of  envelope  and  core  structural  gene  products  
of  HTLV-­‐‑III  with  sera  from  AIDS  patients.  Science  228:593-­‐‑595.  
  
260.   Rock,  R.  B.,  G.  Gekker,  S.  Hu,  W.  S.  Sheng,  M.  Cheeran,  J.  R.  Lokensgard,  and  P.  
K.  Peterson.  2004.  Role  of  microglia  in  central  nervous  system  infections.  Clinical  
microbiology  reviews  17:942-­‐‑964,  table  of  contents.  
  
261.   Rosenstiel,  P.  E.,  T.  Gruosso,  A.  M.  Letourneau,  J.  J.  Chan,  A.  LeBlanc,  M.  Husain,  
V.  Najfeld,  V.  Planelles,  V.  D.  D'ʹAgati,  M.  E.  Klotman,  and  P.  E.  Klotman.  2008.  
HIV-­‐‑1  Vpr  inhibits  cytokinesis  in  human  proximal  tubule  cells.  Kidney  international  
74:1049-­‐‑1058.  
  
262.   Rossi,  F.,  B.  Querido,  M.  Nimmagadda,  S.  Cocklin,  S.  Navas-­‐‑Martin,  and  J.  Martin-­‐‑
Garcia.  2008.  The  V1-­‐‑V3  region  of  a  brain-­‐‑derived  HIV-­‐‑1  envelope  glycoprotein  
  206  
determines  macrophage  tropism,  low  CD4  dependence,  increased  fusogenicity  and  
altered  sensitivity  to  entry  inhibitors.  Retrovirology  5:89.  
  
263.   Roth,  W.  K.,  H.  Brandstetter,  and  M.  Sturzl.  1992.  Cellular  and  molecular  features  of  
HIV-­‐‑associated  Kaposi'ʹs  sarcoma.  AIDS  6:895-­‐‑913.  
  
264.   Russell,  E.  S.,  J.  J.  Kwiek,  J.  Keys,  K.  Barton,  V.  Mwapasa,  D.  C.  Montefiori,  S.  R.  
Meshnick,  and  R.  Swanstrom.  2011.  The  genetic  bottleneck  in  vertical  transmission  
of  subtype  C  HIV-­‐‑1  is  not  driven  by  selection  of  especially  neutralization-­‐‑resistant  
virus  from  the  maternal  viral  population.  J  Virol  85:8253-­‐‑8262.  
  
265.   Ryan,  E.  L.,  S.  Morgello,  K.  Isaacs,  M.  Naseer,  P.  Gerits,  and  H.  I.  V.  B.  B.  
Manhattan.  2004.  Neuropsychiatric  impact  of  hepatitis  C  on  advanced  HIV.  
Neurology  62:957-­‐‑962.  
  
266.   Rybarczyk,  B.  J.,  D.  Montefiori,  P.  R.  Johnson,  A.  West,  R.  E.  Johnston,  and  R.  
Swanstrom.  2004.  Correlation  between  env  V1/V2  region  diversification  and  
neutralizing  antibodies  during  primary  infection  by  simian  immunodeficiency  virus  
sm  in  rhesus  macaques.  J  Virol  78:3561-­‐‑3571.  
  
267.   Ryzhova,  E.  V.,  P.  Crino,  L.  Shawver,  S.  V.  Westmoreland,  A.  A.  Lackner,  and  F.  
Gonzalez-­‐‑Scarano.  2002.  Simian  immunodeficiency  virus  encephalitis:  analysis  of  
envelope  sequences  from  individual  brain  multinucleated  giant  cells  and  tissue  
samples.  Virology  297:57-­‐‑67.  
  
268.   Sacktor,  N.,  M.  P.  McDermott,  K.  Marder,  G.  Schifitto,  O.  A.  Selnes,  J.  C.  
McArthur,  Y.  Stern,  S.  Albert,  D.  Palumbo,  K.  Kieburtz,  J.  A.  De  Marcaida,  B.  
Cohen,  and  L.  Epstein.  2002.  HIV-­‐‑associated  cognitive  impairment  before  and  after  
the  advent  of  combination  therapy.  J  Neurovirol  8:136-­‐‑142.  
  
269.   Sadek,  J.  R.,  O.  Vigil,  I.  Grant,  R.  K.  Heaton,  and  H.  Group.  2007.  The  impact  of  
neuropsychological  functioning  and  depressed  mood  on  functional  complaints  in  
HIV-­‐‑1  infection  and  methamphetamine  dependence.  Journal  of  clinical  and  
experimental  neuropsychology  29:266-­‐‑276.  
  
270.   Safai,  B.,  K.  G.  Johnson,  P.  L.  Myskowski,  B.  Koziner,  S.  Y.  Yang,  S.  Cunningham-­‐‑
Rundles,  J.  H.  Godbold,  and  B.  Dupont.  1985.  The  natural  history  of  Kaposi'ʹs  
sarcoma  in  the  acquired  immunodeficiency  syndrome.  Ann  Intern  Med  103:744-­‐‑750.  
  
  207  
271.   Sagar,  M.,  O.  Laeyendecker,  S.  Lee,  J.  Gamiel,  M.  J.  Wawer,  R.  H.  Gray,  D.  
Serwadda,  N.  K.  Sewankambo,  J.  C.  Shepherd,  J.  Toma,  W.  Huang,  and  T.  C.  
Quinn.  2009.  Selection  of  HIV  variants  with  signature  genotypic  characteristics  
during  heterosexual  transmission.  J  Infect  Dis  199:580-­‐‑589.  
  
272.   Salazar-­‐‑Gonzalez,  J.  F.,  E.  Bailes,  K.  T.  Pham,  M.  G.  Salazar,  M.  B.  Guffey,  B.  F.  
Keele,  C.  A.  Derdeyn,  P.  Farmer,  E.  Hunter,  S.  Allen,  O.  Manigart,  J.  Mulenga,  J.  A.  
Anderson,  R.  Swanstrom,  B.  F.  Haynes,  G.  S.  Athreya,  B.  T.  Korber,  P.  M.  Sharp,  G.  
M.  Shaw,  and  B.  H.  Hahn.  2008.  Deciphering  human  immunodeficiency  virus  type  1  
transmission  and  early  envelope  diversification  by  single-­‐‑genome  amplification  and  
sequencing.  J  Virol  82:3952-­‐‑3970.  
  
273.   Salazar-­‐‑Gonzalez,  J.  F.,  M.  G.  Salazar,  B.  F.  Keele,  G.  H.  Learn,  E.  E.  Giorgi,  H.  Li,  J.  
M.  Decker,  S.  Wang,  J.  Baalwa,  M.  H.  Kraus,  N.  F.  Parrish,  K.  S.  Shaw,  M.  B.  
Guffey,  K.  J.  Bar,  K.  L.  Davis,  C.  Ochsenbauer-­‐‑Jambor,  J.  C.  Kappes,  M.  S.  Saag,  M.  
S.  Cohen,  J.  Mulenga,  C.  A.  Derdeyn,  S.  Allen,  E.  Hunter,  M.  Markowitz,  P.  
Hraber,  A.  S.  Perelson,  T.  Bhattacharya,  B.  F.  Haynes,  B.  T.  Korber,  B.  H.  Hahn,  and  
G.  M.  Shaw.  2009.  Genetic  identity,  biological  phenotype,  and  evolutionary  
pathways  of  transmitted/founder  viruses  in  acute  and  early  HIV-­‐‑1  infection.  The  
Journal  of  experimental  medicine  206:1273-­‐‑1289.  
  
274.   Salazar-­‐‑Gonzalez,  J.  F.,  M.  G.  Salazar,  G.  H.  Learn,  G.  G.  Fouda,  H.  H.  Kang,  T.  
Mahlokozera,  A.  B.  Wilks,  R.  V.  Lovingood,  A.  Stacey,  L.  Kalilani,  S.  R.  Meshnick,  
P.  Borrow,  D.  C.  Montefiori,  T.  N.  Denny,  N.  L.  Letvin,  G.  M.  Shaw,  B.  H.  Hahn,  S.  
R.  Permar,  and  H.  I.  V.  A.  V.  I.  A.  Center  for.  2011.  Origin  and  evolution  of  HIV-­‐‑1  in  
breast  milk  determined  by  single-­‐‑genome  amplification  and  sequencing.  J  Virol  
85:2751-­‐‑2763.  
  
275.   Samleerat,  T.,  M.  Braibant,  G.  Jourdain,  A.  Moreau,  N.  Ngo-­‐‑Giang-­‐‑Huong,  P.  
Leechanachai,  J.  Hemvuttiphan,  T.  Hinjiranandana,  T.  Changchit,  B.  Warachit,  V.  
Suraseranivong,  M.  Lallemant,  and  F.  Barin.  2008.  Characteristics  of  HIV  type  1  
(HIV-­‐‑1)  glycoprotein  120  env  sequences  in  mother-­‐‑infant  pairs  infected  with  HIV-­‐‑1  
subtype  CRF01_AE.  J  Infect  Dis  198:868-­‐‑876.  
  
276.   Sankaran,  S.,  M.  Guadalupe,  E.  Reay,  M.  D.  George,  J.  Flamm,  T.  Prindiville,  and  
S.  Dandekar.  2005.  Gut  mucosal  T  cell  responses  and  gene  expression  correlate  with  
protection  against  disease  in  long-­‐‑term  HIV-­‐‑1-­‐‑infected  nonprogressors.  Proc  Natl  
Acad  Sci  U  S  A  102:9860-­‐‑9865.  
  
  208  
277.   Sasseville,  V.  G.,  W.  A.  Newman,  A.  A.  Lackner,  M.  O.  Smith,  N.  C.  Lausen,  D.  
Beall,  and  D.  J.  Ringler.  1992.  Elevated  vascular  cell  adhesion  molecule-­‐‑1  in  AIDS  
encephalitis  induced  by  simian  immunodeficiency  virus.  The  American  journal  of  
pathology  141:1021-­‐‑1030.  
  
278.   Satishchandra,  P.,  A.  Nalini,  M.  Gourie-­‐‑Devi,  N.  Khanna,  V.  Santosh,  V.  Ravi,  A.  
Desai,  A.  Chandramuki,  P.  N.  Jayakumar,  and  S.  K.  Shankar.  2000.  Profile  of  
neurologic  disorders  associated  with  HIV/AIDS  from  Bangalore,  south  India  (1989-­‐‑
96).  Indian  J  Med  Res  111:14-­‐‑23.  
  
279.   Scarlatti,  G.,  T.  Leitner,  E.  Halapi,  J.  Wahlberg,  P.  Marchisio,  M.  A.  Clerici-­‐‑
Schoeller,  H.  Wigzell,  E.  M.  Fenyo,  J.  Albert,  M.  Uhlen,  and  et  al.  1993.  Comparison  
of  variable  region  3  sequences  of  human  immunodeficiency  virus  type  1  from  
infected  children  with  the  RNA  and  DNA  sequences  of  the  virus  populations  of  their  
mothers.  Proc  Natl  Acad  Sci  U  S  A  90:1721-­‐‑1725.  
  
280.   Scarlatti,  G.,  E.  Tresoldi,  A.  Bjorndal,  R.  Fredriksson,  C.  Colognesi,  H.  K.  Deng,  M.  
S.  Malnati,  A.  Plebani,  A.  G.  Siccardi,  D.  R.  Littman,  E.  M.  Fenyo,  and  P.  Lusso.  
1997.  In  vivo  evolution  of  HIV-­‐‑1  co-­‐‑receptor  usage  and  sensitivity  to  chemokine-­‐‑
mediated  suppression.  Nat  Med  3:1259-­‐‑1265.  
  
281.   Schacker,  T.  W.,  J.  P.  Hughes,  T.  Shea,  R.  W.  Coombs,  and  L.  Corey.  1998.  Biological  
and  virologic  characteristics  of  primary  HIV  infection.  Ann  Intern  Med  128:613-­‐‑620.  
  
282.   Schmidtmayerova,  H.,  H.  S.  Nottet,  G.  Nuovo,  T.  Raabe,  C.  R.  Flanagan,  L.  
Dubrovsky,  H.  E.  Gendelman,  A.  Cerami,  M.  Bukrinsky,  and  B.  Sherry.  1996.  
Human  immunodeficiency  virus  type  1  infection  alters  chemokine  beta  peptide  
expression  in  human  monocytes:  implications  for  recruitment  of  leukocytes  into  
brain  and  lymph  nodes.  Proc  Natl  Acad  Sci  U  S  A  93:700-­‐‑704.  
283.   Schnell,  G.,  S.  Joseph,  S.  Spudich,  R.  W.  Price,  and  R.  Swanstrom.  2011.  HIV-­‐‑1  
replication  in  the  central  nervous  system  occurs  in  two  distinct  cell  types.  PLoS  
Pathog  7:e1002286.  
  
284.   Schnell,  G.,  R.  W.  Price,  R.  Swanstrom,  and  S.  Spudich.  2010.  
Compartmentalization  and  clonal  amplification  of  HIV-­‐‑1  variants  in  the  
cerebrospinal  fluid  during  primary  infection.  J  Virol  84:2395-­‐‑2407.  
  
285.   Schnell,  G.,  S.  Spudich,  P.  Harrington,  R.  W.  Price,  and  R.  Swanstrom.  2009.  
Compartmentalized  human  immunodeficiency  virus  type  1  originates  from  long-­‐‑
  209  
lived  cells  in  some  subjects  with  HIV-­‐‑1-­‐‑associated  dementia.  PLoS  Pathog  
5:e1000395.  
  
286.   Schols,  D.,  and  E.  De  Clercq.  1996.  Human  immunodeficiency  virus  type  1  gp120  
induces  anergy  in  human  peripheral  blood  lymphocytes  by  inducing  interleukin-­‐‑10  
production.  J  Virol  70:4953-­‐‑4960.  
  
287.   Schrager,  L.  K.,  and  M.  P.  D'ʹSouza.  1998.  Cellular  and  anatomical  reservoirs  of  HIV-­‐‑
1  in  patients  receiving  potent  antiretroviral  combination  therapy.  Jama  280:67-­‐‑71.  
  
288.   Schroder,  A.  R.,  P.  Shinn,  H.  Chen,  C.  Berry,  J.  R.  Ecker,  and  F.  Bushman.  2002.  
HIV-­‐‑1  integration  in  the  human  genome  favors  active  genes  and  local  hotspots.  Cell  
110:521-­‐‑529.  
  
289.   Schubert,  U.,  L.  C.  Anton,  I.  Bacik,  J.  H.  Cox,  S.  Bour,  J.  R.  Bennink,  M.  Orlowski,  
K.  Strebel,  and  J.  W.  Yewdell.  1998.  CD4  glycoprotein  degradation  induced  by  
human  immunodeficiency  virus  type  1  Vpu  protein  requires  the  function  of  
proteasomes  and  the  ubiquitin-­‐‑conjugating  pathway.  J  Virol  72:2280-­‐‑2288.  
  
290.   Schwartz,  O.,  V.  Marechal,  S.  Le  Gall,  F.  Lemonnier,  and  J.  M.  Heard.  1996.  
Endocytosis  of  major  histocompatibility  complex  class  I  molecules  is  induced  by  the  
HIV-­‐‑1  Nef  protein.  Nat  Med  2:338-­‐‑342.  
  
291.   Schweighardt,  B.,  and  W.  J.  Atwood.  2001.  HIV  type  1  infection  of  human  astrocytes  
is  restricted  by  inefficient  viral  entry.  AIDS  Res  Hum  Retroviruses  17:1133-­‐‑1142.  
  
292.   Schweighardt,  B.,  J.  T.  Shieh,  and  W.  J.  Atwood.  2001.  CD4/CXCR4-­‐‑independent  
infection  of  human  astrocytes  by  a  T-­‐‑tropic  strain  of  HIV-­‐‑1.  J  Neurovirol  7:155-­‐‑162.  
  
293.   Shaheen,  F.,  A.  V.  Sison,  L.  McIntosh,  M.  Mukhtar,  and  R.  J.  Pomerantz.  1999.  
Analysis  of  HIV-­‐‑1  in  the  cervicovaginal  secretions  and  blood  of  pregnant  and  
nonpregnant  women.  Journal  of  human  virology  2:154-­‐‑166.  
  
294.   Sharer,  L.  R.,  E.  S.  Cho,  and  L.  G.  Epstein.  1985.  Multinucleated  giant  cells  and  
HTLV-­‐‑III  in  AIDS  encephalopathy.  Human  pathology  16:760.  
  
295.   Sheehy,  A.  M.,  N.  C.  Gaddis,  J.  D.  Choi,  and  M.  H.  Malim.  2002.  Isolation  of  a  




296.   Shibata,  D.,  L.  M.  Weiss,  A.  M.  Hernandez,  B.  N.  Nathwani,  L.  Bernstein,  and  A.  
M.  Levine.  1993.  Epstein-­‐‑Barr  virus-­‐‑associated  non-­‐‑Hodgkin'ʹs  lymphoma  in  patients  
infected  with  the  human  immunodeficiency  virus.  Blood  81:2102-­‐‑2109.  
  
297.   Simmonds,  P.,  P.  Balfe,  C.  A.  Ludlam,  J.  O.  Bishop,  and  A.  J.  Brown.  1990.  Analysis  
of  sequence  diversity  in  hypervariable  regions  of  the  external  glycoprotein  of  human  
immunodeficiency  virus  type  1.  J  Virol  64:5840-­‐‑5850.  
  
298.   Slatkin,  M.,  and  W.  P.  Maddison.  1989.  A  cladistic  measure  of  gene  flow  inferred  
from  the  phylogenies  of  alleles.  Genetics  123:603-­‐‑613.  
  
299.   Smith,  D.  M.,  S.  Zarate,  H.  Shao,  S.  K.  Pillai,  S.  L.  Letendre,  J.  K.  Wong,  D.  D.  
Richman,  S.  D.  Frost,  R.  J.  Ellis,  and  H.  Group.  2009.  Pleocytosis  is  associated  with  
disruption  of  HIV  compartmentalization  between  blood  and  cerebral  spinal  fluid  
viral  populations.  Virology  385:204-­‐‑208.  
  
300.   Smith,  R.,  K.  Malee,  M.  Charurat,  L.  Magder,  C.  Mellins,  C.  Macmillan,  J.  
Hittleman,  T.  Lasky,  A.  Llorente,  and  J.  Moye.  2000.  Timing  of  perinatal  human  
immunodeficiency  virus  type  1  infection  and  rate  of  neurodevelopment.  The  Women  
and  Infant  Transmission  Study  Group.  Pediatr  Infect  Dis  J  19:862-­‐‑871.  
  
301.   Snider,  W.  D.,  D.  M.  Simpson,  K.  E.  Aronyk,  and  S.  L.  Nielsen.  1983.  Primary  
lymphoma  of  the  nervous  system  associated  with  acquired  immune-­‐‑deficiency  
syndrome.  The  New  England  journal  of  medicine  308:45.  
302.   Snider,  W.  D.,  D.  M.  Simpson,  S.  Nielsen,  J.  W.  Gold,  C.  E.  Metroka,  and  J.  B.  
Posner.  1983.  Neurological  complications  of  acquired  immune  deficiency  syndrome:  
analysis  of  50  patients.  Annals  of  neurology  14:403-­‐‑418.  
  
303.   Snyder,  A.,  Z.  Alsauskas,  P.  Gong,  P.  E.  Rosenstiel,  M.  E.  Klotman,  P.  E.  Klotman,  
and  M.  J.  Ross.  2009.  FAT10:  a  novel  mediator  of  Vpr-­‐‑induced  apoptosis  in  human  
immunodeficiency  virus-­‐‑associated  nephropathy.  J  Virol  83:11983-­‐‑11988.  
  
304.   Snyder,  A.,  Z.  C.  Alsauskas,  J.  S.  Leventhal,  P.  E.  Rosenstiel,  P.  Gong,  J.  J.  Chan,  K.  
Barley,  J.  C.  He,  M.  E.  Klotman,  M.  J.  Ross,  and  P.  E.  Klotman.  2010.  HIV-­‐‑1  viral  
protein  r  induces  ERK  and  caspase-­‐‑8-­‐‑dependent  apoptosis  in  renal  tubular  epithelial  
cells.  AIDS  24:1107-­‐‑1119.  
  




306.   Song,  B.,  M.  Cayabyab,  N.  Phan,  L.  Wang,  M.  K.  Axthelm,  N.  L.  Letvin,  and  J.  G.  
Sodroski.  2004.  Neutralization  sensitivity  of  a  simian-­‐‑human  immunodeficiency  
virus  (SHIV-­‐‑HXBc2P  3.2N)  isolated  from  an  infected  rhesus  macaque  with  
neurological  disease.  Virology  322:168-­‐‑181.  
  
307.   Soriano,  V.,  M.  Nunez,  L.  Martin-­‐‑Carbonero,  P.  Barreiro,  J.  Garcia-­‐‑Samaniego,  and  
J.  Gonzalez-­‐‑Lahoz.  2005.  Hepatitis  C,  p.  531-­‐‑540.  In  H.  E.  Gendelman,  I.  Grant,  I.  P.  
Everall,  S.  A.  Lipton,  and  S.  Swindells  (ed.),  The  Neurology  of  AIDS,  vol.  2nd  
Edition.  Oxford  University  Press,  New  York.  
  
308.   Spudich,  S.,  M.  Gisslen,  L.  Hagberg,  E.  Lee,  T.  Liegler,  B.  Brew,  D.  Fuchs,  G.  
Tambussi,  P.  Cinque,  F.  M.  Hecht,  and  R.  W.  Price.  2011.  Central  nervous  system  
immune  activation  characterizes  primary  human  immunodeficiency  virus  1  infection  
even  in  participants  with  minimal  cerebrospinal  fluid  viral  burden.  J  Infect  Dis  
204:753-­‐‑760.  
  
309.   Spudich,  S.  S.,  A.  C.  Nilsson,  N.  D.  Lollo,  T.  J.  Liegler,  C.  J.  Petropoulos,  S.  G.  
Deeks,  E.  E.  Paxinos,  and  R.  W.  Price.  2005.  Cerebrospinal  fluid  HIV  infection  and  
pleocytosis:  relation  to  systemic  infection  and  antiretroviral  treatment.  BMC  
infectious  diseases  5:98.  
  
310.   Stacey,  A.  R.,  P.  J.  Norris,  L.  Qin,  E.  A.  Haygreen,  E.  Taylor,  J.  Heitman,  M.  
Lebedeva,  A.  DeCamp,  D.  Li,  D.  Grove,  S.  G.  Self,  and  P.  Borrow.  2009.  Induction  
of  a  striking  systemic  cytokine  cascade  prior  to  peak  viremia  in  acute  human  
immunodeficiency  virus  type  1  infection,  in  contrast  to  more  modest  and  delayed  
responses  in  acute  hepatitis  B  and  C  virus  infections.  J  Virol  83:3719-­‐‑3733.  
  
311.   Stamatovic,  S.  M.,  P.  Shakui,  R.  F.  Keep,  B.  B.  Moore,  S.  L.  Kunkel,  N.  Van  
Rooijen,  and  A.  V.  Andjelkovic.  2005.  Monocyte  chemoattractant  protein-­‐‑1  
regulation  of  blood-­‐‑brain  barrier  permeability.  Journal  of  cerebral  blood  flow  and  
metabolism  :  official  journal  of  the  International  Society  of  Cerebral  Blood  Flow  and  
Metabolism  25:593-­‐‑606.  
  
312.   Stansell,  E.,  and  R.  C.  Desrosiers.  2010.  Functional  contributions  of  carbohydrate  on  
AIDS  virus  glycoprotein.  The  Yale  journal  of  biology  and  medicine  83:201-­‐‑208.  
  
313.   Strain,  M.  C.,  S.  Letendre,  S.  K.  Pillai,  T.  Russell,  C.  C.  Ignacio,  H.  F.  Gunthard,  B.  
Good,  D.  M.  Smith,  S.  M.  Wolinsky,  M.  Furtado,  J.  Marquie-­‐‑Beck,  J.  Durelle,  I.  
Grant,  D.  D.  Richman,  T.  Marcotte,  J.  A.  McCutchan,  R.  J.  Ellis,  and  J.  K.  Wong.  
2005.  Genetic  composition  of  human  immunodeficiency  virus  type  1  in  cerebrospinal  
  212  
fluid  and  blood  without  treatment  and  during  failing  antiretroviral  therapy.  J  Virol  
79:1772-­‐‑1788.  
  
314.   Strebel,  K.,  T.  Klimkait,  and  M.  A.  Martin.  1988.  A  novel  gene  of  HIV-­‐‑1,  vpu,  and  
its  16-­‐‑kilodalton  product.  Science  241:1221-­‐‑1223.  
  
315.   Strelow,  L.  I.,  D.  Janigro,  and  J.  A.  Nelson.  2001.  The  blood-­‐‑brain  barrier  and  AIDS.  
Advances  in  virus  research  56:355-­‐‑388.  
  
316.   Strickland,  S.  L.,  R.  R.  Gray,  S.  L.  Lamers,  T.  H.  Burdo,  E.  Huenink,  D.  J.  Nolan,  B.  
Nowlin,  X.  Alvarez,  C.  C.  Midkiff,  M.  M.  Goodenow,  K.  Williams,  and  M.  Salemi.  
2012.  Efficient  transmission  and  persistence  of  low-­‐‑frequency  SIVmac251  variants  in  
CD8-­‐‑depleted  rhesus  macaques  with  different  neuropathology.  The  Journal  of  
general  virology  93:925-­‐‑938.  
  
317.   Sturdevant,  C.  B.,  A.  Dow,  C.  B.  Jabara,  S.  B.  Joseph,  G.  Schnell,  N.  Takamune,  M.  
Mallewa,  R.  S.  Heyderman,  A.  Van  Rie,  and  R.  Swanstrom.  2012.  Central  nervous  
system  compartmentalization  of  HIV-­‐‑1  subtype  C  variants  early  and  late  in  infection  
in  young  children.  PLoS  Pathog  8:e1003094.  
  
318.   Tambussi,  G.,  A.  Gori,  B.  Capiluppi,  C.  Balotta,  L.  Papagno,  B.  Morandini,  M.  Di  
Pietro,  D.  Ciuffreda,  A.  Saracco,  and  A.  Lazzarin.  2000.  Neurological  symptoms  
during  primary  human  immunodeficiency  virus  (HIV)  infection  correlate  with  high  
levels  of  HIV  RNA  in  cerebrospinal  fluid.  Clinical  infectious  diseases  :  an  official  
publication  of  the  Infectious  Diseases  Society  of  America  30:962-­‐‑965.  
  
319.   Tamura,  K.,  J.  Dudley,  M.  Nei,  and  S.  Kumar.  2007.  MEGA4:  Molecular  
Evolutionary  Genetics  Analysis  (MEGA)  software  version  4.0.  Mol  Biol  Evol  24:1596-­‐‑
1599.  
  
320.   Tardieu,  M.,  J.  Le  Chenadec,  A.  Persoz,  L.  Meyer,  S.  Blanche,  and  M.  J.  Mayaux.  
2000.  HIV-­‐‑1-­‐‑related  encephalopathy  in  infants  compared  with  children  and  adults.  
French  Pediatric  HIV  Infection  Study  and  the  SEROCO  Group.  Neurology  54:1089-­‐‑
1095.  
  
321.   Thali,  M.,  J.  P.  Moore,  C.  Furman,  M.  Charles,  D.  D.  Ho,  J.  Robinson,  and  J.  
Sodroski.  1993.  Characterization  of  conserved  human  immunodeficiency  virus  type  




322.   Thomas,  E.  R.,  R.  L.  Dunfee,  J.  Stanton,  D.  Bogdan,  J.  Taylor,  K.  Kunstman,  J.  E.  
Bell,  S.  M.  Wolinsky,  and  D.  Gabuzda.  2007.  Macrophage  entry  mediated  by  HIV  
Envs  from  brain  and  lymphoid  tissues  is  determined  by  the  capacity  to  use  low  CD4  
levels  and  overall  efficiency  of  fusion.  Virology  360:105-­‐‑119.  
  
323.   Thompson,  J.  D.,  D.  G.  Higgins,  and  T.  J.  Gibson.  1994.  CLUSTAL  W:  improving  
the  sensitivity  of  progressive  multiple  sequence  alignment  through  sequence  
weighting,  position-­‐‑specific  gap  penalties  and  weight  matrix  choice.  Nucleic  Acids  
Res  22:4673-­‐‑4680.  
  
324.   Tindall,  B.,  L.  Evans,  P.  Cunningham,  P.  McQueen,  L.  Hurren,  E.  Vasak,  J.  
Mooney,  and  D.  A.  Cooper.  1992.  Identification  of  HIV-­‐‑1  in  semen  following  
primary  HIV-­‐‑1  infection.  AIDS  6:949-­‐‑952.  
  
325.   Ullrich,  R.,  M.  Zeitz,  and  E.  O.  Riecken.  1992.  Enteric  immunologic  abnormalities  in  
human  immunodeficiency  virus  infection.  Seminars  in  liver  disease  12:167-­‐‑174.  
  
326.   Valcour,  V.,  T.  Chalermchai,  N.  Sailasuta,  M.  Marovich,  S.  Lerdlum,  D.  Suttichom,  
N.  C.  Suwanwela,  L.  Jagodzinski,  N.  Michael,  S.  Spudich,  F.  van  Griensven,  M.  de  
Souza,  J.  Kim,  J.  Ananworanich,  and  R.  S.  S.  Group.  2012.  Central  nervous  system  
viral  invasion  and  inflammation  during  acute  HIV  infection.  J  Infect  Dis  206:275-­‐‑282.  
  
327.   Van  Rie,  A.,  P.  R.  Harrington,  A.  Dow,  and  K.  Robertson.  2007.  Neurologic  and  
neurodevelopmental  manifestations  of  pediatric  HIV/AIDS:  a  global  perspective.  Eur  
J  Paediatr  Neurol  11:1-­‐‑9.  
  
328.   Veazey,  R.  S.,  M.  DeMaria,  L.  V.  Chalifoux,  D.  E.  Shvetz,  D.  R.  Pauley,  H.  L.  
Knight,  M.  Rosenzweig,  R.  P.  Johnson,  R.  C.  Desrosiers,  and  A.  A.  Lackner.  1998.  
Gastrointestinal  tract  as  a  major  site  of  CD4+  T  cell  depletion  and  viral  replication  in  
SIV  infection.  Science  280:427-­‐‑431.  
  
329.   Vincent  J,  B.  M.,  Shanks  D,  Daigh  D,  Moriarty  R,  Fischer  G.  Presented  at  the  
Presented  at:  Fifth  International  Conference  on  AIDS,  June  4  –9,  1989;  Montreal,  
Quebec,  Canada.  
  
330.   Vogel,  P.,  W.  M.  Kell,  D.  L.  Fritz,  M.  D.  Parker,  and  R.  J.  Schoepp.  2005.  Early  
events  in  the  pathogenesis  of  eastern  equine  encephalitis  virus  in  mice.  The  
American  journal  of  pathology  166:159-­‐‑171.  
  
  214  
331.   Wei,  X.,  S.  K.  Ghosh,  M.  E.  Taylor,  V.  A.  Johnson,  E.  A.  Emini,  P.  Deutsch,  J.  D.  
Lifson,  S.  Bonhoeffer,  M.  A.  Nowak,  B.  H.  Hahn,  and  et  al.  1995.  Viral  dynamics  in  
human  immunodeficiency  virus  type  1  infection.  Nature  373:117-­‐‑122.  
  
332.   Weiss,  J.  M.,  S.  A.  Downie,  W.  D.  Lyman,  and  J.  W.  Berman.  1998.  Astrocyte-­‐‑
derived  monocyte-­‐‑chemoattractant  protein-­‐‑1  directs  the  transmigration  of  leukocytes  
across  a  model  of  the  human  blood-­‐‑brain  barrier.  J  Immunol  161:6896-­‐‑6903.  
  
333.   Weissenhorn,  W.,  A.  Dessen,  S.  C.  Harrison,  J.  J.  Skehel,  and  D.  C.  Wiley.  1997.  
Atomic  structure  of  the  ectodomain  from  HIV-­‐‑1  gp41.  Nature  387:426-­‐‑430.  
  
334.   Westendorp,  M.  O.,  R.  Frank,  C.  Ochsenbauer,  K.  Stricker,  J.  Dhein,  H.  Walczak,  
K.  M.  Debatin,  and  P.  H.  Krammer.  1995.  Sensitization  of  T  cells  to  CD95-­‐‑mediated  
apoptosis  by  HIV-­‐‑1  Tat  and  gp120.  Nature  375:497-­‐‑500.  
  
335.   Wilen,  C.  B.,  N.  F.  Parrish,  J.  M.  Pfaff,  J.  M.  Decker,  E.  A.  Henning,  H.  Haim,  J.  E.  
Petersen,  J.  A.  Wojcechowskyj,  J.  Sodroski,  B.  F.  Haynes,  D.  C.  Montefiori,  J.  C.  
Tilton,  G.  M.  Shaw,  B.  H.  Hahn,  and  R.  W.  Doms.  2011.  Phenotypic  and  
immunologic  comparison  of  clade  B  transmitted/founder  and  chronic  HIV-­‐‑1  
envelope  glycoproteins.  J  Virol  85:8514-­‐‑8527.  
  
336.   Wilen,  C.  B.,  J.  C.  Tilton,  and  R.  W.  Doms.  2012.  HIV:  From  Biology  to  Prevention  
and  Treatment,  p.  23-­‐‑35.  In  F.  Bushman,  G.  J.  Nabel,  and  R.  Swanstrom  (ed.).  Cold  
Spring  Harbor  Laboratory  Press,  Cold  Spring  Harbor,  New  York.  
  
337.   Willey,  R.  L.,  J.  S.  Bonifacino,  B.  J.  Potts,  M.  A.  Martin,  and  R.  D.  Klausner.  1988.  
Biosynthesis,  cleavage,  and  degradation  of  the  human  immunodeficiency  virus  1  
envelope  glycoprotein  gp160.  Proc  Natl  Acad  Sci  U  S  A  85:9580-­‐‑9584.  
  
338.   Willey,  R.  L.,  F.  Maldarelli,  M.  A.  Martin,  and  K.  Strebel.  1992.  Human  
immunodeficiency  virus  type  1  Vpu  protein  induces  rapid  degradation  of  CD4.  J  
Virol  66:7193-­‐‑7200.  
  
339.   Williams,  K.  C.,  S.  Corey,  S.  V.  Westmoreland,  D.  Pauley,  H.  Knight,  C.  deBakker,  
X.  Alvarez,  and  A.  A.  Lackner.  2001.  Perivascular  macrophages  are  the  primary  cell  
type  productively  infected  by  simian  immunodeficiency  virus  in  the  brains  of  
macaques:  implications  for  the  neuropathogenesis  of  AIDS.  The  Journal  of  
experimental  medicine  193:905-­‐‑915.  
  
  215  
340.   Winnock,  M.,  D.  Salmon-­‐‑Ceron,  F.  Dabis,  and  G.  Chene.  2004.  Interaction  between  
HIV-­‐‑1  and  HCV  infections:  towards  a  new  entity?  The  Journal  of  antimicrobial  
chemotherapy  53:936-­‐‑946.  
  
341.   Wong,  J.  K.,  C.  C.  Ignacio,  F.  Torriani,  D.  Havlir,  N.  J.  Fitch,  and  D.  D.  Richman.  
1997.  In  vivo  compartmentalization  of  human  immunodeficiency  virus:  evidence  
from  the  examination  of  pol  sequences  from  autopsy  tissues.  J  Virol  71:2059-­‐‑2071.  
  
342.   Wyatt,  R.,  and  J.  Sodroski.  1998.  The  HIV-­‐‑1  envelope  glycoproteins:  fusogens,  
antigens,  and  immunogens.  Science  280:1884-­‐‑1888.  
  
343.   Zetola,  N.  M.,  and  C.  D.  Pilcher.  2007.  Diagnosis  and  management  of  acute  HIV  
infection.  Infectious  disease  clinics  of  North  America  21:19-­‐‑48,  vii.  
  
344.   Zhang,  H.,  B.  Yang,  R.  J.  Pomerantz,  C.  Zhang,  S.  C.  Arunachalam,  and  L.  Gao.  
2003.  The  cytidine  deaminase  CEM15  induces  hypermutation  in  newly  synthesized  
HIV-­‐‑1  DNA.  Nature  424:94-­‐‑98.  
345.   Zhu,  T.,  H.  Mo,  N.  Wang,  D.  S.  Nam,  Y.  Cao,  R.  A.  Koup,  and  D.  D.  Ho.  1993.  
Genotypic  and  phenotypic  characterization  of  HIV-­‐‑1  patients  with  primary  infection.  
Science  261:1179-­‐‑1181.  
  
346.   Zink,  M.  C.,  G.  D.  Coleman,  J.  L.  Mankowski,  R.  J.  Adams,  P.  M.  Tarwater,  K.  Fox,  
and  J.  E.  Clements.  2001.  Increased  macrophage  chemoattractant  protein-­‐‑1  in  
cerebrospinal  fluid  precedes  and  predicts  simian  immunodeficiency  virus  
encephalitis.  J  Infect  Dis  184:1015-­‐‑1021.  
  
347.   zur  Hausen,  H.  1991.  Viruses  in  human  cancers.  Science  254:1167-­‐‑1173.  
  
  
